Note: (ab) represents abstract.

Aalders, JG, 1244(ab)
Aarsvold, JN, 281(ab), 731(ab), 861(ab)
Abamor, E, 207(ab)
Abdel-Dayem, HM, 1230(ab), 1348(ab)
Abdella, N, 1422(ab)
Abe, O, 551(ab)
Abella-Columna, E, 297(ab)
Abi-Dargham, A, 549(ab), 852(ab), 923(ab), 946(ab), 1465
Abitbol, C, 1955
Abitbol, CA, 1037, 1432(ab)
Abrams, DN, 1024(ab)
Aburano, T, 50(ab), 51(ab), 365(ab), 766(ab), 1031(ab), 1405(ab)
Acar, P, 10(ab), 383(ab), 400
Acio, ER, 185(ab), 500(ab), 793(ab)
Ackermann, BJ, 259(ab)
Ackermann, RJ, 82(ab)
Acland, KM, 304(ab)
Acton, PD, 150(ab), 541(ab), 584, 988(ab), 1065(ab), 1066(ab)
Adachi, H, 12(ab), 760(ab)
Adachi, I, 712(ab)
Adam, C, 1177(ab)
Adam, LE, 81(ab)
Adam, MJ, 490(ab), 1078(ab)
Adams, GP, 115(ab)
Adams, HR, 1069(ab)
Adamson, KL, 830(ab)
Adelstein, SJ, 1204(ab), 1519, 1545
Adler, G, 1138(ab)
Adler, LP, 112(ab), 814(ab)
Adonai, N, 1126(ab)
Adriaenssen, I, 1168(ab)
Afonso, L, 5(ab), 357(ab)
Agafitei, D, 177(ab)
Agalos, G, 1343(ab)
Agdeppa, ED, 95(ab)
Ager, J, 1227
Agnese, G, 306(ab), 1208(ab)
Agostini, DF, 9(ab), 192(ab), 194(ab), 400, 845, 1398(ab)
Ahdoot, R, 107
Ahlman, H, 636
Ahn, BC, 54(ab)
Ahn, C, 263
Ahn, IM, 1140(ab)
Ahn, JY, 65(ab), 183(ab), 386(ab), 387(ab), 789(ab), 845(ab)
Ahn, SH, 144(ab), 1135(ab), 1388(ab)
Ahn, SK, 1000(ab)
Ahn, YK, 26(ab), 797(ab)
Aiazian, EA, 338(ab)
Aigrain, Y, 208(ab)
Akabani, G, 332(ab)
Akamune, A, 836(ab)
Åkerström, G, 275
Akinboboye, O, 772(ab)
Akioka, K, 830
Akiyama, Y, 1777
Aktas, A, 1360(ab), 1386(ab)
Aktas, UO, 207(ab)
Akyuz, C, 1193(ab)
Al Mehaidib, A, 215
Alauddin, MM, 165(ab), 355, 1038(ab), 1714
Alavi, A, 1964
Alavi, AA, 37(ab), 118(ab), 122(ab), 134(ab), 168(ab), 252(ab), 283(ab), 327, 451(ab), 541(ab), 584, 818(ab), 987(ab), 988(ab), 989(ab), 991(ab), 999(ab), 1003(ab), 1034(ab), 1139, 1159(ab), 1196(ab), 1210(ab), 1213(ab), 1220(ab), 1221(ab), 1236(ab), 1251(ab), 1277(ab), 1314(ab), 1330(ab), 1347(ab), 1396(ab), 1411(ab)
Alazraki, NP, 281(ab)
Albelda, SM, 451(ab)
Alberini, JL, 205(ab)
Albin, RL, 542(ab), 968(ab)
Al-Bunni, A, 1422(ab)
Alderson, PO, 1283(ab), 1289(ab), 1409(ab)
Aleem, A, 57
Aleksic, S, 546(ab), 1080(ab), 1361(ab), 1362(ab)
Alessi, A, 780(ab)
Alexander, GE, 247(ab), 575
Alexander, M, 1416(ab)
Alexoff, DL, 854(ab)
Alhaddad, IA, 715(ab)
Alheit, H, 166(ab)
Ali, A, 15(ab)
Ali, H, 1324
Allada, V, 345(ab)
Allenberg, J, 1369(ab)
Alnafisi, NS, 1010
Aloj, L, 1264(ab)
Alonso, O, 106(ab)
Alpert, NM, 104(ab), 226(ab), 397(ab), 899(ab), 931(ab), 1086
Alsop, DC, 987(ab)
Altenhoff, J, 1317(ab)
Altenvoerde, G, 378(ab)
Al-Tikriti, MS, 97(ab), 148(ab), 941(ab), 1552
Altmann, A, 1136(ab), 1139(ab)
Alvarez, E, 920(ab)
Alyasi, A, 14(ab)
Al-Za'abi, K, 1422(ab)
Alzoabi, K, 1357(ab)
Amano, S, 1636
Amar, MH, 845
Amaral, H, 40(ab)
Amici, LA, 234
Amirav, I, 1410(ab), 1412(ab)
Ammannati, F, 545(ab)
Amorosa, LF, 1353(ab)
Amthauer, H, 137(ab)
Andersen, TT, 128(ab), 1029(ab)
Anderson, A, 904(ab)
Anderson, BO, 307(ab)
Anderson, CJ, 322(ab), 565(ab), 1043(ab), 1054(ab)
Anderson, G, 941(ab)
Anderson, H, 827(ab)
Anderson, JR, 612
Ando, A, 744(ab)
Ando, N, 1222(ab)
Andreae, F, 578(ab)
Andrews, T, 857(ab)
Angelberger, P, 36, 250, 578(ab)
Angelos, P, 211(ab)
Angerstein, C, 30(ab), 287(ab), 441(ab), 472(ab)
Angusti, T, 1006
Annovazzi, A, 242
Anthony, CT, 133(ab), 1256
Antich, PP, 185(ab)
Antoine, JC, 1286(ab)
Anton, M, 3(ab)
Antonescu, C, 1184(ab)
Antonietti, T, 400
Antonini, A, 781, 994(ab)
Antonyshyn, OM, 1075
Anzai, Y, 246(ab), 968(ab)
Aoyagi, H, 283
Apostolidis, C, 441(ab), 1174(ab), 1177(ab)
Appel, M, 1199(ab)
Aquino, SL, 234(ab)
Aramburu, I, 754(ab)
Aranda, R, 1206(ab), 1373(ab)
Arano, Y, 1016(ab)
Araujo, LI, 1139
Araujo, W, 767(ab)
Archambaud, F, 208(ab)
Ardakani, N, 1358(ab)
Areeda, JS, 712, 720
Arevalo, A, 947(ab)
Ariannejad, M, 277(ab), 428(ab), 430(ab), 1232(ab), 1303(ab)
Arisaka, Y, 85
Aronen, HJ, 788
Arslan, G, 1382(ab)
Art, T, 1414(ab)
Asada, T, 963(ab), 964(ab), 1155
Asano, T, 86(ab)
Asenbaum, S, 36
Ashburn, W, 1355(ab)
Ashford, JW, 57
Asmuth, J, 234(ab)
Aso, H, 24(ab)
Assaad, PS, 1099(ab)
Assayag, P, 393
Asselin, M-C, 1636
Astrom, K, 49(ab)
Atasever, T, 1382(ab)
Atkins, HL, 98(ab), 1119(ab)
Atochina, O, 1396(ab)
Attia, G, 18(ab)
Aubier, M, 1274(ab), 1808
Aubineau-Laniècе, I, 1041(ab)
Aubriot, JH, 1398(ab)
Auch-Schwelk, W, 350(ab)
Audenaert, K, 240(ab), 483(ab), 534(ab), 835(ab), 843(ab), 898(ab), 908(ab), 951(ab), 952(ab)
Aufschnaiter, M, 308(ab)
Augensen, F, 493
Augustine, S, 1109(ab), 1179(ab)
Aung, MT, 348(ab), 349(ab)
Aung, W, 257
Austin-Seymour, MM, 109(ab)
Avery, RA, 257(ab)
Avril, N, 3(ab), 443(ab)
Axelrod, D, 1230(ab)
Axworthy, DB, 131, 565(ab), 1033(ab), 1054(ab), 1148(ab), 1150(ab), 1152(ab)
Ayabe, K, 1295(ab)
Aykac, M, 223(ab)
Ayvaz, G, 1349(ab)
Azhdarinia, A, 127(ab), 1027(ab), 1075(ab), 1245(ab)
Azinovic, I, 556(ab)
Azizoglu, FY, 191(ab), 1349(ab)
Aznar, M, 1851
Azuma, M, 600
Azure, MT, 1142(ab)

Babich, JW, 410(ab), 933(ab)
Bach, O, 907(ab)
Bacharach, SL, 69(ab), 532(ab), 700, 729(ab), 757(ab), 811(ab), 826(ab), 1784
Bacher-Stier, C, 1190
Backfrieder, W, 1365(ab)
Baden, M, 702(ab)
Badimon, JJ, 25(ab)
Bading, JR, 143(ab), 1038(ab), 1161(ab), 1714
Badran, A, 205(ab)
Bae, SA, 1070(ab)
Bae, YT, 568(ab), 569(ab), 1257(ab)
Baehre, MH, 376(ab), 558(ab), 1067, 1219(ab), 1290(ab), 1329(ab)
Baer, FM, 362(ab)
Baez, L, 1166(ab)
Baghaei, H, 524(ab), 812(ab)
Bagnato, A, 1372(ab)
Bahk, YW, 368(ab), 371(ab), 1426(ab)
Bai, J, 1222(ab)
Bai, WG, 355
Baidoo, KE, 155(ab), 1056
Bailey, DL, 830(ab)
Baird, WH, 523(ab)
Bajén, MT, 2038
Bakchine, S, 421(ab)
Bakheet, SM, 215
Bakker, H, 622
Bakker, WH, 120(ab), 437(ab), 438(ab), 439(ab), 579(ab), 1248(ab)
Bal, CS, 201(ab)
Bal, G, 813(ab)
Balan, A, 84(ab)
Balanzó, J, 405
Balatoni, J, 145(ab), 314(ab), 316(ab), 320(ab), 1158(ab)
Baldessarini, RJ, 148(ab)
Baldeyrou, P, 1274(ab)
Baldwin, RM, 97(ab), 148(ab), 234, 1343, 1552
Baldwin, SW, 1025(ab)
Ball, DL, 296(ab), 431(ab)
Ballangrud, ÅM, 314(ab), 323(ab), 1176(ab)
Balleari, E, 1208(ab)
Ballester, M, 499(ab)
Ballinger, JR, 169, 1024(ab), 2036
Balon, H, 18N(11), 1335(ab)
Baltes, N, 31(ab)
Bamberg, M, 445(ab)
Bander, NH, 315(ab), 562(ab)
Bando, K, 761(ab)
Bandopadhyaya, GP, 203(ab)
Banerjee, S, 1089(ab), 1090(ab), 1095(ab)
Bangard, M, 590(ab), 1657
Bangsaard, R, 171(ab)
Bankiewicz, KS, 944(ab)
Bao, T, 1129(ab)
Baranowska-Kortylewicz, J, 1056(ab), 1109(ab)
Barbanoj, M, 980(ab)
Barbet, J, 480, 1185(ab)
Barbosa, FJ, 74(ab)
Bardiès, M, 335(ab), 1041(ab)
Barendswaard, E, 1175(ab)
Bares, R, 141(ab), 278(ab), 290(ab), 291(ab), 333(ab), 445(ab), 518(ab), 871(ab), 966(ab), 1018(ab), 1255(ab)
Barker, WC, 700
Barnes, D, 43(ab)
Barnes, WE, 725(ab)
Barnett, CA, 15(ab), 388(ab)
Barnett, JA, 129(ab)
Barone, R, 370(ab), 436(ab)
Barrett, CL, 1579
Barrett, HH, 804(ab)
Barrett, JA, 132(ab), 498(ab), 1141(ab)
Barrieras, D, 210(ab)
Barrio, JR, 95(ab), 146(ab), 147(ab), 228(ab), 289(ab), 317(ab), 321(ab), 851(ab), 1081(ab), 1098(ab)
Barritault, L, 383(ab), 400, 1417(ab)
Barron, BJ, 36(ab)
Barrow, SA, 839(ab)
Bar-Sever, Z, 385(ab), 509(ab), 1771
Bartenstein, P, 41(ab), 444(ab), 458(ab), 897(ab), 1279
Barthel, H, 139(ab)
Barthel, P, 358(ab)
Bartis, J, 132(ab), 1141(ab)
Bartlett, NL, 113(ab)
Bassam, M, 18(ab)
Bateman, TM, 529(ab), 778(ab), 860
Battelli, LA, 505(ab)
Batth, D, 861(ab)
Baudouin, V, 208(ab)
Bauer, A, 64(ab), 73(ab), 1068(ab)
Bauer, E, 146(ab), 317(ab), 321(ab)
Bauer, TL, 283(ab)
Bauer, TW, 283(ab)
Bauer, W, 262(ab)
Bauerschaper, B, 868(ab)
Baum, JK, 1973
Baum, RP, 233(ab), 1242(ab), 1280(ab)
Baumgartl, HJ, 1178(ab)

Baxter, K, 516(ab)
Beanlands, RS, 348(ab), 349(ab), 1426
Beattie, BJ, 972(ab)
Beaumier, PL, 131
Becherer, A, 1304(ab), 1339(ab)
Becker, DV, 1048(ab)
Becker, G, 518(ab)
Becker, H, 313(ab)
Becker, I, 452(ab), 1174(ab)
Becker, K, 1174(ab)
Becker, MD, 1353(ab)
Becker, W, 30(ab), 117(ab), 287(ab), 313(ab), 378(ab), 441(ab), 472(ab), 1128(ab)
Bednarczyck, EM, 433(ab)
Bedrosian, I, 283(ab)
Beekman, FJ, 521(ab)
Beets, AL, 588(ab), 1271
Begent, RH, 830(ab)
Beggs, AD, 1323(ab)
Behe, M, 30(ab), 117(ab), 287(ab), 441(ab), 472(ab), 590(ab), 1128(ab)
Behr, TM, 30(ab), 117(ab), 287(ab), 313(ab), 378(ab), 441(ab), 472(ab), 1128(ab)
Beju, D, 784(ab)
Belanger, MJ, 858(ab)
Belcourt, M, 970(ab)
Belhocine, TZ, 1154(ab)
Belin, A, 9(ab), 845
Belldegrun, A, 560(ab)
Bellemans, J, 1419(ab)
Belli, F, 1491
Bellon, JR, 109(ab), 574(ab)
Belzberg, AS, 15(ab)
Benada, A, 768(ab), 769(ab), 770(ab), 782(ab), 799(ab)
Benali, H, 401(ab), 729(ab), 1400
Benard, F, 43(ab), 818(ab), 1238(ab), 1282(ab)
Benayoun, S, 491(ab)
Bencherif, B, 417(ab), 902(ab), 909(ab)
Bender, H, 1657
Bendriem, B, 78(ab), 402(ab)
Ben-Eliezer, D, 1842
Bengel, FM, 3(ab), 7(ab), 13(ab), 172(ab), 195(ab), 358(ab), 773(ab), 837
Ben-Haim, S, 1025, 1403(ab)
Benillouche, E, 355(ab)
Benjamin, C, 19(ab), 21(ab), 714(ab)
Benjegård, SA, 636
Benkelfat, C, 536(ab)
Bennett, JA, 128(ab)
Bennett, PR, 218(ab)
Benoit, JP, 409(ab)
Bense, S, 967(ab)
Bensinger, W, 576(ab)
Benti, R, 515(ab), 994(ab), 1368(ab)
Bentourkia, M, 227(ab), 396(ab)
Benz, P, 444(ab), 458(ab)
Berenji, B, 228(ab)
Beresten, T, 320(ab)
Bergamasco, A, 1332(ab)
Berger, F, 1823
Berger, KL, 229(ab)
Berghammer, P, 426, 1495
Bergmann, H, 548, 1365(ab)
Bergmann, L, 531
Bergmann, R, 166(ab)
Bergmann, SR, 17(ab), 772(ab), 848(ab), 850(ab)
Bergner, U, 709(ab), 1271(ab)
Bergsneider, M, 243(ab)
Bergström, M, 275, 1746
Berkmen, YM, 1283(ab)
Berkowitz, MJ, 1218(ab)
Berlin, J, 1964
Berman, DS, 4(ab), 177(ab), 712, 720, 737(ab), 1190
Bermel, RA, 929(ab)
Bernà, LI, 405, 499(ab)
Bernante, P, 1343(ab)
Bernard, HF, 158(ab), 439(ab), 579(ab), 1030(ab), 1249(ab)
Bernardo-Filho, M, 1100(ab), 1101(ab)
Bernhardt, P, 636
Bernstein, MP, 1075
Bernstein, V, 1260(ab)
Berr, F, 139(ab)
Berridge, MS, 232(ab), 1413(ab), 1603
Berry, GJ, 1(ab)
Berry, I, 1063(ab), 1341(ab)
Besnard, JC, 409(ab)
Bestetti, A, 780(ab), 1597
Bettinardi, V, 399(ab)
Beuthien-Baumann, B, 166(ab), 280(ab), 907(ab), 992(ab), 1006(ab), 1312(ab)
Beutler, JJ, 1337
Beyer, T, 1369
Bhambhvani, D, 1335(ab)
Bhargava, B, 28(ab)
Bhargava, KK, 474
Bhatnagar, A, 40(ab), 311(ab)
Bhattacharya, A, 1367(ab)
Bianchi, P, 306(ab), 1208(ab)
Bianco-Batlles, D, 5(ab)
Biancone, L, 242
Bichler, KH, 1018(ab)
Biederman, J, 104(ab)
Biela, BH, 1129(ab)
Bieler, S, 77(ab)
Biersack, HJ, 590(ab), 960(ab), 1124(ab), 1271, 1657
Bifano, D, 1264(ab)
Bigner, DD, 332(ab)
Bihl, H, 123(ab), 135(ab), 460(ab), 462(ab)
Bilger, K, 291(ab), 871(ab)
Bilkenroth, U, 1133(ab)
Billinghurst, MW, 1024(ab)
Binaghi, G, 1935
Binns, DS, 296(ab), 431(ab)
Bird, VG, 1813
Birnbaumer, L, 1206(ab), 1373(ab)
Bischof Delaloye, A, 1184(ab)
Biselli, M, 556
Bishayee, A, 941, 2043
Bishop, HA, 298(ab), 299(ab), 505(ab), 890(ab)
Bisi, G, 982(ab)
Bissoli, S, 705(ab)
Bitner, S, 1106(ab)
Bjørnholm, B, 930(ab)
Black, CM, 199(ab)
Black, SE, 45
Bladuell, N, 263
Blair, JB, 942(ab), 1035(ab)
Blake, GM, 2015
Blankenberg, FG, 1(ab), 589(ab), 793(ab)
Blanksma, PK, 353(ab), 356(ab)
Blasberg, RG, 145(ab), 316(ab), 320(ab), 972(ab), 1158(ab)
Blasini, R, 837
Blaufox, MD, 1627
Bleckmann, C, 429(ab), 1317(ab)
Blier, P, 536(ab)
Blocher, AA, 582(ab), 1018(ab)
Block, NL, 1813
Blok, JJ, 231(ab)
Blood, C, 1021(ab)
Bloodworth, G, 1192(ab)
Bloomfield, PM, 1737
Blower, PJ, 159(ab), 485(ab), 1134(ab), 1202(ab)
Blumhardt, R, 857(ab), 1390(ab)
Boan, J, 1278(ab)
Boasquevisque, EM, 1100(ab)
Boaz, M, 716(ab)
Bobinski, KP, 560(ab)
Bocher, M, 1287
Bock, M, 160(ab)
Bockisch, A, 553(ab), 837(ab), 1333(ab)
Bodei, L, 1519
Boellaard, R, 231(ab), 346(ab), 406(ab)
Boening, G, 77(ab), 887(ab)
Boerman, OC, 129(ab), 456, 462(ab), 463, 498(ab), 517(ab), 563(ab), 622, 896, 912, 1088(ab), 1125(ab), 1182(ab), 1404(ab)
Boerner, AR, 121(ab), 169(ab), 212(ab), 1307(ab)
Boers, M, 1328(ab)
Bofilias, I, 1345(ab)
Bogicevic, M, 1370(ab), 1433(ab)
Boguslavsky, L, 1397(ab)
Bohnen, NI, 968(ab)
Bohuslavizki, KH, 429(ab), 816, 844(ab), 921(ab), 1205(ab), 1317(ab)
Boileau, R, 1282(ab)
Bok, BD, 208(ab)
Bolch, WE, 189, 326(ab), 331(ab), 682 , 941, 1049(ab), 1053(ab), 1062(ab), 2043
Bolzati, C, 475(ab), 1096(ab)
Bom, HS, 26(ab), 797(ab), 1000(ab)
Bomanji, JB, 733(ab)
Bombardieri, E, 1270(ab), 1491
Bonab, AA, 104(ab), 226(ab), 410(ab), 819(ab), 839(ab), 899(ab), 931(ab), 933(ab), 1086
Bonanno, E, 242
Bonasera, TA, 275
Bonavina, L, 515(ab)
Bonet, J, 1063(ab)
Bongers, V, 1252(ab)
Bonne, O, 915(ab)
Bonnefoi, F, 771(ab)
Bonnet, R, 1280(ab)
Bonnette, P, 1417(ab)
Bonnin, FA, 208(ab)
Bonofiglio, R, 1372(ab)
Bonson, KR, 658
Bonte, FJ, 901(ab)
Booij, J, 419(ab), 900(ab)
Boon, P, 1145
Boonstra, H, 1244(ab)
Borchardt, P, 463(ab)
Bordoni, C, 978(ab)
Borek, PP, 874
Borg, BD, 44(ab), 45(ab), 866(ab)
Borges, AC, 722(ab), 723(ab)
Borges-Neto, S, 740(ab), 1235
Bormans, G, 1419(ab)
Borrelli, G, 1264(ab)
Bosch, W, 1241(ab)
Boschi, A, 1096(ab)
Bossuyt, A, 351(ab), 849(ab)
Both, SA, 458(ab)
Botti, G, 1261(ab)
Bottlaender, M, 934(ab)
Botvinick, EH, 79(ab), 1287
Boucher, L, 1238(ab), 1282(ab)
Bouchet, LG, 189, 326(ab), 682, 941, 1049(ab), 1053(ab), 1062(ab), 2043
Bouchet, LP, 331(ab)
Bouhou, J, 480
Bouhour, F, 1286(ab)
Boulay, G, 1206(ab), 1373(ab)
Bouman, CA, 875(ab)
Bousson, V, 1801
Bouvard, G, 9(ab), 192(ab), 194(ab), 400, 845, 1398(ab)
Bouwens, L, 2051
Bouwens, LR, 224(ab)
Boy, C, 212(ab)
Bozan, H, 1400(ab)
Bradley, LA, 990(ab)
Braga, AC, 1101(ab)
Brake, S, 1106(ab)
Brandau, W, 1076(ab)
Brandes, D, 915(ab)
Brandes, K, 1177(ab)
Brandt, D, 31(ab)
Brandt, T, 967(ab)
Brandt-Mainz, K, 1333(ab)
Brans, B, 1145, 1194(ab), 1195(ab), 1337(ab), 1351(ab)
Brasse, D, 802(ab), 821(ab)
Braunstein, GD, 1354(ab)
Braunstein, RH, 1813
Breau, J-L, 1801
Brechbiel, MW, 116(ab), 474(ab), 755, 1144(ab), 1148(ab), 1149(ab), 1150(ab), 1152(ab), 1175(ab), 1177(ab), 2089
Brecht-Krauss, D, 1695
Bredow, J, 166(ab), 1312(ab)
Breeman, WA, 158(ab), 435(ab), 439(ab), 579(ab), 940(ab), 1030(ab), 1169(ab), 1249(ab)
Breidert, I, 350(ab)
Breier, A, 522
Breithardt, G, 190(ab)
Breitz, HB, 131, 328(ab), 863, 2011
Bremer, S, 315(ab)
Bremner, JD, 910(ab)
Brenner, W, 42(ab), 377(ab), 1042(ab), 1114(ab), 1187(ab), 1429(ab)
Breuer, F, 1522
Bricker, J, 44(ab)
Briganti, V, 1247(ab)
Brill, AB, 1391
Brittinger, G, 117(ab)
Britton, KE, 14(ab), 40(ab), 62(ab)
Brix, G, 1266(ab)
Brochet, E, 355(ab), 393
Broft, A, 415(ab), 549(ab)
Brooks, DJ, 418(ab), 538(ab)
Brossa, V, 499(ab)
Brouwers, AH, 460(ab), 462(ab), 517(ab), 563(ab), 1404(ab)
Brouwers, FM, 498(ab)
Brower, KJ, 539(ab)
Brown, BP, 811(ab)
Brown, EJ, 715(ab)
Brown, JK, 1287
Brown, PR, 1361(ab), 1362(ab)
Brown, RS, 449(ab), 450(ab), 2026
Brownell, A-L, 407(ab)
Bruce, W, 1415(ab)
Bruch, HP, 1329(ab)
Bruchertseifer, F, 160(ab)
Brücke, T, 36
Bruckner, JD, 372(ab)
Bruehlmeier, M, 781
Bruemmer, C, 1187(ab)
Brugarolas, A, 556(ab)
Brugere, S, 754(ab)
Brun, E, 1198(ab)
Brun, T, 1369
Bruni, A, 1276(ab)
Bruni, WL, 874
Brunken, RC, 178(ab), 708(ab)
Bruns, J, 429(ab)
Bruyant, PP, 1913
Bryan, K, 131
Buchberger, R, 973
Buchegger, F, 1184(ab)
Buchert, R, 429(ab), 816, 844(ab), 921(ab), 1205(ab), 1317(ab)
Buchheimer, N, 413(ab)
Buchholz, H.-G., 897(ab)
Buchmann, I, 119(ab), 310(ab), 1058(ab), 1145(ab)
Buchpiguel, CA, 255(ab)
Buchsbaum, DJ, 318(ab), 319(ab), 887
Buchsbaum, MS, 25(ab)
Buchwald, DS, 970(ab)
Buck, AK, 107(ab), 310(ab), 834(ab), 1145(ab), 1297(ab)
Budinger, TF, 79(ab)
Buell, U, 174(ab), 237(ab), 347(ab), 774(ab), 914(ab), 1275(ab)
Bueller, JA, 266(ab), 539(ab)
Buettner, TL, 455(ab)
Buffoni, F, 306(ab), 978(ab), 1208(ab)
Bugaj, JE, 120(ab), 156(ab), 439(ab), 440(ab), 1030(ab), 1248(ab), 1249(ab)
Buijs, WC, 622
Bukberg, P, 1348(ab)
Buma, P, 896

Bumann, D, 1205(ab)
Bunjes, D, 119(ab), 531, 1058(ab)
Bunker, S, 36(ab)
Burchert, W, 166(ab), 169(ab), 907(ab), 992(ab), 1006(ab)
Burger, C, 833(ab)
Burke, PA, 564(ab)
Burker, M, 839(ab), 1067(ab)
Burns, A, 199(ab)
Burns, HD, 1080(ab)
Burton, F, 138(ab)
Burton, J, 2089
Burzstein-De Mytttnaere, S, 1403(ab)
Buschmann, I, 590(ab)
Buscombe, JR, 110(ab), 199(ab), 448(ab), 463(ab), 572(ab), 883(ab), 1172(ab), 1258(ab), 1311(ab), 1346(ab)
Bush, B, 422(ab)
Bushman, MJ, 1107(ab), 1111(ab)
Bushnell, DL, 829(ab), 1288(ab)
Butler, J, 852(ab)
Buurlage, H, 1040(ab)
Buvat, I, 401(ab), 729(ab), 1400
Buxton-Thomas, MS, 53(ab), 842(ab)
Byars, L, 1369
Bybel, B, 1385(ab)
Byrd, DR, 307(ab)
Byrne, FR, 1206(ab), 1373(ab)
Byun, BH, 371(ab)

Caceres, W, 1166(ab)
Caglioni, C, 305(ab)
Cai, H-Z, 1021(ab)
Caldwell, CB, 45, 1075
Caldwell, JC, 189(ab)
Callans, LS, 283(ab)
Calonder, C, 781
Calonje, E, 304(ab)
Caltabiano, S, 946(ab)
Calvo, E, 556(ab)
Calvo, R, 439
Camargo, EE, 996(ab), 1224(ab)
Camaya, MV, 474
Cambier, JP R, 124(ab)
Cameron, RB, 295(ab), 432(ab)
Cameron, RG, 429, 903
Camici, PG, 187(ab)
Camp, VM, 151(ab), 167(ab)
Campbell, C, 903(ab)
Campbell, GT, 1342(ab)
Campisi, R, 11, 11(ab), 708(ab)
Camprecios, M, 499(ab)
Canavese, G, 306(ab)
Canclini, S, 494(ab), 732(ab)
Candell-Riera, J, 752(ab)
Caner, B, 1163
Canizales, A, 14(ab)
Cantilena, L, 262(ab)
Cantwell, MN, 1842
Canzi, C, 515(ab)
Caplin, ME, 1172(ab), 1311(ab)
Caras, D, 263
Carballido Brea, M, 159(ab)
Cardoso, VN, 1100(ab)
Carel, I, 16(ab), 769(ab), 770(ab)
Caretto, E, 216(ab)
Cargnel, S, 8(ab), 705(ab), 973
Carletto, M, 1208(ab)
Carlier, P, 436(ab)
Carmona, AJ, 1037
Carnevale, V, 1478
Carnevali-Ricci, P, 1597
Carola, F, 1597
Carpentier, P, 1689
Carr, JG, 874
Carr, JM, 535(ab)
Carrasquillo, JA, 318, 532(ab), 700, 755, 826(ab), 1033(ab), 1093, 1149(ab), 1150(ab), 1152(ab), 1784
Carretta, RF, 36(ab)
Carrió, I, 405, 499(ab), 920(ab), 980(ab)
Carroll, M, 14(ab)
Carson, JM, 757(ab), 811(ab)
Carson, RE, 334(ab), 522, 944(ab), 1784
Carter, EA, 1376(ab), 1384(ab), 1424(ab), 1428(ab)
Casara, D, 216(ab), 303(ab), 1332(ab), 1343(ab)
Cascinelli, N, 1491
Case, JA, 529(ab), 778(ab), 860
Caselles, O, 1063(ab), 1341(ab)
Casey, KL, 945(ab)
Casi, M, 1191(ab)
Casoni, R, 982(ab)
Castagnola, F, 978(ab)
Castellani, M, 1368(ab)
Castellano, G, 982(ab)
Castiglioni, I, 399(ab)
Castillon, J, 923(ab)
Castle, VP, 379(ab)
Catafau, AM, 405, 499(ab), 920(ab), 980(ab)
Cataldo, JL, 1224(ab)
Catena, C, 1522
Catturich, A, 306(ab)
Caty, A, 1689
Cavagnaro, F, 1955
Celegon, L, 973
Celler, AM, 864(ab), 869(ab), 894(ab)
Cendes, F, 996(ab)
Cerci, R, 276(ab), 891(ab), 1207(ab), 1235(ab)
Ceriani, L, 1935
Cesati, RR, 148(ab)
Chae, I-H, 504(ab)
Chaimovitz, D, 716(ab)
Chalker, BA, 823(ab)
Chalon, S, 409(ab)
Chamorro, H, 754(ab)
Champailler, A, 393(ab), 717(ab)
Champlin, RE, 327(ab)
Chan, KY, 1315(ab)
Chang, CH, 1185(ab)
Chang, CP, 33(ab), 292(ab)
Chang, CW, 1121(ab), 1350(ab)
Chang, HS, 512(ab)
Chang, HT, 1262(ab)
Chang, JY, 1342(ab)
Chang, KJ, 37(ab)
Chang, KP, 256(ab), 1102(ab)
Chang, L, 420(ab), 865(ab)
Chang, MJ, 343(ab)
Chang, SL, 986(ab)
Chang, W, 222(ab)
Chang, YS, 841(ab)
Channing, MA, 944(ab)
Chao, C, 229(ab), 1241(ab)
Chapman, BE, 525(ab)
Chapron, F, 194(ab)
Charlop, A, 109(ab), 442(ab)
Charlton, DE, 1041(ab), 1176(ab)
Charney, DS, 234, 910(ab), 1343
Charpentier, E, 1274(ab)
Charron, M, 206(ab), 1369
Chatal, JF, 215(ab), 330(ab)
Chaudhari, PR, 1089(ab)
Chaudhuri, G, 11(ab)
Chaudhuri, TR, 318(ab), 319(ab), 887
Chehne, F, 1495
Chen, B, 382(ab)
Chen, CC, 1342(ab)
Chen, CH, 815(ab), 865(ab)
Chen, C-T, 822(ab)
Chen, D, 893(ab)
Chen, J, 161(ab)
Chen, JC, 815(ab)
Chen, JL, 269
Chen, MK, 546(ab), 1361(ab), 1362(ab)
Chen, P, 151(ab)
Chen, PM, 1211(ab)
Chen, SH, 145(ab), 1315(ab)
Chen, SL, 571(ab), 884(ab), 1165(ab)
Chen, T, 974(ab), 1250(ab)
Chen, Y-I, 407(ab)
Cheng, DW, 514(ab)
Cheng, JC, 1315(ab)
Cheng, KT, 1112(ab)
Cheng, TI, 1392(ab)
Cheng, Y-F, 1209
Cheng, Z, 161(ab)
Cheon, GJ, 183(ab), 373(ab), 751(ab), 789(ab), 852, 1047(ab)
Cheon, JH, 1399(ab), 1401(ab)
Chérel, M, 330(ab), 1041(ab)
Cherry, SR, 228(ab), 1206(ab)
Chessa, F, 1259(ab)
Chianelli, M, 242
Chida, M, 2063
Child, JS, 708(ab)
Chin, BB, 496(ab), 497(ab), 755(ab)
Chin, Y, 516(ab)
Chinol, M, 1173(ab)
Chintakayala, DP, 1362(ab)
Chiodini, I, 1478
Chiou, TJ, 1211(ab)
Chiou, YH, 1359(ab)
Chirakal, R, 1087(ab), 1636
Chisin, R, 915(ab), 1234(ab)
Chiti, A, 1247(ab), 1270(ab)
Chiu, PF, 865(ab), 1246(ab)
Chmielowiec, CJ, 570(ab), 581(ab), 1170(ab)
Chmielweski, GW, 1281(ab)
Cho, B-K, 983(ab)
Cho, JH, 797(ab), 998(ab)
Cho, SW, 1060(ab)
Cho, YP, 1836
Choe, J-G, 1027(ab)
Choe, W, 342(ab), 363(ab)
Choe, YS, 810(ab), 888(ab), 955(ab), 1073(ab), 1265(ab), 1296(ab), 1395(ab)
Choi, BI, 1045(ab)
Choi, CW, 144(ab), 1059(ab), 1135(ab), 1301(ab), 1309(ab), 1388(ab)
Choi, EY, 1047(ab)
Choi, JR, 1263(ab)
Choi, JS, 28(ab)
Choi, JY, 6(ab), 361(ab), 730(ab), 808, 1225(ab), 1265(ab), 1296(ab)
Choi, NC, 1253(ab)
Choi, SR, 150(ab), 476(ab), 1036(ab), 1064(ab), 1065(ab), 1066(ab)
Choi, TH, 144(ab)
Choi, Y, 6(ab), 730(ab), 810(ab), 888(ab), 955(ab), 1073(ab), 1225(ab), 1265(ab), 1296(ab), 1395(ab)
Choi, YS, 6(ab), 504(ab), 730(ab), 1225(ab)
Choi, YW, 1130(ab), 1132(ab), 1338(ab)
Choi, YY, 447(ab)
Cholewinski, SP, 1198
Chon, JH, 593(ab)
Chossat, F, 141
Chou, KL, 256(ab), 292(ab), 815(ab), 986(ab), 1211(ab), 1350(ab)
Chou, YW, 152(ab), 924(ab), 994
Christian, B, 94(ab)
Christian, BT, 101(ab), 264(ab), 481(ab)
Christian, PE, 83(ab), 391(ab), 525(ab), 813(ab)
Chu, J, 467(ab)
Chu, LS, 33(ab), 292(ab), 1211(ab), 1350(ab)
Chu, WJ, 965(ab), 997(ab)
Chu, YK, 292(ab), 986(ab)
Chuang, J-H, 1209
Chuang, S, 981(ab)
Chuang, VP, 1392(ab)
Chugani, DC, 245(ab)
Chugani, HT, 245(ab)
Chumpradit, S, 1036(ab)
Chun, GJ, 386(ab)
Chun, KA, 54(ab), 495(ab), 1212(ab), 1285(ab)
Chun, KJ, 514(ab)
Chun, KS, 1135(ab)
Chung, AJ, 955(ab)
Chung, CK, 253(ab)
Chung, J-K, 27, 65(ab), 183(ab), 253(ab), 254(ab), 271(ab), 343(ab), 373(ab), 386(ab), 387(ab), 447(ab), 504(ab), 751(ab), 781(ab), 789(ab), 841(ab), 845(ab), 852, 912(ab), 961(ab), 983(ab), 998(ab), 1047(ab), 1130(ab), 1132(ab), 1338(ab), 1427(ab)
Chung, MH, 1047(ab)
Chung, SK, 368(ab), 371(ab), 1408(ab), 1426(ab)
Chung, WS, 144(ab), 1388(ab)
Chung, YA, 368(ab), 371(ab), 1408(ab), 1426(ab)
Chyan, MK, 474(ab)
Ciarmiello, A, 1261(ab)
Cicchetti, F, 407(ab)
Çiftçi, İ, 1163
Cindoruk, M, 1382(ab)
Cinotti, L, 1011(ab), 1286(ab)
Clackdoyle, R, 813(ab)
Clairand, I, 1049(ab), 1053(ab), 1062(ab)
Clark, CM, 252(ab)
Clark, V, 773
Classic, KL, 1052(ab)
Clausen, M, 429(ab), 816, 844(ab), 921(ab), 1205(ab), 1317(ab)
Clinthorne, NH, 68(ab), 76(ab)
Clorius, JH, 1369(ab)
Cluckie, A, 53(ab), 842(ab)
Coakley, AJ, 1202(ab)
Coates, G, 1010
Codegone, A, 1006
Cody, HS, 282(ab)
Coenen, HH, 64(ab), 73(ab), 333(ab), 488(ab), 533(ab), 1068(ab), 1250
Cohade, C, 19(ab), 21(ab), 43(ab), 714(ab)
Cohen, DJ, 1813
Cohen, I, 4(ab)
Cohen, P, 859(ab)
Cohen, R, 1445
Colak, T, 1400(ab)
Colantuoni, C, 909(ab)
Colburn, M, 328(ab)
Colcher, D, 1109(ab)
Cole, CE, 1020(ab)
Cole, GM, 95(ab)
Coleman, M, 279(ab), 311(ab), 466(ab)
Coleman, RE, 36N(8)
Coleman, RE, 1, 56(ab), 692, 740(ab), 879(ab), 1025(ab), 1920
Coles, D, 878(ab)
Coll, C, 754(ab)
Collart, JP, 437(ab)
Collignon, M-A, 1043, 1417(ab)
Collins, JM, 1160(ab), 1162(ab)
Collins, L, 206(ab)
Colnot, DR, 1999
Colsher, J, 383
Comans, EF, 1216(ab)
Comtat, C, 402(ab)
Condos, SG, 874
Connett, JM, 455(ab)
Connolly, JL, 1973
Connolly, LP, 596, 1632
Conrad, EU, 125(ab), 372(ab)
Consigny, PM, 161
Constable, RT, 874
Constantinescu, A, 185(ab)
Conti, D, 1522
Conti, PS, 143(ab), 165(ab), 230(ab), 1038(ab), 1161(ab), 1714
Cook, ND, 183
Cooke, CD, 176(ab), 752(ab), 846(ab), 1941
Cooke, D, 1308
Cool, C, 57
Cooper, MS, 463(ab)
Cooper, PW, 1075
Cooper, TB, 102(ab), 903(ab)
Coover, LR, 1868
Copello, F, 978(ab)
Coplan, JD, 904(ab)
Corbett, JR, 762(ab), 763(ab), 765(ab)

Cordier, JF, 1286(ab)
Cordoliani, YS, 979(ab)
Cornelius, SS, 855(ab)
Corripio, I, 920(ab)
Corsi, M, 257(ab)
Corstens, FH, 129(ab), 136(ab), 456, 462(ab), 463, 498(ab), 517(ab), 563(ab), 622, 643, 896, 912, 1088(ab), 1125(ab), 1182(ab), 1404(ab)
Cortés-Blanco, A, 991(ab), 1003(ab), 1210(ab), 1213(ab), 1220(ab), 1221(ab), 1396(ab)
Coskun, M, 1386(ab)
Costa, DC, 405(ab), 935(ab), 954(ab)
Costa, PA, 255(ab)
Costa de Beauregard, M-A, 78
Cottin, V, 1286(ab)
Cottu, P, 1259(ab)
Coulon, C, 934(ab)
Coupal, JJ, 57, 1103(ab)
Courbon, F, 1063(ab), 1341(ab)
Coussement, P, 1040(ab)
Couturier, O, 330(ab)
Cowley, H, 946(ab)
Craig, JC, 986
Crain, B, 1920
Cremerius, U, 237(ab), 1275(ab)
Cremonesi, M, 1173(ab)
Crepin, M, 591(ab)
Crespo-Jara, AA, 439, 1278(ab)
Crestani, B, 1274(ab), 1808
Crijns, HJGM, 356(ab)
Crippa, F, 1491
Croasdale, ID, 883(ab), 1346(ab)
Croasdale, PL, 1172(ab)
Crocker, AC, 132(ab)
Cronin, BF, 1284(ab)
Crook, JM, 99(ab)
Cross, DJ, 246(ab), 259(ab), 945(ab), 948(ab), 1879
Cryer, PE, 244(ab)
Cuchiara, AJ, 1277(ab)
Cullom, SJ, 529(ab), 778(ab), 860
Cunningham, VJ, 538(ab), 605, 706, 827(ab)
Curcio, MJ, 116(ab), 1175(ab)
Curran, KM, 1323(ab)
Currie, DW, 869(ab)
Cutler, CS, 1084(ab)
Cutler, PD, 115(ab), 1054(ab), 1241(ab)
Cuvelier, B, 224(ab)
Cwikla, JB, 110(ab), 448(ab), 572(ab), 883(ab), 1258(ab), 1346(ab)
Czech, N, 42(ab), 1042(ab), 1114(ab)
Czerniecki, BJ, 283(ab)
Czernin, J, 11, 247(ab), 248(ab), 251(ab), 277(ab), 295(ab), 428(ab), 430(ab), 432(ab), 461(ab), 540(ab), 560(ab), 708(ab), 867(ab), 1177, 1206(ab), 1232(ab), 1291(ab), 1303(ab), 1373(ab)
Czitrom, D, 393
Czuczman, M, 118(ab)
Czuzcman, M, 465(ab)

Da Silva, AJ, 67(ab), 398(ab), 528(ab)
Daaboul, B, 516(ab)
Dabbs, KA, 1074(ab)
Dacey, RG, 88(ab)
Dacher, JN, 209(ab)
Dadachova, K, 1149(ab)
Dae, MW, 75(ab)
Daghighian, F, 1239(ab)
Daglish, MR, 418(ab)
D'Agnolo, A, 468(ab), 469(ab), 1001(ab), 1218(ab), 1354(ab)
Dahlberg, ST, 872(ab)
Dahlbom, M, 394(ab), 867(ab), 880(ab), 1291(ab)
Dahlheimer, J, 163(ab)
Dahman, BA, 1204(ab)
Dai, D, 309
Dainty, S, 53(ab)
Daisu, M, 1777
D'Aiuto, G, 1261(ab)
Dalipaj, MM, 1426
Damiani, C, 71(ab)
Damiano, M, 1264(ab)
Damien, P, 491(ab)
Damrongpipatkij, Y, 715(ab)
Dams, ET, 517(ab), 622, 896, 912, 1404(ab)
Dancey, JE, 1673
Dangleis, K, 276(ab), 891(ab), 1207(ab)
Dani, A, 575
Daniel, L, 480
Dann, EJ, 274(ab), 557(ab), 1243(ab)
Dannals, RF, 417(ab), 902(ab), 909(ab), 1080(ab), 1361(ab), 1417
Dansereau, RN, 1117(ab), 1264
Daou, D, 16(ab), 567, 768(ab), 769(ab), 770(ab), 782(ab), 799(ab)
Darcey, TM, 1619
Darcourt, J, 405(ab)
Darlas, Y, 9(ab), 192(ab), 194(ab), 845, 1398(ab)
Das, SS, 40(ab)
Das, T, 1090(ab), 1095(ab)
D'Asseler, Y, 181(ab), 240(ab)
Daube-Witherspoon, ME, 81(ab)
Daum, S, 452(ab)
Davidson, T, 448(ab), 572(ab), 1258(ab)
Davies, RG, 570(ab)
Davila-Roman, VG, 344(ab)
Davis, CM, 757(ab)
Davis, J, 183
Davis, N, 1260(ab)
Davison, A, 475(ab)
Day, CS, 476(ab)
de Beco, V, 1267(ab), 1308(ab), 1316(ab), 1801
de Boer, J, 353(ab), 356(ab)
De Bondt, P, 59(ab), 181(ab), 359(ab), 734(ab), 1421(ab)
de Bruin, K, 419(ab), 900(ab)
De Camps, J, 370(ab)
De Clercq, D, 57(ab)
De Cristofaro, M, 545(ab)
de Dreuille, O, 802(ab), 821(ab), 979(ab)
de Fernex, R, 399(ab)
de Jong, DJ, 517(ab)
de Jong, HWAM, 521(ab)
De Jong, M, 158(ab), 439(ab), 579(ab), 1030(ab), 1248(ab), 1249(ab), 1704
de Keizer, B, 1340(ab)
de Klerk, JM, 369(ab), 1337, 1340(ab), 1876
De La Pena-Almaguer, E, 749(ab)
de Leon, MJ, 247(ab)
De Ley, G, 483(ab)
De Reuck, J, 408(ab), 1071(ab)
De Ridder, LI, 17, 1195(ab)
De Sadeleer, C, 23, 198(ab), 366(ab)
De Smet, K, 57(ab), 1421(ab)
De Sutter, J, 181(ab), 359(ab), 734(ab)
De Vos, F, 408(ab)
De Vos, FJ, 483(ab), 1071(ab)
de Vries, DJ, 514
de Vries, EFJ, 1157(ab)
de Vries, EG, 1793
de Vries, JDH, 302(ab)
De Winter, F, 57(ab), 59(ab), 181(ab), 359(ab), 734(ab), 1337(ab), 1351(ab), 1421(ab)
De Winter, H, 1337(ab), 1351(ab)
De Winter, O, 952(ab)
de Wit, M, 1205(ab)
de Wolff, FA, 419(ab)
Deal, KA, 1017(ab)
Dean, RT, 1142(ab)
Debonnel, G, 536(ab)
DeBraal, L, 846(ab)
Debreuve, E, 405(ab)
Debruyne, J, 408(ab)
Debus, O, 1431(ab)
Deckel, AW, 773
Decker, C, 1006(ab)
Decker, P, 1657
Decristoforo, C, 1114
DeGrado, TR, 56(ab), 1025(ab), 1727
Deguchi, K, 425(ab)
deGuzman, AF, 1200(ab)
Dehdashti, F, 130(ab), 229(ab), 1241(ab)
Dei, S, 86(ab), 756(ab), 758(ab), 1393(ab), 1407(ab)
deKemp, RA, 348(ab), 349(ab), 1426
Del Guerra, A, 71(ab)
Del Rosario, F, 206(ab)
Del Sole, A, 780(ab)
Del Vecchio, S, 1261(ab), 1264(ab)
Delahaye, N, 567, 1274(ab)
Delbeke, D, 34(ab), 276(ab), 891(ab), 1207(ab), 1235(ab), 1364
Delforge, J, 934(ab)
Delius, W, 701(ab)
Demeter, SJ, 1094(ab), 1310(ab)
Demphel, S, 934(ab)
den Heeten, GJ, 419(ab)
DeNardo, GL, 324(ab), 328(ab), 470, 564(ab), 567(ab), 952, 1215(ab)
DeNardo, SJ, 104, 324(ab), 564(ab), 567(ab), 952, 1215(ab)
Dence, CS, 244(ab), 484(ab)
Deng, FH, 1163(ab)
Denizot, B, 335(ab)
DePalatis, LR, 816(ab)
Depreux, P, 1689
DePuey, EG, 15(ab), 176(ab), 339(ab), 364(ab), 767(ab), 1308, 1445
Der, MG, 944(ab)
Derdeyn, CP, 800
Desai, D, 816(ab)
Desai, M, 749(ab)
DeScheerder, I, 1040(ab)
Desgeorges, M, 979(ab)
Desideri, A, 973
Desiderio, L, 991(ab)
Desiderio, LM, 1003(ab)
Desmond, TJ, 480(ab)
Desnos, M, 196(ab)
Detre, JA, 987(ab)
Dettori, G, 1259(ab)
Deutsch, G, 228, 422(ab), 965(ab), 990(ab)
Devaux, JY, 205(ab)
DeVincentes, G, 235(ab)
Devish, K, 1109(ab)
Devlin, PR, 456(ab), 776(ab)
Devous Sr, MD, 901(ab)
Dewaraja, Y, 329(ab), 1579
Dewaraja, YK, 123, 808(ab), 1760
Dewey, SL, 411(ab), 414(ab)
Dey, D, 233(ab)
Di Bella, EV, 525(ab), 886(ab)
Di Benedetto, M, 591(ab)
Di Carli, MF, 5(ab), 357(ab), 1227
Di Domenico, G, 71(ab)
Di Gennaro, F, 1264(ab)
Di Leo, C, 780(ab)
Di Lorenzo, C, 206(ab)
Di Martino, E, 1275(ab)
Di Paola, R, 401(ab), 729(ab), 1400
DiCanzio, J, 596, 1632
Dicembrino, F, 1478
Dick, DW, 80(ab), 1015(ab)
Dick, S, 270(ab)
Dickinson, C, 1335(ab)
Diederichs, CG, 1695
Diehl, M, 350(ab)
Dierck, R, 2051
Dierckx, P, 224(ab)
Dierckx, RA, 17, 57(ab), 59(ab), 181(ab), 224(ab), 240(ab), 359(ab), 483(ab), 534(ab), 734(ab), 835(ab), 843(ab), 898(ab), 908(ab), 951(ab), 952(ab), 1071(ab), 1145, 1194(ab), 1195(ab), 1337(ab), 1351(ab), 1421(ab)
Dieterich, M, 967(ab)
Diethelm, AG, 1332
Dietlein, M, 32(ab), 362(ab)
Dietz, A, 559(ab)
Diggles, LE, 107, 235(ab)
Diksic, M, 536(ab)
Dilsizian, V, 69(ab), 729(ab), 757(ab), 811(ab)
Dilworth, JR, 485(ab)
DiMeo, AJ, 820(ab)
Dimitrakopoulou-Strauss, A, 446(ab), 863(ab), 1256(ab), 1319(ab), 1322(ab)
Ding, Y, 1545
Ding, YS, 98(ab), 103(ab), 416(ab), 420(ab), 854(ab), 922(ab), 929(ab), 949(ab)
Dinitis, A, 122(ab)
Dinkelborg, LM, 27(ab)
Dione, DP, 787(ab), 794(ab), 874
Diringer, MN, 85(ab), 88(ab)
Dittmann, H, 278(ab), 291(ab)
Divgi, CR, 538
Dobbeleir, AA, 718(ab)
Dobrowolskij, D, 429(ab)
Dodig, D, 1061(ab), 1203(ab)
Doehner, H, 119(ab)
Doenst, T, 488
Doerner, J, 378(ab)
Doerr, U, 123(ab), 135(ab), 460(ab)
Dogan, AS, 478(ab)
Dogan, S, 262(ab), 925(ab)
Dohmen, BM, 141(ab), 278(ab), 290(ab), 291(ab), 333(ab), 445(ab), 518(ab), 966(ab), 1255(ab)
Dohr, D, 531
Doi, I, 828(ab)
Doi, K, 1302(ab)
Dolbier, WR, 168(ab)
Dolbier, WR, Jr, 327
Doll, J, 559(ab), 1266(ab)
Dolle, F, 934(ab)
Dolphin, D, 587(ab)
Domingues, C, 1409(ab)
Donahay, T, 1237
Dopichaj-Menge, U, 507(ab), 1233(ab)
Doppman, JL, 1646
Dorantes, TM, 794(ab)
Dörr, U, 462(ab)
Dose, J, 443(ab)
Doublet, J-D, 78
Dougherty, DD, 104(ab), 899(ab)
Doumit, D, 355(ab), 393
Doze, P, 96(ab), 1157(ab)
Dragoiescu, C, 1328(ab)
Dragotakes, SD, 104(ab)
Dragu, A, 790(ab), 1587
Dresel, S, 105(ab), 868(ab), 1228(ab), 1823
Driedger, AA, 111, 1010
Driver, DR, 811(ab)
Dronne, F, 192(ab)
Drouant, GJ, 133(ab)
Drubach, L, 596, 1632
Drumm, D, 318
Drumm-Giuseppe, DL, 1148(ab)
Drzezga, A, 250(ab), 837, 897(ab), 948(ab), 967(ab), 1008(ab)
Du, Y, 1214(ab)
Duarte, PS, 134(ab)
Duatti, A, 71(ab), 1096(ab)
Dubovsky, EV, 200(ab), 1332
Dubrovin, M, 145(ab), 316(ab), 320(ab), 1158(ab)
Duda, SH, 27(ab)
Dudczak, R, 578(ab), 786(ab), 1124(ab), 1304(ab), 1339(ab)
Duerk, JL, 232(ab)
Dumont, FL, 240(ab), 534(ab), 843(ab), 898(ab), 908(ab), 951(ab), 1071(ab)
Dumot, JA, 1385(ab)
Duncan, J, 169
Duncker, C, 531
Dunigan, KA, 573(ab)
Dunn, WL, 113(ab), 115(ab)

Dunnwald, LK, 307(ab), 442(ab), 574(ab)
Dupont, C, 205(ab)
Dupont, P, 275(ab)
Durack, LD, 576(ab)
Durbin, MK, 809(ab)
Durie, BGM, 468(ab)
Dustan, K, 199(ab)
Dutertre, G, 979(ab)
Duthil, P, 1341(ab)
Duvivier, DH, 1414(ab)
Duysinx, B, 1154(ab)
Dwamena, BA, 434(ab), 1269(ab)
Dworak, E, 1365(ab)
Dworkin, HJ, 1281(ab), 1335(ab)
Dymond, D, 14(ab)
Dzewas, B, 270(ab), 272(ab)

Earl, N, 1920
Early, ML, 543(ab)
Eary, JF, 109(ab), 125(ab), 307(ab), 372(ab), 576(ab)
Eaton, MW, 785(ab)
Ebara, H, 836(ab)
Eberl, S, 1737
Echt, E, 457(ab)
Eck, SL, 1034(ab), 1159(ab)
Eckelman, WC, 153(ab), 154(ab), 334(ab), 479(ab), 522, 944(ab), 1020(ab), 1069(ab), 1149(ab), 1150(ab)
Eckelt, U, 1312(ab)
Eckerle, S, 558(ab), 1329(ab)
Eckholt, M, 548
Edell, SL, 44(ab), 1214, 1973
Edenbrandt, L, 49(ab)
Edmondson, S, 14(ab)
Edrisinghe, Y, 741(ab)
Edwards, DS, 129(ab), 132(ab), 1141(ab)
Edwards, GK, 1682
Efange, SMN, 2069
Egan, MF, 100(ab)
Eggli, DF, 48(ab), 866(ab)
Ehninger, G, 280(ab)
Ehrenkaufer, RL, 413(ab)
Ehrenkaufer, RLE, 2069
Ehrlich, LE, 1075
Ehrlichmann, W, 582(ab)
Eickelberg, C, 257(ab)
Eilles, C, 709(ab), 739(ab), 1271(ab)
Eiseman, JL, 1160(ab)
Eisenbarth, JA, 1123(ab)
Eisenhut, M, 23(ab), 475(ab), 559(ab), 1123(ab), 1139(ab), 1266(ab)
Ejiri, K, 1009(ab)
El Fakhri, G, 241(ab), 404(ab)
El Ghoneimy, A, 208(ab)
El-Deeb, HH, 14(ab)
Elfving, B, 930(ab)
Elgazzar, AH, 1357(ab), 1420(ab), 1422(ab)
El-Haddad, K, 1311(ab)
Elias, S, 197(ab)
Eliashiv, DS, 1001(ab)
Elkashef, A, 262(ab)
Ell, PJ, 477(ab), 733(ab), 935(ab), 953(ab), 954(ab)
Elliott, E, 111
Ellis, GK, 109(ab), 442(ab), 574(ab)
Ellis, RJ, 456(ab)
Eloot, S, 224(ab)
Elsaid, M, 1420(ab)
Elsamaloty, HM, 391(ab)
Elsamra, SE, 2089
Elsinga, PH, 96(ab), 1830
Elson, HR, 336(ab)
Ely, TD, 151(ab)
Embleton, MJ, 561(ab)
Emir, S, 1193(ab)
Emmett, L, 1415(ab)
Emond, P, 934(ab)
Endo, K, 337, 345, 1272(ab)
Endres, CJ, 522
Engel, A, 1243(ab)
Engel, JC, 286(ab)
Engelbach, JA, 798(ab)
Engels, R, 556
Enzweiler, CN, 47(ab)
Epelbaum, R, 274(ab), 557(ab), 1243(ab)
Epstein, AL, 355, 1129(ab)
Epstien, S, 772(ab)
Erbas, G, 207(ab)
Ercoli, LM, 248(ab)
Erdi, YE, 1234(ab)
Erdil, TY, 1163
Eriks-Fluks, E, 1153(ab)
Erion, JL, 120(ab), 439(ab), 440(ab), 1248(ab)
Erlandsson, K, 935(ab), 953(ab), 954(ab), 962(ab)
Ermert, J, 488(ab)
Ernst, N, 792(ab)
Erwin, WD, 15(ab), 55(ab), 113(ab), 115(ab), 388(ab), 526(ab), 1181(ab)
Esato, K, 510(ab), 511(ab)
Eschmann, SM, 333(ab), 445(ab)
Eshima, D, 1013(ab), 2077
Eshima, L, 2077
Eskandar, Y, 1231(ab)
Espenan, GD, 1256
Esposito, G, 496(ab), 497(ab), 755(ab), 925(ab)
Esser, PD, 519(ab)
Essner, R, 1239(ab)
Estalji, S, 533(ab)
Estes, J, 309(ab)
Estorch, M, 499(ab), 920(ab), 980(ab)
Etchebehere, EC, 996(ab), 1224(ab)
Eubank, WB, 109(ab), 574(ab)
Evander, E, 49(ab)
Evans, DG, 449
Evans, SM, 168(ab), 327
Everaert, H, 351(ab), 849(ab)
Ewbank, D, 252(ab)
Ezquerra, NF, 846(ab)
Ezzat, S, 18(ab)
Ezuddin, S, 1955

Faber, TL, 176(ab), 400(ab), 731(ab), 752(ab), 1308, 1941
Fagret, D, 141
Faintuch, BL, 1116(ab)
Faivre-Chauvet, A, 215(ab), 330(ab), 1041(ab)
Fakhri, GE, 1400
Falchi, A, 1259(ab)
Falllon, JT, 25(ab)
Fan, YM, 131(ab), 783(ab)
Fanti, S, 1247(ab)
Faraggi, M, 355(ab), 393, 567, 769(ab), 1274(ab)
Farboud, B, 300(ab)
Farde, L, 152(ab), 477(ab), 548(ab)
Fares, MA, 883
Farfaglia, R, 1227(ab)
Farncombe, TH, 864(ab), 894(ab)
Farnsworth, RH, 1030
Farquhar, TH, 745, 880(ab)
Fassotte, MF, 1154(ab)
Fasth, K-J, 1746
Faulhaber, PF, 456(ab), 457(ab), 776(ab)
Fauroux, B, 506(ab)
Fava, M, 899(ab)
Favero, A, 1006
Fawwaz, RA, 1283(ab), 1289(ab)
Fazel, A, 138(ab)
Fazio, F, 399(ab), 1702, 1849
Feeney, AJ, 538(ab)
Feggi, L, 62(ab)
Fehrm, A, 1203
Felder, C, 916(ab)
Feldman, LJ, 393
Feldmann, HJ, 270(ab), 272(ab)
Feliciano, GD, 1101(ab)
Felix, R, 137(ab)
Fendrick, AM, 434(ab)
Ferlin, G, 8(ab), 705(ab), 973
Fernando, J, 383
Ferrand, SK, 757(ab)
Ferrari, M, 1173(ab)
Ferretti, JA, 28(ab)
Ferry, G, 506(ab)
Fessler, JA, 870(ab)
Festa, A, 647
Fey, J, 282(ab)
Ficaro, EP, 246(ab), 762(ab), 763(ab), 765(ab), 870(ab), 948(ab)
Fielding, H, 184(ab)
Figlin, R, 461(ab)
Filmont, JE, 9(ab), 192(ab), 194(ab), 1398(ab)
Fimm, B, 914(ab)
Finco, C, 216(ab)
Fine, EJ, 1627
Fini, A, 705(ab)
Fink, D, 1281(ab), 1335(ab)
Finley, BR, 300(ab)
Finley, P, 478(ab)
Finn, RD, 314(ab), 316(ab), 323(ab), 493, 817(ab), 1158(ab), 1175(ab), 1905
Firestone, M, 1231(ab)
Fischer, A, 1076(ab)
Fischer, K, 1174(ab)
Fischer, M, 31(ab), 970(ab)
Fischer, S, 792(ab), 1402(ab)
Fischer, T, 1037(ab), 1108(ab), 1128(ab)
Fischer, U, 378(ab)
Fischman, AJ, 104(ab), 226(ab), 234(ab), 410(ab), 819(ab), 839(ab), 899(ab), 931(ab), 933(ab), 1067(ab), 1086, 1253(ab), 1376(ab), 1384(ab), 1424(ab), 1428(ab)
Fischman, MW, 416(ab)
Fiset, P, 926
Fishbein, MC, 345(ab)
Fisher, SJ, 82(ab), 450(ab), 1151(ab), 1155(ab), 2026
Fissekis, JD, 165(ab), 1038(ab), 1714
Fitzpatrick, JM, 500(ab)
Flamen, P, 124(ab)
Fleming, LM, 1098(ab)
Fletcher, JW, 126(ab), 138(ab)
Flores, JA, 250
Flores, LG, 111(ab), 268(ab)
Flotats, A, 499(ab), 980(ab)
Flower, MA, 825(ab)
Flux, GD, 825(ab)
Foa, P, 1276(ab)
Foehrenbach, H, 802(ab), 979(ab)
Fogelman, I, 1323(ab), 1324(ab), 1325(ab), 2015
Folks, RD, 731(ab), 752(ab), 1308, 1941
Foltin, R, 416(ab)
Fonti, R, 1261(ab)
Forssell-Aronsson, EB, 636
Forster, GJ, 444(ab)
Forstrom, LA, 934
Foster, NL, 246(ab)
Fourme, T, 16(ab), 768(ab), 769(ab), 770(ab), 782(ab)
Fowler, JS, 98(ab), 103(ab), 416(ab), 420(ab), 550(ab), 854(ab), 916(ab), 917(ab), 922(ab), 929(ab), 949(ab), 1352
Fox, PT, 66(ab)
Fragen, RJ, 55(ab)
Franceschi, D, 98(ab), 103(ab), 416(ab), 420(ab), 916(ab), 917(ab), 922(ab), 1352
Franceschi, G, 1191(ab)
Franceschi, M, 103(ab), 411(ab), 414(ab), 416(ab), 916(ab), 917(ab)
Francis, IR, 1579
Francis, RJ, 830(ab)
Francois, P, 1063(ab)
Frank, G, 1842
Frank, RK, 1044(ab)
Franke, WG, 166(ab), 280(ab), 907(ab), 992(ab), 1146(ab), 1167(ab), 1312(ab)
Franken, PR, 351(ab), 849(ab)
Frappaz, D, 1011(ab)
Frattarelli, M, 1191(ab)
Freedman, M, 1456
Freeman, LM, 514(ab)
Freimanis, RI, 112(ab), 814(ab)
Freimuth, P, 1026(ab)
Freitas, RS, 1100(ab)
French, JA, 987(ab)
Freneaux, E, 205(ab)
Frese, T, 875(ab)
Frey, EC, 389(ab), 502, 522(ab), 523(ab), 823(ab), 874(ab), 876(ab), 892(ab)
Frey, KA, 535(ab), 542(ab), 968(ab)
Fricke, H, 121(ab), 169(ab)
Friebe, M, 475(ab)
Friedel, G, 445(ab)
Friedman, JD, 4(ab), 177(ab), 737(ab), 1190
Friedman, MI, 767(ab), 1050(ab)
Friedman, NC, 725(ab)
Frielink, C, 563(ab)
Fritzberg, AR, 565(ab), 576(ab), 1033(ab), 1054(ab), 1148(ab), 1150(ab), 1152(ab)
Froelich, L, 919(ab)
Frohlich, DE, 269
Front, A, 1025
Front, D, 35(ab), 274(ab), 557(ab), 1243(ab)
Frost, JJ, 417(ab), 902(ab), 909(ab)
Frusciante, V, 1478
Frye, J, 816(ab)
Fu, X, 941(ab)
Fu, ZL, 131(ab), 341(ab)
Fuechtner, F, 166(ab)
Fujibayashi, Y, 301(ab), 455(ab), 798(ab), 938(ab), 958(ab)
Fujii, H, 1222(ab), 1223(ab), 1240(ab), 1268(ab)
Fujii, R, 1484, 2063
Fujii, S, 1313(ab)
Fujii, T, 1389(ab)
Fujikawa, Y, 1418(ab)
Fujimori, K, 1387(ab)
Fujino, K, 1237(ab)
Fujino, S, 360(ab), 727(ab)
Fujioka, H, 836(ab)
Fujioka, S, 712(ab)
Fujioka, Y, 1016(ab)
Fujisawa, T, 283
Fujishima, M, 975(ab)
Fujita, M, 97(ab), 1343, 1552
Fujita, T, 840(ab)
Fujiwara, H, 71
Fukuchi, K, 87(ab), 90(ab), 726(ab), 761(ab), 919, 1134, 1318
Fukuchi, M, 1418(ab), 2063
Fukuchi, T, 1134
Fukuda, H, 1561, 1612
Fukuhara, R, 1010(ab)
Fukui, A, 1389(ab)
Fukunaga, K, 411
Fukushima, K, 87(ab), 90(ab), 726(ab), 761(ab), 919, 993(ab), 1318
Fulton, RR, 239(ab)
Furey, ML, 575
Furudate, M, 502(ab)
Fuseau, C, 934(ab)
Fuselier, J, 133(ab)
Fussell, B, 543(ab)
Fuster, V, 25(ab)
Futami, S, 111(ab), 268(ab)
Futatsubashi, M, 1209(ab), 1318(ab)
Fuyibayashi, Y, 454(ab)
Fuzioka, M, 710(ab)
Fyfe, B, 500(ab)

Gabriel, JL, 1056
Gabruk-Szostak, B, 1037(ab)

Gabrys, J, 1673
Gadient, KR, 1105(ab)
Gaetz, WC, 981(ab)
Gaffga, CM, 133(ab)
Gage, BF, 800
Gage, HD, 413(ab), 832(ab), 2069
Gagnon, A, 19(ab), 21(ab), 714(ab)
Gagnon, JH, 1851
Gaidouk, M, 1108(ab)
Gail, R, 488(ab), 1068(ab)
Gaillard, JF, 802(ab), 821(ab), 979(ab)
Gaitini, D, 274(ab), 557(ab), 1243(ab)
Gali, H, 471(ab), 1079(ab)
Galla, A, 62(ab)
Gallino, F, 1491
Galt, JR, 151(ab)
Gambhir, SS, 146(ab), 147(ab), 228(ab), 277(ab), 289(ab), 295(ab), 317(ab), 321(ab), 392(ab), 428(ab), 430(ab), 432(ab), 1081(ab), 1098(ab), 1126(ab), 1177, 1232(ab), 1291(ab), 1303(ab)
Gambino, A, 8(ab)
Gamez, C, 556(ab)
Gann, T, 426(ab)
Gansbacher, B, 3(ab)
Gao, DW, 75(ab)
Gao, JH, 66(ab)
Garancini, S, 1935
Garces, N, 106(ab)
Garcia, A, 585(ab)
Garcia, EV, 176(ab), 752(ab), 846(ab), 1308, 1941
García, JR, 2038
García-Velloso, MJ, 439, 556(ab)
Gardin, I, 331(ab)
Garel, C, 208(ab)
Garg, P, 941(ab)
Garg, PK, 234
Gariépy, J, 429, 903
Garmestani, K, 1148(ab), 1149(ab), 1150(ab), 1152(ab)
Garre, S, 1208(ab)
Garty, B, 385(ab)
Garza, V, 929(ab), 949(ab)
Gaskill, M, 1281(ab)
Gasparini, MD, 1276(ab)
Gaston, RS, 1332
Gatley, SJ, 103(ab), 261(ab), 265(ab), 412(ab), 416(ab), 420(ab)
Gattegno, B, 78
Gautherot, E, 480
Gay, D, 750(ab)
Gebhardt, BM, 1256
Geisinger, KR, 112(ab), 814(ab)
Gemmell, HG, 1451
Genereau, T, 1808
Georges, B, 366(ab)
Georgi, P, 139(ab)
Georgiou, M, 1955
Georgiou, MF, 1037, 1813
Gerasimiov, MR, 411(ab)
Gerasimov, M, 103(ab)
Gerasimov, MR, 414(ab)
Gerlach, J, 177(ab), 720
Germadnik, D, 250
Germano, G, 4(ab), 177(ab), 348(ab), 712, 720, 728, 737(ab), 1190
Gerundini, P, 515(ab), 994(ab), 1276(ab), 1368(ab)
Getzenberg, RH, 1160(ab)
Geworski, L, 895(ab), 1233(ab)
Ghesani, M, 1050(ab)
Ghio, R, 1208(ab)
Gialafos, I, 703(ab)
Giannarelli, D, 647
Gibbons, RJ, 1383
Gibril, F, 1646
Gibson, RE, 1080(ab)
Giersing, BK, 159(ab), 1134(ab)
Gifford, AN, 261(ab), 265(ab), 412(ab)
Gifford, HC, 514, 1391
Giganti, M, 71(ab)
Gilardi, MC, 399(ab)
Gilbert, KL, 1619
Gilbride, M, 14(ab)
Gilland, DR, 692
Gillet, MO, 1184(ab)
Gimenez, M, 1278(ab)
Gimi, R, 98(ab)
Gimsing, P, 464(ab)
Giobbe, D, 982(ab)
Giordani, BJ, 535(ab)
Giovanella, L, 1935
Gipponi, M, 306(ab)
Gips, S, 1403(ab)
Giralt, S, 327(ab)
Girard, P, 1274(ab)
Girtler, N, 978(ab)
Giubbini, R, 305(ab), 494(ab), 732(ab), 1227(ab)
Giuliani, G, 1191(ab)
Giuliano, AE, 1682
Gjedde, A, 262(ab), 925(ab)
Glabe, AR, 1093(ab)
Glaser, RL, 573(ab)
Glass, EC, 1239(ab), 1682
Glatting, G, 119(ab), 310(ab), 531, 882(ab), 1058(ab), 1138(ab), 1145(ab)
Glenn, T, 243(ab)
Glennon, RA, 1069(ab)
Glick, SJ, 219(ab), 803(ab)
Gobar, LS, 1056(ab), 1109(ab), 1179(ab), 1180(ab)
Goddu, SM, 682, 941
Goeke, BJ, 31(ab)
Goerges, R, 1333(ab)
Goethals, I, 952(ab)
Goin, JE, 1673
Goins, BA, 857(ab), 1019(ab), 1390(ab)
Gokcora, N, 191(ab)
Goldberg, J, 970(ab)
Goldenberg, DM, 93, 117(ab), 118(ab), 213(ab), 312(ab), 313(ab), 473(ab), 566(ab), 1016, 1023(ab), 1055(ab), 1182(ab), 1185(ab), 1186(ab), 1210(ab), 1327(ab), 2089
Goldman, CK, 1152(ab)
Goldman, R, 289(ab)
Goldsmith, SJ, 279(ab), 311(ab), 315(ab), 466(ab), 562(ab), 1171(ab)
Goldstein, DS, 1215(ab)
Golish, SR, 392(ab)
Golubovic, E, 1433(ab)
Gomes, ML, 1100(ab)
Gomez-Peralta, F, 1278(ab)
Gonen, M, 282(ab), 1234(ab)
Gonzalez, P, 106(ab), 754(ab)
Gonzalez-Atavales, J, 987(ab)
Goodgold, HM, 126(ab)
Goodman, MM, 151(ab), 167(ab), 263(ab)
Goodman, SL, 564(ab)
Goodman, T, 449(ab)
Gordon, LI, 115(ab), 1112(ab), 1192(ab)
Gorelick, D, 417(ab)
Gorenberg, M, 1410(ab), 1412(ab)
Gorey, JG, 92(ab), 99(ab), 100(ab), 1069(ab)
Goris, ML, 513(ab)
Gorman, JM, 904(ab)
Gosalbez, R, 1432(ab)
Goswami, R, 201(ab)
Goto, S, 736(ab)
Gotthardt, M, 31(ab)
Gottschalk, A, 1049
Gottschild, D, 1242(ab)
Gouhier, C, 409(ab)
Govindan, R, 130(ab)
Govindan, SV, 566(ab), 2089
Gowda, S, 357(ab)
Goya, T, 1642
Goyal, A, 206(ab)
Grace, DM, 286(ab)
Gracias, SC, 1166(ab)
Graf, C, 834(ab)
Graham, MM, 269(ab), 970(ab), 1254(ab)
Grahek, D, 78, 1267(ab), 1308(ab), 1316(ab)
Gralow, JR, 108(ab), 109(ab), 442(ab), 574(ab)
Gramatzki, M, 117(ab)
Grant, SJ, 281(ab), 658
Gratz, S, 30(ab), 378(ab)
Graves, MW, 1104(ab), 1868
Graves, S, 131
Greco, M, 1491
Green, AJ, 830(ab)
Green, AM, 22(ab)
Green, LA, 228(ab), 321(ab)
Green, MA, 164(ab), 309, 1014(ab), 1032(ab), 1113(ab)
Green, MV, 74(ab)
Greenson, JK, 449(ab)
Greer, JP, 276(ab), 1207(ab)
Greer, PJ, 1842
Greiner-Bechert, L, 313(ab)
Gremillet, E, 393(ab), 717(ab)
Greten, F, 1138(ab)
Grierson, JR, 142(ab), 582(ab), 966(ab)
Griesinger, F, 117(ab)
Griffiths, GL, 473(ab), 566(ab), 1023(ab), 1186(ab), 2089
Grillo-Lopez, AJ, 113(ab), 115(ab)
Grimm, D, 1136(ab)
Grizio, J, 1107(ab)
Grizzle, WE, 318(ab), 887
Groch, MW, 15(ab), 55(ab), 388(ab), 526(ab), 1181(ab)
Grochowalski, DL, 344(ab)
Groen, HJ, 1199(ab)
Groiselle, C, 1801
Grollier, G, 9(ab), 194(ab), 845
Grönroos, T, 1980
Gropler, RJ, 344(ab), 798(ab)
Grosev, D, 1061(ab)
Groshar, D, 1025, 1410(ab), 1412(ab)
Gross, MD, 82(ab)
Grossman, AM, 779(ab)
Grossman, S, 1200(ab)
Grossman, Z, 465(ab)
Grosu, A, 270(ab), 272(ab)
Grotz, K-A, 444(ab)
Grubb, RL, 88(ab)
Grubb, RL, Jr, 800
Grucker, D, 375
Gruenauer, A, 308(ab)
Gruenwald, F, 350(ab), 919(ab)
Grunder, GM, 897(ab)
Grünwald, F, 1657, 1996
Grunwald, T, 960(ab)
Gualtieri, E, 878(ab)
Guaraldi, MT, 1142(ab)
Guarda, A, 909(ab)
Guazzelli, M, 575
Guerot, C, 196(ab)
Guerraty, A, 500(ab)
Guethlin, M, 701(ab)
Guhlke, S, 590(ab), 1124(ab), 1271
Guhlmann, AC, 294(ab), 1695
Guhlmann, CA, 310(ab), 1145(ab), 1297(ab)
Guiducci, G, 1191(ab)
Guillot, S, 393(ab)
Guilloteau, D, 409(ab), 934(ab)
Guiraud, R, 482(ab)
Gulec, SA, 133(ab), 1226(ab)
Gullberg, GT, 83(ab), 391(ab), 405(ab), 530(ab)
Gumerlock, PH, 567(ab)
Gungor, F, 1400(ab)
Gunn, JW, 1099(ab)
Gunn, RN, 538(ab), 605, 706
Gunning, WB, 419(ab)
Guo, N, 923(ab)
Guo, YF, 1306(ab)
Gupta, AK, 203(ab), 258(ab)
Gupta, NC, 298(ab), 299(ab), 505(ab), 890(ab), 1292(ab)
Gupta, S, 474, 1127(ab)
Guralnik, L, 274(ab), 1243(ab)
Gutmann, LM, 427(ab), 427(ab), 971(ab), 1002(ab)
Guy, MJ, 825(ab)

Haase, A, 558(ab), 1219(ab), 1290(ab)
Haase, U, 358(ab)
Haber, SB, 1973
Haberal, M, 1360(ab), 1386(ab)
Haberkorn, U, 23(ab), 559(ab), 1123(ab), 1136(ab), 1139(ab), 1266(ab)
Hachiya, T, 838(ab)
Hacker, M, 868(ab)
Hackett, MT, 1103(ab)
Hackman, T, 316(ab)
Hadji, S, 205(ab)
Hadley, J, 438(ab)
Hagege, A, 196(ab)
Hagen, R, 123(ab)
Hagge, RJ, 740(ab)
Hahn, J, 32(ab)
Hahn, K, 105(ab), 868(ab), 969(ab), 1004(ab), 1228(ab), 1823, 1989
Hahn, T, 465(ab)
Haigh, PI, 1239(ab), 1682
Haim, N, 274(ab), 557(ab), 1243(ab)
Hain, SF, 1323(ab), 1324(ab)
Hajjar, G, 93, 213(ab)
Ha-Kawa, SK, 54(ab)
Halaby, H, 215
Haldemann, AR, 577(ab), 1007(ab)
Halkar, RK, 400(ab), 731(ab)
Hallaj, I, 383(ab)
Halldin, C, 152(ab), 477(ab), 548(ab), 924(ab), 941(ab)
Hallett, WA, 1284(ab)
Halling, H, 64(ab), 73(ab)
Halls, SB, 570(ab)
Halvadijeva, E, 578(ab)
Ham, HR, 23, 198(ab), 366(ab)
Hamacher, KA, 323(ab), 533(ab), 556, 1176(ab)
Hamada, S, 702(ab)
Hamamoto, K, 1005(ab)
Hamberg, L, 1253(ab)
Hambÿe, ASE, 718(ab)
Hamill, T, 1080(ab)
Hamilton, TW, 765(ab)
Hamlin, DK, 474(ab)
Hammersley, PA, 1366(ab)
Hamon, M, 845
Hamouda, A, 1420(ab)
Hampson, R, 53(ab)
Han, G, 873(ab), 877(ab), 893(ab)
Han, JM, 1140(ab)
Han, MH, 1293(ab)
Handschuh, G, 1177(ab)
Hanke, H, 503(ab)
Hannequin, D, 421(ab)
Hannequin, P, 728
Hanrahan, SM, 1093(ab)
Hansen, HJ, 473(ab), 566(ab), 1023(ab), 1185(ab)
Hansen, L, 2077
Hansen, LK, 612, 1082(ab)
Hansen, NM, 1682
Hansen, PD, 1254(ab)
Hanson, MW, 740(ab), 1920
Hara, T, 1507
Harada, Y, 1561
Hardoff, R, 385(ab), 509(ab), 1771
Harel, F, 769(ab)
Hareyama, M, 1387(ab)
Harf, A, 506(ab)
Harmegnies, NF, 1414(ab)
Harper Mozley, LM, 541(ab)
Harris, AR, 1141(ab)
Harris, TS, 901(ab)
Harrop, R, 894(ab)
Hart, CL, 785(ab)
Hartman, S, 970(ab)

Hartsough, NE, 806(ab)
Hartwig, E, 1695
Harvey-White, J, 944(ab)
Hasebe, N, 766(ab)
Hasegawa, BH, 67(ab), 75(ab), 218(ab), 398(ab), 528(ab), 1287
Hasegawa, S, 20(ab), 180(ab), 713(ab), 742(ab), 795(ab), 1102, 1237(ab)
Haseley, DR, 492(ab)
Hashemi, SH, 636
Hashemzadeh-Gargari, H, 155(ab)
Hashikawa, K, 1237(ab)
Hashimoto, D, 383
Hashimoto, J, 1222(ab), 1223(ab)
Hashimoto, K, 1102
Hashimoto, T, 549(ab), 946(ab), 947(ab)
Hatada, K, 702(ab)
Hatazawa, J, 552(ab), 950(ab)
Hatori, T, 720(ab), 721(ab), 759(ab)
Hattner, RS, 1287
Hattori, N, 7(ab), 293
Haubner, R, 3(ab), 160(ab), 162(ab)
Haufe, S, 1369(ab)
Hauk, M, 36
Haut, MW, 427(ab)
Hautmann, RE, 294(ab)
Hautzel, H, 1250
Havlik, E, 250
Hawighorst, H, 1266(ab)
Hawkins, RA, 398(ab), 1358(ab)
Hawkins, RE, 561(ab)
Hayafune, N, 736(ab)
Hayashi, H, 748(ab)
Hayashi, K, 1405(ab)
Hayashida, K, 87(ab), 90(ab), 761(ab), 919, 993(ab), 1318
Hayes, SW, 177(ab), 737(ab)
Haynes, NG, 309
Hays, SR, 939(ab)
Hayward, RM, 1254(ab)
Hazra, DK, 561(ab)
He, Z-X, 1299
Heald, DL, 1413(ab), 1603
Healey, C, 304(ab)
Heaton, N, 53(ab)
Heiba, S, 1230(ab), 1348(ab), 1422(ab)
Heichel, T, 1256(ab), 1322(ab)
Heifetz, L, 1218(ab)
Heindel, W, 267(ab)
Heinz, A, 537(ab), 918(ab)
Heiss, D, 868(ab)
Helal, BO, 16(ab), 768(ab), 769(ab), 770(ab), 782(ab), 799(ab)
Helft, G, 25(ab)
Heller, EN, 715(ab)
Hellman, RS, 1086(ab)
Heminway, S, 132(ab)
Hendel, RC, 15(ab), 179(ab)
Hendler, AL, 429, 903, 1673
Hendrikse, HN, 1830
Hendrikse, NH, 260(ab), 1153(ab)
Hendrix, G, 1112(ab)
Hene, RJ, 369(ab)
Henneken, H, 790(ab), 1587
Henriguez, J, 772(ab)
Henriksen, G, 1115(ab)
Henze, E, 42(ab), 377(ab), 1042(ab), 1114(ab), 1187(ab), 1429(ab)
Henze, M, 559(ab), 1139(ab), 1266(ab)
Herbel, A, 137(ab)
Herbst, R, 127(ab)
Hernandez, JL, 556(ab)
Hernandez Pampaloni, M, 11(ab), 170(ab), 345(ab), 764(ab)
Herregods, MC, 775(ab)
Herrero, P, 344(ab), 798(ab)
Herschman, HR, 146(ab), 147(ab), 228(ab), 289(ab), 317(ab), 321(ab)
Herscovitch, P, 334(ab), 944(ab)
Herskovic, T, 93
Hertel, A, 350(ab), 919(ab)
Herz, M, 272(ab), 452(ab), 1279
Herzog, HR, 64(ab), 73(ab), 533(ab), 928(ab)
Hesse, B, 171(ab), 464(ab)
Hesse, S, 139(ab)
Hewitt, T, 1426
Heymer, B, 1695
Hichwa, RD, 223(ab), 1288(ab)
Hicks, RJ, 296(ab), 431(ab)
Hiddemann, W, 117(ab)
Higashi, K, 85, 973(ab), 1295(ab)
Higashi, T, 82(ab), 450(ab), 1155(ab), 1381(ab), 2026
Higashino, H, 728(ab)
Higginbotham, C, 1013(ab)
Higgins, E, 304(ab)
Higuchi, T, 193(ab), 374(ab), 390(ab), 727(ab), 738(ab), 1151(ab), 1272(ab), 1313(ab), 1321(ab)
Hikosaka, K, 1131(ab)
Hill, J, 43(ab)
Hill, RP, 429
Hillali, Y, 1801
Hillier, S, 839(ab), 1067(ab)
Hilson, AJ, 110(ab), 199(ab), 448(ab), 463(ab), 572(ab), 883(ab), 1172(ab), 1258(ab), 1311(ab), 1346(ab)
Hilton, J, 478(ab), 1361(ab)
Hiltunen, J, 477(ab)
Hines, H, 383
Hirai, M, 744(ab)
Hirakata, H, 975(ab)
Hiramatsu, T, 1189(ab), 1244
Hirasawa, K, 502(ab)
Hirata, K, 830
Hirata, M, 1389(ab)
Hiroi, T, 12(ab), 760(ab)
Hirokawa, N, 1387(ab)
Hitzel, A, 209(ab)
Hitzemann, R, 416(ab), 420(ab), 916(ab), 917(ab), 922(ab)
Hlawitschka, M, 1312(ab)
Hliscs, R, 1167(ab)
Hnatowich, DJ, 128(ab), 363, 486(ab), 586(ab), 788(ab), 1028(ab), 1092(ab), 1097(ab), 1127(ab)
Ho, Y-J, 1969
Hobbs, G, 1292(ab)
Hochhauser, D, 1172(ab)
Hocke, C, 1068(ab)
Hoda, S, 1358(ab)
Hodgson, N, 286(ab)
Hoefnagel, CA, 1229(ab), 1500
Hoekstra, A, 1040(ab)
Hoekstra, CJ, 1279(ab)
Hoekstra, OS, 1216(ab), 1279(ab), 1328(ab)
Hoer, G, 350(ab), 919(ab)
Hoess, B, 267(ab)
Hoeven, JJ, 1216(ab)
Hoff, M, 1341(ab)
Hoffend, J, 23(ab)
Hoffman, EJ, 220(ab), 745, 880(ab)
Hoffman, JM, 247(ab), 263(ab), 1920
Hoffman, TJ, 471(ab), 1013(ab), 1079(ab)
Hofland, LJ, 435(ab)
Hofmann, M, 121(ab)
Hogg, A, 296(ab), 431(ab)
Hoh, CK, 394(ab), 461(ab)
Hoher, M, 503(ab)
Holdsworth, CH, 880(ab)
Hollema, H, 1244(ab)
Holliday, RL, 286(ab)
Holloway, B, 110(ab), 572(ab), 1258(ab)
Holm, S, 959(ab), 1363(ab)
Holschbach, M, 1068(ab), 1250
Holst, H, 49(ab)
Holthoff, V, 907(ab)
Holubarsch, C, 790(ab), 1587
Hombach, V, 503(ab)
Homma, Y, 1072(ab)
Hommer, D, 537(ab), 918(ab)
Honda, N, 86(ab), 424(ab), 747(ab), 756(ab), 758(ab), 1393(ab), 1406(ab), 1407(ab)
Hondo, M, 1393(ab)
Hong, ES, 342(ab), 363(ab)
Hong, MK, 1122(ab), 1338(ab)
Hong, SW, 1059(ab), 1301(ab), 1309(ab)
Honnorat, J, 1011(ab), 1286(ab)
Hook, L, 869(ab)
Hopper, W, 1235(ab)
Hordijk, GJ, 1252(ab)
Horie, T, 736(ab)
Horii, H, 1484
Horita, Y, 993(ab)
Horn, M, 1429(ab)
Hornick, CA, 1256
Hornick, JL, 355
Horwitz, B, 575
Hosaka, K, 976(ab)
Hoshizaki, H, 12(ab), 720(ab), 721(ab), 759(ab), 760(ab)
Hoskinson, ME, 1094(ab)
Hosono, M, 86(ab), 424(ab), 747(ab), 756(ab), 758(ab), 1393(ab), 1406(ab), 1407(ab)
Hosoya, T, 421
Hospers, GAP, 1157(ab)
Hossfeld, DK, 1205(ab)
Hosten, N, 137(ab)
Hostetler, ED, 1017(ab)
Hott, BJ, 731(ab)
Hou, C, 150(ab), 1065(ab), 1066(ab)
Houck, PR, 1842
Houle, AM, 210(ab)
Houle, S, 149(ab), 585(ab), 932(ab), 981(ab), 1673
Houlihan, MJ, 1973
Hovda, D, 243(ab)
Hove, JD, 392(ab)
Howel, LL, 263(ab)
Howell, RW, 189, 682, 941, 2043
Howman-Giles, RB, 204(ab), 986
Hoyt, G, 1(ab)
Hsieh, J-F, 1892, 1969
Hsu, CH, 1350(ab)
Hsu, JL, 986(ab)
Hsu, PI, 1380(ab)
Hsueh, EC, 1239(ab)
Hsueh, WA, 170(ab)
Hu, J, 794(ab)
Hu, P, 355, 1129(ab)
Hu, W, 5
Hua, C, 68(ab), 76(ab)
Huang, AT, 1392(ab)
Huang, CC, 230(ab)
Huang, F-C, 1209
Huang, G, 2(ab), 800(ab)
Huang, H, 549(ab)
Huang, SC, 243(ab), 395(ab), 851(ab), 867(ab), 1246(ab)
Huang, WS, 783(ab)
Huang, Y, 923(ab), 947(ab), 1070(ab)
Hubbs, AF, 505(ab)
Hubner, KF, 291, 459(ab), 1664
Hudkins, K, 859(ab)
Hudson, SL, 1332
Huebner, RH, 1177
Huefner, M, 30(ab)
Huesman, MK, 1093(ab)
Huesman, RH, 70(ab), 79(ab)
Hughes, RA, 1324(ab)
Hughey, S, 1256
Huguelet, P, 535(ab)
Huijgens, PC, 1216(ab), 1999
Hulette, C, 1920
Humbert, M, 16(ab), 768(ab), 782(ab)
Humeres, P, 754(ab)
Humm, JL, 493, 538, 817(ab), 1082, 1905
Hummel, S, 269(ab)
Hung, JC, 934, 1052(ab), 1105(ab)
Hung, JC, 9N(9)
Hungspreugs, P, 236(ab)
Hunt, S, 589(ab)
Hunter, G, 1253(ab)
Huo, L, 482(ab)
Hur, MG, 1135(ab)
Hurless, LM, 1104(ab)
Hussain, SA, 248(ab)
Hussey, D, 932(ab)
Hustinx, R, 327, 818(ab), 1154(ab), 1159(ab)
Hutchings, M, 1363(ab)
Hutchins, GD, 875(ab)
Hutchinson, RJ, 379(ab)
Hutton, BF, 239(ab)
Hwang, DR, 102(ab), 415(ab), 549(ab), 904(ab), 923(ab), 946(ab), 947(ab), 1070(ab), 1465
Hwang, EH, 193(ab), 727(ab)
Hwang, FL, 1102(ab)
Hwang, JH, 1225(ab)
Hwang, JJ, 1102(ab)
Hwang, KH, 554(ab), 777(ab), 1045(ab), 1060(ab), 1217(ab), 1293(ab), 1430(ab), 1434(ab)
Hwang, SC, 52(ab), 1293(ab)
Hyde, TM, 99(ab)
Hyun, IY, 342(ab), 363(ab), 493(ab)
Hyun, JW, 1047(ab)

Ibanez, V, 834(ab)
Ibarrola, D, 1063(ab)
Ibbotson, M, 14(ab)
Ibrahim, T, 701(ab)
Ibsen, H, 171(ab)
Ichihara, K, 1287(ab)
Ichihara, T, 501(ab), 748(ab)
Ichikawa, A, 1272(ab)
Ichikawa, T, 710(ab)
Ichiki, T, 590
Ichimura, K, 1387(ab)
Ichise, M, 833(ab), 1024(ab), 1456
Ide, M, 1240(ab), 1268(ab)
Ido, A, 75(ab)
Ido, T, 1377(ab), 1484, 2063
Iida, H, 173(ab), 552(ab), 838(ab), 841(ab), 950(ab), 1737
Iida, I, 889(ab)
Iizuka, H, 973(ab)
Ikeda, M, 1010(ab)
Ikeda, T, 1223(ab)
Ikezoe, J, 89(ab), 590, 836(ab), 1005(ab), 1010(ab), 1389(ab)
Ilic, S, 1370(ab), 1433(ab)
Im, KC, 810(ab), 888(ab)
Imabayashi, E, 963(ab)
Imahashi, K, 1102
Imahori, Y, 1484, 2063
Imai, K, 736(ab)
Imamura, M, 1381(ab)
Imbriaco, M, 1264(ab)
Imran, H, 339(ab)
Inagaki, K, 1507
Innes, G, 1214
Innis, RB, 97(ab), 148(ab), 234, 543(ab), 544(ab), 941(ab), 985(ab), 1343, 1552
Inoue, K, 728(ab)
Inoue, M, 791(ab)
Inoue, T, 337, 759(ab), 836(ab), 1075(ab), 1272(ab)
Inoue, Y, 551(ab), 823, 1947
Intenzo, CM, 1416(ab)
Inubushi, M, 87(ab), 293, 726(ab), 761(ab)
Iqbal, A, 339(ab)
Irwig, L, 986
Irwin, AG, 199(ab), 1346(ab)
Isacson, O, 407(ab)
Iseda, T, 1642
Ishibashi, K, 600
Ishida, S, 791(ab)
Ishida, Y, 726(ab), 761(ab), 919, 1127, 1318
Ishigaki, T, 744(ab)
Ishii, K, 397(ab), 926(ab), 948(ab), 976(ab), 1008(ab), 1612
Ishii, S, 1072(ab)
Ishikawa, K, 736(ab), 965

Ishikawa, Y, 50(ab), 51(ab), 365(ab), 766(ab), 1031(ab), 1405(ab)
Ishimaru, Y, 836(ab)
Ishimori, T, 1144(ab), 1190(ab), 1313(ab), 1381(ab), 1898
Ishiwata, K, 345, 1072(ab)
Ishizaki, A, 50(ab), 51(ab)
Ishizu, K, 173(ab), 301(ab), 840(ab)
Iskandrian, AE, 1299
Isobe, S, 744(ab)
Israel, O, 28N(4), 35(ab), 274(ab), 557(ab), 1243(ab)
Ito, H, 548(ab), 552(ab), 950(ab)
Ito, T, 728(ab)
Ito, Y, 600
Itoh, H, 977(ab), 1012(ab), 1364(ab)
Itoh, M, 1377(ab)
Itoh, Y, 352(ab), 354(ab)
Itti, E, 491(ab), 506(ab)
Itti, R, 17N(11)
Ivancevic, V, 284(ab), 1233(ab)
Iwanczyk, JS, 220(ab)
Iwasaka, T, 702(ab)
Iwasaki, R, 1223(ab)
Iwasaki, T, 720(ab), 721(ab), 759(ab), 1418(ab)
Iwata, K, 67(ab), 218(ab)
Iwata, Y, 1298(ab), 1299(ab), 1378(ab), 1379(ab), 1391(ab), 1394(ab)
Iyer, M, 289(ab), 317(ab), 1126(ab)
Izawa, H, 744(ab)
Izhaki, A, 716(ab)
Izumi, T, 795(ab)

Jackson, LE, 1156(ab), 1753
Jacob, JS, 236(ab)
Jacobs, MP, 573(ab)
Jacobsen, JM, 853(ab)
Jacobson, AF, 189(ab), 492(ab), 1325(ab)
Jadvar, H, 819(ab)
Jaeger, BR, 172(ab)
Jaekel, C, 42(ab)
Jaenicke, S, 1275(ab)
Jager, GJ, 136(ab)
Jager, PL, 353(ab), 356(ab), 1793
Jagoda, E, 153(ab), 154(ab), 479(ab)
Jagust, WJ, 247(ab)
Jain, D, 185(ab), 741(ab)
Jamar, F, 370(ab), 436(ab), 437(ab), 438(ab), 1143(ab)
Jan, H, 14(ab)
Jana, S, 1230(ab), 1348(ab)
Jang, JJ, 1338(ab)
Jang, JS, 1045(ab), 1060(ab)
Jang, MJ, 386(ab), 751(ab), 781(ab)
Jang, S, 991(ab), 1196(ab)
Jang, SY, 1236(ab)
Janier, MF, 771(ab), 1286(ab)
Janisse, J, 1227
Janowitz, WR, 337(ab)
Jansen, L, 302(ab), 1229(ab), 1500
Jansen, P, 1250
Janson, ET, 1514
Janssen, MLH, 129(ab)
Janssens, J, 1168(ab)
Jao, GH, 1359(ab)
Jarritt, P, 842(ab)
Jarritt, PH, 733(ab)
Jarund, A, 49(ab)
Jaszczak, RJ, 502
Jay, V, 981(ab)
Jayet, PY, 1184(ab)
Jen, TK, 1211(ab)
Jenkins, BG, 407(ab)
Jenkins, RM, 1973
Jenkins, WT, 168(ab), 327
Jennings, D, 544(ab)
Jensen, M, 853(ab), 959(ab), 1015(ab), 1363(ab)
Jensen, RT, 1646
Jentzen, W, 837(ab)
Jeon, TJ, 384(ab), 913(ab)
Jeong, HJ, 26(ab), 797(ab), 1000(ab), 1033(ab)
Jeong, HW, 271(ab)
Jeong, JM, 373(ab), 789(ab), 1130(ab), 1132(ab)
Jeong, MH, 26(ab), 797(ab)
Jerin, J, 1369
Jerusalem, G, 1154(ab)
Jewett, DM, 266(ab), 539(ab)
Jian, JJ, 1315(ab)
Jiang, S, 1136(ab), 1139(ab)
Jimenez, H, 1013(ab)
Jimenez-Hoyuela, JM, 1139
Jin, YP, 519(ab)
Jindal, SK, 1367(ab)
Jinnouchi, S, 111(ab), 268(ab)
Jivan, S, 1078(ab)
Joerg, L, 308(ab), 375(ab)
Jofre, J, 754(ab)
Joh, CW, 1045(ab), 1060(ab)
Johannsen, B, 475(ab)
John, CS, 1020(ab)
Johnson, G, 784(ab), 785(ab)
Johnson, LL, 1237, 1535
Johnson, MR, 1324(ab)
Johnson, TK, 807(ab)
Jokisch, DW, 326(ab)
Jomura, H, 1298(ab), 1299(ab)
Jonard, P, 437(ab), 438(ab), 1143(ab)
Jonczyk, A, 564(ab)
Jones, A, 1260(ab)
Jones, AG, 475(ab)
Jones, AL, 448(ab)
Jones, DW, 92(ab), 99(ab), 100(ab), 537(ab), 1069(ab)
Jones, LA, 454(ab), 565(ab)
Jones, RM, 1535
Jones, T, 605, 706, 827(ab)
Jones, W, 78(ab)
Jones, WB, 1142(ab)
Jong, IJ, 293(ab)
Jonkhoff, AR, 1216(ab)
Jonsson, L, 860(ab), 1039(ab)
Jonsson, V, 464(ab)
Jorge, CL, 255(ab)
Joseph, K, 31(ab)
Joshua, AV, 288(ab)
Joska, TM, 741(ab)
Joung, J, 1714
Jouvet, A, 1011(ab)
Judy, PF, 1391
Jueptner, M, 553(ab)
Juhasz, C, 245(ab)
Juhlin, C, 275
Julin, P, 423(ab)
Jungbluth, A, 1905
Junkermann, H, 1266(ab)
Jurcic, JG, 323(ab)
Jurisson, SS, 161(ab), 1084(ab)
Juweid, ME, 93, 118(ab), 213(ab), 312(ab), 328(ab), 566(ab), 1055(ab), 1210(ab), 1327(ab)
Jyrkkiö, S, 1980

Kaasinen, V, 65
Kabasakal, L, 1163
Kachaner, J, 10(ab), 400
Kachur, AV, 168(ab), 327
Kadkade, PP, 1287
Kado, H, 1012(ab)
Kadrmas, DJ, 391(ab), 525(ab), 813(ab), 886(ab)
Kagaya, Y, 2063
Kailasnath, P, 787(ab)
Kaiser, HJ, 174(ab), 237(ab), 347(ab), 774(ab), 914(ab)
Kakeshita, K, 973(ab)
Kakiuchi, T, 1409
Kalen, JD, 831(ab)
Kalff, V, 296(ab), 431(ab)
Kalifa, G, 205(ab)
Kalifa, JE, 519(ab)
Kalinowska, W, 1495
Kalinowski, E, 107
Kallinowski, F, 1369(ab)
Kallisvaart, J, 1194(ab)
Kalmar, A, 843(ab)
Kameda, K, 367(ab)
Kaminski, MS, 114(ab), 309(ab), 325(ab), 999, 1579
Kamoto, Y, 840(ab)
Kamp, O, 338(ab)
Kampen, AM, 377(ab)
Kampen, WU, 42(ab), 377(ab), 1042(ab), 1114(ab), 1187(ab), 1429(ab)
Kamran, M, 15(ab), 176(ab), 364(ab), 767(ab)
Kanatsuna, T, 1484
Kanayama, S, 360(ab)
Kandlhofer, S, 36
Kaneko, A, 1777
Kaneko, S, 365(ab)
Kaneko, Y, 1947
Kanemitsu, S, 360(ab)
Kang, DY, 54(ab), 495(ab), 1212(ab), 1285(ab)
Kang, HJ, 1000(ab), 1045(ab)
Kang, JC, 26(ab), 797(ab)
Kang, KW, 65(ab), 254(ab), 343(ab), 386(ab), 751(ab), 781(ab), 961(ab), 983(ab), 998(ab)
Kang, WC, 202(ab)
Kang, X, 720
Kang, YM, 54(ab)
Kanmaz, B, 1163
Kanno, I, 889(ab), 950(ab)
Kanno, T, 1209(ab), 1318(ab)
Kanz, L, 278(ab)
Kao, AW, 469(ab), 1218(ab)
Kao, C-H, 1969
Kao, C-HK, 1033(ab)
Kao, CK, 755
Kao, C-M, 822(ab)
Kao, P-F, 994
Kao, T, 862(ab)
Kapucu, OL, 207(ab), 1349(ab)
Kapustin, Z, 197(ab)
Karabacak, NI, 191(ab)
Karacay, H, 473(ab), 1023(ab), 1185(ab), 1186(ab)
Karakayali, H, 1386(ab)
Karam-Hage, M, 539(ab)
Karamychev, VN, 1093
Karayalcin, G, 380(ab), 382(ab)
Karila-Cohen, D, 355(ab), 393
Karlsson, P, 477(ab)
Karonen, JO, 788
Karp, JS, 81(ab), 327, 1159(ab)
Karpman, H, 11
Karstens, JH, 1307(ab)
Karvelis, KC, 1200(ab)
Kasagi, K, 1214(ab)
Kasai, S, 50(ab), 51(ab)
Kasai, T, 710(ab)
Kasama, S, 720(ab), 721(ab), 759(ab)
Kasanuki, H, 704(ab)
Kashimada, A, 86(ab), 756(ab), 758(ab), 1393(ab), 1406(ab), 1407(ab)
Kashiwagi, T, 600
Kassing, WM, 336(ab)
Kassis, AI, 1204(ab), 1519, 1545
Kastin, A, 1025
Kastrati, A, 753(ab)
Katafuchi, T, 1318
Katamihardja, AH, 40(ab)
Katayama, K, 600
Katayama, M, 1009(ab)
Katayama, N, 823
Kates, AM, 344(ab)
Kato, K, 744(ab)
Kato, T, 747(ab), 1131(ab), 1300(ab), 1326(ab)
Kato-Azuma, M, 1102
Katoh, C, 186(ab), 352(ab), 354(ab), 403(ab), 584(ab), 847(ab), 1300(ab), 1326(ab)
Katou, S, 710(ab)
Katti, KV, 1079(ab)
Katz, R, 197(ab)
Katzellenbogen, JA, 148(ab)
Kaufmann, CC, 117(ab), 287(ab)
Kauppinen, T, 2051
Kavanagh, PB, 177(ab), 712, 720, 1190
Kavitha, NR, 905(ab)
Kawagoe NM Study Group, 424(ab)
Kawaguchi, R,
Kawaguchi, R, 12(ab), 760(ab)
Kawai, K, 111(ab), 268(ab)
Kawai, Y, 743(ab)
Kawakami, H, 728(ab)
Kawamura, K, 1072(ab)
Kawano, M, 390(ab), 738(ab)
Kawashima, A, 1244
Kayayan, R, 383
Kaye, WH, 1842
Ke, CY, 1032(ab)
Keane, MJ, 505(ab)
Kegeles, LS, 102(ab), 903(ab), 1070(ab), 1465
Kehoe, KM, 269
Kehren, F, 64(ab)
Keidar, Z, 35(ab), 274(ab), 1243(ab)
Keilp, J, 903(ab)
Kelepesis, G, 703(ab)
Kellar, KJ, 478(ab)
Kelly, C, 500(ab)
Kema, IP, 1793
Kemna, L, 928(ab)
Kemp, BJ, 1569
Kempf, JS, 1353(ab)
Kempski, O, 936(ab)
Kenemans, P, 1168
Keng, FY, 764(ab)
Kent, JM, 904(ab), 946(ab)
Kepe, V, 95(ab)
Keppens, J, 408(ab)
Kerenyi, L, 546(ab), 1080(ab), 1362(ab)
Kerich, M, 918(ab)
Kerner, MM, 969(ab), 1004(ab)
Kernstine, KH, 1288(ab)
Kerrou, K, 78, 1267(ab), 1308(ab), 1316(ab)
Kertesz, A, 1569
Kerwin, RW, 935(ab), 954(ab)
Kessler, H, 157(ab), 160(ab), 162(ab)
Ketring, AR, 1084(ab)
Ketteler, S, 956(ab)
Kettle, AG, 1202(ab)
Kettner, BI, 47(ab), 284(ab), 507(ab), 1233(ab), 1344(ab), 1402(ab)
Khalkhali, I, 235(ab), 1973
Khandekhar, SP, 178(ab)
Khanvali, B, 878(ab)
Khaw, BA, 188(ab), 711(ab), 785(ab), 1535
Khawli, LA, 355, 1129(ab)
Kiarash, R, 429, 903
Kiefer, CR, 788(ab)
Kiefer, VH, 57
Kies, P, 707(ab)
Kiesewetter, DO, 479(ab), 1020(ab)
Kihara, K, 745(ab)
Kijewski, MF, 241(ab), 404(ab), 819(ab)
Kikuchi, K, 365(ab), 766(ab)
Kikuchi, T, 89(ab), 1005(ab), 1010(ab)
Kikukawa, K, 1009(ab)
Kilbourn, MR, 266(ab), 480(ab), 535(ab), 539(ab), 542(ab), 942(ab)
Kilts, CD, 151(ab), 263(ab)
Kim, BG, 1309(ab)
Kim, BI, 1059(ab), 1301(ab)
Kim, BK, 1130(ab), 1132(ab), 1338(ab)
Kim, BT, 6(ab), 447(ab), 730(ab), 808, 810(ab), 888(ab), 955(ab), 1073(ab), 1225(ab), 1265(ab), 1296(ab), 1395(ab)
Kim, BY, 1385(ab)
Kim, C-G, 1245(ab)
Kim, CH, 1285(ab)
Kim, CK, 1231(ab)
Kim, C-S, 961(ab)

Kim, DH, 1073(ab)
Kim, DI, 913(ab), 1225(ab), 1263(ab)
Kim, EE, 127(ab), 337, 1027(ab), 1051(ab), 1075(ab), 1147(ab), 1201(ab), 1245(ab)
Kim, EH, 797(ab)
Kim, ES, 52(ab), 91(ab), 202(ab), 1423(ab)
Kim, GE, 1164(ab), 1836
Kim, HC, 1217(ab)
Kim, HM, 368(ab)
Kim, HS, 28(ab), 504(ab), 1045(ab), 1217(ab)
Kim, IJ, 568(ab), 569(ab), 1257(ab), 1352(ab)
Kim, I-O, 983(ab)
Kim, JH, 810(ab), 888(ab), 1309(ab)
Kim, JJ, 808
Kim, JS, 52(ab), 91(ab), 1374(ab), 1423(ab), 1836
Kim, JW, 961(ab)
Kim, JY, 1000(ab)
Kim, K, 1112(ab)
Kim, KM, 838(ab), 841(ab), 845(ab), 852
Kim, KS, 202(ab)
Kim, MK, 755, 1093, 1430(ab)
Kim, NH, 797(ab)
Kim, S, 554(ab), 777(ab), 1045(ab), 1060(ab), 1217(ab), 1293(ab), 1430(ab), 1434(ab)
Kim, SE, 6(ab), 342(ab), 363(ab), 416, 730(ab), 808, 810(ab), 888(ab), 955(ab), 1073(ab), 1225(ab), 1265(ab), 1296(ab), 1395(ab)
Kim, SH, 253(ab), 254(ab), 368(ab), 371(ab), 1408(ab), 1426(ab)
Kim, SJ, 568(ab), 569(ab), 1257(ab), 1352(ab)
Kim, SK, 65(ab), 183(ab), 254(ab), 271(ab), 386(ab), 387(ab), 789(ab), 961(ab), 983(ab)
Kim, SM, 1000(ab), 1416(ab)
Kim, SP, 235(ab)
Kim, SW, 1135(ab)
Kim, YJ, 789(ab)
Kim, YK, 271(ab), 568(ab), 569(ab), 1257(ab), 1352(ab)
Kim, YM, 1045(ab), 1060(ab)
Kimura, H, 1357
Kimura, K, 87(ab)
Kimura, Y, 397(ab), 1777
Kinahan, PE, 402(ab), 1369
King, LD, 831(ab)
King, MA, 514, 872(ab), 1391, 1425(ab)
Kingdon, EJ, 199(ab)
Kinney, C, 422(ab)
Kinney, MC, 276(ab), 1207(ab)
Kino, S, 50(ab)
Kinoshita, T, 552(ab), 950(ab)
Kinuya, K, 1383(ab)
Kinuya, S, 374(ab), 1183(ab), 1188(ab), 1189(ab), 1244, 1383(ab)
Kipper, M, 1355(ab)
Kipper, SL, 36(ab), 38(ab), 39(ab), 60(ab), 449
Kirac, S, 1436
Kirch, DL, 807(ab)
Kiriakidis, M, 703(ab)
Kiriakogonas, S, 703(ab)
Kirkman, E, 1038(ab)
Kirsch, CM, 936(ab)
Kishibe, Y, 957(ab)
Kison, PV, 82(ab), 309(ab), 999
Kitabatake, A, 352(ab), 354(ab)
Kitagawa, K, 501(ab)
Kitagawa, Y, 1222(ab), 1223(ab)
Kitajima, M, 1222(ab), 1223(ab)
Kitamura, K, 838(ab), 889(ab), 1737
Kitayama, M, 360(ab)
Kitsiou, AN, 729(ab)
Kitsukawa, S, 763
Kiziloglu, ZN, 95(ab)
Kjellen, E, 1198(ab)
Klecker, RW, 1160(ab)
Klein, D, 926
Klein Gebbinck, JW, 1022(ab)
Klein, GJ, 79(ab)
Klein, JL, 752(ab), 1056(ab)
Klein, LJ, 231(ab), 338(ab), 346(ab)
Kleinman, D, 263
Kleinschmidt, J, 1136(ab)
Kleinschmidt, K, 294(ab)
Klemm, E, 960(ab)
Klepper, J, 837(ab)
Kletter, K, 1304(ab), 1339(ab)
Klieger, PS, 1198
Klimke, A, 533(ab)
Klingelhoefer, J, 914(ab)
Klipper, R, 857(ab), 1019(ab), 1390(ab)
Klok, RP, 1022(ab)
Klonecke, A, 36(ab)
Kluge, R, 139(ab)
Kluizenaar, M, 231(ab)
Klutmann, S, 429(ab), 816, 1317(ab)
Knable, MB, 92(ab), 99(ab), 100(ab)
Knapp, FF, 93(ab), 588(ab), 1167(ab), 1202(ab)
Knapp, FF, Jr, 1271
Knapp, WH, 121(ab), 169(ab), 212(ab), 895(ab), 1006(ab), 1307(ab)
Knapstein, PG, 458(ab)
Knešaurek, K, 527(ab), 896(ab)
Knesewitsch, P, 1989
Knickmeier, M, 190(ab), 707(ab)
Knight, CJ, 199(ab)
Knight, LC, 1056
Knoll, P, 881(ab)
Knoop, BO, 895(ab)
Knopp, M, 1266(ab)
Knudsen, GM, 930(ab)
Ko, YY, 1060(ab)
Kobayashi, H, 318, 704(ab), 755, 1144(ab), 1287(ab), 1898
Kobayashi, J, 761(ab)
Kobayashi, K, 1183(ab), 1188(ab)
Kobayashi, M, 1209(ab)
Kobayashi, S, 367(ab)
Kobayashi, T, 502(ab)
Koch, CJ, 168(ab), 327
Koch, L, 441(ab)
Kochan, LD, 102(ab)
Kocoshis, SA, 206(ab)
Kodama, Y, 1295(ab)
Koehn, H, 881(ab)
Koelbl, H, 1133(ab)
Koenders, EB, 1088(ab)
Koenemann, S, 937(ab)
Koenig, B, 1365(ab)
Koeppe, RA, 266(ab), 535(ab), 539(ab), 542(ab), 968(ab)
Koerfer, R, 790(ab)
Koëter, GH, 1199(ab)
Koga, S, 1009(ab)
Kogure, D, 1155
Koh, JH, 1045(ab)
Kohlmyer, SG, 72(ab)
Kohsaka, T, 823
Kohya, T, 352(ab), 354(ab)
Koitabash, N, 760(ab)
Koitabashi, N, 12(ab)
Koito, K, 1387(ab)
Kok, PJ, 622
Kolasinska, AD, 110(ab), 448(ab), 572(ab)
Kolb, PE, 142(ab)
Kolbe, H, 1006(ab)
Kolbert, K, 329(ab)
Kölby, L, 636
Kolesnikov-Gauthier, H, 1689
Koller, E, 786(ab)
Kolodgie, FD, 185(ab), 793(ab)
Kolsky, KL, 1091(ab)
Komai, K, 193(ab)
Komatani, A, 421
Komori, T, 712(ab), 1302(ab)
Konaka, R, 736(ab)
Kondas, D, 1281(ab)
Konijnenberg, MW, 149, 1046(ab)
Konishi, J, 173(ab), 293, 840(ab), 1016(ab), 1144(ab), 1190(ab), 1214(ab), 1313(ab), 1381(ab), 1612, 1898
Konishi, S, 1183(ab), 1188(ab), 1189(ab), 1244
Konno, H, 795
Konno, M, 352(ab), 354(ab)
Kontaxakis, G, 863(ab)
Konz, B, 1228(ab)
Koo, J-W, 961(ab)
Kooij, PP, 120(ab)
Koole, M, 240(ab), 843(ab), 952(ab), 2051
Koomaegi, R, 1256(ab)
Koomans, HA, 1337
Kopka, K, 937(ab), 943(ab), 956(ab)
Koppeschaar, HP, 1340(ab)
Koral, KF, 123, 808(ab), 1579, 1760
Korf, J, 951(ab)
Körfer, R, 1587
Koriska, K, 881(ab)
Kornmehl, E, 113(ab)
Kosaka, N, 1507
Koshu, K, 795
Koslowsky, IL, 1106(ab)
Koss, JE, 807(ab)
Kostakoglu, L, 279(ab), 311(ab), 315(ab), 466(ab), 1171(ab)
Koster, J, 878(ab)
Kosuda, S, 1287(ab)
Kosugi, S, 1898
Koszalka, GW, 143(ab)
Kotagal, P, 258(ab)
Kothari, K, 1079(ab), 1089(ab), 1090(ab), 1095(ab)
Kothari, PJ, 493
Kotz, D, 12N(1), 17N(4)
Kotzerke, J, 119(ab), 294(ab), 310(ab), 503(ab), 531, 1058(ab), 1145(ab), 1695
Kotzki, PO, 421(ab)
Kouji, T, 710(ab)
Koulibaly, PM, 405(ab)
Kouyoumdjian, JC, 592(ab)
Kovacs, Z, 1085(ab)
Kovalsky, E, 276(ab), 1207(ab)
Kown, MH, 1(ab), 589(ab)
Koyama, K, 1272(ab)
Koyama, Y, 728(ab)
Koziorowski, J, 314(ab), 817(ab)
Kraeber-Bodéré, F, 215(ab)
Kraemer, M, 591(ab)
Kragh, TJ, 68(ab)
Kraitchman, DL, 496(ab), 497(ab), 755(ab)
Kramer, MR, 509(ab), 1771
Krasikova, R, 1121(ab)
Krasnow, AZ, 1086(ab)
Krause, J, 105(ab)
Krause, KH, 105(ab)
Krauss, ES, 58(ab)
Krausz, Y, 509(ab), 915(ab), 1771
Krawczynska, EG, 731(ab), 752(ab), 1941
Kreissig, M, 137(ab)
Kreitman, RJ, 755
Krenning, EP, 120(ab), 158(ab), 370(ab), 435(ab), 436(ab), 437(ab), 438(ab), 439(ab), 579(ab), 940(ab), 1030(ab), 1143(ab), 1169(ab), 1248(ab), 1249(ab), 1704
Kreuzer, E, 172(ab)
Kriekinge, SV, 712
Krishnamurthy, GT, 688
Krishnamurthy, S, 688
Kritzman, JN, 763(ab), 765(ab)
Kroeger, S, 429(ab), 1317(ab)
Kroger, LA, 564(ab), 567(ab), 952, 1215(ab)
Kröger, S, 816
Kroiss, A, 1339(ab)
Krol, GS, 972(ab)
Kroll, SM, 114(ab), 309(ab), 311(ab), 325(ab)
Kroon, BB, 1500
Kroon, BBR, 302(ab)
Kropp, J, 280(ab), 1146(ab), 1167(ab)
Krueger, A, 452(ab)
Krug, B, 340(ab), 1168(ab)
Kruger, RL, 885(ab)
Kruse, MA, 583(ab)
Krynyckyi, BR, 1231(ab)
Kuan, HM, 28(ab)
Kuan, SY, 256(ab)
Kuang, RA, 217(ab), 1163(ab)
Kubista, E, 426
Kubo, A, 453(ab), 1222(ab), 1223(ab), 1268(ab)
Kubo, N, 354(ab), 847(ab)
Kubo, S, 173(ab), 293
Kubota, K, 1561
Kudo, T, 395(ab)
Kudoh, T, 293, 764(ab)
Kudrevich, SV, 587(ab)
Kuehn, T, 107(ab)
Kuehnel, G, 169(ab), 1307(ab)
Kuenzi, G, 1184(ab)
Kuge, Y, 352(ab), 354(ab), 584(ab), 847(ab), 1131(ab), 1300(ab), 1326(ab), 1525
Kuhl, DE, 246(ab), 259(ab), 542(ab), 948(ab), 968(ab), 1569, 1879
Kuhn, PJ, 1868
Kuhn, W, 443(ab)
Kuijk, DJ, 1328(ab)
Kuikka, JT, 788
Kujat, C, 1133(ab)
Kuji, I, 279(ab), 466(ab)
Kukis, DL, 952
Kula, NS, 148(ab)
Kulasegaram, R, 1134(ab)
Kulisevsky, J, 405, 980(ab)
Kulkarni, PV, 185(ab)
Kumar, A, 201(ab)
Kumar, R, 203(ab)
Kumar, SS, 203(ab)
Kumaresan, KN, 905(ab)
Kume, N, 510(ab), 511(ab)
Kunath, B, 992(ab)
Kung de Aburto, MA, 247(ab)
Kung, HF, 105(ab), 150(ab), 476(ab), 541(ab), 584, 988(ab), 989(ab), 1036(ab), 1064(ab), 1065(ab), 1066(ab)
Kung, MP, 150(ab), 1036(ab), 1065(ab), 1066(ab)
Kunieda, E, 1222(ab), 1223(ab)
Kunihiro, T, 911(ab), 963(ab), 964(ab), 1155
Kunishio, K, 411
Kunkel, M, 444(ab)
Kunselman, AR, 48(ab)
Kunstman, S, 754(ab)
Kuntzsch, M, 141(ab), 582(ab), 966(ab)
Kunze, W-D, 1067
Kupferschlaeger, J, 871(ab)
Kurdziel, KA, 831(ab)
Kuribayashi, S, 1127
Kurlemann, G, 995(ab), 1431(ab)
Kuroki, M, 337, 1190(ab)
Kurooka, H, 1378(ab), 1379(ab), 1391(ab), 1394(ab)
Kurtaran, A, 578(ab), 1304(ab), 1339(ab)
Kurthen, M, 960(ab)
Kurz, A, 250(ab)
Kusacic-Kuna, S, 723(ab)
Kusakabe, K, 704(ab)
Kusano, S, 1287(ab)
Kusterer, GP, 17(ab)
Kusuhara, T, 1371(ab)
Kusuoka, H, 1102
Kuten, A, 1243(ab)
Kutzner, J, 444(ab)
Kuwabara, H, 427(ab), 971(ab), 1002(ab), 1057(ab)

Kuwabara, Y, 974(ab), 975(ab), 1250(ab)
Kuwamura, S, 889(ab)
Kuwert, T, 790(ab), 1587
Kuyama, J, 1364(ab)
Kvaternik, H, 250
Kvols, L, 370(ab), 436(ab), 437(ab), 438(ab), 1143(ab)
Kwak, DS, 1212(ab)
Kwan, J, 342(ab), 363(ab), 493(ab)
Kwekkeboom, DJ, 120(ab), 1248(ab), 1704
Kwon, JS, 912(ab)
Kyotani, S, 1127

Laatsch, H, 1128(ab)
Labar, D, 436(ab), 437(ab), 1143(ab)
LaBarbara, J, 1355(ab)
Labbie, AS, 1432(ab)
LaCroix, KJ, 502
Lacy, JL, 309
Ladner, RC, 363
Laffin, SP, 1632
Lafont, J, 405(ab)
Laforest, R, 164(ab), 1043(ab), 1054(ab)
Lai, CP, 735(ab)
Lai, KH, 1380(ab)
Lai, LT, 116(ab), 1175(ab)
Laine, AF, 519(ab), 850(ab)
Lajeunesse, S, 19(ab), 21(ab), 714(ab)
Lalush, DS, 389(ab), 737, 820(ab), 824(ab), 874(ab), 876(ab)
Lambert, R, 210(ab)
Lambertini, R, 1368(ab)
Lamberts, SW, 435(ab)
Lamborn, KR, 564(ab), 1215(ab)
Lambrecht, L, 898(ab)
Lambright, E, 451(ab), 1159(ab)
Lammertsma, AA, 231(ab), 346(ab), 406(ab), 1279(ab)
Lamonica, DM, 118(ab), 465(ab)
Lampe, D, 1133(ab)
Lancaster, JL, 66(ab)
Landoni, C, 1702
Landry, AJ, 857(ab)
Lands, BJ, 1181(ab)
Landsnes, DG, 1283(ab), 1289(ab)
Lang, LL, 153(ab), 154(ab)
Lang, O, 123(ab), 135(ab), 460(ab)
Lang, S, 250
Lange-Asschenfeldt, C, 897(ab)
Langen, K-J, 212(ab), 556, 1250
Langleben, DD, 1861
Langsteger, WF, 308(ab), 375(ab)
Långström, B, 275, 1746
Lantsberg, S, 1397(ab)
Lantzsch, T, 1133(ab)
Lanuti, M, 1159(ab)
Lapointe, D, 227(ab), 396(ab)
Laraia, C, 17(ab), 848(ab), 850(ab)
Larisch, R, 533(ab)
Larsen, RH, 1115(ab)
Larsen, T, 281(ab)
Larson, SM, 140(ab), 282(ab), 323(ab), 493, 817(ab), 1082, 1234(ab), 1905
Larsson, S, 477(ab)
Lartizien, C, 402(ab), 802(ab), 821(ab)
Laruelle, L, 852(ab)
Laruelle, M, 102(ab), 225(ab), 415(ab), 549(ab), 904(ab), 923(ab), 946(ab), 947(ab), 1070(ab), 1465, 2083
Las, L, 1025
Lastoria, S, 1065
Lauer, B, 13(ab)
Lauer, I, 376(ab), 558(ab), 1219(ab), 1290(ab)
Laurette, I, 405(ab)
Lautenschlager, N, 250(ab)
Lavalaye, J, 419(ab), 900(ab)
Laverman, P, 517(ab), 622, 896, 912, 1404(ab)
Law, I, 959(ab)
Law, MP, 187(ab)
Lawhorn-Crews, JM, 290(ab)
Laymon, CM, 692
Laznicek, M, 177
Laznickova, A, 177
Lazzari, L, 1227(ab)
Le Boterff, J, 215(ab)
Le Doussal, J-M, 480
Le Guludec, D, 355(ab), 393, 567, 769(ab), 1274(ab)
Le, N, 318, 755, 1093
Leach, MO, 1156(ab), 1753
Leach, SG, 427(ab), 971(ab), 1002(ab)
Lebtahi, R, 355(ab), 393, 567, 1274(ab), 1808
Leclercq, S, 1398(ab)
Lecomte, R, 227(ab), 396(ab)
Lee, HK, 1836
Lee, BB, 1225(ab)
Lee, CH, 33(ab), 361(ab), 1209, 1350(ab)
Lee, DS, 27, 65(ab), 183(ab), 253(ab), 254(ab), 271(ab), 343(ab), 373(ab), 386(ab), 387(ab), 447(ab), 504(ab), 751(ab), 781(ab), 789(ab), 841(ab), 845(ab), 852, 912(ab), 961(ab), 983(ab), 998(ab), 1130(ab), 1132(ab), 1338(ab), 1427(ab)
Lee, DW, 912(ab)
Lee, EB, 373(ab)
Lee, ED, 1309(ab)
Lee, EH, 1293(ab)
Lee, HD, 1263(ab)
Lee, HK, 52(ab), 91(ab), 202(ab), 361(ab), 368(ab), 512(ab), 593(ab), 1122(ab), 1132(ab), 1140(ab), 1374(ab), 1399(ab), 1401(ab), 1423(ab)
Lee, IJ, 74(ab)
Lee, J, 54(ab), 495(ab), 1073(ab), 1212(ab), 1285(ab)
Lee, J-B, 493
Lee, JD, 384(ab), 913(ab), 1164(ab), 1263(ab), 1263(ab)
Lee, JH, 451(ab), 1263(ab), 1396(ab)
Lee, JR, 829(ab)
Lee, JS, 65(ab), 183(ab), 253(ab), 254(ab), 386(ab), 387(ab), 845(ab), 912(ab), 961(ab), 998(ab), 1059(ab), 1301(ab)
Lee, KB, 54(ab), 495(ab), 1212(ab), 1285(ab)
Lee, KH, 6(ab), 730(ab), 808, 810(ab), 888(ab), 955(ab), 1073(ab), 1225(ab), 1265(ab), 1296(ab), 1309(ab), 1395(ab)
Lee, KS, 92(ab), 99(ab), 100(ab), 808, 1069(ab)
Lee, MC, 27, 65(ab), 183(ab), 253(ab), 254(ab), 271(ab), 343(ab), 373(ab), 386(ab), 387(ab), 416, 447(ab), 504(ab), 751(ab), 781(ab), 789(ab), 841(ab), 845(ab), 852, 912(ab), 961(ab), 983(ab), 998(ab), 1130(ab), 1132(ab), 1338(ab), 1427(ab)
Lee, MG, 1164(ab), 1374(ab)
Lee, MK, 6(ab), 730(ab)
Lee, MM, 27, 504(ab), 751(ab), 852
Lee, RL, 1034(ab)
Lee, SC, 1380(ab)
Lee, SG, 52(ab), 254(ab), 998(ab), 1374(ab)
Lee, SH, 6(ab), 730(ab)
Lee, SJ, 144(ab), 1388(ab)
Lee, SK, 253(ab)
Lee, SW, 54(ab), 495(ab), 1212(ab), 1285(ab)
Lee, SY, 1073(ab), 1408(ab)
Lee, T-T, 1209
Lee, T-W, 386(ab)
Lee, WH, 342(ab), 363(ab), 493(ab)
Lee, WR, 6(ab), 730(ab)
Lee, YJ, 373(ab), 1130(ab), 1132(ab), 1338(ab)
Lee, YW, 504(ab), 903
Lee, Z, 232(ab), 1413(ab), 1603
Leenders, KL, 781
Lees, RS, 858(ab)
Lefebvre, B, 1324
Lefkowitz, D, 1308
Lehikoinen, P, 65, 1980
Lehner, B, 1322(ab)
Leibovitch, FS, 45
Leigh, BR, 113(ab), 115(ab), 564(ab)
Leinsinger, G, 1823
Leischner, P, 1056(ab)
Leitha, T, 1356(ab)
Lekeux, PM, 1414(ab)
Lemahieu, I, 835(ab)
Lembcke, AE, 47(ab)
Lemmens, JM, 896
Lenzo, NP, 259(ab), 379(ab)
Leo, R, 515(ab)
Leonard, EF, 493
Leonard, JP, 279(ab), 311(ab), 466(ab)
Leonard, SM, 179(ab)
Leong, LK, 885(ab), 1383
Leonhardi, J, 1242(ab), 1280(ab)
Leonhardt, G, 553(ab)
Leonidas, JC, 380(ab), 382(ab)
Leopold, NA, 541(ab), 584
Leppo, JA, 872(ab)
Lerner, I, 1813
Lerut, T, 124(ab)
Lesko, NM, 112(ab), 814(ab)
Le Guludec, D, 1808
Le Pham, H, 107
Leung, SO, 1185(ab)
Leutner, M, 1491
Levchenko, A, 493
Leveillee, RJ, 1813
Leveque, C, 979(ab)
Levesque, N, 349(ab)
Levin, CS, 880(ab)
Levine, EA, 112(ab), 814(ab)
Levy, WC, 189(ab)
Levy-Reis, I, 987(ab)
Lewellen, BL, 531(ab)
Lewellen, TK, 72(ab), 531(ab)
Lewin, HC, 4(ab), 177(ab), 712, 720, 737(ab), 1190
Lewis, DH, 970(ab)
Lewis, JS, 130(ab), 229(ab), 322(ab), 454(ab), 455(ab), 798(ab), 1017(ab), 1043(ab), 1126(ab), 1241(ab)
Lewis, MR, 164(ab), 565(ab), 1043(ab), 1054(ab)
Lewis, PJ, 1619
Ley, A, 1127(ab)
Ley, AC, 363
Leysen, DC, 483(ab)
Li, AR, 168(ab)
Li, CY, 1163(ab)
Li, H, 524(ab), 812(ab), 1021(ab)
Li, J, 585(ab), 1579
Li, L, 873(ab), 893(ab), 1163(ab)
Li, PY, 122(ab), 451(ab), 584, 1251(ab), 1314(ab)
LI, S, 786(ab)
Li, WP, 1084(ab)
Li, X-F, 1189(ab)
Li, Y, 1627
Liang, LZ, 1163(ab)
Liang, Q, 146(ab), 228(ab)
Liang, Z, 873(ab), 877(ab), 893(ab)
Liani, M, 509(ab), 1771
Liao, MH, 1102(ab)
Liao, SQ, 292(ab), 986(ab), 1350(ab)
Liard-Zmuda, A, 209(ab)
Libutti, SK, 532(ab), 826(ab), 1784
Licho, R, 1391, 1425(ab)
Lichtenauer-Kaligis, EG, 435(ab)
Liepe, K, 1167(ab)
Liersch, T, 313(ab)
Lill, M, 1218(ab)
Lim, SJ, 144(ab), 1135(ab), 1388(ab)
Lim, SM, 144(ab), 1059(ab), 1135(ab), 1301(ab), 1309(ab), 1388(ab)
Lima, EA, 1101(ab)
Lima, MC, 996(ab), 1224(ab)
Limouris, GS, 703(ab)
Lin, BH, 285(ab)
Lin, CH, 1120(ab)
Lin, CL, 735(ab)
Lin, E, 596, 1139, 1632
Lin, HD, 856(ab)
Lin, HM, 1121(ab)
Lin, JH, 131(ab), 341(ab)
Lin, KP, 856(ab)
Lin, KS, 155(ab)
Lin, LC, 1262(ab), 1380(ab)
Lin, MS, 402(ab), 783(ab)
Lin, PC, 467(ab)
Lin, WY, 801(ab), 1892
Lin, X, 106(ab)
Lin, YM, 1392(ab)
Linder, KE, 470(ab)
Lindsley, KL, 109(ab)
Lindholm, P, 1980
Line, BR, 36(ab), 128(ab), 1029(ab), 1264
Lingford-Hughes, AR, 418(ab), 538(ab)
Link, EM, 1134(ab)
Link, JM, 189(ab)
Linke, DB, 960(ab)
Linke, G, 23(ab)
Linke, R, 220, 1004(ab), 1989
Links, JM, 16N(7), 658,
Linnoila, M, 537(ab), 918(ab)
Lionnet, M, 771(ab)
Liow, JS, 612, 1077(ab)
Lipowska, M, 1082(ab), 2077
Lips, CM, 1340(ab)
Lipton, J, 380(ab)
Lisbona, A, 335(ab)
Lisbona, R, 1851
Lister-James for the Multicenter Trial Investigators, J, 1214
Lister-James, J, 1142(ab)
Liu, HG, 228, 422(ab), 965(ab), 990(ab), 997(ab)
Liu, HL, 857(ab)
Liu, M, 465(ab)
Liu, N, 486(ab), 922(ab), 929(ab), 949(ab), 1028(ab), 1097(ab), 1127(ab)
Liu, Q, 5
Liu, RS, 33(ab), 256(ab), 292(ab), 815(ab), 856(ab), 862(ab), 865(ab), 986(ab), 1121(ab), 1211(ab), 1246(ab), 1262(ab), 1350(ab), 1359(ab), 1380(ab)
Liu, S, 132(ab), 1141(ab)
Liu, W, 5
Liu, WG, 571(ab)
Liu, X, 329(ab)
Liu, Y-H, 1436
Liu, Z, 784(ab), 785(ab)
Livi, U, 8(ab)
Livingston, RB, 108(ab), 109(ab), 442(ab), 574(ab)
Livni, E, 407(ab), 410(ab), 899(ab), 931(ab), 933(ab)
Ljungberg, M, 123, 329(ab), 808(ab), 860(ab), 1039(ab), 1760
Llacer, J, 745
Lobaugh, NJ, 45
Lobdell, K, 1281(ab)
Lodge, MA, 826(ab), 1784
Loevner, LA, 1196(ab)
Logan, J, 98(ab), 103(ab), 416(ab), 420(ab), 550(ab), 854(ab), 922(ab), 929(ab), 949(ab), 1352
Logus, JW, 288(ab), 570(ab), 1170(ab)
Lohman, J, 1093(ab)
Loirat, C, 208(ab)
Loizzo, P, 1372(ab)
Loman, JC, 37(ab), 1396(ab)
Lombardo, I, 549(ab), 904(ab), 947(ab)
Lomonica, D, 113(ab)
Loncaric, S, 1061(ab)
London, ED, 658
Long, Y, 1214(ab)
Longari, V, 515(ab), 1368(ab)

Lonn, AH, 733(ab)
Lopatta, E, 1242(ab), 1280(ab)
Lopera, J, 106(ab)
Lopes-Cendes, I, 996(ab)
Lopez, H, 754(ab)
Lorberboym, M, 197(ab), 716(ab)
Lord, EM, 327
Lorenz, E, 77(ab), 887(ab)
Losman, MJ, 1185(ab)
Lottgen, J, 1431(ab)
Lottmann, H, 208(ab)
Loucif, E, 480
Loutfi, A, 1851
Loutfi, I, 184(ab), 1422(ab)
Louzoun, Y, 915(ab)
Love, C, 58(ab), 60(ab), 61(ab), 63(ab), 1336(ab)
Low, PS, 164(ab), 1014(ab)
Lu, CS, 251(ab), 426(ab), 994
Lu, H, 893(ab)
Lu, J, 1078(ab)
Lu, L, 1746
Lu, LFL, 487(ab)
Lu, P, 1159(ab)
Lubensky, IA, 1646
Lucht, R, 1266(ab)
Luddens, H, 897(ab)
Luders, HO, 258(ab)
Ludwig, T, 488(ab)
Luettges, J, 1042(ab)
Luk, P, 78(ab)
Lukasiewicz, R, 1264
Lukinius, A, 1514
Lundberg, G, 263
Lundberg, H-J, 1203
Luo, J, 1230(ab), 1348(ab)
Lupo, J, 150(ab)
Lydiatt, WM, 1056(ab)
Lynne, CM, 1813
Lyster, D, 894(ab)
Lyster, DM, 869(ab)

Ma, D, 116(ab), 1175(ab)
Ma, Y, 153(ab), 154(ab), 479(ab)
Maag, K, 739(ab), 1271(ab)
Mabuchi, M, 186(ab), 352(ab), 354(ab), 847(ab), 1326(ab)
Macapinlac, HA, 140(ab), 1234(ab)
MacDermott, K, 1258(ab)
Macdonald, JE, 939(ab), 1417
MacDonald, JR, 489(ab)
MacDonald, LR, 220(ab)
MacGregor, R, 929(ab), 949(ab)
Mach, RH, 413(ab), 476(ab), 832(ab), 2069
Machac, J, 25(ab), 527(ab), 1231(ab)
Machado e Silva, RA, 1224(ab)
Machecourt, J, 141
Machida, K, 86(ab), 424(ab), 747(ab), 756(ab), 758(ab), 1393(ab), 1406(ab), 1407(ab)
Machtay, M, 122(ab)
Machulla, HJ, 141(ab), 290(ab), 291(ab), 333(ab), 518(ab), 582(ab), 966(ab), 1018(ab), 1110(ab), 1118(ab), 1255(ab)
MacIntyre, WJ, 178(ab)
MacManus, MP, 296(ab), 431(ab)
Madar, I, 417(ab)
Madeddu, G, 1259(ab)
Madras, BK, 104(ab), 410(ab), 839(ab), 933(ab), 1067(ab)
Madsen, MT, 520(ab), 829(ab), 1288(ab)
Maecke, HR, 121(ab), 577(ab), 590(ab)
Maeda, H, 367(ab), 501(ab), 748(ab), 1009(ab)
Maeda, M, 1318(ab)
Maeght, J, 894(ab)
Maes, A, 37(ab), 124(ab), 775(ab), 1419(ab)
Magata, Y, 173(ab), 293
Magee, M, 1415(ab)
Magnuson, DE, 311(ab), 1180(ab)
Magri, GC, 305(ab), 494(ab), 732(ab)
Mahmarian, JJ, 1299
Mahmood, A, 475(ab)
Mahoney, DW, 1105(ab)
Maini, CL, 647
Maisey, MN, 1325(ab)
Maisey, NR, 1156(ab), 1753
Makino, I, 50(ab), 51(ab)
Maksud, P, 404(ab)
Makuuchi, H, 1240(ab)
Mal, H, 1808
Malago', E, 1096(ab)
Malamitsi, J, 40(ab)
Maldjian, JA, 987(ab)
Malet, Y, 375
Malguria, N, 456(ab)
Malholtra, S, 1445
Malhotra, A, 203(ab)
Malison, RT, 941(ab)
Malizia, A, 946(ab)
Mallet, J-J, 1913
Mallett, RW, 565(ab), 1033(ab), 1054(ab), 1148(ab), 1150(ab), 1152(ab)
Mallin, W, 1955
Malone, KM, 903(ab)
Malveaux, EJ, 151(ab), 167(ab)
Mamede, M, 173(ab)
Mamidi, R, 513(ab)
Manalili, E, 380(ab)
Manca, G, 305(ab)
Mandal, AK, 1367(ab)
Mandel, S, 1330(ab), 1347(ab)
Mandigers, CM, 1182(ab)
Mañé, S, 2038
Manetou, A, 703(ab)
Manetti, C, 480
Mang, C, 162(ab)
Manganoni, MA, 305(ab)
Mangin, JF, 979(ab)
Mangner, TJ, 141(ab), 290(ab), 1162(ab)
Mankoff, DA, 108(ab), 109(ab), 269(ab), 442(ab), 531(ab), 574(ab), 1260(ab)
Mankoff, DK, 307(ab)
Mann, JJ, 102(ab), 225(ab), 903(ab), 904(ab), 946(ab), 947(ab), 1465
Mannting, F, 749(ab)
Manoj, C, 1289(ab)
Manrique, A, 209(ab), 421(ab)
Mansour, PM, 69(ab), 826(ab)
Manthey, N, 1989
Mantil, JC, 573(ab)
Marcel, R, 363
Marchais, S, 152(ab)
Marchesini, R, 71(ab)
Marcus, CS, 107
Mardirossian, G, 1055(ab)
Mardon, K, 796(ab)
Mare, K, 49(ab)
Marek, KL, 543(ab), 544(ab), 985(ab)
Mari, C, 499(ab), 920(ab), 980(ab)
Mariani, G, 306(ab), 978(ab), 1208(ab), 1519
Mariani, L, 1007(ab)
Marie, SK, 255(ab)
Markert, U, 558(ab), 1329(ab)
Markham, J, 244(ab)
Marmion, ME, 156(ab), 489(ab), 1014(ab), 1107(ab)
Marotta, G, 515(ab)
Marquet, RL, 1169(ab)
Marsden, PK, 1284(ab)
Marshall, RC, 15(ab), 388(ab)
Martarello, L, 167(ab), 263(ab)
Marteaux, C, 340(ab)
Martell, AE, 322(ab)
Martí-Climent, JM, 439
Martin, CC, 66(ab)
Martin, CS, 309
Martin, EW, 816(ab)
Martin, HJ, 119(ab)
Martin, JC, 405, 499(ab), 920(ab), 980(ab)
Martin, LA, 126(ab), 138(ab)
Martin, M, 480
Martin, SJ, 335(ab), 1123(ab)
Martin, WH, 34(ab), 276(ab), 891(ab), 1207(ab), 1235(ab)
Martinez, D, 102(ab), 415(ab), 549(ab), 946(ab)
Martínez-Lázaro, R, 991(ab), 1003(ab), 1213(ab), 1220(ab), 1221(ab), 1396(ab)
Martinoff, S, 753(ab)
Maruyama, A, 713(ab)
Maruyama, K, 180(ab), 713(ab), 742(ab)
Maruyama, T, 1134
Maruyama, Y, 747(ab)
Marwin, SE, 58(ab), 63(ab)
Marzilli, LG, 1082(ab), 2077
Mas, J, 728
Masai, M, 1418(ab)
Masaki, K, 1378(ab), 1379(ab), 1391(ab), 1394(ab)
Masamura, S, 1223(ab)
Massa, R, 459
Massardo, T, 106(ab), 754(ab)
Massari, L, 62(ab)
Massumi, PP, 1354(ab)
Mast, ST, 1235
Mastrofrancesco, P, 1237
Masud, MM, 1377(ab)
Masuda, K, 974(ab), 975(ab), 1250(ab)
Masuda, Y, 29(ab), 175(ab), 763
Masuhara, A, 728(ab)
Masunaga, S, 1190(ab)
Masuyama, K, 360(ab)
Maszelin, P, 802(ab)
Matheja, P, 190(ab), 707(ab), 984(ab), 995(ab), 1431(ab)
Matheoud, R, 994(ab)
Mather, SJ, 177, 1114
Mathews, D, 927(ab)
Mathews, WB, 417(ab), 902(ab), 909(ab), 1361(ab)
Mathias, CJ, 164(ab), 309, 1014(ab), 1032(ab), 1113(ab)
Mathieu, I, 1143(ab)
Mathieu, JP, 141
Matsuda, H, 424(ab), 906(ab), 911(ab), 963(ab), 964(ab), 1155
Matsuda, K, 293
Matsuda, N, 704(ab)
Matsuda, S, 712(ab)
Matsui, M, 976(ab)
Matsui, S, 360(ab)
Matsui, T, 86(ab)
Matsuki, T, 502(ab)
Matsumoto, K, 173(ab)
Matsumoto, N, 177(ab)
Matsumoto, T, 424(ab)
Matsumura, K, 24(ab), 367(ab), 501(ab), 748(ab)
Matsunaga, N, 510(ab), 511(ab), 1409(ab)
Matsunari, I, 193(ab), 358(ab), 727(ab)
Matsuno, K, 1072(ab)
Matsuo, H, 71
Matsuoka, H, 728(ab)
Matsuoka, Y, 337
Matsuzawa, Y, 1134
Mattar, AG, 286(ab)
Mattes, MJ, 2089
Matthews, J, 296(ab), 431(ab)
Matthews, K, 222(ab)
Matthiasson, P, 935(ab), 954(ab)
Matthies, A, 118(ab), 818(ab), 1210(ab), 1277(ab)
Mattos, DM, 1100(ab)
Matzku, S, 564(ab)
Maunoury, C, 383(ab), 400
Maurer, AH, 16N(7), 1056,
Maurer, K, 919(ab)
Mausner, LF, 1091(ab), 1119(ab)
Mawlawi, O, 102(ab), 415(ab), 549(ab), 852(ab), 904(ab), 946(ab), 947(ab), 1465
Mayberg, HS, 970(ab)
Maynard, LS, 103(ab), 916(ab), 917(ab)
Mays, TL, 1052(ab)
Maza, S, 284(ab)
Mazza, SM, 427(ab), 505(ab), 971(ab), 1002(ab), 1057(ab)
Mazzadi, AN, 771(ab)
Mazzarotto, R, 1343(ab)
McAfee, JG, 26N(4), 318,
McAndrew, P, 1218(ab)
McBride, A, 1070(ab)
McBride, WJ, 473(ab), 1023(ab), 1185(ab), 1186(ab)
McCallum, RW, 516(ab)
McCarthy, DJ, 1417
McCarthy, DW, 1126(ab)
McCarthy, M, 1094(ab)
McCarthy, TJ, 315, 484(ab), 1017(ab)
McClellan, JR, 1139
McColl, R, 927(ab)
McConathy, JE, 167(ab)
McCullough, NT, 82(ab), 114(ab), 309(ab), 325(ab)
McCullough, SP, 327(ab), 580(ab)
McDevitt, MR, 116(ab), 314(ab), 323(ab), 1175(ab), 1176(ab)
McDonald, D, 1159(ab)
McDonald, RJ, 36(ab)
McDonald, T, 459(ab)
McDougall, IR, 1331(ab)
McElroy, D, 220(ab)
McEwan, AJ, 288(ab), 570(ab), 581(ab), 1170(ab), 1310(ab)
McGhie, AI, 529(ab), 778(ab)
McGlashan, T, 910(ab)
McGoron, AJ, 336(ab)
McGowan, DG, 581(ab)
McKenney, JB, 788(ab)
McLaughlin, K, 1288(ab)
McLendon, RE, 332(ab)
McLoud, TC, 234(ab), 1253(ab)
McMillan, K, 1044(ab)
McNelis, P, 724(ab), 779(ab)
McPherson, DW, 93(ab)
Meacke, HR, 1173(ab)
Meares, CF, 952
Mecz, Y, 1025
Medvedec, M, 1061(ab), 1203(ab)
Meer, JW, 498(ab)
Mehilli, J, 753(ab)
Mehta, A, 463(ab)
Mehta, BM, 493
Meier, D, 76(ab)
Meignan, M, 491(ab), 506(ab)
Meijer, WG, 1793
Meinken, GE, 1026(ab), 1119(ab)
Meisetschläger, G, 238(ab)
Melacrinis, FF, 1522
Melcher, CL, 1051
Melendez-Alafort, L, 1114
Melichar, JK, 418(ab)
Melief, MJ, 940(ab)
Melis, K, 23
Meller, B, 558(ab), 1219(ab), 1290(ab)
Meller, J, 378(ab)
Melo, T, 169
Meltzer, CC, 1842
Meltzer, PC, 839(ab), 933(ab), 1067(ab)
Menard, JF, 421(ab)
Menda, Y, 829(ab), 1288(ab)
Mende, T, 1133(ab)
Mendiondo, MS, 57
Mensink, HJ, 293(ab)
Mentis, MJ, 575
Meoli, DF, 794(ab)
Meredith, RF, 115(ab), 328(ab)
Mergenthaler, H-G, 460(ab)
Merkle, P, 135(ab)
Merlet, P, 10(ab), 196(ab), 796(ab)
Mertens, IJ, 369(ab), 1337
Mesotten, LV, 775(ab)

Messa, C, 1702
Messelt, S, 1115(ab)
Mester, J, 429(ab), 816, 844(ab), 1317(ab)
Meta, J, 295(ab), 432(ab), 1291(ab), 1303(ab)
Methe, BM, 1117(ab)
Meurer, M, 1146(ab)
Meyer, C, 171(ab)
Meyer, E, 926
Meyer, GJ, 169(ab)
Meyer, JH, 833(ab)
Meyer, PT, 541(ab), 968(ab), 988(ab), 991(ab), 1003(ab)
Michigishi, T, 1183(ab), 1188(ab), 1189(ab), 1244, 1383(ab)
Mick, R, 283(ab)
Miederer, M, 116(ab), 1174(ab), 1177(ab)
Mielke, R, 247(ab)
Mier, W, 559(ab), 1123(ab)
Miers, LA, 564(ab)
Migneco, O, 405(ab)
Mihara, H, 728(ab)
Mikkelsen, T, 1200(ab)
Milan, E, 8(ab), 705(ab), 973
Miller, CM, 391(ab)
Miller, TR, 236(ab)
Millet, P, 834(ab)
Mills, C, 1230(ab)
Min, JJ, 1000(ab)
Minai, K, 736(ab)
Minami, C, 107
Mineura, K, 1484
Minisola, S, 1478
Minn, H, 1980
Minoshima, S, 246(ab), 250(ab), 259(ab), 945(ab), 948(ab), 1008(ab), 1879
Mintun, MA, 130(ab), 229(ab), 1241(ab)
Mintzer, RA, 861(ab)
Miranda, RS, 4(ab), 1190
Mirzadeh, S, 588(ab), 1271
Mirzaei, S, 881(ab)
Misaki, T, 1898
Mitani, M, 508(ab)
Mitchell, JH, 927(ab)
Mitchell, K, 596, 1632
Mitchell, TA, 765(ab)
Mitra, A, 1409(ab)
Mittal, BR, 1367(ab)
Miura, S, 360(ab), 889(ab)
Miyahara, D, 1642
Miyajima, A, 720(ab), 721(ab), 759(ab)
Miyama, H, 1009(ab)
Miyaoka, RS, 72(ab)
Miyazaki, S, 712(ab)
Miyazaki, T, 1777
Miyokawa, N, 51(ab)
Mizokami, MM, 355
Mobilia, G, 8(ab), 705(ab), 973
Mochizuki, T, 89(ab), 836(ab), 1005(ab), 1131(ab)
Mochizuki, Y, 1240(ab), 1268(ab)
Moe, RE, 108(ab), 307(ab)
Moeller, T, 864(ab)
Mohammed, A, 23(ab), 475(ab), 559(ab), 1422(ab)
Mohammed, F, 715(ab)
Moka, D, 32(ab), 362(ab)
Molina, IL, 1166(ab)
Molinet, R, 441(ab)
Molloy, PT, 1003(ab)
Molls, M, 270(ab), 272(ab)
Mölne, J, 636
Molthoff, CF, 1022(ab), 1168
Momose, M, 704(ab)
Momose, T, 424(ab), 828(ab)
Monden, T, 1371(ab)
Monsieurs, M, 2051
Monsieurs, MA, 17, 1194(ab), 1195(ab)
Montagne, O, 796(ab)
Montane, B, 1955
Montane, BS, 1037, 1432(ab)
Montesano, T, 1522
Montesco, MC, 303(ab)
Montravers, F, 78, 1267(ab), 1308(ab), 1316(ab)
Moog, F, 1989
Moon, DH, 52(ab), 91(ab), 202(ab), 361(ab), 512(ab), 593(ab), 1122(ab), 1140(ab), 1374(ab), 1399(ab), 1401(ab), 1423(ab), 1836
Moon, SH, 1408(ab)
Moore, RH, 234(ab)
Moore, SC, 241(ab), 404(ab), 819(ab)
Moore, T, 413(ab)
Mooro, M, 1422(ab)
Moote, DJ, 1010
Mor, M, 35(ab), 274(ab), 557(ab), 1243(ab)
Morales, JA, 469(ab)
Morano, GN, 257(ab)
Morch, N, 612
Moreno, M, 556(ab)
Moreno, SR, 1101(ab)
Moreno-Cantú, JJ, 926
Moretti, JL, 591(ab), 592(ab), 1801, 1808
Morgan, DS, 276(ab), 1207(ab)
Morgan, VL, 1197(ab)
Morgan, WP, 927(ab)
Mori, I, 805(ab)
Mori, T, 976(ab)
Morin, CA, 581(ab), 1170(ab), 1310(ab)
Morishita, K, 1102
Morita, K, 186(ab), 214(ab), 352(ab), 354(ab), 403(ab), 502(ab), 847(ab), 1300(ab), 1326(ab), 1525
Morita, T, 1507
Morita, Y, 847(ab)
Moritake, K, 1777
Moriyama, T, 1642
Morris, HH, 258(ab)
Morris, MM, 1043(ab)
Morris, TI, 846(ab)
Morrow, TJ, 945(ab)
Morteau, S, 335(ab)
Mortelmans, L, 124(ab), 275(ab), 775(ab), 1419(ab)
Morton, TE, 413(ab)
Moscatelli, G, 1191(ab)
Moskovitz, B, 1025
Mostbeck, A, 1365(ab)
Motekaitis, RJ, 322(ab)
Motohashi, N, 906(ab)
Motoishi, S, 1183(ab), 1188(ab)
Motomura, N, 805(ab)
Motta, A, 71(ab)
Mountz, JM, 228, 318(ab), 319(ab), 422(ab), 887, 965(ab), 990(ab), 997(ab)
Moustafa, H, 40(ab)
Moyer, BR, 1142(ab)
Mozley, PD, 122(ab), 541(ab), 584, 988(ab), 989(ab), 999(ab), 1251(ab), 1314(ab), 1964
Mruck, S, 790(ab), 1587
Mu, M, 150(ab), 1065(ab), 1066(ab)
Mu, X, 713(ab), 742(ab)
Mueller, C, 1304(ab)
Mueller, S, 819(ab)
Mueller-Brand, J, 577(ab)
Mueller-Vahl, K, 1006(ab)
Mueller-York, A, 137(ab)
Mufti, OI, 1104(ab)
Mühlensiepen, H, 556, 1250
Mukai, M, 1222(ab)
Mukai, T, 173(ab), 1016(ab)
Mukherjee, J, 94(ab), 101(ab), 264(ab), 481(ab)
Mulder, NH, 1157(ab)
Mullah, N, 912
Mullan, BP, 934
Mullani, NA, 263
Mullen, GE, 485(ab)
Muller, F, 137(ab)
Muller, SH, 1229(ab), 1500
Müller, SP, 553(ab), 837(ab), 1333(ab)
Müller-Gärtner, HW, 533(ab)
Müller-Schauenburg, W, 871(ab)
Müller-Suur, R, 1203
Mulligan, RS, 477(ab), 935(ab), 954(ab)
Mulnix, TL, 80(ab)
Muñoz, A, 2038
Munz, DL, 47(ab), 284(ab), 507(ab), 722(ab), 723(ab), 792(ab), 895(ab), 1233(ab), 1344(ab), 1402(ab)
Munz, F, 238(ab), 1279
Murase, K, 590, 836(ab), 1010(ab), 1389(ab)
Murata, H, 283, 337, 1147(ab)
Murata, T, 938(ab), 958(ab)
Murland, K, 1094(ab)
Murray, AD, 1451
Murray, JA, 1105(ab)
Murthy, K, 1851
Musachio, JL, 417(ab), 478(ab), 902(ab), 909(ab), 1417
Muschick, P, 27(ab)
Mutic, S, 1241(ab)
Muto, M, 736(ab)
Muto, P, 1065
Muzic RF, Jr, 855(ab)
Muzik, O, 141(ab), 245(ab), 290(ab), 357(ab), 1162(ab), 1227
Myers, RW, 297(ab)
Myles, JS, 418(ab)

Nabeshima, K, 268(ab)
Nabi, HA, 433(ab)
Nachar, O, 1324
Nader, MA, 413(ab)
Nader, SH, 413(ab)
Naehrig, J, 443(ab)
Nagai, R, 978
Nagamachi, S, 111(ab), 268(ab)
Nagamatsu, H, 704(ab)
Nagamatsu, T, 1377(ab)
Nagao, M, 590, 1010(ab)
Nagaraj, N, 1218(ab)
Nagasawa, M, 600
Nagashima, K, 71
Nagashima, S, 1318(ab)
Nagatsu, K, 584(ab)
Nagaya, N, 1127
Någren, K, 65
Nahmias, C, 1087(ab), 1636
Nair, A, 203(ab)
Nair, M, 184(ab)
Nair, N, 1027(ab), 1245(ab)
Naito, M, 600
Naito, S, 12(ab), 760(ab)
Najafi, AA, 1092(ab)
Naji, S, 1357(ab)
Nakabeppu, Y, 745(ab), 1334(ab)
Nakada, K, 214(ab), 450(ab), 1155(ab), 2026
Nakagawa, K, 29(ab), 175(ab)
Nakagawa, M, 974(ab), 975(ab), 1250(ab)
Nakagawa, Y, 29(ab), 175(ab)
Nakahara, H, 111(ab), 268(ab)
Nakahara, T, 1222(ab), 1223(ab), 1268(ab)
Nakajima, K, 193(ab), 390(ab), 727(ab), 738(ab), 1383(ab)
Nakajima, S, 1031(ab), 1484
Nakajima, T, 736(ab)
Nakajo, M, 745(ab), 1334(ab)
Nakamoto, Y, 1144(ab), 1190(ab), 1313(ab), 1381(ab), 1898
Nakamura, K, 50(ab), 51(ab), 453(ab), 1222(ab), 1223(ab)
Nakamura, N, 805(ab)
Nakamura, S, 301(ab), 702(ab)
Nakamura, T, 712(ab), 1484
Nakanishi, N, 1127
Nakano, S, 963(ab), 964(ab), 1155, 1642
Nakano, T, 710(ab)
Nakao, S, 745(ab)
Nakasaki, H, 1240(ab)
Nakata, S, 89(ab), 1005(ab)
Nakata, T, 502(ab)
Nakatani, S, 761(ab)
Nakayama, M, 1016(ab)
Nam, S-J, 1265(ab)
Namavari, M, 146(ab), 147(ab), 228(ab), 289(ab), 317(ab), 321(ab), 851(ab)
Namba, S, 1016(ab)
Nambu, Y, 85
Namiuchi, S, 2063
Nanasato, M, 744(ab)
Narabayashi, I, 712(ab), 1302(ab)
Narayan, M, 910(ab)
Narayanan, MV, 872(ab)
Narayanan, TK, 94(ab), 101(ab), 264(ab), 481(ab)
Nariai, T, 345
Narula, J, 185(ab), 188(ab), 499(ab), 500(ab), 793(ab), 1541
Narula, N, 185(ab), 500(ab)
Naruse, H, 1418(ab)
Nash, MM, 1107(ab)
Natale, D, 794(ab)
Nateman, DR, 337(ab)
Nathan, L, 11(ab)
Nativ, O, 1025
Naumann, R, 280(ab)
Navarro, V, 562(ab)
Nayak, N, 309
Nazer, H, 215
Neal, CE, 36(ab)
Nebu, A, 1010(ab)
Neeleman, N, 136(ab)
Neise, E, 1312(ab)
Nekolla, SG, 7(ab), 13(ab), 172(ab), 195(ab), 358(ab), 701(ab), 753(ab), 773(ab)
Nelles, G, 553(ab)
Nelson, AD, 232(ab), 456(ab), 776(ab)
Nelson, CA, 1142(ab)
Nelson, RA, 417(ab)
Nestadt, G, 925(ab)
Netusil, N, 550(ab), 1352
Neuber, K, 1317(ab)
Neuberg, D, 269
Neumaier, B, 294(ab), 531, 1058(ab), 1138(ab), 1145(ab)
Neumann, DR, 178(ab)
Neumann, RD, 1093
Neumeister, A, 36
Neurath, M, 41(ab)
Neverve, J, 753(ab)
Newberg, AB, 252(ab), 999(ab), 1964
Newman, CC, 400(ab)
Newman, D, 1420(ab), 1422(ab)
Newman, DP, 112(ab), 814(ab)
Ng, CK, 234
Ng, DC, 631
Ngo, K, 415(ab)
Nguyen, H, 1141(ab)
Nguyen, K, 146(ab), 228(ab), 317(ab), 321(ab), 1126(ab)
Nichols, K, 15(ab), 17(ab), 176(ab), 364(ab), 848(ab), 850(ab), 1308, 1445
Nicholson, RL, 1569
Nickerson, LD, 66(ab)
Nickles, RJ, 80(ab), 959(ab), 1015(ab), 1074(ab), 1363(ab)
Nicolo, G, 306(ab)
Niederle, B, 1339(ab)
Nielsen, F, 171(ab)
Niesen, A, 1280(ab)
Nieweg, OE, 302(ab), 1229(ab), 1500
Nijhof, MW, 896
Nikolov, G, 197(ab)
Nikula, T, 1174(ab), 1177(ab)
Nilsson, O, 636
Nilsson, T, 49(ab)
Nioche, C, 979(ab)
Nishida, H, 71
Nishide, Y, 24(ab)
Nishigaki, K, 71

Nishii, R, 111(ab), 268(ab)
Nishijima, K, 584(ab)
Nishikawa, M, 906(ab), 911(ab)
Nishimura, K, 293, 758(ab)
Nishimura, S, 1879
Nishimura, T, 20(ab), 180(ab), 713(ab), 742(ab), 795(ab), 1009(ab), 1102, 1134, 1137(ab), 1237(ab), 1273(ab)
Nishiooeda, Y, 993(ab)
Nishiyama, S, 1409
Nishiyama, Y, 273(ab), 411, 425(ab), 508(ab), 1294(ab), 1371(ab)
Nishizawa, S, 840(ab), 977(ab)
Nitta, K, 919
Niu, ZT, 451(ab), 1396(ab)
Noachtar, S, 1004(ab)
Nobezawa, S, 1209(ab), 1318(ab)
Nobili, F, 978(ab)
Nobuhara, K, 477(ab)
Nobuta, A, 1300(ab)
Noda, A, 1409, 1879
Noda, T, 71
Noguchi, J, 345
Noll, B, 27(ab)
Noll, D, 894(ab)
Noll, T, 556
Nollert, J, 559(ab)
Nonokawa, M, 744(ab)
Norenberg, J, 438(ab), 1109(ab)
Norrby, PO, 1083(ab)
Nosotti, M, 1276(ab)
Novotny, C, 578(ab), 786(ab)
Nowak, B, 174(ab), 347(ab), 774(ab), 1275(ab)
Nowak, PA, 1064(ab)
Nowicki, B, 152(ab)
Nozaki, S, 1134
Nozaki, Y, 743(ab)
Nuesslin, F, 871(ab)
Nunan, TO, 304(ab)
Nunez, M, 106(ab)
Núñez, RF, 140(ab), 282(ab)
Nunn, AD, 470(ab)
Nutt, DJ, 418(ab), 538(ab)
Nutt, R, 78(ab), 1369
Nuutinen, J, 788
Nuyts, J, 775(ab), 1419(ab)
Nyberg, S, 924(ab)
Nygaard, E, 76(ab)

Obaldo, JM, 575(ab)
Öberg, K, 1514
Obrocki, J, 921(ab)
Obuchowski, NA, 178(ab)
Obwegeser, R, 426
Ochi, H, 830, 1298(ab), 1299(ab), 1378(ab), 1379(ab), 1391(ab), 1394(ab)
Ochiai, K, 1393(ab)
O'Connor, M, 1964
O'Connor, MK, 885(ab), 1383
Odaka, K, 7(ab), 172(ab), 701(ab)
O'Doherty, MJ, 159(ab), 304(ab), 1134(ab), 1202(ab), 1284(ab)
O'Donnell, JK, 457(ab), 776(ab)
O'Donnell, RT, 324(ab), 564(ab), 952, 1215(ab)
O'Donoghue, JA, 538, 1905
Oetjen, K, 1271
Offord, RE, 1184(ab)
Ofluoglu, S, 578(ab), 1304(ab)
Ogasawara, K, 795
Ogawa, A, 795
Ogawa, H, 736(ab)
Ogawa, K, 906(ab), 1016(ab)
Ogawa, T, 706(ab), 1012(ab)
Ogawa, Y, 365(ab)
Ogi, N, 345
Oguchi, M, 85, 973(ab), 1295(ab)
Oh, BH, 504(ab)
Oh, KK, 1263(ab)
Oh, SH, 961(ab)
Oh, SJ, 202(ab), 593(ab), 1122(ab), 1399(ab), 1401(ab)
Ohbayashi, N, 257
Ohira, H, 1561
Ohkawa, M, 273(ab), 411, 425(ab), 508(ab), 1294(ab), 1371(ab)
Ohkubo, S, 360(ab)
Ohkura, K, 584(ab)
Ohlsson, T, 962(ab), 1198(ab)
Ohmichi, M, 86(ab), 747(ab), 756(ab), 758(ab), 1393(ab), 1407(ab)
Ohmiya, Y, 584(ab)
Ohnishi, T, 906(ab), 911(ab), 963(ab), 964(ab), 1155
Ohno, R, 805(ab)
Öhrvall, U, 1514
Ohshima, M, 424(ab)
Ohta, K, 352(ab)
Ohta, T, 766(ab)
Ohtake, T, 828(ab), 978
Ohtomo, K, 551(ab), 823, 828(ab), 978, 1947
Ohuchi, N, 1561
Ohyanagi, M, 1418(ab)
Oikonen, V, 65
Ojha, BC, 422(ab), 990(ab)
Okabe, M, 712(ab)
Okada, H, 1209(ab), 1318(ab)
Okada, M, 51(ab)
Okada, RD, 784(ab), 785(ab)
Okamoto, K, 973(ab)
Okamoto, R, 501(ab)
Okazaki, H, 727(ab)
Okazaki, K, 1381(ab)
Okazawa, H, 242(ab), 957(ab)
O'Keefe, JH, 529(ab), 778(ab)
O'Kelly, KF, 1094(ab)
Okizaki, A, 50(ab), 365(ab)
Oku, S, 828(ab)
Okubo, Y, 548(ab)
Okumura, W, 721(ab)
Okuno, A, 1405(ab)
Olea, E, 575(ab)
Olgunturk, R, 191(ab)
Oliveira, JF, 1101(ab)
Oliveira, MB, 1101(ab)
Olivi, A, 1200(ab)
O'Loughlin, E, 204(ab)
Olsen, E, 1115(ab)
Olsen, MH, 171(ab)
Olsen, NV, 1363(ab)
Olsson, CL, 831(ab)
Omar, WM, 18(ab)
O'Mara, RE, 1198
Omata, N, 938(ab), 958(ab)
Omiecinski, E, 846(ab)
Ong, GL, 2089
Onizuka, T, 111(ab)
Ono, M, 1016(ab)
Ono, Y, 1737
Onoma, K, 1188(ab)
Önsel, Ç, 1163
Onthank, DC, 132(ab), 1141(ab)
Onuma, K, 1183(ab)
Oosterwijk, E, 462(ab), 563(ab)
Ootawa, N, 756(ab), 1407(ab)
Oquendo, MA, 903(ab)
Orchard, KH, 463(ab)
Ordonez, C, 222(ab), 846(ab)
Orenstein, SR, 206(ab)
Oriuchi, N, 337, 1272(ab)
Orlandi, C, 1299
Orr, MD, 1025(ab)
Osada, H, 86(ab), 747(ab), 756(ab), 758(ab), 1393(ab), 1406(ab), 1407(ab)
Osaki, S, 28(ab)
Oshima, S, 12(ab), 720(ab), 721(ab), 759(ab), 760(ab)
Osman, S, 605, 706
Oster, ZH, 28(ab)
Ostertag, H, 1042(ab)
Osugi, K, 710(ab)
O'Sullivan, F, 125(ab)
Otermin, P, 405
Otsubo, H, 981(ab)
Ottowitz, W, 899(ab)
Ouchi, Y, 1209(ab), 1318(ab)
Ouellet, R, 1324
Oumichi, M, 1406(ab)
Outif, AM, 182(ab)
Overoye, KL, 1141(ab)
Ovize, M, 771(ab)
Owega, A, 914(ab)
Owen, NK, 471(ab), 1079(ab)
Oya, H, 1127
Oya, S, 150(ab), 1064(ab), 1065(ab), 1066(ab)
Øye, I, 1279
Oyen, WJ, 129(ab), 136(ab), 456, 462(ab), 463, 498(ab), 517(ab), 563(ab), 622, 643, 896, 912, 1125(ab), 1182(ab), 1404(ab)
Ozaki, K, 1377(ab)
Ozawa, S, 1222(ab)
Ozdemir, H, 207(ab)
Ozkaya, O, 207(ab)
Ozker, KS, 1086(ab)
Ozugur, S, 1400(ab)

Paans, AMJ, 353(ab)
Pache, J, 753(ab)
Padhy, A, 106(ab)
Padhy, AK, 40(ab), 575(ab)
Paek, MY, 845(ab)
Paganelli, G, 1173(ab)
Page, CJ, 304(ab), 1134(ab)
Page, D, 263
Paik, CH, 318, 755, 1033(ab), 1093, 1149(ab), 1152(ab)
Paik, JY, 1395(ab)
Pak, KY, 785(ab)
Palestro, CJ, 36(ab), 58(ab), 60(ab), 61(ab), 63(ab), 380(ab), 382(ab), 474, 1224, 1336(ab)
Palkovic, S, 984(ab), 995(ab)
Pallela, VR, 107, 161, 1108
Pallone, F, 242
Palmer, J, 49(ab)
Pan, D, 1081(ab)
Pan, WHT, 1102(ab)
Pan, ZM, 1375(ab)
Panageas, KS, 323(ab)
Panarotto, B, 494(ab), 732(ab)
Pangerl, T, 786(ab)
Panholzer, PJ, 308(ab), 375(ab)
Panico, L, 1264(ab)
Panin, VY, 530(ab)
Panyutin, IG, 1093
Papaspyrou, M, 556
Papatheofanis, FJ, 1021
Papavasileiou, P, 825(ab)
Papke, K, 267(ab)
Pappas, NR, 98(ab), 103(ab), 411(ab), 420(ab), 550(ab), 916(ab), 917(ab), 922(ab), 1352
Parbhoo, SP, 110(ab), 448(ab), 572(ab), 1258(ab)
Pardo, M, 106(ab)
Parent, F, 16(ab), 768(ab), 782(ab)
Park, B-N, 1073(ab)
Park, CC, 888(ab)
Park, CH, 554(ab), 777(ab), 1045(ab), 1060(ab), 1217(ab), 1293(ab), 1430(ab), 1434(ab)
Park, CW, 1033(ab), 1148(ab)
Park, HJ, 1140(ab)
Park, HW, 26(ab), 384(ab)
Park, JH, 368(ab)
Park, JM, 6(ab), 730(ab), 1225(ab), 1265(ab), 1296(ab), 1395(ab)
Park, JY, 1285(ab)
Park, KB, 26(ab), 1045(ab), 1060(ab), 1164(ab)
Park, KC, 1177
Park, KS, 342(ab), 363(ab), 386(ab), 387(ab), 493(ab), 845(ab), 912(ab)
Park, KY, 1140(ab)
Park, LS, 1033(ab), 1149(ab)
Park, SG, 447(ab)
Park, SH, 1000(ab), 1212(ab)
Park, SJ, 361(ab), 1122(ab)
Park, SW, 361(ab), 1122(ab)
Park, SY, 1309(ab)
Park, T, 202(ab)
Park, YB, 504(ab)
Park, YH, 368(ab), 371(ab), 1408(ab)
Park, YM, 371(ab)
Parkey, RW, 185(ab)
Parma, E, 575(ab)
Parr, L, 15N(3)
Parsey, RV, 225(ab), 903(ab), 904(ab), 947(ab), 1465
Partanen, PK, 788
Partyka, DV, 322(ab)
Parving, HH, 171(ab)
Pascual-Sedano, B, 980(ab)
Pasqualini, R, 141
Pasqualoni, R, 647
Passaro, EA, 259(ab)
Passchier, J, 260(ab), 547(ab), 1830
Pastan, I, 755, 1033(ab), 1148(ab), 1150(ab)
Pastor, M, 328(ab)
Patel, S, 1192(ab)
Patel, T, 985(ab)
Patillo, M, 263
Patt, BE, 220(ab)
Patt, M, 1018(ab)
Patton, DD, 16N(2), 26N(11),
Patton, JA, 34(ab), 84(ab), 891(ab), 1197(ab), 1235(ab), 1364
Patton, PW, 326(ab)
Paul, AK, 20(ab), 713(ab), 742(ab), 1237(ab)
Paul, K, 1673
Paula, EF, 1100(ab)
Paulson, OB, 959(ab)
Paulson, PE, 945(ab)
Paus, T, 845(ab)
Pauwels, S, 370(ab), 436(ab), 437(ab), 438(ab), 1143(ab)
Pavel, DG, 249(ab)
Pavlinovic, Z, 1061(ab), 1203(ab)
Payne, JK, 901(ab)
Peacock, K, 204(ab)
Pearson, DA, 1142(ab)
Pedersen, H, 464(ab)
Peeters, C, 275(ab)
Peghini, PL, 1646
Pegoix, M, 1398(ab)
Peker, C, 567
Pelizzo, MR, 216(ab), 1332(ab), 1343(ab)
Pellegrini, VD, 45(ab), 116(ab), 1175(ab)
Pellerito, R, 1006
Pelosi, E, 982(ab)
Peng, NJ, 1262(ab), 1359(ab), 1380(ab)
Pentlow, KS, 817(ab)
Peñuelas, I, 439, 1278(ab)
Peppert, E, 1042(ab)
Perani, D, 1849
Pereira, M, 93
Pereira, NS, 1116(ab)
Perez, V, 920(ab)
Perloff, JK, 708(ab)
Perng, HW, 783(ab)
Perrier, ND, 112(ab), 814(ab)
Peschel, C, 1178(ab)
Peschke, P, 1139(ab)
Peschl, S, 395(ab)
Pestell, SJ, 1451
Peter, W, 235(ab)
Petersen, K, 921(ab)
Peterson, CD, 573(ab)
Peterson, LM, 108(ab), 442(ab), 1254(ab)
Petorius, H, 1055(ab)
Petrelli, N, 1016
Petric, A, 95(ab)
Petrich, T, 1006(ab)
Petrov, A, 793(ab)
Pettinato, G, 1264(ab)

Pezzoli, G, 994(ab)
Pfluger, T, 1823
Pham, AN, 1281(ab)
Phelps, ME, 1, 11, 146(ab), 147(ab), 228(ab), 243(ab), 247(ab), 248(ab), 251(ab), 277(ab), 289(ab), 295(ab), 317(ab), 321(ab), 394(ab), 428(ab), 430(ab), 432(ab), 461(ab), 540(ab), 560(ab), 661, 867(ab), 1081(ab), 1098(ab), 1177, 1206(ab), 1232(ab), 1291(ab), 1303(ab), 1373(ab), 1929
Phillips, WT, 857(ab), 1019(ab), 1390(ab)
Pi, B, 806(ab)
Pica, CM, 163(ab)
Pichler, BJ, 77(ab), 887(ab)
Picker, W, 837
Pidcock, J, 415(ab)
Piel, M, 897(ab)
Piepsz, A, 23, 198(ab), 366(ab)
Piers, DA, 353(ab), 1793
Piert, M, 518(ab), 1255(ab)
Pieterman, RM, 260(ab), 1199(ab), 1830
Pieters, GF, 643
Pietrini, P, 247(ab), 575
Pietrzyk, U, 73(ab)
Piffanelli, A, 71(ab), 1096(ab)
Pigeot, J, 506(ab)
Pihet, P, 1041(ab)
Pijpers, R, 1168
Pike, VW, 152(ab), 477(ab)
Pilartz, M, 1145(ab)
Pilger, A, 250
Pillai, MRA, 1089(ab), 1090(ab), 1095(ab)
Pillarsetty, NK, 1079(ab)
Pilotti, S, 1491
Pilowsky, LS, 477(ab), 935(ab), 954(ab)
Pimpl, W, 77(ab)
Pinkert, J, 1146(ab)
Pinsky, D, 772(ab)
Pio, BS, 1206(ab), 1373(ab)
Piot, O, 196(ab)
Piotto, A, 216(ab), 1332(ab)
Pipes, DW, 336(ab), 1111(ab)
Pirich, C, 7(ab), 250
Pirker, W, 36
Pistorius, K, 350(ab)
Pither, RJ, 183
Piwnica-Worms, D, 163(ab)
Pizzocaro, C, 305(ab), 494(ab), 732(ab), 1227(ab)
Plaizier, MA, 1168
Plascjak, P, 334(ab)
Pless, M, 577(ab)
Plichta, K, 1242(ab), 1280(ab)
Plössl, K, 150(ab), 541(ab), 584, 988(ab)
Plukker, JT, 555(ab)
Pocock, N, 467(ab)
Podda, M, 1276(ab)
Podio, V, 982(ab)
Podoloff, DA, 113(ab), 115(ab), 127(ab), 327(ab), 580(ab), 1027(ab), 1051(ab), 1075(ab), 1201(ab), 1245(ab)
Poepperl, G, 969(ab)
Poepping, D, 937(ab)
Pointon, B, 859(ab)
Pointurier, I, 16(ab), 768(ab), 769(ab), 770(ab), 799(ab)
Polat, B, 1145(ab)
Pollak, A, 487(ab)
Pollock, CM, 487(ab)
Pomper, MG, 939(ab), 1417
Ponomarev, V, 145(ab), 316(ab), 320(ab), 1158(ab)
Ponto, JA, 44(ab)
Porcu, A, 1259(ab)
Porlier, N, 429
Porn, U, 204(ab)
Postema, EJ, 1182(ab)
Posthauer, J, 263
Poterio, J, 1224(ab)
Potier, JC, 9(ab), 194(ab), 845
Potts, NV, 344(ab)
Pötzi, C, 1339(ab)
Pounds, TR, 297(ab)
Pourdehnad, M, 37(ab), 118(ab), 134(ab), 451(ab), 1210(ab), 1396(ab), 1411(ab)
Powe, JE, 215
Powers, WJ, 85(ab), 88(ab), 244(ab), 800, 1363
Powitan, Y, 125(ab)
Pozzato, C, 1702
Pozzilli, P, 242
Prabhu, KR, 1079(ab)
Prakash, S, 1096(ab)
Prandini, N, 62(ab)
Prang, JU, 294(ab)
Prasad, GS, 905(ab)
Praschak-Rieder, N, 36
Pratap, M, 102(ab)
Prato, FS, 1569
Prcevski, P, 1227
Prentice, HG, 463(ab)
Presselt, N, 1280(ab)
Pretorius, PH, 872(ab), 1391
Price, DT, 1025(ab)
Price, JC, 1842
Price, PM, 706, 827(ab)
Prigent, A, 16(ab), 768(ab), 769(ab), 770(ab), 799(ab)
Prigent, FM, 746(ab)
Prior, JO, 1184(ab)
Pritikin, TT, 22N(4)
Prueter, I, 1219(ab)
Prüfert, U, 250
Pruim, J, 260(ab), 293(ab), 1199(ab), 1244(ab), 1830
Prvulovich, E, 733(ab)
Przetak, C, 233(ab), 1242(ab), 1280(ab)
Pujol, J, 405
Pullman, J, 363
Puls, R, 137(ab)
Pumiglia, K, 1029(ab)
Punjabi, GV, 201(ab)
Pupi, A, 545(ab)
Pursel, SE, 1281(ab)
Pusuwan, P, 575(ab)
Putnam, P, 206(ab)
Pyatt, B, 412(ab)

Qi, J, 70(ab)
Qin, SW, 217(ab)
Qu, T, 363
Qu, Z, 1185(ab)
Quaden, C, 1154(ab)
Quadri, SM, 463(ab)
Quaife, RA, 762(ab)
Quak, JJ, 1999
Que, TH, 293(ab), 555(ab), 1244(ab)
Quinn, TP, 161(ab)
Quinones, M, 170(ab)
Quinton, TM, 1104(ab)
Quiroz, M, 106(ab)
Qureshi, E, 364(ab)

Raaymakers, PR, 1216(ab)
Rachinsky, I, 1397(ab)
Radau, PE, 220, 423(ab), 969(ab)
Radcliffe, O, 902(ab)
Raderer, M, 1304(ab)
Rades, D, 1307(ab)
Rae, MT, 159(ab), 1134(ab)
Raedler, TJ, 92(ab), 99(ab), 100(ab)
Raemaekers, JM, 1182(ab)
Raes, B, 340(ab)
Rafecas, M, 77(ab), 887(ab)
Raffelt, K, 32(ab)
Raja, S, 258(ab)
Rajeevan, N, 1343
Rajendran, JG, 576(ab)
Rajic, M, 1370(ab), 1433(ab)
Rajon, DA, 326(ab)
Rajopadhye, M, 129(ab), 132(ab), 1141(ab)
Rajvanshi, P, 474
Rakotonirina, H, 1274(ab)
Ramackers, JM, 1011(ab)
Ramalingam, K, 470(ab)
Ramamoorthy, N, 1090(ab)
Ramappa, P, 5(ab), 357(ab)
Rammohan, R, 185(ab), 711(ab)
Ramos, CD, 996(ab), 1224(ab), 1234(ab)
Ramsey, J, 541(ab), 988(ab)
Ranicar, A, 605
Rao, DV, 189, 682, 941, 2043
Rao, J, 297(ab), 300(ab)
Rao, PS, 161, 211(ab), 1021(ab)
Rao, SP, 1108
Raphael, SJ, 1010
Rapoport, SI, 575
Rasey, JS, 142(ab), 442(ab)
Rastad, J, 275
Rattat, D, 119(ab)
Ratzlaff, NW, 1287
Rau, FC, 452(ab)
Rauch, SL, 104(ab), 899(ab)
Rauser, L, 1070(ab)
Rauth, AM, 169, 1024(ab)
Raven, PB, 927(ab)
Ravert, HT, 417(ab), 902(ab), 909(ab), 1080(ab), 1361(ab)
Ravikrishnan, KP, 1281(ab)
Ravizzini, GC, 740(ab)
Raylman, RR, 221(ab)
Reddy, K, 1021(ab)
Reed, MW, 1093
Rees, JH, 1324(ab)
Rees, SE, 583(ab)
Refosco, F, 1096(ab)
Regan, DD, 114(ab), 309(ab), 325(ab), 1579
Rehm, K, 612
Reichart, B, 172(ab), 195(ab), 773(ab)
Reichert, DE, 164(ab), 1083(ab)
Reidel, G, 1178(ab)
Reidl, G, 270(ab)
Reif, DW, 939(ab), 1417
Reilly, RM, 429, 903, 1024(ab)
Reiman, RE, 1057(ab)
Reimold, M, 966(ab), 1018(ab)
Reinartz, P, 237(ab), 914(ab)
Reinhardt, M, 1362(ab)
Reischl, G, 333(ab), 1110(ab), 1118(ab)
Rela, M, 53(ab)
Remmert, S, 376(ab)
Ren, C, 1214(ab)
Ren, XQ, 2(ab)
Reneman, L, 419(ab), 900(ab)
Rennen, HJ, 1088(ab), 1125(ab)
Reno, JM, 131
Rentschler, M, 531
Rescigno, J, 1409(ab)
Reske, SN, 107(ab), 119(ab), 294(ab), 310(ab), 503(ab), 531, 882(ab), 1058(ab), 1138(ab), 1145(ab), 1695
Reske, SS, 1297(ab)
Reuner, U, 992(ab)
Reutens, DC, 926
Reutter, BW, 79(ab)
Reynolds, CA, 485(ab)
Reynolds, JC, 1646
Rha, YS, 91(ab)
Rhodes, B, 449
Rhodes, CG, 827(ab)
Ricaurte, G, 546(ab)
Riccabona, G, 575(ab)
Ricci, A, 867(ab)
Richard, B, 205(ab)
Richard, J, 335(ab)
Richter, E, 376(ab), 558(ab), 1067, 1219(ab), 1290(ab), 1329(ab)
Richter, JA, 439, 556(ab), 1278(ab)
Richter, S, 936(ab)
Richter, WS, 722(ab), 723(ab), 792(ab)
Rickert, C, 984(ab), 995(ab)
Riddell, C, 532(ab)
Riedel, E, 1234(ab)
Riedel, ER, 282(ab)
Riehl, J, 7(ab)
Riemann, B, 267(ab), 937(ab), 943(ab), 956(ab), 984(ab), 995(ab)
Riemenschneider, M, 250(ab)
Riggs, JE, 1002(ab)
Righi, E, 1522
Righini, A, 994(ab)
Rigo, P, 1154(ab)
Rijo, J, 1282(ab)
Rikimaru, H, 1377(ab)
Rimoldi, O, 187(ab)
Ringelstein, EB, 937(ab), 943(ab), 956(ab)
Rini, JN, 382(ab)
Rinne, JO, 65
Rioux, A, 1324
Rippin, G, 444(ab)
Riva, N, 1191(ab)
Riva, P, 1191(ab)
Rizzo, G, 399(ab)
Robbins, RC, 1(ab), 589(ab)
Robert, F, 331(ab)
Roberts, AD, 80(ab), 1074(ab)
Roberts, DW, 1619
Roberts, RA, 1107(ab), 1111(ab)
Robertson, CN, 1025(ab)
Robins, PD, 934
Rockey, DC, 56(ab), 1727
Rodari, M, 1270(ab)
Roddy, R, 1369
Rodrigues, M, 426, 1495
Rodriguez, G, 978(ab)
Rodriguez, O, 25(ab)
Rodrigus, PT, 1328(ab)
Roe, DG, 487(ab)
Roeber, N, 864(ab)
Roesch, F, 441(ab), 897(ab), 1110(ab)
Rogers, BE, 318(ab), 319(ab), 887
Rogers, JS, 1292(ab)
Rogers, WL, 68(ab), 76(ab)
Rognoni, M, 1276(ab)
Rogoz, R, 265(ab)
Rogulski, K, 316(ab)
Rohatgi, R, 772(ab)
Rohde, GK, 1197(ab)
Roivainen, R, 788
Romano, JE, 1056
Romeike, BF, 936(ab)
Rommelfanger, SG, 114(ab), 325(ab), 999, 1579
Ronen, SM, 1156(ab), 1753
Ronga, G, 1522
Roos, JC, 1168, 1999
Roozendaal, GK, 302(ab)
Rosa, P, 536(ab)
Rosato, F, 306(ab)
Rose, DS, 945(ab)
Rosenberg, J, 113(ab)
Rosenblum, ML, 1200(ab)
Rosenthal, DI, 122(ab)
Rossert, J, 78
Rossi, CR, 303(ab)
Rossini, PL, 305(ab), 494(ab), 732(ab), 1227(ab)
Rossleigh, MA, 1030
Rossman, MD, 451(ab), 1396(ab), 1411(ab)
Rosso, J, 491(ab)
Rosso, L, 1276(ab)
Roth, BL, 1070(ab)
Rottenberg, DA, 612, 1077(ab)
Rousseau, JA, 1324
Rouvier, E, 480
Rouze, NC, 875(ab)
Roy, PK, 1646
Rozanski, A, 339(ab), 364(ab), 1308, 1445
Rozenman, Y, 716(ab)
Rozet, I, 1403(ab)
Ruan, S, 1905

Rubello, D, 216(ab), 303(ab), 1332(ab), 1343(ab)
Rubin, AD, 93, 213(ab)
Rudat, V, 559(ab)
Ruddy, TD, 348(ab), 349(ab), 1426
Rudge, P, 1324(ab)
Rudi, J, 446(ab)
Rüdiger, HW, 250
Ruechel, R, 1128(ab)
Ruers, TJ, 136(ab)
Runge, R, 1167(ab)
Ruottinen, HM, 65
Rusckowski, M, 363, 486(ab), 586(ab), 788(ab), 1028(ab), 1127(ab)
Russel-Jones, R, 304(ab)
Russell, CD, 200(ab), 1332
Rutar, F, 1109(ab), 1179(ab)
Rutgers, EJ, 1500
Ruth, TJ, 859(ab)
Rutka, JT, 981(ab)
Ryan, C, 1080(ab)
Ryding, E, 962(ab)
Rypins, EB, 36(ab), 38(ab), 39(ab), 449
Ryu, JS, 52(ab), 91(ab), 361(ab), 447(ab), 512(ab), 593(ab), 1122(ab), 1140(ab), 1374(ab), 1399(ab), 1401(ab), 1423(ab), 1836
Ryu, YH, 384(ab), 913(ab), 1263(ab)

Sabatier, R, 194(ab)
Sabba, N, 71(ab)
Sabbah, P, 979(ab)
Sabri, O, 237(ab), 347(ab), 914(ab)
Sadato, N, 301(ab), 938(ab), 958(ab), 977(ab), 1357, 1612
Sadek, S, 1348(ab)
Saeed, S, 107
Saegusa, S, 1947
Safaei, A, 461(ab)
Safi, N, 1801
Saga, T, 727(ab), 1016(ab), 1144(ab), 1190(ab), 1313(ab), 1381(ab), 1898
Sage, L, 331(ab)
Sago, M, 919
Saha, GB, 258(ab)
Sai-Maurel, C, 215(ab)
Sain, JD, 804(ab)
Saint-Pierre, G, 1011(ab)
Saito, K, 501(ab), 710(ab)
Saitoh, M, 89(ab), 1364(ab)
Saitou, R, 926(ab)
Saitta, B, 8(ab), 705(ab)
Saji, H, 1016(ab)
Sajjad, M, 1077(ab)
Sakahara, H, 1190(ab), 1313(ab), 1381(ab), 1898
Sakai, S, 590
Sakaki, T, 1418(ab)
Sakamaki, F, 1127
Sakamoto, S, 964(ab), 976(ab)
Sakamoto, T, 963(ab)
Sakanoue, Y, 830
Sakata, I, 1031(ab)
Sakuma, H, 24(ab)
Sakurai, A, 85
Sakurai, M, 743(ab)
Saladini, G, 1332(ab)
Salazar, I, 934
Saleemi, K, 514(ab)
Salem, S, 1230(ab), 1348(ab)
Salgam, M, 128(ab), 1029(ab)
Salmon, E, 247(ab)
Salopek, TG, 288(ab)
Salvador, J, 1278(ab)
Salvatore, M, 1261(ab), 1264(ab)
Salvatore, V, 994(ab)
Samal, M, 546(ab), 1365(ab)
Sambataro, G, 1597
Samejima, T, 268(ab)
Sameshima, T, 1642
Samnick, S, 936(ab)
Samuel, G, 1089(ab), 1090(ab), 1095(ab)
Samuels, LE, 500(ab)
San Pedro, EC, 228, 965(ab), 997(ab)
Sanchez, AF, 140(ab)
Sanchez-Pernaute, R, 944(ab)
Sandberg, K, 1361(ab), 1362(ab)
Sandell, A, 962(ab), 1198(ab)
Sandell, J, 152(ab)
Sandgren, EP, 321(ab)
Sandhu, J, 429, 903
Sandler, MP, 34(ab), 84(ab), 771, 891(ab), 1123, 1197(ab), 1235(ab), 1364
Sandrock, D, 47(ab), 284(ab), 507(ab), 1402(ab)
Sandrock, DH, 1344(ab)
Santambrogio, L, 1276(ab)
Santana, CA, 752(ab), 846(ab), 1941
Santens, P, 1071(ab)
Santiago, JF, 1230(ab), 1348(ab)
Santimaria, M, 1191(ab)
Santos, AO, 996(ab), 1224(ab)
Sapienza, MT, 255(ab)
Sarda, L, 355(ab), 1274(ab)
Sari, O, 1193(ab)
Saris, E, 643
Sarkar, MR, 1695
Sarkar, SD, 63(ab), 1336(ab)
Sarma, HD, 1089(ab), 1090(ab), 1095(ab)
Sarosiek, I, 516(ab)
Sarrazin, JL, 979(ab)
Sartori, L, 71(ab)
Sasai, K, 1190(ab)
Sasaki, M, 974(ab), 975(ab), 976(ab), 1250(ab)
Sasaki, N, 1298(ab), 1299(ab), 1378(ab), 1379(ab), 1391(ab), 1394(ab)
Sasaki, Y, 283, 337, 1147(ab)
Sasako, K, 726(ab)
Sass, H, 914(ab)
Sato, J, 50(ab), 51(ab), 365(ab), 766(ab), 1031(ab), 1405(ab)
Sato, M, 763
Sato, N, 1144(ab), 1190(ab), 1898
Satoh, K, 273(ab), 411, 425(ab), 508(ab), 1294(ab), 1371(ab)
Satoh, T, 1127
Satomi, S, 1561
Satya, R, 422(ab)
Satyamurthy, N, 95(ab), 146(ab), 147(ab), 228(ab), 289(ab), 317(ab), 321(ab), 560(ab), 851(ab), 1081(ab), 1098(ab)
Sau, J, 1913
Sauer, K, 875(ab)
Saul, JM, 1353(ab)
Savage, JE, 1070(ab)
Savelli, G, 1270(ab)
Savi, A, 399(ab)
Saviolaki-Olowson, E, 723(ab)
Sawai, T, 1009(ab)
Sawitowski, T, 1076(ab)
Saxena, PM, 249(ab)
Sayman, HB, 1163
Sayre, J, 745
Sayre, JS, 170(ab), 764(ab)
Sayre, JW, 11(ab)
Scagnet, B, 303(ab)
Scanu, A, 1259(ab)
Scarfone, C, 1197(ab)
Schaadt, B, 464(ab)
Schaar, M, 579(ab), 1030(ab), 1249(ab)
Schadrack, J, 1279
Schaefer, A, 936(ab)
Schaefer, WM, 174(ab), 347(ab), 774(ab)
Schaefers, K, 190(ab), 707(ab)
Schaefers, KP, 187(ab)
Schaefers, M, 190(ab), 707(ab)
Schaeffer, JM, 435(ab)
Schaeffer, U, 458(ab)
Schaffrinski, M, 1128(ab)
Schaper, KA, 612
Schapiro, MB, 575
Schauer, A, 287(ab)
Scheffel, U, 478(ab), 1080(ab), 1417
Scheiber, C, 375
Scheidhauer, K, 157(ab), 1178(ab)
Scheinberg, DA, 116(ab), 323(ab), 1175(ab), 1176(ab)
Schelbert, HR, 11, 11(ab), 170(ab), 345(ab), 392(ab), 395(ab), 708(ab), 764(ab)
Schelling, M, 443(ab)
Scheuba, C, 1339(ab)
Schicha, H, 32(ab), 362(ab), 1037(ab), 1108(ab)
Schieck, C, 1069(ab)
Schiepel, N, 195(ab)
Schiepers, C, 295(ab), 394(ab), 432(ab), 461(ab), 1291(ab)
Schild, H, 960(ab)
Schillaci, O, 459, 1215(ab)
Schima, W, 1304(ab)
Schirmer, L, 280(ab)
Schirrmacher, R, 897(ab)
Schirrmeister, HH, 107(ab), 310(ab), 1145(ab), 1297(ab)
Schlenger, KH, 458(ab)
Schlyer, D, 98(ab)
Schmaljohann, J, 1124(ab), 1304(ab), 1339(ab)
Schmall, B, 522
Schmid, E, 1177(ab)
Schmid, G, 1076(ab)
Schmid, RM, 1138(ab)
Schmidt, B, 1178(ab)
Schmidt, F, 139(ab)
Schmidt, G, 358(ab)
Schmidt, MA, 120(ab), 156(ab), 440(ab), 1030(ab), 1043(ab), 1248(ab), 1249(ab)
Schmidt, RP, 1170(ab)
Schmitt, FA, 57
Schmitz, T, 928(ab)
Schmuecking, M, 1242(ab), 1280(ab)
Schnakenberg, H, 1091(ab)
Schneider, A, 57
Schneider, CA, 362(ab)
Schneider, JS, 541(ab), 584
Schneider, K, 123(ab)
Schneider, PB, 1391
Schnell, O, 7(ab)
Schnell, PO, 477(ab)
Schnitt, SJ, 1973
Schober, O, 187(ab), 190(ab), 267(ab), 707(ab), 937(ab), 943(ab), 956(ab), 984(ab), 995(ab), 1431(ab)
Schöder, H, 11, 11(ab)
Schoenberger, JA, 709(ab), 739(ab), 1271(ab)
Schofield, LM, 1237, 1535
Scholz, MC, 560(ab)
Schomaecker, K, 1037(ab), 1108(ab)
Schomig, A, 753(ab)
Schotte, A, 920(ab)
Schottelius, M, 157(ab)
Schraffordt Koops, H, 302(ab)
Schraml, FV, 811(ab)
Schramm, J, 960(ab)
Schreckenberger, M, 914(ab)
Schreiber, K, 701(ab)
Schricke, U, 358(ab), 753(ab)
Schroth, G, 1007(ab)
Schubert, EK, 307(ab)
Schubert, R, 383
Schueller, MJ, 80(ab), 1074(ab)
Schuler, G, 13(ab)
Schulte, M, 1695
Schumacher, C, 1174(ab), 1177(ab)
Schunk, K, 41(ab)
Schuster, SL, 118(ab)
Schwaiger, M, 3(ab), 7(ab), 13(ab), 77(ab), 157(ab), 160(ab), 162(ab), 172(ab), 195(ab), 238(ab), 250(ab), 270(ab), 272(ab), 358(ab), 443(ab), 701(ab), 753(ab), 773(ab), 837, 887(ab), 948(ab), 967(ab), 1008(ab), 1174(ab), 1178(ab), 1279
Schwameis, E, 250
Schwarz, ER, 174(ab), 774(ab)
Schwarzbach, M, 1256(ab), 1319(ab)
Schwimmer, J, 1177
Sciacca, RR, 17(ab), 848(ab), 850(ab)
Sciagra, R, 545(ab)
Scillitani, A, 1478
Sciuto, R, 647
Scopinaro, F, 459
Scott, JR, 288(ab)
Scotto, A, 545(ab)
Seabold, JE, 44(ab)
Sebahoun, S, 383(ab)
Sebastian, G, 1146(ab)
Sedler, M, 420(ab)
Seed, P, 304(ab)
Seese, A, 139(ab)
Sega, W, 308(ab)
Segall, GA, 1331(ab)
Segall, GM, 513(ab), 1861
Segars, WP, 389(ab)
Segel, S, 244(ab)
Segmueller, MA, 739(ab)
Seibyl, JP, 97(ab), 148(ab), 257(ab), 543(ab), 544(ab), 941(ab), 985(ab), 1343, 1552
Seidel, D, 172(ab)
Seidel, J, 74(ab)
Seiler, C, 131
Seiler, RW, 1007(ab)
Seitz, U, 119(ab), 531, 1058(ab), 1138(ab)
Seki, H, 85, 1295(ab)
Seki, K, 584(ab)
Seki, R, 720(ab), 721(ab)
Sekiguchi, M, 12(ab), 760(ab)
Seldin, DW, 46(ab), 1391
Selivanov, V, 227(ab), 396(ab)
Selivanova, SV, 587(ab)
Seltzer, MA, 277(ab), 295(ab), 394(ab), 428(ab), 430(ab), 432(ab), 461(ab), 560(ab), 1232(ab), 1291(ab), 1303(ab)
Semnani, S, 978(ab)
Senba, Y, 1005(ab)
Senda, K, 1009(ab)
Senda, M, 345, 397(ab), 926(ab), 1072(ab), 1612, 1888
Senekowitsch-Schmidtke, R, 157(ab), 160(ab), 162(ab), 452(ab), 1174(ab), 1177(ab)
Sengupta, S, 350(ab), 919(ab)
Seo, JK, 342(ab)
Seo, KJ, 363(ab)
Seong, SC, 1427(ab)
Serafini, A, 1016
Sestini, S, 545(ab)
Seta, Y, 12(ab), 760(ab)
Setani, K, 914(ab)
Sethi, Y, 1230(ab), 1348(ab)
Setoguchi, T, 111(ab)
Sfakianakis, E, 1813, 1955
Sfakianakis, GN, 1037, 1432(ab), 1813, 1955
Sgouros, G, 314(ab), 323(ab), 329(ab), 538, 1176(ab), 2089
Shabib, S, 215
Shadiack, A, 1021(ab)
Shah, KS, 218(ab)
Shahinian, AH, 143(ab), 1161(ab), 1714
Shalabh, C, 258(ab)
Shalev, A, 915(ab)
Shankar, LK, 1330(ab), 1347(ab)
Shanks, MF, 1451
Shanley, TJ, 109(ab)
Shao, L, 809(ab), 878(ab)
Sharaf, BL, 1535
Sharifi, J, 355, 1129(ab)
Sharir, T, 4(ab), 712, 720, 1190
Sharkey, RM, 93, 118(ab), 213(ab), 313(ab), 473(ab), 1185(ab), 1186(ab)
Sharma, A, 1037

Van de Wiele, C, 57(ab), 59(ab), 181(ab), 359(ab), 734(ab), 1421(ab)
Van den Abbeele, AD, 269
van den Brink, W, 419(ab)
van den Broek, WJ, 643
van den Hoff, J, 169(ab), 1006(ab)
van der Laken, CJ, 463
van der Meer, JW, 463, 622, 896, 1125(ab)
van der Pluijm, ME, 120(ab), 1248(ab)
Van der Steenhoven, T, 1(ab)
Van der Wall, H, 1415(ab)
Van der Weerdt, AP, 346(ab)
Van Dijk, D, 1194(ab)
van Dongen, AJ, 1315
van Dongen, GA, 1182(ab)
van Dongen, GAMS, 1999
van Dyck, CH, 234
van Eijck, CH, 1169(ab)
Van Gameren, A, 158(ab), 579(ab), 1030(ab), 1249(ab)
Van Hagen, PM, 1249(ab)
van Heeringen, C, 534(ab), 908(ab)
Van Heertum, RL, 102(ab), 415(ab), 549(ab), 903(ab), 904(ab), 946(ab), 947(ab), 1283(ab), 1289(ab), 1465
van Isselt, JW, 1252(ab)
van Kamp, GJ, 1999
Van Kriekinge, SD, 348(ab)
Van Laere, K, 2051
Van Laere, KJ, 240(ab), 408(ab), 534(ab), 835(ab), 843(ab), 898(ab), 908(ab), 951(ab), 952(ab), 1145
van Lier, JE, 587(ab), 1324
van Lingen, A, 78(ab), 406(ab), 1999
van Poll, D, 302(ab)
van Rijk, PP, 369(ab), 1040(ab), 1252(ab), 1315
Van Steenweghen, S, 275(ab)
Van Tassel, P, 1192(ab)
van Waarde, A, 96(ab), 260(ab), 547(ab), 1157(ab)
van Zanten-Przybysz, I, 1168
VanBoven, AJ, 356(ab)
VanBrocklin, HF, 1093(ab)
Vandecapelle, MN, 483(ab), 1071(ab)
VanDecker, WA, 724(ab), 779(ab)
Vandekerckhove, T, 1145
Vandenberghe, S, 835(ab)
Vandenput, SN, 1414(ab)
Vander Heide, R, 1227
Vanderheyden, JL, 1111(ab)
Vandermeiren, RP, 718(ab)
VanderWall, EE, 356(ab)
vanHagen, PM, 435(ab), 940(ab), 1030(ab)
Vanhove, C, 351(ab), 849(ab)
vanKoetsveld, PM, 435(ab)
Vanninen, EJ, 788
Vanninen, RL, 788
vanRosmalen, JG, 940(ab)
Vansant, JP, 731(ab), 1941
Van De Wiele, C, 17
van Dongen, AJ, 1859
Van Espen, M-B, 23
van Rijk, PP, 1859
van Waarde, A, 1830
Vanzetto, G, 141
Vaquero, JJ, 74(ab)
Vargas, HI, 235(ab)
Varpula, M, 1980
Varrone, A, 148(ab), 544(ab), 941(ab), 1343
Vaterlein, O, 546(ab), 1080(ab)
Vecchio, C, 306(ab)
Vedala, G, 344(ab)
Vedstesen, H, 464(ab)
Veerapan, B, 357(ab)
Vehling, D, 41(ah), 458(ab)
Velloso, MJ, 1278(ab)
Venegas, R, 235(ab)
Venier-Julienne, MC, 409(ab)
Venneri, A, 1451
Vennin, P, 1689
Vensel, EE, 1432(ab)
Vento, J, 773
Ventroni, G, 1522
Venz, S, 137(ab)
Vera, P, 209(ab), 421(ab)
Verani, MS, 1299
Verbilloen, H, 1040(ab)
Verbruggen, A, 1040(ab)
Verdesca, SA, 1535
Verdonck, P, 224(ab)
Verdonk, R, 57(ab), 59(ab), 1421(ab)
Verelst, J, 23
Vergote, J, 591(ab), 592(ab)
Verhagen, C, 643
Verheijen, RH, 1168
Verheugt, FW, 498(ab)
Verhoef, G, 275(ab)
Verhoeff, NP, 833(ab), 1343
Vermeirsch, H, 483(ab)
Verna, E, 1935
Vernaleken, I, 897(ab)
Vernon, C, 125(ab), 372(ab)
Vernon, P, 383
Verpoest, W, 835(ab)
Verreault, J, 818(ab), 1238(ab)
Versijpt, JJ, 408(ab), 843(ab), 898(ab), 951(ab), 952(ab), 1337(ab), 1351(ab)
Vervaet, AM, 718(ab)
Vervaet, M, 908(ab)
Vesselle, HJ, 109(ab), 531(ab)
Vessileva-Belnikolovska, D, 161
Videen, TO, 85(ab), 88(ab), 244(ab)
Vielpeau, C, 1398(ab)
Vierhapper, H, 1339(ab)
Viggiano, J, 1139
Vighetto, A, 1286(ab)
Vilain, D, 567, 770(ab), 799(ab)
Villa, G, 306(ab), 1208(ab)
Villar, LM, 439, 556(ab), 1278(ab)
Villemagne, VL, 402(ab), 1417
Villanueva-Meyer, J, 1973
Vincent, F, 1398(ab)
Vines, D, 1456
Vinters, HV, 95(ab)
Virgolini, I, 578(ab), 786(ab), 1304(ab), 1339(ab)
Virmani, R, 185(ab), 1535
Visser, CA, 338(ab), 346(ab)
Visser, FC, 338(ab), 346(ab)
Visser, GW, 1022(ab), 1168
Visvikis, D, 935(ab), 953(ab), 954(ab)
Vitali, P, 978(ab)
Vlachos, L, 703(ab)
Vlajkovic, M, 1370(ab), 1433(ab)
Vlasenko, AG, 972(ab)
Vleugels, S, 1419(ab)
Voelk, M, 238(ab)
Vogelaers, D, 57(ab), 59(ab), 1421(ab)
Vogg, AT, 1138(ab)
Voliotopoulos, V, 703(ab)
Volkert, WA, 471(ab), 1013(ab), 1079(ab)
Volkow, ND, 98(ab), 103(ab), 261(ab), 265(ab), 411(ab), 412(ab), 414(ab), 416(ab), 420(ab), 550(ab), 854(ab), 916(ab), 917(ab), 922(ab), 929(ab), 949(ab), 1352
Vollmar, C, 1823
Voltini, F, 515(ab), 1368(ab)
Volz, S, 701(ab)
vom Dahl, J, 174(ab)
Von Baer, A, 1695
von Forstner, C, 1187(ab)
von Schilling, C, 1178(ab)
Vonck, K, 1145
Vontobel, P, 781
Vorontsova, E, 733(ab)
Vose, JA, 1179(ab)
Vose, JM, 1180(ab)
Votaw, JR, 263(ab), 400(ab)
Votion, DM, 1414(ab)
Voytko, ML, 832(ab), 2069
Vral, AM, 17, 1195(ab)
Vuong, H, 337(ab)
Waaijers, M, 435(ab)
Wachtell, K, 171(ab)
Wackers, FJ, 874, 1436
Wackers, FT, 26N(5)
Wada, H, 71
Wada, Y, 938(ab), 958(ab)
Waddington, WA, 935(ab), 954(ab)
Waechter, PB, 712, 720
Wagenknecht, G, 914(ab)
Wagner, HN, 155(ab)
Wagner, M, 1138(ab)
Wagner, HN, Jr, 9N(8)
Wagner, W, 444(ab)
Wagner-Utermann, U, 1123(ab)
Wahl, LM, 1636
Wahl, RL, 82(ab), 114(ab), 309(ab), 325(ab), 381(ab), 434(ab), 449(ab), 450(ab), 999, 1151(ab), 1155(ab), 1269(ab), 1579, 2026
Wahlund, LO, 423(ab)
Waibel, R, 1184(ab)
Wakabayashi, S-i, 345
Waki, A, 938(ab), 958(ab)
Wakisaka, S, 268(ab), 1642
Wakita, K, 1484
Waksman, R, 28(ab)
Waldherr, C, 577(ab)
Waldmann, TA, 1148(ab), 1149(ab), 1150(ab), 1152(ab)
Walicka, MA, 1545
Wallace, WE, 505(ab)
Wallack, MK, 1230(ab)
Wallis, JW, 119
Walrand, S, 436(ab), 437(ab), 1143(ab)
Walsh, JC, 1081(ab), 1098(ab), 1126(ab)
Walter, GL, 2026
Wang, CH, 735(ab)
Wang, GJ, 98(ab), 103(ab), 416(ab), 420(ab), 550(ab), 916(ab), 917(ab), 922(ab), 1352
Wang, HJ, 1060(ab)
Wang, JK, 856(ab), 862(ab), 865(ab), 1246(ab)
Wang, K-C, 983(ab)
Wang, M, 565(ab), 1043(ab)
Wang, P-W, 1209
Wang, RF, 131(ab), 341(ab), 482(ab), 1306(ab)
Wang, S, 56(ab), 1727
Wang, SJ, 801(ab), 1892
Wang, WT, 522(ab), 523(ab), 892(ab)
Wang, Y, 524(ab), 586(ab), 812(ab), 1028(ab), 1127(ab)
Wängberg, B, 636
Wanivenhaus, A, 250
Ware, RE, 296(ab), 431(ab)
Wareham, DW, 40(ab)
Warren, J, 1112(ab)
Wartski, M, 1043
Wassmann, H, 267(ab), 984(ab), 995(ab)
Watabe, H, 522, 838(ab)
Watanabe, J, 702(ab)
Watanabe, M, 1287(ab)
Watanabe, N, 337, 1147(ab), 1244
Watanabe, S, 71
Watanabe, T, 255(ab), 1947
Watanabe, W, 756(ab), 758(ab), 1406(ab), 1407(ab)
Waterhouse, RN, 923(ab)
Waterstram-Rich, K, 20N(7)
Watkins, GL, 583(ab)
Waxman, AD, 36(ab), 468(ab), 469(ab), 1001(ab), 1218(ab), 1354(ab)
Webb, EG, 1107(ab)
Weber, PB, 1264
Weber, S, 64(ab), 73(ab)
Weber, WA, 238(ab), 270(ab), 272(ab), 452(ab), 1008(ab)
Weckesser, E, 121(ab), 169(ab), 212(ab), 1307(ab)
Weckesser, M, 984(ab), 995(ab), 1431(ab)
Wedeking, P, 470(ab)
Wedler, J, 1317(ab)
Weerdt, AP, 231(ab)
Wegener, WA, 1016
Wei, R, 291(ab), 582(ab)
Weiden, PL, 131
Weil, S, 1004(ab)
Weiland, FL, 36(ab), 60(ab)
Weilhammer, P, 76(ab)
Weinberg, IN, 112(ab), 235(ab), 814(ab)
Weinberger, DR, 92(ab), 99(ab), 100(ab), 537(ab), 1069(ab)
Weindl, A, 781
Weiner, R, 773
Weinmann, P, 1801, 1808
Weisman, E, 263
Weiss, MF, 1228(ab)
Weiss, R, 102(ab)
Welch, MJ, 130(ab), 164(ab), 229(ab), 315, 322(ab), 454(ab), 455(ab), 484(ab), 565(ab), 798(ab), 1017(ab), 1083(ab), 1126(ab), 1241(ab)
Welcke, U, 31(ab)
Weller, R, 1058(ab)
Wells, P, 605, 706
Wells, RG, 1391, 1425(ab)
Welsh, RJ, 1281(ab)
Welsh-Bohmer, KA, 1920
Welt, S, 1176(ab), 1905
Wen, TW, 735(ab)
Wendt, RE, 327(ab), 526(ab), 580(ab)
Wendt, TG, 1242(ab)
Weng, Y-H, 994
Wennerberg, J, 1198(ab)
Werner, JA, 816
Werner, M, 443(ab)
Wessels, B, 328(ab)
Wester, HJ, 157(ab), 160(ab), 162(ab), 272(ab), 452(ab), 1279
Westlin, J-E, 1514
Wey, SP, 426(ab), 994, 1102(ab), 1120(ab)
Whatley, M, 826(ab), 1784
Wheeler, DM, 986
Wheeler, KT, 476(ab)
White, CA, 113(ab), 115(ab)
White, ML, 400(ab)
Wichter, T, 190(ab), 707(ab)
Wielepp, JP, 1007(ab)
Wiens, LW, 142(ab)
Wijdenes, J, 463(ab)
Wikström, H, 152(ab)
Wilbur, DS, 474(ab)
Wilder, MS, 1354(ab)
Wilderman, SJ, 68(ab), 76(ab)
Wildfang, I, 1307(ab)
Wilhelm, AJ, 1999
Wilk, M, 84(ab), 522(ab)
Willeit, M, 36
Willeke, F, 1319(ab)
Willemse, PH, 1793
Willemsen, AT, 260(ab), 353(ab), 547(ab), 1153(ab), 1199(ab), 1830
Willey, LM, 164(ab)
Willi, JP, 1184(ab)
Williams, CM, 469(ab), 1218(ab)
Williams, JA, 1044(ab)
Williams, K, 337(ab)
Williams, RC, 112(ab), 814(ab)
Williams, W, 918(ab)
Williamson, JW, 927(ab)
Williamson, PD, 1619
Williamson, RA, 159(ab), 1134(ab)
Willich, N, 937(ab)
Willkomm, P, 1657
Willoch, F, 948(ab), 1279
Wilson, AA, 149(ab), 585(ab), 932(ab)
Wilson, DM, 1142(ab)
Wilson, SJ, 538(ab)
Winkler, PA, 1004(ab)
Winters, S, 943(ab)
Winthrop, MD, 567(ab)
Wiseman, GA, 113(ab), 115(ab)
Wismüller, A, 1823
Withers, SG, 490(ab)

Witt, C, 1402(ab)
Wobbes, T, 136(ab)
Woehrle, J, 503(ab)
Woermann, B, 117(ab), 287(ab), 313(ab)
Wojcik, C, 434(ab)
Wolf, I, 1178(ab)
Wolf, RL, 987(ab)
Wolfangel, R, 1111(ab)
Wolter, A, 722(ab)
Woltering, EA, 133(ab), 1256
Won, JH, 1060(ab)
Wong, A, 490(ab)
Wong, C, 1303(ab)
Wong, CS, 428(ab), 1232(ab)
Wong, CT, 103(ab), 416(ab), 420(ab), 550(ab), 916(ab), 917(ab), 1352
Wong, CYO, 1281(ab), 1335(ab)
Wong, DC, 1030
Wong, DF, 262(ab), 478(ab), 925(ab), 939(ab), 1417
Wong, FC, 1051(ab), 1075(ab), 1201(ab)
Wong, KH, 67(ab), 75(ab)
Wong, KJ, 1033(ab), 1148(ab), 1149(ab), 1152(ab)
Wong, TT, 256(ab)
Wong, TZ, 740(ab)
Wong, W-H, 524(ab), 812(ab)
Woo, KS, 144(ab), 1388(ab)
Woo, SK, 810(ab), 888(ab)
Woo, SL, 145(ab)
Woodcock, J, 1420(ab)
Worstell, WA, 112(ab), 814(ab)
Worthley, SG, 25(ab)
Wu, HM, 243(ab), 395(ab)
Wu, K, 1085(ab)
Wu, LC, 476(ab), 815(ab), 856(ab), 862(ab), 865(ab), 1246(ab)
Wu, MC, 67(ab), 75(ab)
Wuchenauer, M, 882(ab)
Wuest, F, 484(ab)
Wuest, M, 322(ab)
Wurthmann, A, 128(ab), 1029(ab)
Wyllie, E, 258(ab)
Wyndaele, D, 340(ab), 1168(ab)

Xiao, Y, 478(ab)
Xiong, CY, 567(ab)

Yachiku, S, 365(ab)
Yacoub, TY, 1422(ab)
Yacubian, EM, 255(ab)
Yaghoubi, SS, 146(ab), 289(ab)
Yagishita, M, 85
Yama, N, 1387(ab)
Yamada, I, 257
Yamada, N, 978
Yamada, S, 352(ab)
Yamagishi, H, 830
Yamaguchi, H, 20(ab), 180(ab), 713(ab), 742(ab)
Yamaguchi, K, 421, 1377(ab)
Yamamichi, Y, 1102
Yamamoto, AJ, 37(ab), 451(ab), 1330(ab), 1347(ab), 1411(ab)
Yamamoto, I, 85, 973(ab), 1295(ab)
Yamamoto, N, 283, 1005(ab)
Yamamoto, W, 50(ab), 51(ab), 365(ab), 766(ab), 1405(ab)
Yamamoto, Y, 273(ab), 411, 425(ab), 508(ab), 1294(ab), 1371(ab), 1777
Yamasaki, K, 1134
Yamasaki, T, 1777
Yamashita, H, 1223(ab)
Yamashita, S, 1134
Yamauchi, H, 957(ab)
Yanagawa, M, 367(ab)
Yanagisawa, A, 965
Yanch, JC, 858(ab)
Yang, B, 476(ab)
Yang, DJ, 127(ab), 1027(ab), 1075(ab), 1245(ab)
Yang, H, 1332
Yang, J-H, 1265(ab)
Yang, SD, 1135(ab)
Yang, W, 978, 1021(ab)
Yang, W-H, 314(ab), 1176(ab)
Yang, WI, 1059(ab), 1301(ab)
Yang, ZF, 164(ab), 1014(ab)
Yano, K, 1209(ab)
Yanovskaya, L, 1416(ab)
Yao, IA, 540(ab)
Yao, R, 806(ab)
Yao, S, 339(ab), 364(ab)
Yao, S-S, 1308, 1445
Yao, ZS, 1033(ab), 1148(ab), 1149(ab), 1150(ab), 1152(ab)
Yap, CS, 277(ab), 295(ab), 430(ab), 432(ab), 1291(ab)
Yap, JT, 605, 706, 827(ab)
Yasuda, S, 1240(ab), 1268(ab), 1371(ab)
Yasuhara, Y, 590
Yasukawa, T, 283
Ye, J, 809(ab), 878(ab)
Ye, W, 1682
Yefremov, N, 35(ab), 274(ab), 557(ab)
Yeh, DM, 37(ab), 1196(ab), 1236(ab)
Yeh, EL, 243(ab), 851(ab)
Yeh, SD, 282(ab)
Yeh, SH, 256(ab), 292(ab), 862(ab), 865(ab), 1211(ab), 1246(ab), 1350(ab)
Yeldell, D, 312(ab), 1055(ab)
Yen, LK, 1315(ab)
Yen, SH, 292(ab)
Yen, T-C, 426(ab), 994
Yen, V, 1348(ab)
Yeo, JS, 27, 253(ab), 254(ab), 271(ab), 343(ab), 373(ab), 447(ab), 751(ab), 789(ab), 961(ab), 983(ab), 998(ab), 1427(ab)
Yester, MV, 990(ab)
Yeung, HW, 140(ab), 282(ab), 1082, 1234(ab)
Yeung, RS, 307(ab), 1254(ab)
Yildirim, IS, 1382(ab)
Yildiz, A, 1400(ab)
Yin, YQ, 571(ab)
Yokogami, H, 268(ab)
Yokoi, F, 262(ab), 478(ab), 925(ab), 939(ab), 1417
Yokota, M, 744(ab)
Yokoyama, I, 552(ab), 823, 950(ab), 978, 1947
Yokoyama, K, 1183(ab), 1188(ab), 1189(ab), 1244
Yokoyoyama, I, 828(ab)
Yonekura, K, 828(ab), 978
Yonekura, Y, 301(ab), 791(ab), 833(ab), 938(ab), 958(ab), 977(ab), 1012(ab), 1357, 1612
Yoneyama, T, 738(ab)
Yoo, KS, 1198
Yoo, TM, 318
Yoon, CS, 384(ab)
Yoon, JK, 6(ab), 730(ab), 1225(ab), 1395(ab)
Yoon, PH, 913(ab)
Yoon, SN, 554(ab), 777(ab), 1045(ab), 1060(ab), 1217(ab), 1293(ab), 1430(ab), 1434(ab)
Yoshida, K, 29(ab), 175(ab), 763
Yoshida, S, 1387(ab)
Yoshida, T, 974(ab), 975(ab), 1250(ab)
Yoshikawa, E, 1209(ab), 1318(ab)
Yoshikawa, J, 830
Yoshikawa, K, 283, 551(ab), 823, 1947
Yoshimoto, M, 938(ab), 958(ab)
Yoshimoto, N, 747(ab)
Yoshimoto, T, 795
Yoshimura, K, 1009(ab)
Yoshinaga, K, 186(ab), 352(ab), 354(ab), 847(ab), 1326(ab)
Yoshino, N, 257
Yoshioka, J, 20(ab), 180(ab), 713(ab), 742(ab)
Yoshioka, N, 1947
Yoshioka, S, 1389(ab)
Yoshitama, T, 745(ab)
Yoshiyama, M, 830
Yoshizumi, T, 1134
Yotsukura, A, 743(ab)
You, DL, 1315(ab), 1392(ab)
Young, I, 1348(ab)
Young, J, 78(ab), 1369
Young, LH, 794(ab)
Younsi, N, 78, 1267(ab), 1308(ab), 1316(ab)
Yovanovich, J, 754(ab)
Yu, CL, 856(ab), 862(ab), 865(ab), 1246(ab)
Yu, D-F, 1027(ab)
Yu, KH, 1135(ab)
Yu, LZ, 1306(ab)
Yu, X, 230(ab)
Yuan, A, 324(ab), 952
Yucel, C, 207(ab)
Yudd, AP, 1353(ab)
Yun, MJ, 1196(ab), 1236(ab)
Yutani, K, 795(ab), 1237(ab)

Zabel, PL, 286(ab)
Zabjek, A, 95(ab)
Zachs, J, 35(ab)
Zagar, I, 333(ab)
Zaini, MR, 1077(ab)
Zajac, JM, 482(ab)
Zalipsky, S, 912
Zalutsky, MR, 332(ab)
Zaman, AG, 25(ab)
Zamora, PO, 28(ab)
Zamwar, U, 741(ab)
Zanco, P, 8(ab), 705(ab), 973
Zannetti, A, 1261(ab)
Zanzonico, PB, 297, 1048(ab)
Zare, F, 1027(ab), 1245(ab)
Zareneyrizi, F, 327(ab), 580(ab)
Zaret, BL, 794(ab)
Zasadny, KR, 114(ab), 309(ab), 325(ab), 381(ab), 449(ab), 999, 1579
Zatorre, RJ, 926
Zavattini, G, 71(ab)
Zawarzin, VG, 112(ab), 814(ab)
Zazulia, AR, 85(ab), 88(ab)
Zea-Ponce, Y, 549(ab), 923(ab)
Zee, AG, 1244(ab)
Zehelein, J, 23(ab)
Zelissen, PM, 1340(ab)
Zeng, GL, 83(ab), 391(ab), 530(ab), 813(ab)
Zeng, J, 794(ab)
Zerdoud, S, 1341(ab)
Zervos, EE, 816(ab)
Zhang, CL, 131(ab), 1306(ab)
Zhang, L, 68(ab), 1069(ab)
Zhang, M-L, 1148(ab), 1150(ab), 1152(ab)
Zhang, MY, 285(ab)
Zhang, S, 1085(ab)
Zhang, Y, 1256(ab)
Zhang, YM, 1028(ab), 1097(ab)
Zhang, Z, 25(ab), 855(ab)
Zhao, CL, 766(ab), 1405(ab)
Zhao, CY, 285(ab)
Zhao, HY, 800(ab)
Zhao, S, 1131(ab)
Zheng, Y, 485(ab)
Zhou, Y, 243(ab)
Zhu, L, 131(ab)
Zhu, M, 341(ab)
Zhu, Q, 106(ab)
Zhu, SL, 131(ab), 341(ab)
Zhu, TC, 1196(ab)
Zhu, Z, 586(ab), 788(ab), 1028(ab)
Zhuang, HM, 37(ab), 122(ab), 134(ab), 451(ab), 1159(ab), 1213(ab), 1220(ab), 1221(ab), 1251(ab), 1314(ab), 1396(ab), 1411(ab)
Zhuang, ZP, 150(ab)
Ziegler, SI, 77(ab), 172(ab), 238(ab), 773(ab), 837, 887(ab)
Zielinski, C, 1495
Ziemons, K, 64(ab), 73(ab)
Zieron, J, 376(ab)
Ziffer, JA, 337(ab)
Zijlstra-Baalbergen, JM, 1216(ab)
Zilleruelo, G, 1955
Zilleruelo, GE, 1037, 1432(ab)
Zilles, K, 64(ab), 73(ab)
Zimmerman, RE, 819(ab)
Zimny, M, 237(ab), 347(ab), 1275(ab)
Zinn, KR, 318(ab), 319(ab), 887
Zips, D, 166(ab)
Zito, F, 994(ab)
Zoboli, S, 1173(ab)
Zoghbi, SS, 97(ab), 148(ab), 794(ab), 1343, 1552
Zubaid, M, 184(ab)
Zubal, IG, 257(ab)
Zubeldia, JM, 433(ab)
Zubieta, JK, 266(ab), 535(ab), 539(ab)
Zucker, RA, 539(ab)
Zuhayra, M, 1114(ab), 1187(ab), 1429(ab)
Zurakowski, D, 596, 1632
Zweers, HM, 293(ab)

Note: (ab) represents abstract.

A

A33 antibody, fractionated external beam and, sequence of combination therapy, 1905
Academy of Radiology Research, 17N(5), 13N(11)
Acetate, modeling index for nasopharyngeal cancer diagnosis, 1246(ab)
Acetazolamide
^{99m}Tc HMPAO SPECT and, crossed cerebellar diaschisis, 416
stress brain-perfusion SPECT, carotid endarterectomy, 1836
Acetazolamide challenge
brain and heart crossover safety study, 982(ab)
comparison of brain SPECT and MRI, 983(ab)
oxygen extraction fraction, predicting increase of, 974(ab)
Acetylcholine receptors
age-related changes in, 92(ab)
measuring receptor occupancy of, 480(ab)
Acquired immunodeficiency syndrome (AIDS), HIV nephropathy, diuretic MAG3 scintirenography, pediatric, 1037
Activation states
HMPAO SPECT, 990(ab)
^{14}O water PET imaging for, 1077(ab)
PET, 945(ab)
PET studies of early functional reorganization following stroke, 553(ab)
Tourette syndrome, function studies of, 1006(ab)
visual stimulation with PET rCBF tracer C10-CO2, 959(ab)
Activation study
cerebral infarction, PET scan of, 967(ab)
L-DOPA during cognitive performance in Parkinson's disease, 980(ab)
^{99m}Tc HMPAO scan, 1000(ab)
neural activation in thalamus and prefrontal cortex during dipyridamole stress, 552(ab)
Acute pyelonephritis, Power Doppler ultrasonography, 207(ab)
Adaptive response, treatment with ^{131}I, 17
Adenosine A_{2A} receptor ligand, ^{11}C KF18446, central nervous system, 345
Adenovirus
biodistribution of ^{111}In and ^{131}I, 1026(ab)
therapeutic gene delivery, 146(ab)
Adhesion molecules, angiotensin receptors, 1362(ab)
Adrenal cortex, tumors
11 [beta]-hydroxylase tracer PET imaging of, 275
^{11}C metomidate PET imaging of, letter, 1933
Adrenal gland, FDG PET evaluation of in lung carcinoma, 1278(ab)
Adrenal mass, intermediate, 963(le)
Aebersold, Paul C., 23N(6)
Aerosol
scintigraphic assessment of two nebulization methods, 506(ab)
senescence-accelerated mouse (SAM), 938(ab)
Aging
binding kinetics and, ^{123}I-β CIT imaging of serotonin transporter, 36
cerebral blood flow in, PET with partial volume correction, 1842, 1849
effect on 5HT2A receptors, 951(ab)
^{99m}TC HMPAO brain templates, SPECT regions of interest, 45
normal brain patterns, ^{99m}Tc SPECT, 1456
uptake of ^{99m}Tc MDP and, regional and skeletal, 1478
Agonist
comparison of radiolabeled receptors for PET, 94(ab)
radiosynthesis of F-18-OH-FPPAT, 481(ab)
Air, expired, measurement of $^{11}CO_2$ exhaled during PET, 605
Alavi, Abass, 16N(9)
Alcohol
FDG PET assessment of different doses of ethanol, 917(ab)
gender differences in regional brain metabolism, 916(ab)
opioid receptor availability in alcoholics, 539(ab)
orbitofrontal activation in alcoholism, 918(ab)
reduced serotonin transporters in alcoholism, 537(ab)
role of benzodiazepine receptor in addiction, 538(ab)
Algorithms
automatic determination of left ventricular ejection fraction, 849(ab)
Bi radiolabeled DOTA-biotin, 1150(ab)
Alpha-emitting radionuclides
dose-response analysis, 323(ab)
pharmacokinetics of Bi-213-labeled antibodies, 1174(ab)
radioimmunotherapy of breast cancer micrometastases, 1176(ab)
Alpha-particle emitters
At-211, optimizing production parameters, 1115(ab)
biochemistry of Ac-225-Anti-CD33 antibody, 116(ab)
cytotoxicity of Bi-213, 1177(ab)
radioimmunotherapy of lymphoma, 1175(ab)
Alzheimer's disease
analog probes, 95(ab)
CBF-SPECT analysis of, 423(ab)
cerebral metabolic response to audiovisual stimulation, FDG PET, 575
cortical pathology, 246(ab)
dementia severity in, SPECT measure of cerebral cortical perfusion, 57
diagnosis with SPECT, 963(ab)
differentiation of dementia with SPECT, 422(ab)
early cerebral metabolic decline, 248(ab)
early diagnosis of dementia, 249(ab)
evaluation
brain perfusion SPECT, 1155
M1 and M2 mAChR subtypes, 93(ab)
FDG PET imaging of hypometabolic regions, 976(ab)
HMPAO SPECT imaging, comparison with statistical parametric mapping, 1451
pathologically verified dementia, FDG PET in, 1920, 1929
quantitative uptake procedures of two FDG region of interest programs, 919(ab)
regional cerebral blood flow as prognostic index of, 978(ab)
SPECT study of apolipoprotein E genotype, 964(ab)
stereotactic normalization of functional changes, 948(ab)
American Board of Medical Specialties (ABMS), 15N(2)
American Board of Nuclear Medicine (ABNM)
dual certification with American Board of Radiology, 15N(2)
1999 members, 15N(2)
results of 1999 certifying examination, 15N(2)
American College of Nuclear Physicians (ACNP)
comments with SNM on NRC petition, 22N(10)
forms nuclear medicine political action committee, 37N(7)
partnership agreement with SNM, 14N(4)
plans to comment to NRC Advisory Committee on Medical Uses of Isotopes, 14N(11)
American College of Radiology (ACR), nuclear medicine accreditation and, 26N(5)
American College of Surgeons Oncology Group (ACOSOG), 26N(2)
American Society of Radiologic Technologists, 28N(6)
Amino acids
biodistribution of F-18 analog, 167(ab)
F-18-methytyrosine, rapid synthesis of, 1075(ab)
F-18-OMFD for tumor detection with PET, 166(ab)
neonatal astrocytes, transport kinetics of I-123-IMT in, 943(ab)
renal protection, 370(ab)
single substitution, FC region, solid tumors, in immunoscintigraphy, 355
transport, human glioma cell line, 1250
Amobarbital, hippocampal inactivation, 960(ab)
Amphetamines, dopamine response and, measurement with ^{11}C raclopride, 522
Amyloidosis, ^{99m}Tc aprotinin detection of, 464(ab)
Anger, Hal, 29N(11)
Angina, preinfarction, effects on damage with acute myocardial infarction, SPECT, 830
Angiocardiography, exercise radionuclide, predicting future cardiac events in MI patients, 965
Angioplasty
intracoronary administration of verapamil, beneficial effect of, 702(ab)
renal, captopril-induced changes in MAG3 clearance, 1203
Angiotensin II, pharmacologic intervention with, radioimmunotherapy in human colon cancer xenografts, 1244
Angulation errors, parallel-hole and fanbeam collimators, 548
Animal study
F-18-fluoropalmitic acid imaging of canine myocardial fatty acid metabolism, 789(ab)
myocardial imaging in mice, 75(ab)
pulmonary perfusion redistribution, 1414(ab)
Annexin
blood clearance, 589(ab)
^{99m}Tc recombinant human annexin for detection of, 22(ab)
suppression of cardiac allograft rejection, 1(ab)
Antibodies
anti-PSMA antibody in treatment of prostate cancer, 315(ab)
sensitivity of immunoassay vs ELISA, 711(ab)
Antibody fragments, radioimmunoscintigraphy of solid tumors, 1129(ab)
Antibody labeling, pharmacokinetics of radioiodinated antibodies, 1022(ab)
Antibody pharmacokinetics
^{111}In human anti-CD22, 1210(ab)
targeted radiotherapy, 463(ab)
AntiCD74 antibody, radionuclides linked to, B-cell lymphoma, 2089
Anti-CEA antibodies, biokinetics in liver metastasis, 1184(ab)
Antifibrin antibody, radiolabeling of, reduction of background activity, 1264
Antigranulocyte antibody
bone marrow distribution in hematologic malignancy, 1212(ab)
cost-effectiveness of infection imaging, 39(ab)
diagnosis of skeletal infection, 60(ab)
equivocal appendicitis, imaging of, 36(ab)
infection imaging, 38(ab)
Antimyosin antibody, myocardial antimyosin uptake in hypertension, 719(ab)
Antineoplastic agents, radiotherapy of neuroendocrine tumors, 1172(ab)
Antisense imaging
follicular lymphoma, 1145(ab)
^{99m}Tc behavior in cell culture, 1097(ab)
tissue culture uptake, 1028(ab)
Antithrombotic agents, for acute pulmonary embolism, incomplete lung perfusion after, 1043, 1049
Aphasia, progressive, brain SPECT in, 228
Apoptosis
^{99m}Tc annexin-V detection of, 500(ab)
^{99m}Tc MIBI uptake in MCF7 human breast cancer cells, 591(ab)
^{99m}Tc recombinant human annexin V, biodistribution and dosimetry of, 22(ab)
^{99m}Tc rh-annexin V, as marker of, 1154(ab)
radiation-induced G2/M arrest, 1047(ab)
^{188}Re, irradiated dose of, 2(ab)
thermal injury, 1424(ab)
transient sarcolemmal phosphatidyl serine expression, 793(ab)
untreated breast cancer, 1261(ab)
Appendicitis
cost-effectiveness of infection imaging, 39(ab)
efficacy of monoclonal antibodies imaging for, 36(ab)
equivocal, ^{99m}Tc-labeled anti-CD15 MoAb imaging for, 449, 456
radiolabeled leukocyte imaging in detection of, 38(ab)
radiolabeled white blood cell imaging of, 1400(ab)
Arterial input function, PET assessment of tumor blood flow, 826(ab)
Arthritis, radiation synovectomy in, 250
Artifacts
backprojection due to gallbladder uptake, 725(ab)
digital mammograms, 814(ab)

soft-tissue attenuation, 767(ab)
streak, reduction, in filtered backprojection, 1913
Asialo-glycoprotein receptor
correlation with histopathology in chronic liver disease, 51(ab)
estimation by single blood sample method, 50(ab)
malaria, 54(ab)
Asociacion Iberamericana de Sociedades de Biologia y Medicina Nuclclear (ALASBIMN), 9N(9), 20N(3)
Aspirin, renography, diagnosis of renal artery stenosis, 1337
Astatine-211, microdosimetry of alpha-particle-emitting MAB in gliomas, 332(ab)
Asthma, pulmonary distribution of fluticasone propionate, 1413(ab)
Atherosclerosis
carotid atheroma, 858(ab)
coronary microangiopathy, in non-insulin-dependent diabetes, 978
false-positive findings, myocardial perfusion scintigraphy, 1935
LOX-1, depletion of, 788(ab)
monocytes and endothelial cells, 786(ab)
progression and regression of, 25(ab)
scintigraphic imaging with ^{111}In, 185(ab)
Attention deficit hyperactivity disorder
assessment of dopamine transporter pre- and post-methylphenidate treatment, 105(ab)
dopamine transporter density, assessment of, 104(ab)
MR/SPECT and, 30N(6)
segmented, patient contour determination for, 80(ab)
transmission reconstruction algorithm, 870(ab)
Attenuation compensation, ordered-subset algorithms, myocardial SPECT, 737
Attenuation correction
aerosol scintigraphy, 1410(ab)
brain SPECT, 241(ab)
inferring head anatomy, 1569
cardiac dual-head gamma camera coincidence imaging, myocardial perfusion SPECT, 919
cardiac SPECT imaging with dual-head camera, 84(ab)
consistency-based alignment, 824(ab)
does it work, 960(le)
effect of subject movement, 845(ab)
enhanced acquisition and processing, tomographic myocardial perfusion imaging with, 1139
in evaluation of renal function, camera-based method, children and adults, 823
fuzzy logic methodology, 871(ab)
^{67}Ga SPECT, small lesion detection, filtered backprojection, 1391
Helgason-Ludwig consistency conditions, 520(ab)
image registration, 862(ab)
intrinsic dual-energy processing, myocardial perfusion imaging, 1287
lesion detection improvement, 879(ab)
myocardial perfusion SPECT imaging, 340(ab)
prestudy information density scan, 809(ab)
quality control, 869(ab)
relative impact, cardiac SPECT, 1400
ROC study of, cardiac SPECT, 502
SPECT, rest/stress myocardial perfusion SPECT, CAD, 852, 860
SPECT emission data, 530(ab)
SPECT myocardial perfusion images, 391(ab)
SPECT myocardial perfusion imaging, 341(ab)
transmission image, 889(ab)
transmission scanning system, gamma camera coincidence scanner, 692
transmission studies with Gd-153, 529(ab)
Auger electrons
radionuclides, DNA cleavage, 1093
radiopeptide therapy with cholecystokinin, 441(ab)
Autism
abnormal regional cerebral blood flow, 911(ab)
developmental language disorder, 913(ab)
Autonomic disorder, early Parkinson's disease, cardiac sympathetic denervation, ^{123}I MIBG study, 71
Autoradiography
myocardial glucose uptake among 3 tracers, isolated working heart, 488
phosphor plate, combination therapy, 1905
Avidin, clearance of ^{99m}Tc biotin-PET liposomes induced by, infection imaging, 912

B

Backprojection, filtered
ordered-subsets expectation maximization, small lesion detection, ^{67}Ga SPECT, 1391
streak artifact reduction in, 1913
Benard, François, 14N(9)
Benzodiazepine receptor
PET and SPECT binding parameters, 834(ab)
PET imaging with ^{18}F fluorethylflumazenil, 897(ab)
role in alcohol dependence, 538(ab)
semiquantification and reproducibility, 408(ab)
Benzodiazepines, high-specific activity labeling, 1096(ab)
Bequerel, Antoine-Henri, 26N(11)
Bernard, François, 14N(9)
Best, Edward, in memoriam, 31N(9)
Beta-adrenergic downregulation, pre- and post-synaptic, potential mechanism of, 796(ab)
Beta-adrenergic receptor
cardiac function after cardiomyopathy, 704(ab)
PET brain imaging studies, 96(ab)
Beta-ray emitters
simulated dosimetry, 1051(ab)
Y radiolabeled DOTA-biotin, 1148(ab)
Beven, Terence, 27N(7)
Biliary atresia, functioning gallbladder visualization, hepatobiliary scintigraphy, infants, 1209
Biliary tract stasis, postoperative complication, 1374(ab)
Binding potential, ^{11}C altropane, 931(ab)
Biodistribution
carrier-free lanthanides, Pm-149, 1084(ab)
^{11}C FMAU, thymidine analog, 143(ab)
^{131}I and ^{111}In, 1026(ab)
^{125}I paclitaxel, synthesis of, 1020(ab)
^{99m}Tc ciprofloxacin, 593(ab)
new copper chelates, 322(ab)
radiation dosimetry and, stabilized ^{99m}Tc exametazime-labeled leukocytes, 934
radiolabeled interleukin-8, infection imaging, 463, 470
somatostatin receptor-binding peptide, 1142(ab)
Tc-99m-N2S2 annexing V, 589(ab)
V-48, intravenously administered as vanadate, 1057(ab)
Biotin analogs
biotinidase stabilized, 474(ab)
polylysine-ased biotin radiopharmaceuticals, 1033(ab)
Bladder tumor
^{11}C choline PET imaging to detect, 293(ab)
^{99m}Tc BDI-1 as a radioprobe for, 1306(ab)
Blahd, Mitzi, 17N(9), 28N(7)
Blahd, William H, 17N(9), 28N(7)
Blocklet, Didier, 14N(9)
Blood-brain barrier, P-glycoprotein transport and modulation, 1153(ab)
Blood flow
cerebral
acupuncture, neural basis of, 1000(ab)
aging effects, PET with partial-volume correction, 1842, 1849
early Alzheimer's disease, perfusion SPECT, 1155
effects of electroconvulsive therapy on, 906(ab)
effects of vascular radioactivities on oxygen-15 PET images, 242(ab)
hypnosis-induced changes, effect of, 927(ab)
^{99m}Tc SPECT, normal brain patterns in adults, 1456
PET depiction of perfusion changes in Parkinson's disease, 427(ab)
PET study with O-15-butanol, 928(ab)
post-traumatic stress disorders, 915(ab)
quantification with I-123-IMP double-injection protocol, 840(ab)
SPECT
dementia, diagnosis of, 424(ab)
in Huntington's disease, 773
localization of epileptogenic foci, 255(ab)
Tc-99m ECD for detection of vasospasm in aneurysmal subarachnoid hemorrhage, 86(ab)
three-dimensional fractal analysis of, 1010(ab)
Xe-127 production, 1091(ab)
coronary, false-positive findings in myocardial perfusion scintigraphy, 1935
myocardial
detection of viable myocardium with BMIPP, 800(ab)
effects of H.E.L.P.-apheresis, 172(ab)
flow heterogeneity, 787(ab)
input function extraction from ^{15}O water PET, 386(ab)
left ventricular hypertrophy, 171(ab)
mental stress effects, with coronary artery disease, 11
PET evaluation of after heart transplantation, 8(ab)
PET quantitation, 187(ab)
quantification of dynamic ^{15}O PET scans, 174(ab)
in repetitive stunning, 1227, 1235
serial changes, ^{82}Rb PET, 1426
tetrofosmin marker of perfusion and cell integrity, 774(ab)
uniformity on perfusion SPECT studies, 389(ab)
PET assessment of tumor blood flow, 826(ab)
renal and splenic perfusion, assessment with C-10-oxygen, 1363(ab)
tumor, parametric images using ^{15}O water PET, 1784
Blood-pool imaging
gated
angina, 14(ab)
assessment of cardiac complications after radiotherapy, 18(ab)
determination of global function with SPECT, 849(ab)
gated blood-pool SPECT, left ventricular ejection fraction, computation of, 388(ab)
gated SPECT, ventricular performance, evaluation of, 15(ab)
Blood sampling
1-point, in FDG PET, 1484
quantification of cerebral blood flow, 841(ab)
Blumgart, Hermann, 29N(11)
BMIPP (15-(p-iodophenyl)-3-(R,S)-methyl pentad
cardiotoxicity, 710(ab)
detection of viable myocardium, 800(ab)
left ventricular remodeling, 728(ab)
prognostic value in coronary patients without prior infarction, 502(ab)
Rutland analysis of cardiomyopathy, 501(ab)
Boerman, Otto C., 24N(9)
Bolton-Hunter, radiolabeled interleukin-8, infection imaging, 463, 470
Bombesin, Tc-99m-labeled analogy, 155(ab)
Bone
high-dose Ho-166-DOTMP bone marrow ablation therapy, 580(ab)
normalization of blood-pool activity, 1420(ab)
skeletal dosimetry with photon sources, 1049(ab)
three-dimensional semiquantitative analysis, CT and SPECT spatial and temporal resolution, 1075
tumors and tumorlike lesions, grading with FDG PET, 1695, 1702
Bone densitometry, different approaches, 2015
Bone loss, pathogenesis of, uptake of ^{99m}Tc MDP, skeletal and regional, 1478
Bone marrow
metabolism of FDG, local irradiation effects, normal rodent, 2026
radionuclides localized within the skeleton, S values for, 189
scintigraphy, comparison of multimodalities in evaluation of malignancies, 1214(ab)
transplantation, radioimmunotherapy for conditioning before, 531
Bone metastases
painful, treatment with ^{186}Re HEDP, 647, 655
from prostate or breast cancer, ^{186}Re HEDP toxicity and efficacy, 1689
therapy, marrow toxicity of ^{33}P- *versus* ^{32}P-orthophosphate in, 941
Bone mineralization, $^{89}SrCl_2$ incorporation, type I collagen, 183
Bone neoplasms, biologic mechanisms of $^{89}SrCl_2$ incorporation, type I collagen, 183
Bone pain
cancer, radionuclide therapy, marrow-sparing effects of ^{117}Sn DTPA, 2043
palliation
bone uptake of Re-186-HEDP and Sm-153-EDTMP, 377(ab)
metastatic prostate cancer, E-selectin concentration after ^{89}Sr chloride therapy, 1021
pharmacokinetics of Re-188-HEDP, 1059(ab)
preparation and pharmacological evaluation of Re-186 agents, 1089(ab)
Re-186-HEDP and Sm-153-EDTMP, 1187(ab)
Re-188-HEDP, 1165(ab)

selection of radiopharmaceuticals, 682, 688
therapy, marrow toxicity of ^{33}P- *versus* ^{32}P-orthophosphate in, 941
Bone scan
joint replacement, 63(ab)
metastases detection, 570(ab)
pretherapeutic three-phase scanning following radiosynoviorthesis, 1429(ab)
therapeutic response, evaluation of, 1315(ab)
Bone scintigraphy
bone metastases, diagnosis of, 1270(ab)
^{99m}Tc MDP imaging of hepatocellular carcinoma, 1305(ab)
nonuniform attenuation and scatter correction, 1425(ab)
preoperative diagnosis of head and neck cancer, 376(ab)
tumor marker assays, 111(ab)
Bone tumor
allograft imaging with F-18-fluoride, 372(ab)
diagnosis with Tl-201, 1321(ab)
FDG PET diagnosis of, 1322(ab)
Book review, *Essentials of Nuclear Medicine Physics,* 565
Boston Naming Test, brain SPECT, in progressive aphasia, 228
Bowel, activity, minimizing in myocardial perfusion SPECT, 1315
Brain
activation by audiovisual stimulation, FDG PET in Alzheimer's disease, 575
atrophy, aging effects, 926(ab)
bipolar disorder, regional increases in monoamine transporter, 535(ab)
cardiac sympathetic dysfunction in panic disorder, 706(ab)
cholinergic terminal density, ^{18}F FBT PET, monkey, 2069
FDG input function, noninvasive estimation, 1612
ictal-interictal SPECT of temporal lobe epilepsy, 259(ab)
ictal SPECT, neocortical seizures, 1619
image analysis, three-dimensional stereotactic surface projection, PET, monkey, 1879, 1888
image registration, spatially noncoherent interferometry, 375
I-123-SB 207710 exhibits 5-HT4 receptor-selective binding, 477(ab)
^{38}K uptake, PET, 763
mapping, lesions near central sulcus, ^{99m}Tc ECD SPECT visualization of, 411
monoamine oxidase A measurements, 98(ab)
MRI-SPECT image registration, automatic and interactive methods, 1823
^{99m}Tc SPECT, normal patterns in adults, 1456
neoplasm, ^{123}I IMP SPECT in non-Hodgkin's lymphoma, 1777
neuroreceptor binding parameters, 225(ab)
opioid receptor availability in alcoholics, 539(ab)
perfusion deficits, 901(ab)
PET studies
cerebral glucose metabolism, effect of ethanol on, 917(ab)
dopamine transporter inhibition, 922(ab)
responses to tonic pain, 266(ab)
serotonin receptors, ^{18}F MPPF, 1830
serotonin transporter, quantification with ^{11}C McN 5652 PET, 1465
SPECT
attenuation distributions inferred from head atlas, 1569
quantification of dopamine transporters, 1086
region-of-interest templates, elderly, 45
subacute infarction, hypoxification and hyperfixation of ^{99m}Tc HMPAO, 795
temporal lobe, lobectomy for seizures, FDG PET after, 1964
transporter binding of ^{11}C altropane, 931(ab)
Brain imaging
atrophy correction, 417(ab)
autoradiography of serotonin receptor agonist, 1069(ab)
dopamine transporter, status of, 105(ab)
frontal 5-HT2a binding potential, 908(ab)
function studies in Tourette syndrome, 1006(ab)
metabolism of ^{99m}Tc ECD in infarcted brain tissue, 551(ab)
PET, comparative studies of nicotinic acetylcholine receptors, 949(ab)
PET studies of beta-adrenoceptors, 96(ab)
reduced frontal 5HT2A binding potential, 534(ab)
transcranial magnetic stimulation combined with, 845(ab)
trauma, 243(ab)
Brain neoplasm. *see also* Brain Tumor
brachytherapy of malignant glioma, 1200(ab)
detection of tumor recurrence, comparison of FDG PET, MRI and MRS, 1003(ab)
FDG PET in high-dose conformal radiation, 269(ab)
neuronavigation, 979(ab)
oligodendrogliomas, characterization of, 1011(ab)
PET evaluation of brain lesions, 271(ab)
post-treatment necrosis, 273(ab)
radioiodine amino acid derivatives, 936(ab)
SPECT imaging of nonparenchymal brain tumors, 984(ab)
Brain perfusion, changes in after deep brain stimulation, 545(ab)
Brain phantom, quantitation, three-dimensional measurements, 405(ab)
Brain tumor. *see also* Brain neoplasm
recurrent, from radiation injury, PET in differentiation of, 1861
^{201}Tl SPECT imaging, 5
Breast
abnormalities, chemotherapy, monitoring with FDG PET, 443(ab)
biopsy, stereotactic techniques for, 235(ab)
biopsy specimen imaging, 112(ab)
digital mammography, artifacts on, 814(ab)
milk excretion of radiopharmaceuticals, 863
^{99m}Tc MIBI uptake in MCF7 human breast cancer cells, 591(ab)
Breast cancer
bone metastases from, ^{186}Re HEDP toxicity and efficacy, 1689
cell line expressing sodium/iodide symporters, radioiodide concentrator gene therapy, 1898
estrogen receptor imaging of, 1324
external radiation therapy and Rhenium-186-HEDP therapy, comparison of, 1168(ab)
FDG coincidence imaging, 1267(ab)
FDG PET
detection of internal mammary nodes, 109(ab)
internal mammary lymph node assessment, 1260(ab)
imaging, comparison of ^{111}In-labeled EGF and MAb 528 for, 903
lymphatic mapping, 307(ab), 1226(ab)
mouse models, intratumoral distribution of deoxyglucose and ^{99m}Tc MIBI, 1561
^{99m}Tc MIBI and tetrofosmin uptake in cell lines, 1495
nonpalpable lesions, ^{99m}Tc furifosmin scintigraphy, 426
overexpression of EGFR, ^{111}In-labeled EGF radiotoxic to, 429
positron emission mammography system PEM-I, FDG glucose metabolic images, 1851, 1859
preoperative lymphoscintigraphy, sentinel node localization during, 1682
scintimammography, ^{99m}Tc sestamibi, diagnostic accuracy, 1973
sentinel node biopsy for small tumors, 306(ab)
sentinel node detection, intratumoral injection in mammary lymphoscintigraphy1500
suspected, ^{99m}Tc MIBI scintimammography and mammography in, 390(le)
Breast cell lines
expressing sodium-iodide symporters, radioiodide concentrator gene therapy, 1898
malignant and nonmalignant, ^{99m}Tc uptake in, 1495
Breast neoplasm
bone marrow biopsy, 1263(ab)
breast cancer recurrence, diagnosis, 110(ab)
chemotherapeutic response, assessment with sestamibi, 448(ab)
clinical utility of mammography, 1258(ab)
clinical utility of scintimammography, 568(ab)
cost-effectiveness of FDG PET, 1269(ab)
detection of recurrent cancer, 572(ab)
FDG PET
detection of lymph nodes, 573(ab)
management of, 430(ab)
screening, 1268(ab)
GLUT-1 overexpression, 449(ab)
heterogeneity of estrogen receptor expression, 108(ab)
internal mammary lymph node chain evaluation with PET, 574(ab)
localization with lymphoscintigraphy and sentinel node localization, 282(ab)
paraffinoma, a late complication of paraffin injection, 1262(ab)
pharmacokinetic magnetic resonance mapping, 1266(ab)
scintigraphic assessment of palpable breast lesions, 106(ab)
sentinel node detection with intratumoral injection, 1229(ab)
sentinel node imaging, 308(ab), 1227(ab)
localization, 1230(ab)
role of ^{99m}Tc nanocolloid, 284(ab)
staging with FDG PET, 107(ab)
tumor marker assays, 111(ab)
Breast scintigraphy
comparison of diagnostic accuracy in breast cancer, 1265(ab)
comparison of technetium-labeled MIBI and MDP, 571(ab)
palpable breast lesions, 106(ab)
Briner, William H., 30N(11)
Bromofluorodeoxyuridine, PET, DNA, rats, 1746
Brucer, Marshall, 29N(11)
Burt, Robert W., 28N(7)

C

Calcium disodium ethylenediaminetetraacetic acid ($CaNa_2EDTA$), use in human colorectal cancer in mice, 337
Camera systems, hybrid tomograph, 78(ab)
Cancer. *see also* specific type or site
lognormal SUVs in diagnosis, 1664
molecular imaging with PET, 661
unknown primary, FDG PET in, 816
Cancer cell line
effect of glucose transporter and hexokinase on F-18-FDG uptake, 1130(ab)
mitochondrial DNA depletion cells, 1132(ab)
Cancer imaging
FDG PET assessment of primary uterine cervical carcinoma, 458(ab)
hybrid tomograph, 78(ab)
neurological paraneoplastic syndrome detection with PET, 1324(ab)
radioimmunoscintigraphy of solid tumors, 1129(ab)
synthesis and evaluation radiolabeled peptides, 1141(ab)
tumor detection with radiolabeled peptides, 132(ab)
tumor vasculature and, 128(ab), 1029(ab)
water-soluble phosphine BFCA, 1079(ab)
whole-body PET studies, 1307(ab)
Cancer staging
detection of mediastinal node metastasis, 109(ab)
esophageal, FDG PET, 808
therapeutic management of lung cancer, 1280(ab)
unkown tumors, FDG PET, 816
whole-body FDG PET, 428(ab)
Captopril, renography
diagnosis of medical complications post-transplantation, 368(ab)
diagnosis of renal artery stenosis, 1337
liver disease, diagnosis of, 371(ab)
^{99m}Tc DTPA, parenchymal mean transit time analysis, 1627
Carbon-11
PET studies of dopamine transporters, 1071(ab)
random coincidence, 815(ab)
Carbon-11-acetate
lymphoma, whole-body imaging of, 1211(ab)
thyroid cancer, whole-body imaging of, 1350(ab)
whole-body PET imaging of malignant neoplasms, 292(ab)
Carbon-11 choline, PET, detection of mediastinal lymph node metastases, lung cancer, 1507
Carbon-11 CO_2, exhaled, measurement of, during PET, 605
Carbon-11 colchicine, PET, multiple drug resistance, 493
Carbon-11 DAG, visualization of phosphoinositide turnover, in myocardial infarction, 2063
Carbon-14 2-deoxyglucose, tracer, myocardial glucose uptake with, 488

Carbon-11-FMAU, thymidine analog, 1038(ab)
Carbon-11 KF18446, adenosine A_{2A} receptor ligand, central nervous system, 345
Carbon-11 McN 5652, PET, quantification of brain serotonin transporter, 1465
Carbon-11 MET
effect of exercise on methionine uptake in skeletal muscle, 1155(ab)
FDG comparison, PET, nodal staging of lymphoma, 1980
low F-18-FDG uptake on PET studies of brain lesions, 271(ab)
Carbon-11 metomidate
PET imaging with
adrenal cortical tumors, 275
hilar and mediastinal lymph node metastasis, lung cancer, 283, 291
tracer, PET imaging of adrenal cortical tumors, letter, 1933
Carbon-11 NMSP, PET study, upregulation of dopamine D2 receptors in early Parkinson's, 65
Carbon-11 RAC, PET study, upregulation of dopamine D2 receptors in early Parkinson's, 65
Carbon-11 raclopride
measurement of dopamine release with, 522
PET, striatal dopamine release, 1352
Carbon-11 TAA, inhaled, pulmonary distribution and kinetics, 1603
Carbon-14 urea breath test, helicobacteria overgrowth in large intestine, 1376(ab)
Carbon-11 vinblastine, 1018(ab)
Carcinoembryonic antigen, high-dose radioimmunotherapy, medullary lung cancer, 93
Carcinoid tumors, ^{123}I IMT scintigraphy in, 1793
Cardiac function
additive effects of aging, 344(ab)
comparison of beta-blocker therapy with amiodarone therapy, 760(ab)
detection of cardiac torque on perfusion images, 176(ab)
effectiveness of gated perfusion PECT, 17(ab)
FDG PET gated imaging of left ventricular ejection fraction, 348(ab)
gated myocardial perfusion SPECT, 848(ab)
Gd-DTPA estimation of myocardial flow reserve, 701(ab)
L-Carnitine, utility of to assess free fatty acid metabolism, 12(ab)
left ventricular ejection fraction, gated SPECT compared to planar imaging, 388(ab)
left ventricular ejection fraction measurement with myocardial perfusion SPECT, 359(ab)
neuronal, childhood dilated cardiomyopathy, 400
Cardiac imaging
attenuation correction, 872(ab)
automated quantitation of infarct size and myocardial salvage, 762(ab)
dual-isotope studies, 740(ab)
endocarditis, 498(ab)
fusion images of perfusion and function, 729(ab)
gamma camera coincidence imaging with FDG, 811(ab)
metabolic imaging of myocardial glucose utilization, 186(ab)
multigated image correction, 526(ab)
myocardial glucose metabolism, 350(ab)
myocardial perfusion, absolute quantification of with ^{11}C acetate PET, 169(ab)
myocardial viability assessment, 342(ab)
nonrotational system for, 807(ab)
parameters of left ventricular dysfunction, 716(ab)
perfusion changes in ST depression, 749(ab)
radiopharmaceutical uptake in myocardial tissue, 790(ab)
scatter correction, 391(ab)
simultaneous dual-isotope versus FDG, 353(ab)
syringe type affecting quality of, 1104(ab)
three-dimensional SPECT images using electrophysiology, 184(ab)
transmission map acquisition, 809(ab)
transmission reconstruction algorithm, 870(ab)
uptake of fluoro-iodo-arabinofuranosyl-uracil in heart cells, 3(ab)
verapamil, benefit of after primary angioplasty, 702(ab)
Cardiac output, blood flow, measurement of, 827(ab)
Cardiac phantom study, multicenter, quantitative myocardial SPECT, 1383
Cardiac sympathetic function, beta antagonist therapy, 704(ab)
Cardiac sympathetic innervation, cardiac efficiency in transplanted heart, 195(ab)
Cardiac sympathetic nervous system
dilated cardiomyopathy, 703(ab)
I-123-MIBG SPECT to depict impairment, 194(ab)
Cardiac volume
PET assessment of cardiac sympathetic function, 189(ab)
quantification, 799(ab)
Cardiomyopathy
cardiac symptoms predictive of clinical outcomes, 357(ab)
diabetic, Rutland analysis, 748(ab)
dilated, impairment of cardiac neuronal function, childhood, 400
effect of long-term rehabilitation to beta blockers on left ventricular ejection fraction, 9(ab)
fatty acids, role in cardiac imaging, 1525
idiopathic dilated
carvedilol and neuronal function, 845
coronary microvascular reactivity to sympathic stimulation in, 837
I-123-MIBG prognosis of, 720(ab)
I-123-9MPA, 24(ab)
improved cardiac function with amiodarone, 760(ab)
MIBG
altered adrenergic innervation function, assessment of in pediatric patients, 10(ab)
diminished uptake of, 196(ab)
neuroimaging techniques to assessment, 796(ab)
Cardiovascular disease, molecular imaging with PET, 661
Carotid artery disease (CAD), brain metabolism in, proton MR spectroscopy and PET, 1357, 1363
Carotid occlusion, symptomatic, analysis of therapy for, 800
Carvedilol, cardiac neuronal function after, in cardiomyopathy, ^{123}I MIBG scintigraphy, 845
Cassen, Benedict, 29N(11)
CD36 deficiency, ^{123}I MIBG fatty acid analog effects, 1134
CD74 antibody, radiolabeled, therapeutic agent for B-cell lymphoma, 2089
Cell proliferation, non-small cell lung cancer, FDG PET detection, 85
Central nervous system (CNS)
adenosine A_{2A} receptor ligand, ^{11}C KF18446, 345
PET studies, ecstasy, long-term effects of, 921(ab)
Cerebellar diaschisis, crossed, stroke patients, acetazolamide and ^{99m}Tc HMPAO SPECT, 416
Cerebral artery, middle, occlusion, PET, monkey model of cerebral ischemia, 1409
Cerebral blood volume
percutaneous transluminal angioplasty, 89(ab)
two-dimensional projection image, clustering, 926(ab)
Cerebral glucose metabolism
correction of labeled arterial metabolites on PET scans, 244(ab)
obsessive compulsive disorder, 912(ab)
postprandial hyperglycemia, effect of, 977(ab)
Cerebral infarction
^{99m}Tc HMPAO hyperactivity in, 1005(ab)
PET activation studies of motor recovery, 553(ab)
risk stratification, 993(ab)
Cerebral ischemia, EC-IC bypass surgery, cerebral blood flow measurement with I-123-IMP, 90(ab)
Cerebral oxygen metabolism, PET image quantitation, 957(ab)
Cerebral perfusion SPECT
epilepsy-related perfusion changes, 257(ab)
^{99m}Tc HMPAO upright test, 993(ab)
^{99m}Tc MAA, embolization, detection of, 87(ab)
quantitative measurement with I-123-IMP, 90(ab)
Cerebral postischemic hyperperfusion
chronic fatigue syndrome, 970(ab)
multiple system atrophy, 425(ab)
Cerebral vasospasm, regional difference in cerebral vascular response, 950(ab)
Cerebrovascular disease, intracerebral hemorrhage, pharmacologic blood pressure reduction on, 85(ab)
Cerquiera, Manuel D., 26N(2)
Cervical interbody fusion, radiographic and scintigraphic courses of union, 1642
Channelized hotelling observer (CHO), human observer correlation and, SPECT, 514
Chelating agents
comparison of technetium-labeled peptide, 1127(ab)
^{99m}Tc chelates as markers of hypoxia, 1024(ab)
N2S2 ligand, 1095(ab)
tumor imaging with EDTA derivatives, 1031(ab)
Chemotherapy
blocking catabolism with eniluracil, PET studies with ^{18}F FU and, colorectal cancer, 1714, 1725
CHOP, residual disease after, hilar uptake of ^{67}Ga citrate and, 269
^{18}F FAU, biodistribution and metabolism, 1162(ab)
medullary thyroid carcinoma, 1327(ab)
radiopharmaceutical distribution in renal studies, 1100(ab)
response
^{11}C vinblastine, 1018(ab)
FDG PET monitoring of colorectal cancer, 446(ab)
lung cancer, 447(ab)
^{99m}Tc rh-annexin V, 1154(ab)
Taxol, efficacy of, 215(ab)
Tomudex and Oxaliplatin, glucose transport, SW620 cells, 1753
Cholangiocarcinoma, FDG PET detection and staging of, 139(ab)
Cholecystokinin receptor ligands, staging of metastatic medullary thyroid cancer, 30(ab)
Choline, gastroesophageal cancer, staging of gastroesophageal cancer with PET tracers, 555(ab)
Cholinergic neurons, measurement with F-18-FBT, 832(ab)
Cholinergic terminals, density, ^{18}F FBT PET, monkey brain, 2069
C3H 10T1/2 cells, morphological transformation, ^{99m}Tc cardiolite, 1545
Chung, June-Key, 24N(9)
Clearance
algorithms for estimating MAG3 clearance, 365(ab)
effect of sampling time in renal studies, 198(ab)
Cocaine
dopamine, synergistic elevation of, 414(ab)
downregulation of dopamine D2 receptors, 413(ab)
PET quantitation of dopamine transporter occupancy, 263(ab)
Cocaine analogs, pharmacokinetics of Tc-labeled conjugates, 148(ab)
Cochlear implant, FDG PET analysis of, 961(ab)
Cognition, cerebral metabolic response to audiovisual stimulation, FDG PET in Alzheimer's disease, 575
Cognitive dysfunction, dementia severity, SPECT measures of cerebral cortical perfusion, 57
Coincidence detection camera
clinical utility of FDG in pediatric oncology studies, 1430(ab)
comparison of hybrid and dedicated scanner, 1271(ab)
comparison with convention imaging in diagnosis of colorectal cancer, 1308(ab)
evaluation of metastatic bone disease, 554(ab)
FDG assessment of malignant lymphoma, 1217(ab)
head and neck cancer, diagnosis of, 1275(ab)
hybrid scanner, 71(ab)
image contrast, effect of shielding on, 859(ab)
image registration, 1235(ab)
iterative reconstruction and filtered backprojection, comparison of, 891(ab)
lung cancer staging, 1293(ab)
methods for resolution improvement, 222(ab)
nonattenuation-corrected imaging, 986(ab)
quantification of FDG uptake, 237(ab)
SPECT myocardial perfusion imaging, 341(ab)
spondylitis, comparison of FDG imaging and MRI, 378(ab)
Coincidence imaging
attenuation correction, with and without, 347(ab)
breast cancer, 1267(ab)
cardiac studies, 811(ab)
comparison with Ga-67 in staging of lymphoma, 467(ab)
dual-head, FDG, malignancy in pulmonary images, 1801
dual-head camera, Fourier rebind for, 878(ab)
dual-head camera, PET with, 1067
gamma camera
attenuation correction for, myocardial perfusion SPECT, 919
FDG uptake by renal malignancies, 78
PET comparison, lung lesions, 959(le)
transmission scanning system for, 692

lung and breast cancers, detection of, 1237(ab)
myocardial viability
assessment of, 181(ab)
evaluation of with FDG PET and gated SPECT, 759(ab)
remission or non-remission, detection of, 1219(ab)
unknown primary tumors, 1290(ab)
viable myocardium, detection of, 739(ab)
whole-body hybrid FDG PET to stage non-Hodgkin's lymphoma, 1273(ab)
X-ray attenuation, image fusion with, 1364, 1380
Colchicine, PET imaging, multiple drug resistance, 493
Cold pressor test, coronary microvascular reactivity to, idiopathic dilated cardiomyopathy, PET, 837
Collagen, type I, biologic mechanisms of $^{89}SrCl_2$ incorporation, 183
Collimation, Collimators, 823(ab)
dual-planar, circular orbit, 820(ab)
parallel-hole and fanbeam, angulation errors in, 548
response, cardiac SPECT, 1400
scatter penetration in I-123 imaging, 523(ab)
SPECT, 776(ab)
ultra-high-energy, ^{131}I SPECT quantification, 1760
Colon cancer
FDG PET detection of recurrent malignancy, 1297(ab)
human xenografts, pharmacologic intervention for RIT, 1244
Colorectal cancer
arcitumomab imaging in, 1016
biokinetics of labeled antibodies, 1184(ab)
blocking catabolism with eniluracil, PET studies with ^{18}F FU and, 1714, 1725
comparison of coincidence gamma camera and conventional imaging in diagnosis of, 1308(ab)
FDG PET, ^{99m}Tc labeled antibody fragments, 1657
FDG PET detection of, 136(ab)
FDG PET management of, 1303(ab)
F-18-FDG, 433(ab)
hepatic metastases, assessment with whole-body FDG PET, 137(ab)
Metastasis, FDG PET evaluation of, 134(ab)
PET and intraoperative beta and gamma probes, correlation of, 816(ab)
recurrent, whole-body FDG PET detection of, 1177
therapy with I-131-labeled hMN-14, 313(ab)
whole-body PET imaging to detect recurrence, 135(ab)
xenografts, pretargeted radioimmunotherapy, 480
Colorimetric test, indication of lymphocyte damage, after ^{131}I therapy, 1522
Compartmental models
^{123}I I-A-85380 SPECT, measurement of nicotinic receptors, 1552
radioiodinated acetylcholine receptors, 97(ab)
Compton camera
animal PET studies, 76(ab)
prostate, 68(ab)
Computed tomography (CT)
combined PET scanner, clinical oncology, 1369, 1380
emission, role of fatty acids in cardiac imaging, 1525
helical, positive for urolith, renal colic after, MAG3 scintigraphy, 1813
hybrid PET machines, 961(le)
improved localization of endocrine sites, 34(ab)
quantitative, bone densitometry and, 2015
reprojected data, registration of planar emission data with, 700
spatial and temporal registration, 1075
transmission, brain SPECT, 2051
Computer-assisted image archival system, 867(ab)
Computer simulation, biodistribution data, 1039(ab)
Congestive heart failure
MIBG to assess therapeutic response in pediatric patients, 10(ab)
prognostic value of MIBG to predict arrhythmias, 743(ab)
Consumer Assurance of Radiologic Excellence Act
Lazio to introduce bill, 37N(7)
technologists support, 28N(6)
Contrast, ROC/LROC study of lesions, PET, 745
Copper-52 citrate, PET, Wilson's disease, 781
Copper-62 PTSM, PET perfusion agent, clinical trials, 309
Copper-64, radiotherapeutic effect of labeled ATSM in tumor studies, 455(ab)
Coronary artery disease (CAD)
cost-effectiveness of myocardial SPECT, 781(ab)
diagnosis, lung ^{201}Tl uptake with exercise SPECT, 567
exercise-induced myocardial ischemia, 741(ab)
gated SPECT assessment of stunned myocardium, 735(ab)
likelihood of, gated or attenuation-correction SPECT, 852, 860
mental stress effects, blood flow and vasomotion, 11
^{99m}Tc annexin-V imaging of ischemia, 793(ab)
myocardial SPECT perfusion distributions, 3-D color-modulated display, 1941
positive SPECT and PET findings, gender differences, 263
postexercise lung uptake of ^{99m}TC MIBI, new automatic technique, 1190
prevention of restenosis after percutaneous transluminal angioplasty, 503(ab)
quantification of scatter/nonscatter corrected images for detection of, 718(ab)
single exercise stress SPECT image, prognostic value of, 724(ab)
SPECT imaging of myocardial ischemia, 23(ab)
transmyocardial laser revascularization, scintigraphic evaluation of, 14(ab)
Coronary flow reserve
effect of troglitazone on, 175(ab)
erythrocytotic cyanotic congenital heart disease, 708(ab)
PET evaluation, 764(ab)
PET myocardial perfusion study in insulin resistance, 170(ab)
Coronary intervention
intracoronary irradiation, 26(ab), 797(ab)
^{99m}Tc MIBI evaluation of coronary flow reserve, 727(ab)
synthesis of radioactive implants, 1076(ab)
Coronary restenosis, stent, radiolabeled antibody uptake in, 1535, 1541
Cortical bone, radionuclides localized within the skeleton, S values for, 189
Cost-effectiveness, myocardial SPECT studies, 343(ab)
Croft, Lori Bray, 30N(7)
Crohn's disease
assessment of colitis with ^{99m}Tc liposomes, 517(ab)
FDG PET and granulocyte scintigraphy of, 41(ab)
^{123}I IL2 scintigraphy in, 242
Cross-talk correction
comparison of techniques in dual-isotope myocardial perfusion imaging, 527(ab)
convolution-based method in dual-isotope study, 178(ab)
photon energy recovery for, simultaneous dual-isotope imaging, 728
Crumpler, Stuart, 13N(6)
Curie, Irène, 29N(11)
Cwajg, Eduardo, 14N(9)
Cytotoxicity, in vito, B-cell lymphoma, CD74 antibody as therapeutic agent, 2089

D

Data analysis
dynamic SPECT, 864(ab)
myocardial perfusion SPECT databases, 846(ab)
principal component analysis, 526(ab)
standardized uptake values, 829(ab)
Deadtime correction technique
pediatric brain, spatial normalization of, 245(ab)
PET local maximum spatial error, 66(ab)
Deep venous thrombosis
acute, ^{99m}Tc apcitide scintigraphy, letter, 1768
imaging of, thromboscintigraphy with ^{99m}Tc apcitide, 1214, 1224
imaging with ^{99m}Tc bitistatin, 1056, 1065
^{99m}Tc fibrin binding domain imaging of, 43(ab)
^{99m}TC fibrin imaging, 161
thromboscintigraphy with DMP-44, 45(ab)
De Hevesy, Georg Charles, 26N(11)
Deinococcus radiodurans, 28N(2)
Dementia
cerebral metabolic response to audiovisual stimulation, FDG PET, 575
diagnostic accuracy of FDG PET, 247(ab)
pathologically verified, FDG PET in, 1920, 1929
PET, prognostic value of, 251(ab)
severity, SPECT measures of cerebral cortical perfusion, 57
DeNardo, Gerald L., 13N(5)
DeNardo, Sally J., 14N(5)
2-Deoxy-D-glucose, transport, novel chemotherapy and, 1753
Deoxyglucose
effect of glucose transport modification on tumor response, 1156(ab)
^{99m}Tc MIBI and, intratumoral distribution in breast cancer models, 1561
Department of Energy (DOE)
Advanced Nuclear Medicine Initiative (ANMI), 11N(1), 49N(8)
applications available, 22N(2)
Brookhaven research reactor to close, 28N(2)
Hanford Nuclear Facility, 14N(4), 17N(4)
Human Subject Research Database updated, 41N(7)
isotope support funding low, 14N(11)
Joint Genome Institute, 28N(6)
Marcus named head of nuclear energy programs, 28N(2)
Office of Nuclear Energy, Science and Technology (NE), 11N(1)
radioisotope production, seeks partners in, 34N(11)
surplus radioactive materials for clinical trials, 50N(8)
Department of Health and Human Services (HHS)
Office of the Inspector General (OIG), Defining 'excluded individuals,' 21N(1)
standards for privacy of individually identifiable health information, 20N
Depression
Alzheimer's disease, 422(ab)
artificial neural networks and SPECT detection of, 835(ab)
brain perfusion SPECT, 905(ab)
FDG in acute state and remission, 907(ab)
neurobiology of, 533(ab)
perfusion SPECT, 901(ab)
PET receptor studies of, 899(ab)
serotonin responsiveness, PET imaging of, 903(ab)
DeVries, Daniel J., 24N(9)
Diabetes mellitus
effect of troglitazone on glucose utilization, 29(ab)
loss of cardioprotection in premenopausal women, 5(ab)
nitric oxide-dependent vasodilation mechanism, 7(ab)
non-insulin-dependent, coronary microangiopathy in control of, 978
PET evaluation of myocardial blood flow, 175(ab)
prevalence of urinary tract infection, 201(ab)
reduction of blood glucose before FDG PET, 1238(ab)
renal uptake of DMSA in diabetic nephropathy, 1352(ab)
retinopathy present in CAD patients, 6(ab)
scintigraphic assessment cardiac event-free survival, 751(ab)
Diabetic cardiomyopathy, Rutland analysis, 748(ab)
Diabetic foot, ^{99m}Tc MDP and ^{111}In-labeled leukocyte scintigraphy of, 1422(ab)
Diabetic neuropathy, heart rate response to adenosine, 730(ab)
DICOM image display, computer-assisted, 868(ab)
Dimercaptosuccinic acid (DMSA)
comparative study of DMSA and Doppler sonography in acute pyelonephritis, 209(ab)
comparison of Doppler ultrasound and DMSA in detection of pyelonephritis, 207(ab)
diuretic scintigraphy, evaluation of acute pyelonephritis, 1955
^{188}Re complex in bone metastases, 1202(ab)
renal scarring and urinary tract infection in diabetes mellitus, 201(ab)
scintigraphy, accuracy for acute pyelonephritis, 986
Diprenorphine, PET synthesis and biologic evaluation, 1279
Dipyridamole
adverse reactions of pharmacological stress, 722(ab)
depressed heart rate changes during pharmacologic stress test, 730(ab)
evaluation of with MUE, 1112(ab)
stress, stunning induced by, gated myocardial SPECT, 27
DNA
binding, progressive nuclear translocation of somatostatin analogs, 1256
double-strand breaks, ^{111}In-labeled oligodeoxyribonucleotides, 1093

oxidative damage, radiation synovectomy and, arthritis patients, 250
synthesis, ^{76}Br bromofluorodeoxyuridine PET, 1746
Dobutamine, comparison of gated SPECT and echocardiography, 351(ab)
Doctors in Charge, Inc., 20N(3)
Dopamine
blocking by cocaine, 416(ab)
cocaine and nicotine elevation of, 414(ab)
effects depletion on in vivo binding of ^{11}C NNC-112, 941(ab)
imaging, automated quantification of ^{123}I IBZM uptake, striatum, Parkinsonism, 220
mesolimbic and nigrostriatal ketamine-induced release of, 102(ab)
neuronal nitric oxide synthase inhibition, 939(ab)
neuroreceptor and motor activity changes following methamphetamine, 412(ab)
nicotine and methylphenidate, synergistic elevations of, 411(ab)
occupancy of 5HT1A receptors by pindolol, 946(ab)
quantification of transporters with PET, 934(ab)
release
measurement with continuous infusion of ^{11}C raclopride, 522
striatal, exercise effects, PET, 1352
SPECT, gender differences in transporter densities, 900(ab)
striatum, SPECT imaging of, 544(ab)
in vivo binding of raclopride, 265(ab)
Dopamine D2 receptors
acute endogenous depletion of, 923(ab)
binding of atypical neuroleptics, 101(ab)
dopamine concentration, effect of Ritalin on, 103(ab)
extrastriatal, reproducibility, SPECT, 1343
F-18-fallypride and clozapine interaction, 264(ab)
high occupancy following high-dose clozapine, 924(ab)
linear regression models, 833(ab)
putaminal, upregulation in early Parkinson's, PET study, 65
quantification of striatal and extrastriatal with F-18-fallypride, 549(ab)
radiosynthesis of F-18-OH-FPPAT, 481(ab)
striatal binding of I-125-IBZN, 409(ab)
Dopamine neurons, accumulation of ^{11}C tropoxene, 933(ab)
Dopamine receptors
automated analysis of studies, Parkinsonism, 220
^{11}C FLB457 binding to, 548(ab)
halogenated analogs of WAY-100635, 152(ab)
Dopamine transporters
binding, Machado-Joseph disease, 994
binding of ^{99m}Tc to, Parkinson's disease, 584
imaging with ^{123}I-β-CIT SPECT, aging effects, 36
quantification of, SPECT with ^{123}I IAFCT, 1086
Dose escalation study, dopamine D4 receptors, 1070(ab)
Dose estimation
effect of data sampling on, 1181(ab)
optimization of measurement protocol, 1058(ab)
Tc-84m-sestamibi, 334(ab)
voxel dosimetry, 331(ab)
Dosimetry
anthropomorphic models for skeleton, 1062(ab)
anthropomorphic studies, effect on brain quantification, 2051
biodistribution and excretion kinetics of Re-188 agents, 801(ab)
biodistribution of Iotrex, 1044(ab)
bone marrow model adjustments, 328(ab)
chimeric MAb MOv18, radioimmunotherapy in ovarian cancer, 1168
comparison, nuclear cardiology radiopharmaceuticals, 1052(ab)
DOTA amide derivatives, 1085(ab)
high-dose radioiodine, 333(ab)
intratumoral injection of yttrium, 1056(ab)
^{123}I pyridyl ether, as a radioligand for, 478(ab)
^{131}I tositumomab, 325(ab)
marrow toxicity of ^{33}P- *versus* ^{32}P-orthophosphate, bone metastases, 941
^{99m}Tc DTPA-folate, 1014(ab)
^{99m}Tc NOET, myocardial perfusion imaging, 141
NMR microscopy in skeletal dosimetry models, 326(ab)
palliation of bone pain, metastatic osseous lesions, 682, 688
patient, tumor-targeted radionuclide therapy driven by, 104
radiation
absorbed dose calculation of Ho-166, 1060(ab)
absorbed fractions for photons and electrons, 149
beta irradiation, 1045(ab)
bone pain palliation, 1167(ab)
breast milk excretion of radiopharmaceuticals, 863
dose-fractionated radioimmunotherapy, 324(ab)
internal radionuclide, 297
stabilized ^{99m}Tc exametazime-labeled leukocytes, 934
voxel-based anthropomorphic phantom, 1039(ab)
^{90}Y-2IT-BAD-Lym-1, in non-Hodgkin's lymphoma, 952
radioiodinated polymer gel, 1063(ab)
radionuclide dose therapy, 329(ab)
radionuclides localized within the skeleton, 189
^{186}Re-labeled chimeric MoA U36, squamous cell carcinoma, head and neck, 1999, 2011
residence times, 1058(ab)
skeletal dosimetry with photon sources, 1049(ab)
skeletal internal dosimetry in children, 1053(ab)
^{117}Sn DTPA, therapy of bone cancer pain, 2043
stunning overtakes, 1061(ab)
thermoluminescent mini dosimeters, 335(ab)
thyroid disease, 1048(ab)
tracer, thyroid stunning after, 1082
tumor
^{131}I-anti-B_1 antibody therapy, lymphoma, 1579
single-dose *versus* fractionated radioimmunotherapy, 538
Drug targeting, site-specific delivery of small molecules, 1023(ab)
Drug-tracer interaction, ^{99m}Tc DMSA, chemotherapeutic effect of, 1100(ab)
Dual-isotope imaging
quantitation, myocardial perfusion SPECT, 712, 720
simultaneous, crosstalk correction, photon energy recovery for, 728

E

Echocardiography (ECG)
late cardiac complications following radiotherapy, 18(ab)
left ventricular mass index, 713(ab)
myocardial contrast, ^{201}Tl reverse redistribution, acute MI, 393
validation of gated SPECT, ventricular function measurements, 1308
Eckelman, William, 30N(11)
Ejection fraction
accuracy of ^{99m}Tc tetrofosmin vs echocardiography, 758(ab)
FDG PET analysis of, 752(ab)
^{201}T imaging of LVEF, 492(ab)
Electron beam computed tomography, pulmonary embolism, diagnosis of, 47(ab)
Embolism, fat embolism, new technique to diagnose, 1415(ab)
Emission computed tomography
binding characteristics of SSRIs, 930(ab)
improved image generation, 887(ab)
Emission transmission
evaluation of endocrine neoplasms, 35(ab)
FDG and TET evaluation of cancer, 1243(ab)
lymphoma, detection with CT and TET, 274(ab)
Emphysema
MRI and ^{133}Xe SPECT assessment regional respiratory function, 510(ab)
regional severity, technegas SPECT analysis of, 590
single-lung transplant for, value of perfusion lung scintigraphy, 1771
^{133}Xe SPECT and ^{99m}Tc MAA dynamic studies of, 511(ab)
Encephalopathy, subclinical hepatic, brain SPECT in, 405
Endarterectomy, carotid, ^{99m}TC ECD brain perfusion SPECT, 1836
Endocrine carcinoma, transmission and emission tomography, 35(ab)
Endocytosis
insulinlike growth factor-I binding proteins, tumor-bearing nude mice, 318
progressive nuclear translocation, somatostatin analogs, 1256
Endothelin receptors, in vivo labeling of, 1080(ab)
Enteropathy, protein-losing, children, ^{99m}Tc HSA scans in, 215
Enzyme inhibitors, imaging probe for glucocerebrosidase, 490(ab)
Epidermal growth factor (EGF)
^{111}In labeled, breast cancer imaging, 903
^{111}In-labeled, radiotoxicity to breast cancer cells, 429
^{99m}Tc-labeled phage, 486(ab)
Epidermal growth factor receptor (EGFR), breast cancer cells overexpressing of, ^{111}In-labeled EGF radiotoxicity to, 429
Epilepsy
continuous arterial spin-labeled perfusion MRI and PET, 987(ab)
FDG PET evaluation of, 981(ab)
ictal SPECT vs electrode localizations, 1001(ab)
image registration and subtraction, ictal brain SPECT, 1619
lateralization of, multimodality comparison, 991(ab)
occipital lobe epilepsy, 254(ab)
perfusion-related changes, 257(ab)
prognostic value of FDG PET, 256(ab)
quantification of FDG PET images, 998(ab)
refractory, vagus nerve stimulation in, SPECT study, 1145
SPECT imaging of epileptogenic foci, 255(ab)
surgical outcome, 253(ab)
temporal and extratemporal, 1004(ab)
three-dimensional rendering in FDG PET brain images, 400(ab)
Esophageal cancer
FDG PET staging of recurrence, 124(ab)
individual nodal involvement, FDG PET, 808
sentinel node imaging, 1222(ab)
Esophageal scintigraphy
achalasia, laparoscopic esophagomyotomy, 515(ab)
kinetic analysis, 513(ab)
transit time studies in achalasia, 514(ab)
Esophageal varices, bleeding after endoscopic variceal sclerotherapy, SPECT evaluation, 600
Esophagitis, detection by ^{99m}Tc MIBI chest SPECT, 1969
Estrogen receptor ligand, diethyleststilbertrol, radiation effects of, 1037(ab)
Estrogen receptors
breast cancer imaging agents, 1135(ab)
imaging, breast tumors, 1324
Ethylenedicysteine, preparation and evaluation of Re-188-EC for radiation therapy, 1090(ab)
European Association of Nuclear Medicine (EANM)
2000 Congress, 50N(8)
Post-Congress Tour and Symposia, 17N (11)
Task Group on Quality Assurance and Standardization, 18N (11)
Exercise
aerobic, effects on striatal dopamine release, PET, 1352
brain natriuretic peptide, as a marker of left ventricular dysfunction, 783(ab)
control of cardiovascular response, 927(ab)
lung ^{201}Tl uptake, SPECT, coronary artery disease, 567
Expert systems, automatic quantitation, myocardial perfusion SPECT, 712, 720
Extracellular matrix, in vivo evaluation of tumor targeting, 1134(ab)
Extracranial-to-intracranial bypass, PET before, carotid occlusion, 800

F

Factor analysis
algorithms, 393(ab)
blood and tissue time-activity curves, 396(ab)
^{11}C acetate PET studies of prostate cancer, 394(ab)
FDG PET studies, 395(ab)
parenchymal images and curves, 1365(ab)
quantification of hepatic clearance, 55(ab)
regional myocardial blood flow measurement, 183(ab)
Fatty acids
hepatic oxidation, PET tracer of, 1727

^{123}I IPPA SPECT, myocardial viability, 1299
imaging, metabolic studies in cardiomyopathy, 24(ab)
iodinated free, uptake, chronically hypoperfused myocardium, 293
long-chain, effects on CD36 deficiency, 1134
role in cardiac imaging, 1525
synthesis of ^{11}C fatty acids, 484(ab)
Field uniformity, calibration methods for, 806(ab)
Filtering, 1220(ab)
hybrid concept, 1114(ab)
noise reduction of, 889(ab)
spatially adaptive filtering, 888(ab)
standardized uptake value, 381(ab)
Fine-needle aspiration biopsy, diagnostic failure, 1323(ab)
Fisher discriminant analysis, FDG PET, comparison in HIV positive and healthy individuals, 612
Flow-sensitive alternating inversion recovery (FAIR), compared with SPECT, 26N(2)
Fluorine-18
assessment of revascularization in cardiac ischemia, 742(ab)
bone allograft imaging, 372(ab)
comparison of FDG and methyl tyrosine in intracranial and intrathoracic tumors, 1272(ab)
DNA synthesis, 165(ab)
kinetics of labeled tyrosine, 944(ab)
labeled piperidyl benzilate to measure acetylcholine receptors, 480(ab)
lysosomal storage diseases, 490(ab)
non-carrier-added fluoroarylethers, 488(ab)
Fluorine-18 altanserin, PET, 5-HT_{2A} receptors, Human brain, 234
Fluorine-18 DPN, synthesis and biologic evaluation, 1279
Fluorine-18 EF1, PET, noninvasive detection with ^{18}F EF1, PET, 327
Fluorine-18 FBT, PET, cholinergic terminal density, monkey brain, 2069
Fluorine-18 FDG, 776(ab)
attenuation correction, 349(ab)
biopsy specimen imaging, 112(ab)
breast tumor imaging, 1266(ab)
carcinoma of the hypopharynx/larynx, 559(ab)
cerebral reorganization, 965(ab)
chemoembolization of hepatocellular cancer, 1255(ab)
clinical efficacy, 1325(ab)
clinical usefulness and prognostic value of FDG PET in dilated cardiomyopathy, 744(ab)
coincidence detection camera, lymphoma, assessing malignancies, 1217(ab)
coincidence imaging of unknown primary tumors, 1290(ab)
differentiation of inflammation and tumor, 452(ab)
disease management, 1347(ab)
effect of left bundle branch block on cardiac images, 705(ab)
factors affecting yield of, 584(ab)
global lump constant measurements in traumatic brain injury, 243(ab)
gynecological malignancies, 1313(ab)
high uptake locally advanced breast cancer predictor of therapeutic response, 442(ab)
hyperglycemia, no effect FDG uptake in infectious lesions, 1396(ab)
hyperhydration protocol for assessing pelvic tumors, 1244(ab)
infection imaging, 37(ab)
intravenous insulin to reduce blood glucose levels, 1238(ab)
lung cancer, PET tracer for, 1295(ab)
lymphoma, coincidence imaging of, 557(ab)
mitochondrial hexokinase activity, 1132(ab)
oncology studies, evaluation of combined transmission and emission tomography, 1243(ab)
Patlak's plot to measure glucose utilization rate in colorectal cancer, 828(ab)
PET detection of colorectal cancer, 558(ab)
spillover correction, 186(ab)
thyroid cancer, detection of metastatic lesions, 1326(ab)
uptake in gastrointestinal tract, 450(ab)
uptake in monocytic U937 cells, 1395(ab)
Fluorine-18-FDOPA, nigrostriatal pathway, 540(ab)
Fluorine-18-FET
brain tumors, 272(ab)
lymph node metastases, 452(ab)
Fluorine-18-FHPG, herpes simplex virus thymidine kinase gene transfer, 1159(ab)
Fluorine-18-FLT
biodistribution, 141(ab)
preparation of various precursors, 1123(ab)
synthesis of PET tumor tracers, 582(ab)
thoracic tumor visualization, 290(ab)
tumor imaging, 291(ab)
Fluorine-18 fluoro-L-*m*-tyrosine, equilibration, between plasma and erythrocytes, 1636
1-5-Fluorine-18 FOP, PET tracer of hepatic fatty acid oxidation, 1727
Fluorine-18 FU, PET studies with, blocking catabolism with eniluracil and, colorectal cancer, 1714, 1725
Fluorine-18 MPPF, serotonin receptors, human brain, 1830
Fluorodeoxyglucose (FDG)
cell-culture reactor, for on-line evaluation, 556
^{11}C MET comparison, PET, nodal staging of lymphoma, 1980
collimated SPECT, ^{99m}Tc tetrofosmin and, myocardial viability, 1318
dual-head coincidence, malignancy in pulmonary lesions, 1801
effect on bone marrow metabolism, local irradiation effects, normal rodent, 2026
glucose metabolic images, positron emission mammography system PEM-I, 1851, 1859
imaging, assessment of myocardial imaging, 2099(le)
PET
assessment of primary uterine cervical cancer, 458(ab)
biliary carcinoma, 1300(ab)
bowel wall inflammation in Crohn's disease, determination of, 41(ab)
calculating cerebral glucose metabolism, 658
chronic orthopedic infections, 59(ab)
clinical utility in diagnosing liver tumors, 1299(ab)
colorectal cancer metastases, 136(ab)
comparison in HIV positive and healthy individuals, 612
correlation with sentinel node biopsy in malignant melanoma, 304(ab)
detection of lymph node metastases, 1491
effects of left bundle branch block on, 973
grading of tumors and tumorlike lesions of bone, 1695, 1702
hepatocellular cancer imaging, 1298(ab)
intraoperative tumor detection with probe, 1239(ab)
lung cancer, 439, 1284(ab)
lymphoma imaging with hybrid camera, 380(ab)
malignant pleural mesothelioma, 1443(le)
measurement of input functions, 1-point blood sampling, 1484
metastatic papillary thyroid carcinoma, 1358(ab)
^{99m}Tc labeled antibody fragments, colorectal cancer, 1657
nodal involvement in esophageal cancer, 808
noninvasive estimation of input function, 1612
non-small cell lung cancer, 85
normal structures, standardized uptake values in, 1234(ab)
passive audiovisual stimulation in Alzheimer's, 575
in pathologically verified dementia, 1920, 1929
quantification of tumor size, 236(ab)
radioimmunotherapy, metabolic response of non-Hodgkin's lymphoma, 999
recurrent brain tumor from radiation injury, 1861
recurrent or metastatic thyroid cancer, 1010
reproducibility in lung cancer studies, 1279(ab)
standardized uptake values, lognormal, 1664
substance abuse, ecstasy use, long-term effects of, 921(ab)
TSH level effects on uptake, in thyroid cancer, 1989, 1996
unknown primary tumors, 816
whole-body, recurrent colorectal cancer, 1177
whole-body glucose metabolism of FDG, 1377(ab)
tracer, myocardial glucose uptake with, 488
uptake, renal malignancies, coincidence detection, 78
Food and Drug Administration (FDA)
approves Positrace hybrid PET-CT camera, 24N(10)
MIRDOSE and, 13N(6)
Modernization Act, radiopharmaceuticals and, 26N(6)
Fractal analysis, regional severity of emphysema, technegas SPECT, 590
Front, Dove, in memoriam, 24N(3), 28N(4)
Fujiwara, Satomi, 14N(9)

G

GABA, biosynthesis of brain imaging agents, 942(ab)
Gallium-66
potential as PET imaging agent, 817(ab)
production for tumor imaging, 164(ab)
Gallium-67
detection of lymphoma with CT and TET, 274(ab)
hilar uptake of, residual disease after CHOP chemotherapy, 269
imaging chronic osteomyelitis, 896
prognostic value in low-grade non-Hodgkin's lymphoma, 465(ab)
scintigraphic evaluation of fever, 1403(ab)
SPECT, small lesion detection, filtered backprojection, 1391
Gallium-68, staging of somatostatin receptor-expressing tumor, 121(ab)
Gallium scintigraphy
lymphoma, 557(ab)
lymphoma imaging, comparison with hybrid PET camera, 380(ab)
Gamma camera
coincidence detection, FDG uptake by renal malignancies, 78
coincidence scanner, transmission scanning system for, 692
crystal thickness, 219(ab)
high-resolution dedicated system, 220(ab)
optimizing geometry for hybrid PET, 803(ab)
semiautomated regions of interest, evaluation of renal function with ^{99m}Tc MAG3, 1947
semiconductor detectors, 805(ab)
small gamma camera for breast imaging, 810(ab)
unusual problem with, 1298(le)
Gamma probe, 1240(ab)
intraoperative tumor detection with FDG PET, 1239(ab)
Gastric activity, minimizing in myocardial perfusion SPECT, 1315
Gastric carcinoids, somatostatin receptor scintigraphy localization of, 1646
Gastric emptying
comparison of two-hour and four-hour studies, 516(ab)
liquid, early, effects in children, 596
procedure guidelines, 1443(le)
scintigraphic assessment in patients with Hepatitis C, 1379(ab)
Gastrin releasing peptide receptor
pharmacokinetics of ^{99m}Tc GRP, 1013(ab)
targeting of tumor expression, 471(ab)
Gastroenteropancreatic tumors, evaluation of pylorus preservation, 1383(ab)
Gastroesophageal reflux, laryngitis and, ^{99m}Tc sulfur colloid gastroesophageal scintigraphy for, 1597
Geiger, Hans William, 26N(11)
Gender differences
brain metabolic responses to alcohol intoxication, 916(ab)
positive SPECT and PET cardiac findings, patients without heart disease, 263
Gene expression
CEA promoter, 145(ab)
dual-modality imaging of transgene expression, 320(ab)
F-18-FHPG quantitation of herpes simplex virus, 1157(ab)
indirect monitoring of, 321(ab)
low-dose radiation therapy, 567(ab)
molecular imaging with PET, 661
PET with p53, 1158(ab)
radioiodinated iodovinyl deoxyuridine, 144(ab)
Generator
alumina-based ^{188}W—^{188}Re, effective concentration of, 1271
Bacteriostat, 1107(ab)
evaluation of elution volumes and Tc-99m yields, 1103(ab)
irradiation of tungsten target, 588(ab)
Gene therapy
cytosine deaminase, 316(ab)

radioiodide concentrator, cell line expressing sodium/iodide symporters, breast cancer, 1898
tissue-specific AAV vectors, 1136(ab)
transfer of human sodium iodide symporter, 1139(ab)
Gene transfer
herpes simplex virus, 1159(ab)
herpes simplex virus thymidine kinase, 3(ab)
high-capacity imaging of somatostatin receptor, 319(ab)
^{99m}Tc P2-45 somatostatin receptor imaging agent, 318(ab)
noninvasive imaging, ^{99m}Tc or ^{188}Re radiolabeled peptide for, 887
Glioblastoma
intralesional radiotherapy with labeled antitenascin monoclonal antibodies, 1191(ab)
PET imaging of, 966(ab)
tumor shunt evaluation before chemotherapy, 1007(ab)
Glioma
differential effects of PET tumor tracers, rat, 937(ab)
grading of untreated tumors, 267(ab)
kinetics of radioiodinated tracers, 956(ab)
^{99m}Tc MIBI, correlation of uptake and proliferative activity, 268(ab)
noninvasive detection, with ^{18}F EF1 PET
pilocytic astrocytomas, 995(ab)
prognostic value of I-123-IMT uptake, 270(ab)
from radiation injury, differentiation with PET, 1861
Glioma cells
FDG in, cell-culture reactor for on-line evaluation, 556
human, amino acid transport mechanisms in, 1250
Glomerular filtration rate
estimation and calculation, 199(ab)
single-blood sample measurements in children, 1366(ab)
Glucose
cerebral metabolism, validation of analytic method, 658
evaluation of allograft rejection, 1364(ab)
loading, myocardial viability studies in diabetic patients, 709(ab)
uptake, myocardial, 3 different tracers, 488
Glucose metabolic rates
image-derived input function, 346(ab)
1-point blood sampling, in FDG PET, 1484
whole-body FDG PET imaging, 1377(ab)
Glucose metabolism
FDG PET assessment in hepatic lesions, 1301(ab)
neurotoxicity, dynamic changes in rat brain slices, 958(ab)
noninvasive estimation, FDG input function, PET, 1612
three-dimensional stereotactic surface projection, PET, monkey, 1879, 1888
Glucose transport, novel chemotherapy and, SW620 cells, 1753
GLUT-1 (glucose transporter), FDG models of glucose transport, 837(ab)
Goldsmith, Stanley J., 38N(5)
Grant, Sandra, 21N(9)
Granulocyte-macrophage colony-forming cells
marrow-sparing effects of ^{117}Sn DTPA, therapy of bone cancer pain, 2043
marrow toxicity of ^{33}P- *versus* ^{32}P-orthophosphate, bone metastases, 941
Graphic analysis, statistical noise effects on, PET neuroreceptor studies, 2083
Graves' disease, stunning effect, 1345(ab)

H

Hamilton, Joseph G., 29N(11)
Head and neck cancer
cervical lymph node staging, 123(ab)
conformal radiotherapy, FDG PET assessment of, 1196(ab)
FDG PET evaluation of recurrent tumor, 1251(ab)
squamous cell, ^{186}Re-labeled chimeric monoclonal antibody U36 in, 1999, 2011
standardized uptake values, 444(ab)
Head and neck tumors
FDG PET
detection of recurrent laryngeal cancer, 1252(ab)
to determine treatment outcome, 1198(ab)
diagnosis of, 1312(ab)
imaging of, 1314(ab)
preoperative diagnosis of, 376(ab)
Head injury, effect of hyperventilation on regional cerebral oxygen metabolism, 88(ab)
Health Care Financing Administration (HCFA)
Ambulatory Payment Classification, Changes for October 2000, 14N(11)
Hospital Outpatient Prospective Payment System (HOPPS)
final rule released, 24N(6)
Nuclear Medicine Task Force submits comment letter, 37N(7)
radiopharmaceuticals in add-on payments, 21N(1)
strategies for response outlines, 26N(9)
Independent diagnostic testing facilities (IDTF), 40N(5)
SNM comments and response, 22N(9)
Office of Clinical Standards, 21N(2)
relative value units for 2000, 22N(1)
SNM comments on physician payment for 2000, 21N(2)
Heart
acute myocardial infarction, 736(ab)
^{123}I MIBG accumulation, early Parkinson's disease, 71
^{123}I MIBI uptake, in Parkinson's disease, 1442(le)
isolated working, myocardial glucose uptake among 3 tracers, 488
^{38}K uptake, PET, 763
neuronal function, after carvedilol, ^{123}I MIBG scintigraphy, 845
Heart disease, congenital, microcirculatory hyperemic flow response in, 708(ab)
Heart transplantation
cardiac allograft rejection, 499(ab)
myocardial reinnervation, 195(ab), 773(ab)
PET evaluation of myocardial perfusion and coronary reserve changes, 8(ab)
Helicobacter pylori, C-13-urea breath test, 1380(ab)
Hematocrit, ^{18}F fluoro-L-*m*-tyrosine PET, equilibration between plasma and erythrocytes, 1636
Hepatectomy, prognostic estimation after, ^{99m}TC GSA SPECT, 421
Hepatic cancer, biodistribution of iodovinyl fluorodeoxyuridine, 144(ab)
Hepatitis C
detection with I-125-deoxyuridine, 1388(ab)
gastric emptying assessment following interferon therapy, 1379(ab)
Hepatobiliary imaging agent, bone metastasis, 1302(ab)
Hepatobiliary scan
scintigraphic assessment of sphincter of Oddi dysfunction, 1385(ab)
vascular complications, detection of, 1386(ab)
Hepatocellular carcinoma
FDG PET, utility in predicting prognosis, 1298(ab)
nonresectable, treatment with intrahepatic ^{90}Y microspheres, 1673
SPECT imaging of biloma, 1392(ab)
Hepatocytes, metabolism of F-18-FP-TZTP, 479(ab)
Hepatoma, noninvasive detection, with ^{18}F EF1 PET
Hepatotoxicity, bone metastases, 1305(ab)
Herpes simplex virus thymidine kinase
PET monitoring of gene therapy, 316(ab)
PET reporter gene, 289(ab)
PET with p53, 1158(ab)
trans-reporter system, 145(ab)
Histiocytosis, Langerhans' cell, ^{111}In pentetreotide scintigraphy in, 1808
Holmium-166
absorbed dose calculation, 1060(ab)
absorbed dose distribution, 1045(ab)
bone marrow dose distribution and disease response in myeloma, 327(ab)
coated balloon, effect on coronary stent restenosis, 26(ab)
Human immunodeficiency virus (HIV)
FDG PET comparison in, 612
nephropathy, pediatric, ^{99m}Tc MAG3 scintirenography in, 1037
Huntington's disease
assessment of neuroprotective treatment with I-125-IBZM, 409(ab)
regional cerebral blood flow in, SPECT, 773
Hustinx, Roland, 14N(9)
Hwang, Eui-Hyo, 14N(9)
Hybrid camera, assessing anti-cancer therapeutic response, 830(ab)
Hydronephrosis
^{99m}Tc MAG3 detection of, 210(ab)
quantitative gravity-assisted drainage, in diuretic renography, pediatric, 1030
11[beta]-Hydroxylase, tracer, PET imaging of adrenal cortical tumors with, 275
Hyperglycemia
non-insulin-dependent diabetes, coronary microangiopathy in control of, 978
noninvasive measurement of cerebral metabolic rate of glucose in non-diabetic subjects, 977(ab)
Hyperparathyroidism, radioguided surgery, 1329(ab)
Hypertension
depletion of LOX-1 on cardiac endothelium, 788(ab)
myocardial ^{111}In antimyosin uptake in, 719(ab)
pulmonary, ^{123}I MIBG left ventricular imaging correlation, 1127
renal
aspirin and captopril renography diagnosis, 1337
captopril-induced changes in MAG3 clearance, 1203
renovascular, ^{99m}Tc DTPA, parenchymal mean transit time analysis, 1627
Hyperthyroidism, radioiodine treatment, thyroid cancer after, 1006
Hypotension, orthostatic, early Parkinson's, ^{123}I MIBG study, 71
Hypoxia
Copper radiopharmaceuticals, mechanism of selectivity, 485(ab)
^{64}Cu ATSM, 130(ab)
Cu-ATSM PET imaging of, 1241(ab)
direct oxygen measurement, 454(ab)
dosimetry of F-18-labeled agents, 1017(ab)
hypoxic ischemic encephalopathy in term newborn, 962(ab)
kinetic analysis of Cu-60-ATSM, 229(ab)
kinetics of ^{99m}Tc BRU59-21 in hibernating myocardium, 784(ab)
liver tissue oxygenation, 518(ab)
^{99m}Tc-labeled chelating agents as markers of, 1024(ab)
myocardial, kinetics of ^{99m}TC HL91, 1102
tumor, noninvasive detection with ^{18}F EF1, PET, 327
tumor imaging with ^{99m}Tc metronidazole, 1245(ab)
tumors, ^{99m}Tc-labeled nitroimidazole imaging of, 169

I

(ICANL), accreditation and, 26N(5)
Ictal and postictal states, intractable partial epilepsy, 1001(ab)
Ifosfamide, hypoxia imaging agent, 168(ab)
Image analysis
gated myocardial perfusion SPECT, 848(ab)
lesion detectability of MAP reconstruction, 70(ab)
myocardial volume, 712(ab)
segmented attenuation correction, 890(ab)
three-dimensional MSPECT for quantitative studies, 763(ab)
three-dimensional stereotactic surface projection, brain PT, monkey, 1879, 1888
Image background, reduction of activity, radiolabeling of antifibrin Fab' with ^{99m}Tc dextran, 1264
Image enhancement, collimator type for thyroid imaging, 1355(ab)
Image fusion
combined PET/CT scanner, for clinical oncology, 1369, 1380
conformal RT, target delineation for, 1241(ab)
C-PET scanner, 81(ab)
MRI-SPECT, automatic and interactive methods, brain, 1823
X-ray/coincidence imaging, 1364, 1380
Image management
image fusion, 868(ab)
image storage system, 867(ab)
teleradiology system, 866(ab)
Image processing
computer-assisted, SPECT measures of cerebral cortical perfusion, dementia severity, 57
edge detection, 888(ab)
effect of noise on thallium scans, 850(ab)
fusion images of myocardial perfusion and function, 729(ab)
improved regression convergence on FDG model rate constants, 856(ab)

^{99m}Tc HMPAO SPECT images, 249(ab)
registration, diagnosis, classification of Alzheimer's disease, 423(ab)
Image reconstruction
asymmetric detector response, 813(ab)
Fourier rebind, phantom evaluation for, 878(ab)
iterative and filtered backprojection algorithms, 1234(ab)
noise properties in, 401(ab)
ordered-subset-expectation-maximization, 238(ab)
segmented attenuation correction, 890(ab)
simultaneous estimator for emission and attenuation, 882(ab)
three-dimensional binning and rebinning, 886(ab)
three-dimensional tilt angle binning, 525(ab)
tumor imaging, 891(ab)
Image registration
attenuation correction, 862(ab)
automated method for I-131-MIBI therapy, 825(ab)
automated three-dimensional spatial integration, 233(ab)
conjugate view method, 860(ab)
consistency-based alignment, 824(ab)
MRI-SPECT, automatic and interactive methods, brain, 1823
SPECT and CT, 1075
subtraction and, ictal brain SPECT, seizures, 1619
Image smoothing, effect of noise on thallium scans, 850(ab)
Imaging figure of merit
segmented attenuation correction, 531(ab)
simultaneous estimation of emission reconstruction, 882(ab)
whole-body PET scanners, NEC performance of, 821(ab)
Immunoassays, bispecific antibodies-polymer probe, 711(ab)
Immunoconjugates, improving immunoscintigraphy and immunotherapy, 1108
Immunohistochemistry, radiolabeled antibodies and fractionated external beam, combination therapy, 1905
Immunoscintigraphy
arcitumomab imaging, colorectal cancer, 1016
diagnosis of inflammatory diseases, 42(ab)
immunotherapy and, effects of immunoconjugates, 1108
^{99m}Tc labeled antibody fragments, recurrence of colorectal cancer, 1657
solid tumors, single amino acid substitution in Fc region effects, 355
toxicity and therapeutic efficacy of herceptin, 287(ab)
Immunotherapy, immunoscintigraphy and, effects of immunoconjugates, 1108
Immunotoxin, antitac single-chain FV recombinant, pharmacokinetics of, 755
Indium-111
antitac single-chain Fv recombinant immunotoxin, pharmacokinetics of, 755
$CaNa_2EDTA$ for improvement of, human colorectal cancer in mice, 337
EGF and MAb 528 labeled with, breast cancer imaging, 903
EGF labeled with, radiotoxicity to breast cancer cells, 429
imaging chronic osteomyelitis, 896
localization, patients with neuroendocrine tumors, 1514, 1519
oligodeoxyribonucleotides labeled with, DNA cleavage by, 1093
ProstaScint, improved quantitative imaging for, 67(ab)
pulmonary thromboembolism, visualization with labeled oxine platelets, 1418(ab)
receptor-mediated uptake of octreotides, 158(ab)
Indium-111-biotin, folate receptor, 1032(ab)
Indium-111 DTPA
matrix metalloproteinase inhibitor, labeled, 159(ab)
peptide receptor imaging and therapy, 1704
Indium-111-DTPA-D-PHE-octreotide
dependent uptake of, 435(ab)
hepatectomy, intrahepatic tumor growth following, 1169(ab)
somatostatin receptors and, thyroid tumors, 636
tissue distribution of somatostatin receptor subtypes, 940(ab)
Indium-111 2IT-BAD-Lym-1, radiation dosimetry for, in non-Hodgkin's lymphoma, 952
Indium-111-leukocyte
diagnosis of skeletal infection, 60(ab)
joint replacement infection, 58(ab), 63(ab)
osteomyelitis in Charcot joint, 61(ab)
Indium-111-octreotide
neuroendocrine tumors, 1170(ab)
voxel dosimetry, 331(ab)
Indium-111 pentetreotide, scintigraphy
detection of insulinomas, 459
Langerhans' cell histiocytosis, 1808
Infection imaging
ciprofloxacin, 40(ab)
ciprofloxacin in secondary bone infections, 62(ab)
ciprofloxacin pretreatment, effect, 1401(ab)
detection of helicobacteria overgrowth in large intestine, 1376(ab)
FDG PET detection of, 1421(ab)
FDG uptake not affected by hyperglycemia, 1396(ab)
inflammation and, ^{99m}Tc neutrophil elastase inhibitor, monkeys, 363
iodinated blankophor, 1128(ab)
^{99m}Tc biotin-PET liposomes, avidin-induced clearance of, 912
^{99m}Tc ciprofloxacin, biodistribution of, 1399(ab)
^{99m}Tc human neutrophil peptide-1, 2099(le)
^{99m}Tc-labeled anti-CD15 MoAb, equivocal appendicitis, 449, 456
^{99m}Tc liposome scintigraphy, 622
radiolabeled interleukin-8 use in, 463, 470
rapid detection with interleukin-8, ^{99m}Tc-labeled, 1125(ab)
total-knee prosthesis, 1419(ab)
Infection/inflammation scintigraphy
endocarditis, 498(ab)
joint prosthesis infection, 1398(ab)
pyogenic pelvic inflammatory disease, 1397(ab)
Inflammation
FDG-labeled leukocyte imaging of bowel inflammation, 1373(ab)
FDG uptake and GLUT expression in, 1131(ab)
fungal infections, 1128(ab)
Inflammation/infection imaging
FDG PET in management of, 37(ab)
neurodegeneration, 407(ab)
Inflammatory bowel disease
intestinal permeability, assessment of, 1382(ab)
^{99m}Tc antigranulocyte monoclonal antibody imaging of, 206(ab)
^{99m}Tc stannous colloid, 204(ab)
Tc-labeled leukocyte imaging vs ultrasound, 205(ab)
Inflammatory diseases, appendicitis, ^{99m}Tc-labeled anti-CD15 MoAb imaging for, 449, 456
In memoriam
Best, Edward B, 31N(9)
Front, Dove, 24N(3), 28N(4)
Palladino, Nunzio J., 22N(2)
Smith, James Joseph, 32N(11)
Input function
cardiac components, blind separation of, 386(ab)
independent component analysis, 65(ab)
Patlak analysis, 238(ab)
Institute of Genomic Research (TIGR), 28N(2)
Institute of Medicine (IOM), 23N(3)
Members who are also SNM members, 23N(3), 30N(5)
Instrumentation
design studies, 73(ab)
detector defect, linear interpolation, 812(ab)
detector system, 223(ab)
micro crystal element detector unit, 72(ab)
noise equivalent count rate, 802(ab)
small animal PET scanner, 64(ab)
X-ray CT and radionuclide imaging, 218(ab)
Insulinlike growth factor-I, binding proteins, effects on biodistribution, tumor-bearing nude mice, 318
Insulinoma
detection of, ^{111}In pentetreotide scintigraphy, 459
radioiodine imaging of, 31(ab)
Insulin resistance, uptake of I-125-annexin in skeletal muscle, 1428(ab)
Interferon, monoclonal antibody conjugate, for immunoscintigraphy and immunotherapy, 1108
Interleukin-2, ^{123}I-labeled scintigraphy, in Crohn's disease, 242
Interleukin-2 receptor, α-subunit, immunotoxin pharmacokinetics, 755
Interleukin-8, radiolabeled, detection of infection, 463, 470
International Atomic Energy Agency, 26N(9)
Internet, web-based information management, 865(ab)
Interobserver reproducibility, reporting on ^{99m}TC DMSA planar scintigraphy, 23
Intersocietal Commission for the Accreditation of Nuclear Medicine Laboratories (ICANL), accreditation and, 26N(5)
Intrahepatic arterial therapy, ^{90}Y microspheres, treatment of hepatocellular carcinoma, 1673
Intratumoral injection
versus intra-arterial injection, ^{90}Y microspheres, liver tumors, 1892
mammary lymphoscintigraphy, for sentinel node detection, 1500
Iodine-123
amino acid derivatives to image gliomas, 936(ab)
collimator scatter and penetration, 523(ab)
IMT
kinetic parameters, 956(ab)
prognostic value in glioma, 270(ab)
iodovinyl estradiol as radioligand for breast cancer, 1135(ab)
optimal time for scintigraphy, 1330(ab)
Iodine-125
antitac single-chain Fv recombinant immunotoxin, pharmacokinetics of, 755
brachytherapy of malignant glioma, 1200(ab)
Iodine-131
adverse effects of radioiodinated monoclonal antibodies, 1180(ab)
cost-effectiveness of adjuvant radioiodine therapy, 1328(ab)
exhalation of after radioiodine therapy, 1108(ab)
follow-up regimen, thyroid cancer after thyroid hormone withdrawal, 643
low-activity radioiodine, 1203(ab)
Monte Carlo simulation, scatter and penetration, 123
papillary thyroid cancer negative to, FDG PET, 1010
pretargeted radioimmunotherapy, colorectal xenografts, 480
radioiodine therapy of thyroid carcinoma, 1341(ab)
sodium iodide symporter expression in thyroid carcinoma, 1338(ab)
SPECT quantification, ultra-high-energy collimator, 1760
therapeutic, outpatients, regulations, 1868, 1876
therapy
adaptive response with, 17
lymphocyte damage after, 1522
outpatient status and, 28N(6)
radioiodide concentrator gene therapy, 1898
treatment
computer generated safety instructions for, 1050(ab)
hepatoma, 1139(ab)
postsurgical thyroid remnants, 2038
whole body scan, thyroid cancer, 1336(ab)
whole-body scanning, absence of thyroid stunning after, 1198
whole-body scintigraphy, management of thyroid cancer, 631
Iodine-123-[alpha]-methyl tyrosine
carcinoma of the hypopharynx/larynx, 559(ab)
SPECT imaging of nonparenchymal brain tumors, 984(ab)
transport kinetics in neonatal astrocytes, 943(ab)
Iodine-123-β CIT, imaging of serotonin transporter, aging effects, 36
Iodine-123 BMIPP
myocardial SPCT, acute myocardial infarction, 830
uptake, chronically hypoperfused myocardium, 293
Iodine-123 epidepride, SPECT, extrastriatal dopamine D2 receptor imaging, 1343
Iodine-123 IAFCT, SPECT, quantification of dopamine transporters, 1086
Iodine-123 IBZM, uptake, striatum, applied to Parkinsonism, 220
Iodine-123 IL2, scintigraphy, in Crohn's disease, 242
Iodine-123 IMP
double-injection protocol to quantify regional cerebral blood flow, 840(ab)
SPECT, non-Hodgkin's lymphoma in CNS, 1777

Iodine-123 IMT
scintigraphy, carcinoid tumors, 1793
transport mechanism, human glioma cell line, 1250
Iodine-123 IPPA, SPECT, prediction of myocardial viability, 1299
Iodine-123 MIBG
Brugada syndrome, cardiac autonomic dysfunction in, 190(ab)
early Parkinson's, cardiac sympathetic denervation from, 71
estimation of cardiac sympathetic activity, 703(ab)
fatty acid analogs, effects on CD36 deficiency, 1134
left ventricular imaging, correlation with severity of pulmonary hypertension, 1127
myocardial autonomic neuropathy, 748(ab)
scintigraphy, childhood dilated cardiomyopathy, 400
SPECT imaging of neuronal function, 745(ab)
uptake, heart, in Parkinson's disease, letter, 1594
Iodine-131 MIBG
dosimetry, 1194(ab)
radiotoxicity after treatment of neuroblastoma and carcinoid tumors, 1195(ab)
treatment of advanced stage neuroblastoma, 1193(ab)
Iodine-123 MIBI, uptake, heart, in Parkinson's disease, 1442(le)
Iodine-123 MIVE, scintimammography, breast tumors, 1324
Iodine-123-9 MPA, assessment of myocardial metabolism, 791(ab)
Iodine-131 OIH, tubular agent, protein binding on renal extraction of, 2077
Iodine-131-sodium iodide, tumor quantification, 808(ab)
Iron, cerebral uptake, Wilson's disease, ^{52}Fe-citrate PET study, 781
Irradiation
chronic, ^{117}Sn DTPA, therapy of bone cancer pain, 2043
effects on FDG metabolism, bone marrow, normal rodent, 2026
Ischemia
cerebral
in carotid artery disease, proton MR spectroscopy and PET, 1357, 1363
detection of reperfusion injury, PET use in, monkey, 1409
FDG PET depiction of, 180(ab)
kinetics of ^{99m}Tc BRU59-21 in hibernating myocardium, 784(ab)
myocardial
fatty acids in cardiac imaging, 1525
kinetics of ^{99m}TC HL91, 1102
repetitive stunning, PET, 1227, 1235
uptake of ^{99m}Tc nitroheterocycle, swine model of occlusion and reperfusion, 1237
myocardial stress testing, 363(ab)
Ischemic heart disease
detection with Cu-ATSM, 798(ab)
presence of diabetic retinopathy during screening for, 6(ab)
Ischemic penumbra, peripheral artery tonometry, 741(ab)
Isotopes, production method for Xe-127, 1091(ab)
Iterative reconstruction
Bayesian MAP reconstruction, system modeling, 875(ab)
data analysis, 863(ab)
Monte Carlo simulation, 887(ab)
ordered-subset algorithms, myocardial SPECT, 737
quantitative accuracy in PET studies, 231(ab)
quantitative characteristics of inPET, 406(ab)
whole-body SPECT scan, 83(ab)

J

Jadvar, Hossein, 18N(9)
Jaszczak, Ronald, 20N(6)
Jaundice, neonatal, functioning gallbladder visualization in, 1209
Java virtual machine
remote viewing, nuclear medicine images, 111
teleradiology and, 119
Joliot-Curie, Fréderic, 29N(11)
Journal of Nuclear Medicine
authorship, editorial, 771
Outstanding Paper awards, 24N(9)

K

Kidney
extraction, protein binding effects on, ^{131}I OIH and ^{99m}Tc MAG3 tubular agents, 2077
helical CT positive for urolith, MAG3-F_0 scintigraphy for emergency intervention after, 1813
imaging system, design of, 224(ab)
^{38}K uptake, PET, 763
length measurements, reproducibility with ^{99m}Tc DSMA SPECT, 1632
radionuclide therapy, Y-90-DOTA-octreotide, dose-effect relationship, 1046(ab)
scintigraphic detection to revascularization, 1369(ab)
single-sample clearance determination, 198(ab)
Kidney function
accuracy and precision of parenchymal images, 1365(ab)
evaluation
attenuation correction in, children and adults, 823
with ^{99m}Tc MAG3, semiautomated regions of interest, 1947
evaluation of function following extracorporeal shock wave lithotripsy, 1367(ab)
glomerular filtration rate and ERPF, early and late changes of, 1368(ab)
prognostic value of MUC10 in MAG3 renography, 369(ab)
relation of radiopharmaceutical and estimation of, 1370(ab)
Kidney stones, extracorporeal shock wave lithotripsy, 1367(ab)
Kidney transplantation
assessment of function in kidney grafts, 367(ab)
Captopril renography of transplant complications, 368(ab)
prediction of survival, radioisotope studies, 1332
Kinetic modeling
clustering, principal component analysis, 397(ab)
Cu-ATSM retention, 798(ab)
esophageal scintigraphy, 513(ab)
parametric imaging, 226(ab), 853(ab)
quantitative accuracy of iterative reconstruction on, 231(ab)
renovascular hypertension, 1362(ab)
Kininase inhibitor, pharmacologic intervention with, radioimmunotherapy in human colon cancer xenografts, 1244
Kobayashi, Hisataka, 14N(9)

L

Langerhans' cell histiocytosis, ^{111}In pentetreotide scintigraphy in, 1808
Laryngitis, posterior, ^{99m}Tc sulfur colloid gastroesophageal scintigraphy for evaluation, 1597
Latin America, nuclear medicine in, 36N(2)
Lawrence, John H., 29N(11)
Left bundle branch block
effect of on cardiac FDG PET images, 705(ab)
effects on myocardial FDG PET, without coronary artery stenosis, 973
Left ventricular dysfunction
gated SPECT, ^{99m}Tc sestamibi detection of myocardial ischemia, 339(ab)
septal wall motion after cardiac surgery, 494(ab)
Left ventricular ejection fraction
attenuation correction on myocardial SPECT, 765(ab)
comparison of radionuclide methods in determination of, 19(ab)
exercise radionuclide angiocardiography, in acute MI patients, 965
FDG PET gated imaging of, 348(ab)
gated SPECT accuracy in, experimental validation with MRI, 874, 883
gated SPECT and, 1120(le)
gated SPECT studies, 714(ab)
model for predicting normal limits, 768(ab)
volume measurements and, myocardial gated SPECT, 1445
Left ventricular function
after coronary bypass graft surgery, ^{123}I IPPA SPECT prediction, 1299
gated SPECT studies, 769(ab)
postexercise lung uptake of ^{99m}TC MIBI, new automatic technique, 1190
postexercise stunning, 20(ab)
Left ventricular volume, Doppler echocardiography, 715(ab)
Lesion detection, ROC/LROC study, PET, 745
Leukemia
internalization of HAT-streptavidin, 1152(ab)
radioimmunotherapy, acute side effects of, 310(ab)
Leukocytes
scintigraphic detection of appendicitis, 1400(ab)
scintigraphic studies for diabetic foot, 1422(ab)
stabilized ^{99m}Tc exametazime-labeled, biodistribution and radiation dosimetry, 934
Liposomes
encapsulating blue dye for sentinel node detection, 1019(ab)
^{99m}Tc biotin-PEG, clearance in infection imaging, 912
^{99m}Tc-labeled biotin to detect gastrointestinal bleeding, 1390(ab)
scintigraphic evaluation, experimental chronic osteomyelitis, 896
Liver
activity, minimizing in myocardial perfusion SPECT, 1315
blood pool changes in, detection with ^{99m}Tc RBC, 474
fatty acid oxidation, ^{18}F FOP as a PET tracer, 1727
per rectal portal imaging with ^{99m}Tc pertechnetate, 1378(ab)
primary biliary cirrhosis, 1394(ab)
tumor, ^{90}Y microspheres, injection method effects, 1892
Liver disease
captopril renography to diagnose, 371(ab)
glucose metabolism in hepatic lesions, 1301(ab)
intrapulmonary shunting, detection of with ^{99m}Tc MAA, 1393(ab)
pathological staging, 51(ab)
Liver function
asialo-glycoprotein receptor estimation with single-blood sample, 50(ab)
evaluation of hepatic mitochondrial fatty acid oxidation with PET, 56(ab)
primary biliary cirrhosis, scintigraphic assessment of, 1391(ab)
segmental decreased uptake of ^{99m}Tc galactosyl-neoglycoalbumin, 1387(ab)
Liver malignancies
FDG PET, clinical utility of, 1299(ab)
FDG PET studies of, 1304(ab)
^{99m}Tc PMT whole-body imaging of bone metastases from liver cancer, 1302(ab)
PET imaging of, 1271(ab)
Localization, ^{99m}Tc galactosyl-human serum albumin in irradiated liver, 1389(ab)
Lumped constant, FDG, glioma cells, evaluation of, 556
Lung
perfusion recovery, after acute pulmonary embolism, 1043, 1049
postexercise uptake of ^{99m}TC MIBI, new automatic technique, 1190
pulmonary fibrosis, PET detection of, 505(ab)
transplant (*see* Transplantation)
Lung cancer
adrenal masses, FDG PET evaluation of, 1278(ab)
assessing therapeutic response with ^{99m}Tc MIBI, 1250(ab)
comparison of SPECT and PET tracers, 1295(ab)
cost-effectiveness
of combined PET/CT, 1292(ab)
of whole-body FDG PET, 1287(ab)
^{11}C tyrosine assessment of protein synthesis rate, 1199(ab)
FDG PET, 431(ab), 1281(ab), 1288(ab)
monitoring of chemotherapy, 445(ab)
prognosis, 299(ab)
restaging of, 296(ab)
staging of, 432(ab)
staging of recurrence, 295(ab)
staging of solitary pulmonary nodules, 1291(ab)
whole-body imaging of, 300(ab)
FDG uptake on delayed PET images, 301(ab)
hilar and mediastinal lymph node metastasis, ^{11}C methionine PET imaging for, 283, 291
lymph node sampling, 298(ab)

mediastinal lymph node metastases, detection with ^{11}C choline PET, 1507
metabolic activity, 1282(ab)
^{99m}Tc sestamibi
prognostic value of, 1285(ab)
thoracic SPECT imaging for detection of, 1276(ab)
non-small cell
FDG, reproducibility in PET lung cancer studies, 1279(ab)
staging with PET, 1280(ab)
non-small cell, FDG PET measurement, 85
optimal imaging time of tumors with Hybrid PET, 831(ab)
prognostic value of FDG uptake, 1296(ab)
staging of, 297(ab)
staging of with FDG coincidence imaging, 1293(ab)
staging with FDG PET and coincidence imaging, 1274(ab)
three-dimensional clinical PET in, 439
Lung clearance, bronchial stents, 1402(ab)
Lung function
dynamic MRI and Xe-133 SPECT, assessment of, 510(ab)
^{99m}Tc MAA and ^{133}Xe dynamic studies of in smoking-related emphysema, 511(ab)
Lung lesions, gamma camera coincidence imaging comparison with PET, 959(le)
Lung perfusion
adenocarcinoma, Tl and MIBI accumulation, 1294(ab)
lung volume reduction, 509(ab)
^{99m}Tc MAA and MRI, quantification of, 1406(ab)
overutilization of lung scans, 1416(ab)
Lung scintigraphy
automated method for image interpretation, 49(ab)
nebulizer hood aerosol therapy, 1412(ab)
pulmonary embolism, diagnosis of, 47(ab)
pulmonary surfactant associated protein, 1147(ab)
Lung ventilation
aerosol deposition in cystic fibrosis, 506(ab)
overutilization of lung scans, 1416(ab)
^{133} Xe dynamic studies after lung transplant, 1417(ab)
Lutetium oxyorthosilicate, scintillation crystals, in PET, 1051
Lyme disease, FDG PET brain imaging, 999(ab)
Lymphadenopathy
PET assessment of, 1289(ab)
PET atlas of mediastinal nodal stations, 1283(ab)
Lymphangiectasia, primary intestinal, children, ^{99m}Tc HSA scans in, 215
Lymphedema
lymphatic drainage improvement, 1224(ab)
lymphatic mapping in breast cancer, 307(ab)
manual lymphatic drainage, 1225(ab)
Lymph nodes
hilar and mediastinal, lung cancer metastasis, ^{11}C methionine PET imaging for, 283, 291
mediastinal, metastases, lung cancer, detection with ^{11}C choline PET, 1507
metastases, detection with FDG PET, 1491
Lymphocytes
damage, after ^{131}I therapy, indicators of, 1522
effect of anti-lymphoma antibody in non-Hodgkin's lymphoma, 1215(ab)
mucosal, ^{123}I IL2 scintigraphy in Crohn's disease, 242
Lymphoma
B-cell, CD74 antibody as therapeutic agent for, 2089
comparison of hybrid PET and Ga-67 for staging of, 467(ab)
effect of FDG PET on management of, 277(ab)
FDG PET management of, 1209(ab)
^{131}I-anti-B$_1$ antibody therapy, tumor dosimetry, 1579
nodal staging, comparison of ^{11}C MET and FDG PET, 1980
non-Hodgkin's
anti-CD20 monoclonal antibody, comparison of low- and high-dose therapy, 117(ab)
biodistribution and dosimetry of zevalin, 113(ab), 115(ab)
diagnosis with ^{123}I IMP SPECT in, 1777
dosimetry of ^{131}I-labeled monoclonal antibody, 1178(ab)
dual-isotope imaging of, 1218(ab)
Ga scintigraphy vs FDG PET as prognostic indicator, 1216(ab)
metabolic response to radioimmunotherapy, PET, 999
radiation dosimetry for ^{90}Y 2IT-BAD-Lym-1, 952
residual disease after CHOP, hilar uptake of ^{67}Ga citrate, 269
staging and detection with whole-body hybrid FDG PET, 1273(ab)
staging with FDG PET, 278(ab)
stem-cell supported radioimmunotherapy, 118(ab)
tumor grade assessment with PET, 1221(ab)
PET vs hybrid PET analysis, 280(ab)
prediction of outcome with FDG PET, 1205(ab)
prediction of therapeutic response with ^{131}I situmomab, 114(ab)
radioimmunotherapy with ^{131}I-labeled antibody, 309(ab)
staging, ^{67}Ga vs FDG PET, 466(ab)
undifferentiated, FDG and ^{201}Tl, role as preoperative diagnostic tool, 1333(ab)
Lymphoscintigraphy
breast, preoperative, sentinel node localization during, 1682
dual-method injection technique, 1231(ab)
mammary, single intratumoral injection of sentinel node identification, 1500
pneumatic compression, 1224(ab)

M

Machado-Joseph disease, decreased dopamine transporter binding in, 994
Magnetic resonance imaging (MRI)
contrast enhancement, 972(ab)
diagnostic efficacy, 570(ab)
diffusion-weighted, SPECT and, in acute stroke, 788
experimental, gated SPECT for left ventricular ejection fraction, 874, 883
flow-sensitive alternating inversion recovery (FAIR), compared with SPECT, 26N(2)
myocardial perfusion studies, 701(ab)
osteomyelitis in Charcot joint, 61(ab)
vermis hypoperfusion, 996(ab)
lung imaging, radiolabeled antibodies and contrast MR angiography, 1406(ab)
SPECT image fusion, automatic and interactive, 1823
subclinical hepatic encephalopathy, neuropsychologic impairment, 405
Magnetic resonance spectroscopy
proton, brain metabolism in carotid artery disease, 1357, 1363
subclinical hepatic encephalopathy, neuropsychologic impairment in, 405
Malignant pleural mesothelioma, FDG PET prognostic value, 1443(le)
Mammography
^{99m}Tc MIBI scintimammography and, suspected breast cancer, 390(le)
positron emission system PEM-I, glucose metabolic images using FDG, 1851, 1859
Mandell, Gerald, 14N(9)
Marcus, Gail, 28N(2)
Mayberg, Helen, 13N
McKusick, Kenneth, SNM Reimbursement Roadshow and, 21N(1)
Medical Internal Radiation Dose (MIRD) method, quantitative radioimmunoimaging and data sampling, 1181(ab)
Melanoma, 303(ab)
comparison of sentinel node biopsy and FDG PET in staging of, 304(ab)
FDG PET
assessment of, 1317(ab)
detection, lymph node metastases, 1491
management of, 1232(ab)
^{123}I ERC9, evaluation with, 288(ab)
lymphoscintigraphy and detection of sentinel node, 1146(ab)
metastases despite negative sentinel lymph node scan, 1228(ab)
^{99m}Tc-labeled complexes as diagnostic probes for, 475(ab)
sentinel node imaging, 302(ab)
prognostic value of, 305(ab)
Mental stress, effect on myocardial blood flow, with coronary artery disease, 11
Meta-analysis, whole-body FDG PET detection, recurrent colorectal cancer, 1177
Metabolism. *see also* specific type
fatty acid utilization, 344(ab)
microsome, in vitro measurement of metabolites using, 1073(ab)
Metaiodobenzylguanidine (MIBG)
left ventricular function, assessment of, 766(ab)
left ventricular sympathetic nervous function, 191(ab)
pheochromocytoma, radioiodine therapy for, 581(ab)
primary hypertrophic cardiomyopathy, diminished uptake in, sudden death, predictor of, 196(ab)
prognostic indicator of severe arrhythmias, 743(ab)
ventricular function and volume measurements, 192(ab)
Methodology, effects on mismatch, 213 (le)
Methyl-11C-L-methionine, uptake in brain tumors, 272(ab)
***N*-Methylspiperone,** PET study, upregulation of dopamine D2 receptors in early Parkinson's, 65
Microangiopathy, coronary, type 2 diabetes, 978
Micronucleus test, indication of lymphocyte damage, after ^{131}I therapy, 1522
MicroPET I
animal PET, development of, 73(ab)
performance characteristics of, 64(ab)
Microspheres
analysis of drug-induced blood pool changes, liver and other organs, 474
^{90}Y, intrahepatic treatment of hepatocellular carcinoma, 1673
Microvascular reperfusion, reverse redistribution and, acute myocardial infarction, 393
MIRDOSE, distribution suspended, 13N(6)
MIRD schema, internal radionuclide radiation dosimetry, 297
Modeling
graphical analysis method, 854(ab)
kinetic analysis tool, 855(ab)
kinetic parameters, 227(ab)
Modeling software, kinetic analysis tool, 855(ab)
Molecular imaging, biology and imaging, 661
Monoclonal antibodies (MAb)
arcitumomab imaging, colorectal cancer, 1016
biological effects I-131 and Bi-213-labeled antibodies, 330(ab)
cardiotoxicity of herceptin, 287(ab)
cellular catabolism of radiolabeled Mabs, 1149(ab)
characterization of anti-CD 22 in non-Hodgkin's lymphoma, 469(ab)
chimeric
in ovarian cancer patients, 1168
single amino acid substitution in Fc region, in solid tumors, 355
FDG PET scanning of non-Hodgkin's lymphoma, 1210(ab)
high-dose radioimmunotherapy, medullary lung cancer, 93
human SCFV antibodies mimicking murine Mabs, 561(ab)
^{111}In ProstaScint imaging, 456(ab)
^{99m}Tc-labeled anti-CD15, diagnosis of equivocal appendicitis, 449, 456
radiolabeled, uptake to smooth muscle cells, coronary stent restenosis, 1535, 1541
radiolabeled antibodies, 1109(ab)
^{186}Re-labeled chimeric U36, head and neck cancer, 1999, 2011
therapeutic effect of radioimmunotherapy, 1190(ab)
therapy, direct catheter infusion, 1192(ab)
^{188}Re, radioimmunotherapy for conditioning before stem cell transplant, 531
Monoclonal antibody 528, ^{111}In labeled, breast cancer imaging, 903
Monsieurs, Mirian, 14N(9)
Monte Carlo simulations
^{131}I imaging, scatter and penetration, 123
intramural direct injection, 336(ab)
PET datasets, 399(ab)
reevaluation of absorbed fractions, photons and electrons, 149
Motion correction
cardiac SPECT, in, 1298(le)
data-based algorithm, 239(ab)
methodology for myocardial perfusion SPECT, 177(ab)

Motor activation area, ^{99m}Tc ECD SPECT visualization of, lesions near central sulcus, 411
Movement disorders
differential diagnosis of Parkinson's disease and multiple system atrophy, 544(ab)
^{99m}Tc TRODAT-1 binding to dopamine transporters, 584
Moyamoya disease
acetazolamide challenge, 983(ab)
deterioration of vascular territories, 1431(ab)
postoperative follow-up, 91(ab)
Multidrug resistance (MDR)
^{11}C colchicine for PET imaging of, 493
Kaplan-Meier analysis, 1285(ab)
^{99m}Tc HMPAO, 592(ab)
reversing agents, tumor xenograft, 1137(ab)
sarcomas, 1256(ab)
Multimodality display
bulimia nervosa, 909(ab)
chronic cocaine use, 417(ab)
unipolar depression, 902(ab)
Multimodality imaging
CdZnTe, a common detector for both modalities, 218(ab)
optimization for surgery of brain tumors, 979(ab)
Multiple myeloma, 468(ab)
whole-body scintigraphy, 1208(ab)
Muscarinic acetylcholine receptor
mechanism of action, olanzapine and clozapine, 100(ab)
reduced availability in schizophrenia, 99(ab)
Musculoskeletal neoplasms, grading with FDG PET, 1695, 1702
Myeloma, 576(ab)
dose assessment for radioimmunotherapy, 1041(ab)
dual-isotope imaging, 1294(ab)
Myocardial fatty acid metabolism
cardiomyopathy, 766(ab)
PET imaging in canine, 789(ab)
Myocardial flow reserve
amifostine, myeloprotection effects of, 1187(ab)
pharmacological evaluation of regional cerebral blood flow, 982(ab)
Myocardial glucose metabolism
FDG PET cardiac imaging in diabetic patients, 709(ab)
PET vs coincidence imaging to detect viable myocardium, 739(ab)
Myocardial imaging agents, kinetics of fatty acid analog I-123-9MPA, 791(ab)
Myocardial infarction
acute
failed thrombolysis, 753(ab)
measurement of infarct size in area at risk, 360(ab)
percutaneous transluminal coronary angioplasty, 361(ab)
PET evaluation of, 775(ab)
predicting future cardiac events with exercise radionuclide angiocardiography, 965
scintigraphic assessment of functional recovery, 355(ab)
assessment of free fatty acid metabolism and cardiac function with L-Carnitine, 12(ab)
automated quantitation of infarct size and potential myocardial salvage, 762(ab)
experimental old, ^{15}O water-perfusable tissue fraction in, 1737
impaired myocardial energy metabolism, 362(ab)
myocardial perfusion imaging, 337(ab)
myocardial viability, evaluation of with gated SPECT and FDG PET, 759(ab)
PET and SPECT assessment of, 754(ab)
size and severity, quantitative SPECT assessment of, 1383
visualization of phosphoinositide turnover, ^{11}C DAG use for, 2063
Myocardial ischemia
quantitative methods, limitations of, 750(ab)
vascular injury, demonstration of, 188(ab)
Myocardial perfusion imaging
abnormal perfusion gradient, PET assessment of, 764(ab)
agent, biodistribution, dosimetry, and safety, 141
attenuation correction and enhanced acquisition, improved uniformity, 1139
comparison of correction techniques in dual-isotope studies, 527(ab)
^{62}Cu PTSM PET, performance, 309
3-dimensional colon-modulated display, coronary artery disease, 1941
dual-head gamma camera coincidence, attenuation correction for, 919
dual-isotope studies, 740(ab)
experimental validation with MRI, 874, 883
gated SPECT
left ventricular ejection fraction and volume measurements, 1445
likelihood of CAD, 852, 860
^{123}I BMIPP and ^{201}Tl, acute myocardial infarction, 830
intrinsic dual-energy processing, 1287
left ventricular hypertrophy in dilated and nondilated ventricles, 779(ab)
minimizing liver, bowel, and gastric activity in, 1315
^{99m}Tc tetrofosmin-FDG collimated SPECT, 1318
postacquisition list mode rebinning, 778(ab)
prognostic value of normal perfusion scans, 4(ab)
serial changes, PET, 1426
SPECT
ordered-subset algorithms in, 737
quantitation of, 712, 720
SPECT imaging, cost-effectiveness after acute myocardial infarction, 364(ab)
stress tests, long-term reproducibility of normal, 746(ab)
systolic and diastolic parameters, 738(ab)
^{201}Tc SPECT detection of left ventricular remodeling, 777(ab)
Myocardial scintigraphy
BMIPP and tetrofosmin, prediction of functional outcome in stunned myocardium, 721(ab)
^{123}I MIBG, prognostic indicator in dilated cardiomyopathy, 720(ab)
Myocardial stunning, repetitive, blood flow, function, and metabolism in, 1227, 1235
Myocardial trabeculae, uptake of radiopharmaceuticals, force-generating preparation from atria, 1587
Myocardial viability
assessment, FDG imaging, 2099(le)
assessment with FDG coincidence imaging, 181(ab)
coronary abnormalities on PET images, 345(ab)
dual-isotope simultaneous acquisition of rest-stress scans, 353(ab)
exercise-induced ischemia, frequency of, 723(ab)
FDG PET assessment, 726(ab)
^{123}I IPPA SPECT prediction, left ventricular function, 1299
PET assessment of, 772(ab)
revascularization, effects, 732(ab)
SPECT assessment during low-dose dobutamine infusion, 352(ab)
Myocarditis, uptake of C-14-deoxyglucose and Tl-201, 795(ab)
Myocardium
assessing viability with FDG SPECT, 354(ab)
CD36 deficiency, ^{123}I MIBG fatty acid analog effects, 1134
chronically hypoperfused, ^{123}I BMIPP and ^{201}Tl uptake, 293
comparison of PET and SPECT in measuring infarct size, 358(ab)
hibernating
exercise-induced ischemia, frequency of, 723(ab)
PET study of perfusion and glucose uptake, 771(ab)
stunned, kinetics of hypoxic tracer in, 1102
uptake of ^{99m}Tc nitrobeterocycle, swine model of occlusion and reperfusion, 1237

N

22N(9), 22N(10), 14N(11)
Nagy, Edward, 13N(11), 17N(5)
Nasopharyngeal carcinoma
diagnosis, 1246(ab)
SPECT evaluation of radiotherapy, 1315(ab)
National Cancer Institute (NCI), small animal imaging grants, 31N(9)
National Electrical Manufacturers Association (NEMA), SPECT quality control recommendations, 383
National Institute of Biomedical Imaging and Engineering, efforts to create, 13N(11), 17N(5)
National Institutes of Health, new imaging institute and, 17N(5)
National Science Foundation (NSF), National High Magnetic Field Laboratory (NHMFL), 51N(8)
Neoplastic transformation, C3H 10T1/2 cells, ^{99m}Tc cardiolite, 1545
Nephrectomy, radical, kidney function after, quantitative SPECT, 1025
Nephropathy, HIV, pediatric, ^{99m}Tc MAG3 scintirenography in, 1037
Neural networks, 404(ab)
brain SPECT detection of depression, 835(ab)
myocardial SPECT, arterial switch operation for transposition of great arteries, 383(ab)
Neuroblastoma, therapeutic effect of I-131-MIBG and chemotherapy, 1193(ab)
Neuroendocrine tumors
biodistribution of radiolabeled octreotides, 1143(ab)
dosimetric predictor of tumor response, 437(ab)
dosimetry radiolabeled octreotides, 436(ab)
^{111}In octreotide, 1310(ab)
localization of ^{111}In in, after intravenous injection of octreotide, 1514, 1519
malignant carcinoid syndrome, 577(ab)
optimal imaging, 1311(ab)
pharmacokinetic studies of ^{111}In DTPA-Tyr3-octreotate, 1248(ab)
radiotherapy with ^{90}Y DOTA-lanreotide, 1171(ab)
somatostatin receptor scintigraphy localization, 1646
specificity increase of somatostatin receptor imaging, 1247(ab)
targeted radiotherapy in, 438(ab)
therapy with radiopeptides, 1172(ab)
Neuroimaging
binding of atypical neuroleptics, 101(ab)
FDG PET evaluation of focal cortical dysplasia, 981(ab)
inflammation, role in neurodegeneration, 407(ab)
Neurological disease, molecular imaging with PET, 661
Neurophysiology, primary progressive aphasia, 421(ab)
Neuropsychology
primary progressive aphasia, 421(ab)
subclinical hepatic encephalopathy, brain SPECT in, 405
Neutrophil elastase inhibitor, radiolabeled, inflammation and infection imaging with, monkeys, 363
Neutrophils, pulmonary sequestration of, 1384(ab)
Nicotinic acetylcholine receptors
alterations in receptors during nicotine administration, 955(ab)
measurement, ^{123}I I-A-85380 SPECT, 1552
Nicotinic receptors, equilibrium analysis, 97(ab)
Nitric oxide
effect on striatal dopamine efflux, 939(ab)
regional cerebral blood flow and, in Huntington's disease, SPECT, 773
Nitric oxide synthase, neuronal inhibitors, radiolabeled, PET study, 1417
Nitroimidazole, ^{99m}Tc-labeled, imaging hypoxia in tumors, 169
NMDA (N-methyl-D-aspartate) receptor, serotonin transporter in social phobia, 904(ab)
Noise, statistical, effects on graphic analysis, PET neuroreceptor studies, 2083
Nuclear cardiology, positive SPECT and PET cardiac findings, gender differences, 263
Nuclear medicine
Essentials of Nuclear Medicine Physics (book review), 565
new millenium, 1(ed)
Nuclear Regulatory Commission (NRC)
Advisory Committee on Medical Uses of Isotopes
ACNP plans to comment, 14N(11)
Cerquiera named as head, 26N(2)
High-Enriched Uranium Export (HEU), 49N(8)
inspection documentation, SNM comments, 40N(5)
investigates Mallinckrodt, Inc., 41N(7)
Oklahoma as licensing agreement state, 49N(8)
origin of 30-miCi rule on release of patients, 10N(10)
publishes history of radiation protection, 34N(11)
revised medical policy statement, 9N(10)
SNM and ACNP comment on petition, 22N(10)

O

Obesity, effects on red cell mass, 390(le)
Octreotide
^{111}I DTPA, peptide receptor imaging and therapy, 1704
^{111}In, scintigraphy, carcinoid tumors, 1793
intravenous injection, localization of ^{111}In after, neuroendocrine tumors, 1514, 1595
molecular modeling of, 1083(ab)
^{99m}Tc HYNIC-Tyr^3, tumors positive for somatostatin receptors, 1114
therapeutic response, assessment of, 579(ab)
in vitro stability, 1084(ab)
^{90}Y DOA, peptide receptor imaging and therapy, 1704
Oncology, clinical, combined PET/CT scanner, 1369, 1380
Ordered subsets expectation maximization (OSEM)
filtered backprojection, comparison with, 1237(ab)
ring artifacts, 885(ab)
Osseous lesions, metastatic, palliation of bone pain in, radiopharmaceuticals for, 682, 688
Osteomyelitis
chronic, scintigraphic evaluation of, 896
FDG PET diagnosis of, 57(ab)
flow and blood-pool activity at fracture sites, 1420(ab)
Osteoporosis, bone densitometry in, different approaches, 2015
Osteosarcoma, FDG PET, clinical management with, 429(ab)
Ovarian cancer
chimeric MAb MOv18 use, radioimmunotherapy, 1168
FDG PET whole-body imaging, 1318(ab)
follow-up with coincidence imaging, 1316(ab)
Oxidative metabolism, oxygen consumption, 518(ab)
Oxygen extraction, before extracranial-to-intracranial bypass, carotid occlusion, 800
Oxygen-15 water
effect of vascular radioactivities on, 914(ab)
factor analysis and cluster analysis for myocardial PET, 387(ab)
independent component analysis of PET brain images, 65(ab)
parametric images of myocardial blood flow, 183(ab)
perfusable tissue fraction, experimental old myocardial infarction, 1737
PET
abuse-related post-traumatic stress disorder, 910(ab)
parametric images of tumor blood flow, 1784

P

Palladino, Nunzio J., in memoriam, 22N(2)
Pancreatic cancer
FDG PET diagnosis and staging of, 138(ab)
proliferation of 5-^{18}F-Fluoro-2'-deoxyuridine, 1138(ab)
Pancreatitis, FDG uptake, 1381(ab)
Parametric imaging
comparison of numerical methods, 392(ab)
FDG studies, 397(ab)
improved regression convergence on FDG model rate constants, 856(ab)
kinetic analysis, 853(ab)
myocardial blood flow estimation, 387(ab)
reference region model, 226(ab)
tumor blood flow, ^{15}O water PET, 1784
Parathyroid adenoma
comparison of three scintigraphic protocols, 1342(ab)
parathyroidectomy, minimally-invasive radio-guided, 211(ab)
Parathyroid imaging
clinical effectiveness of ^{99m}Tc sestamibi and perchlorate scan with neck ultrasound, 1332(ab)
role of ^{99m}Tc sestamibi and ultrasound, 216(ab)
Parathyroid scintigraphy
comparison of three scintigraphic protocols, 1342(ab)
early and late SPECT studies, 1346(ab)
gamma probe, 1329(ab)
intraoperative probe, 211(ab)
^{99m}Tc pertechnetate, clinical value of, 1353(ab)
Parkinson's disease
automated quantification of ^{123}I IBZM uptake, optimization of, striatum, 220
compartmental and striato-occipital ratio analyses, 540(ab)
differential diagnosis *versus* multiple system atrophy, 994(ab)
disease progression, PET assessment of, 542(ab)
dopamine D2 receptor occupancy after levodopa, 1002(ab)
dopamine regeneration and PET imaging of dopamine transporter, 410(ab)
dopamine transporter pathophysiology, 541(ab)
effects on nerve endings and, 23N(10)
^{18}F fluoro-L-dopa uptake before and after levodopa, 971(ab)
5-HT transporter density, 985(ab)
^{123}I MIBG uptake, heart, letter, 1594
^{123}I MIBI uptake, heart, 1442(le)
L-DOPA induction of higher frontal activation, 980(ab)
^{99m}Tc TRODAT-1 binding to dopamine transporters, 584
perfusion changes in, 545(ab)
peripheral sympathetic dysfunction, 193(ab)
PET depiction of cerebral blood flow, 427(ab)
putaminal dopamine D2 receptors, comparative PET study, 65
quantification of dopamine transporters, SPECT with ^{123}I IAFCT, 1086
SPECT assessment of disease progression with ^{123}I CIT, 543(ab)
vascular parkinsonism, 426(ab)
Parotid gland
ipsilateral thalamic activation, 945(ab)
mechanical pressure, 990(ab)
Partial-volume correction, PET, cerebral blood flow in aging, 1842, 1849
Partial volume effect
brain PET studies of ^{11}C NNC-112, 852(ab)
PET quantitation, 851(ab)
Pediatric patients
biliary atresia, functioning gallbladder visualization, hepatobiliary scintigraphy, 1209
children and adolescents, soft-tissue sarcoma, FDG PET imaging of, 379(ab)
dilated cardiomyopathy, impairment of cardiac neuronal function, 400
diuretic renography, quantitative gravity-assisted drainage with, 1030
early gastric emptying, 596
HIV nephropathy, ^{99m}Tc MAG3 scintirenography in, 1037
inflammatory bowel disease, 206(ab)
PEGylated liposomes
pharmacokinetic studies, 1404(ab)
scintigraphic assessment of colitis with ^{99m}Tc-labeled liposomes, 517(ab)
Peptide-receptor imaging
acute deep vein thrombosis, detection of, 44(ab)
biodistribution and imaging of mammary tumors, 1027(ab)
breast and prostate cancer, 128(ab)
comparison of ^{111}In-labeled octreotate and octreotide, 120(ab)
detection of neuroendocrine tumors, 1247(ab)
glycated octreotides and octreotates, 157(ab)
^{111}In-labeled RGD analog for tumor imaging, 1249(ab)
integrin receptors, 160(ab)
melanoma, 1021(ab)
pharmacokinetics, 1248(ab)
somatostatin receptor-positive tumors, 439(ab)
stability of DTPA chelates, 472(ab)
synthesis of ^{99m}Tc and ^{111}In peptides, 1141(ab)
tumor angiogenesis, 1029(ab)
tumor imaging and radionuclide therapy, 1030(ab)
Peptide-receptor radiotherapy
glycated octreotides and octreotates, 157(ab)
^{111}In-labeled RGD analog, 1249(ab)
metabolic effects, 370(ab)
reduction of renal toxicity during ^{90}Y DOTA therapy, 1173(ab)
somatostatin receptor-positive tumors, 439(ab)
stability of DTPA chelates, 472(ab)
therapeutic response, assessment of, 579(ab)
treatment of somatostatin receptor-positive tumors, 1171(ab)
tumor response, 1169(ab)
tumor targeting, 129(ab)
Peptides
biodistribution of ^{131}I-labeled and ^{99m}Tc endostatin, 127(ab)
cyclic RGDs, 160(ab)
indium and copper force fields, 1083(ab)
^{99m}Tc-labeled derivatized polypeptides, 1016(ab)
plasma brain natriuretic peptide concentrations before and after exercise, 783(ab)
radiolabeled, noninvasive monitoring of gene transfer, 887
synthesis of no-carrier-added ^{18}F-labeled agents, 1092(ab)
Tc-labeled imaging for acute deep vein thrombosis, 43(ab)
Peptidic chelator, ^{99m}Tc-labeled fragments, 1096(ab)
Percutaneous transhepatic portal embolization (PTPE), by ^{99m}TC GSA, response, 421
Percutaneous transluminal coronary angioplasty, left ventricular function and remodeling, prediction of, 361(ab)
Perfusion and metabolism mismatch
perfusion reserve in chronic coronary artery disease, 771(ab)
prognostic studies with PET, 772(ab)
Perfusion imaging, statistical parametric mapping, assessment of application in, 245(ab)
Perfusion lung scan, postoperative lung function, 1408(ab)
Peritoneography, FDG PET detection peritoneal carcinomatosis, 140(ab)
Pertechnegas, alveolar permeability after radiotherapy, 507(ab)
P-glycoprotein, multidrug resistance, 1153(ab)
Pharmacokinetics
^{99m}Tc peptides, renal handling of, 177
^{99m}Tc Stealth-liposomes, 1404(ab)
WAY100635 derivatives with varying affinity constants, 154(ab)
Pharmacologic stress agent
dipyridamole, limited value of, 363(ab)
evaluation of with MUE, 1112(ab)
low-level cycling, 722(ab)
Pharmacologic stress test, regional myocardial blood flow heterogeneity, 787(ab)
Phelps, Michael, 30N(11)
Phosphoinositide, turnover, ^{11}C DAG use for, myocardial infarction, 2063
Phosphorus-32
^{11}C carfentanil, 909(ab)
cerebellar vermis, 902(ab)
image analysis, 230(ab)
local maximum statistical properties, 66(ab)
Phosphorus-32 orthophosphate, marrow toxicity of, bone pain and bone metastases, 941
Photopenic lesion, differences in lesion patterns, 384(ab)
Picture archiving and communication systems, Java-based remote viewing, 111
Pirker, Walter, 14N(9)
Planar radionuclide scintigraphy, registration with reprojected CT data, 700
Plasma integral, calculating cerebral glucose metabolism, FDG PET, 658
Pneumonectomy, postoperative lung function, assessment of, 1408(ab)
Polyethyleneglycol (PEG) liposomes, scintigraphy, infection and inflammation, 622
Positron autoradiography
brain slice, age-related changes in, 938(ab)
neurotoxicity from hypoxia and reoxygenation, 958(ab)
Positron camera, clinical evaluation of, 818(ab)
Positron emission tomography (PET)
abdominal and pelvic neoplasms, whole-body imaging of, 292(ab)
abnormal coronary vasomotion, 170(ab)
activation images, signal-to-noise ratio in, cold-bolus, switched protocol, 926
activation study, 967(ab)
acute intracerebral hemorrhage, 85(ab)
acute myocardial infarction. detection of, 775(ab)
adenosine A_{2A} receptor ligand ^{11}C KF18446, CNS, 345
aging and brain chemistry, 38N(7)
Alzheimer's disease and, 50N(8)
amphetamine-induced endogenous dopamine release, 415(ab)
angiotensin AT1 receptor regulation, 1361(ab)

animal imaging, dedicated tomograph for, 77(ab)
animal studies, 76(ab)
antidrug ads and, 32N(11)
assessment of laser-induced thermo therapy, 137(ab)
atherosclerotic progression, 25(ab)
atlas of mediastinal nodal stations, 1283(ab)
attenuation artifacts, 879(ab)
attenuation correction, 80(ab), 300(ab), 532(ab)
automatic measurement of myocardial thickness, 847(ab)
bed position in ^{11}C PET studies, 815(ab)
11 [beta]-hydroxylase tracer, adrenal cortical tumors, 275
biosynthesis of brain imaging agents, 942(ab)
bone marrow involvement in lymphoma, detection of, 279(ab)
brain
  hypometabolic regions, in Alzheimer's, 976(ab)
  intracranial and intrathoracic tumors, methyl tyrosine and FDG in, 1272(ab)
  modification of serotonin synthesis in depression, 536(ab)
  reduced tracer uptake and atrophy, 844(ab)
  three-dimensional stereotactic surface projection, monkey, 1879, 1888
brain imaging, 12N(1)
^{76}Br bromofluorodeoxyuridine, DNA, rats, 1746
breast cancer, internal mammary lymph node chain, 574(ab)
^{11}C acetate
  prostate cancer studies, 394(ab)
  quantification of stress/perfusion with, 169(ab)
  thyroid cancer, 1350(ab)
cameras, small-animal, 1442(le)
cardiac event-free survival, 356(ab)
cardiac sympathetic function, 189(ab)
^{11}C choline
  imaging of prostate cancer, 294(ab)
  mediastinal lymph node detection, lung cancer, 1507
^{11}C colchicine, imaging of multiple drug resistance, 493
cell labeling with Cu-PTSM, 1126(ab)
central nervous system imaging tracers, 1072(ab)
cerebral blood flow at pCO2, 928(ab)
cerebral glucose metabolism, high-resolution imaging of, 403(ab)
cerebral metabolic heterogeneity in mild cognitive impairment, 250(ab)
changes in brain metabolism in methamphetamine abusers, 420(ab)
clinical optimization of whole-body scans, 802(ab)
^{11}C McN 5652, quantification of serotonin transporter, 1465
^{11}C metomidate, hilar and mediastinal lymph node metastasis, lung cancer, 283, 291
^{11}C metomidate tracer, adrenal cortical tumors, letter, 1933
colorectal cancer, Patlak's plot to measure glucose utilization rate, 828(ab)
comparative studies of MAO A measurements, 98(ab)
comparative study, upregulation of dopamine D2 receptors in early Parkinson's, 65
compensation methods for missing data, 812(ab)
coronary artery disease, mental stress effects on blood flow, 11
coronary microvascular reactivity, idiopathic dilated cardiomyopathy, 837
cortical pathology in Alzheimer's disease, 245(ab)
cost-effectiveness of combined PET/CT in lung cancer screening, 1292(ab)
^{11}C raclopride, 102(ab)
^{11}C TAA pulmonary distribution, 1603
^{11}C tamoxifen, synthesis of, 929(ab)
CT scanner, clinical oncology, 1369, 1380
data correction, tissue metabolites, dual-scan approach, 706
dementia, 1008(ab)
  prognostic value in, 251(ab)
depression, cerebral glucose metabolism in, 907(ab)
detection of reperfusion injury, monkey model of cerebral ischemia, 1409
developmental effects of G protein deficiency, 1206(ab)
differentiated thyroid cancer, 1331(ab)
differentiation, recurrent brain tumor from radiation injury, 1861
dopamine D2 receptor agonists, 94(ab)
dopamine transporter inhibition, 922(ab)
dopamine transporters, 262(ab)
with dual-head coincidence camera, 1067
epilepsy, prognostic value, 256(ab)
evaluation of respiratory compensation efforts, 79(ab)
before extracranial-to-intracranial bypass, carotid occlusion, 800
extrahepatic disease and hepatic metastases, 433(ab)
^{18}F altanserin, quantification of 5-HT$_{2A}$ receptors, human brain, 234
FDG
  after temporal lobectomy for seizures, 1964
  Alzheimer's disease, audiovisual stimulation, 575
  bowel inflammation, labeled leukocyte imaging, 1373(ab)
  brain tumor, recurrence, 1003(ab)
  breast cancer, 430(ab), 443(ab)
  breast cancer screening, 1268(ab)
  breast cancer staging, 1269(ab)
  calculating cerebral glucose metabolism, 658
  cervical cancer, 1309(ab)
  cervical lymph node staging, 123(ab), 468(ab)
  chemotherapeutic response to non-Hodgkin's, 275(ab), 276(ab), 277(ab)
  cholangiocarcinoma, 139(ab)
  cochlear implant, 961(ab)
  colorectal cancer, 1297(ab), 1303(ab)
    liver metastasis, 134(ab)
    therapeutic response, 446(ab)
  comparison in HIV positive and healthy individuals, 612
  congestive heart failure, 757(ab)
  diagnosis of malignancy, 1323(ab)
  dual-time point imaging, 451(ab)
  epilepsy, 998(ab)
    hypometabolism in, 253(ab)
  esophageal cancer, staging recurrence of, 124(ab), 726(ab)
  focal nodular hyperplasia and liver metastasis, 1304(ab)
  glioma, 972(ab)
  grading of tumors and tumorlike lesions of bone, 1695, 1702
  head and neck cancer, 1312(ab), 1314(ab)
    conformal radiotherapy, 1196(ab)
  head and neck cancer recurrence, 122(ab)
  Hodgkin's disease, untreated, 278(ab)
  Hodgkin's disease and lymphoma staging, 1207(ab)
  internal mammary node staging, 1260(ab)
  irradiation effects on bone marrow metabolism, normal rodent, 2026
  ischemic regions, 180(ab)
  labeled leukocyte imaging comparison, 58(ab)
  laryngeal cancer, 1252(ab)
  left ventricular ejection fraction, 752(ab)
  liver metastasis, tumor after ablation of, 1254(ab)
  lung cancer, therapeutic response, 445(ab)
  lung cancer detection, 1281(ab)
  lung cancer prognosis, 299(ab)
  lung cancer staging, 295(ab), 297(ab), 432(ab), 1291(ab)
  lung tumors, 301(ab)
  Lyme disease, 999(ab)
  lymphoma
    management, 1209(ab)
    prognostic value, 1205(ab)
  lymphoma staging, 466(ab)
  malignant pleural mesothelioma, 1443(le)
  measurement of input functions, 1-point blood sampling, 1484
  mediastinal/hilar activity in extrathoracic malignancy, 126(ab), 247(ab)
  melanoma
    histologic results, 1317(ab)
    management of, 434(ab), 1232(ab)
  myocardial glucose metabolism, 350(ab)
  nodal involvement in esophageal cancer, 808
  non-Hodgkin's lymphoma, tumor grade, 1221(ab)
  noninvasive estimation of input function, 1612
  non-small cell cancer, decision-tree analysis, 1287(ab)
  occipital lobe epilepsy, metabolics of, 254(ab)
  oncology, management of cases, 428(ab)
  orbitofrontal activation, in alcoholics, 918(ab)
  orthopedic prosthesis infection imaging, 1421(ab)
  osteomyelitis, 57(ab)
  osteosarcoma, 429(ab)
  ovarian and cervical cancer, 1313(ab)
  ovarian cancer, 1318(ab)
  pancreatic cancer, 138(ab)
  pancreatitis, 1381(ab)
  paraneoplastic syndrome, 1324(ab)
  in pathologically verified dementia, 1920, 1929
  pelvic tumors, hyperhydration protocol for, 1244(ab)
  peritoneal carcinomatosis, 140(ab)
  proliferative potential non-small cell lung cancer, 85
  prostate adenocarcinoma, 457(ab)
  pulmonary nodules, 1277(ab)
  radiation therapy monitoring, 444(ab)
  radioimmunotherapy, metabolic response of non-Hodgkin's lymphoma, 999
  recurrent or metastatic thyroid cancer, 1010
  renal cell carcinoma, 462(ab)
  sarcoidosis, 1411(ab)
  sarcoma
    prognosis, 125(ab)
    soft-tissue, 1319(ab)
  skeletal tumors, 1322(ab)
  standardized uptake values, lognormal, 1664
  standardized uptake values in lung tumors, 1288(ab)
  thymus visualization, 382(ab)
  thyroid cancer, 1335(ab)
    medullary, 1339(ab)
  thyroid cancer recurrence, 33(ab)
  TSH level effects on uptake, in thyroid cancer, 1989, 1996
  unknown primary tumors, 816
  vs choline in gastroesophageal cancer, 555(ab)
  whole-body
    cancer lesions, 1286(ab)
    recurrent colorectal cancer, 1177
  whole-body imaging, 3-D spatial integration, 233(ab)
  whole-body imaging, tumors, 1307(ab)
  whole-body imaging to detect recurrent colorectal cancer, 135(ab)
  whole-body imaging *versus* CT, 1213(ab)
FDG effects of left bundle branch block on, without coronary artery stenosis, 973
^{18}F DPN, synthesis and biologic evaluation, 1279
^{18}F EF1, noninvasive detection of tumor hypoxia, 327
^{18}F FLT, brain tumors, 966(ab)
^{18}F fluoro-L-*m*-tyrosine, between plasma and erythrocytes, 1636
^{18}F flurocholine as prostate cancer tracer, 1025(ab)
^{18}F FOP as a hepatic fatty acid oxidation tracer, 1727
^{18}F FU pharmacokinetics, colorectal cancer, 1714, 1725
^{52}Fe-citrate, Wilson's disease, 781
FHBG, suicide gene therapy, 289(ab)
fluoroestradiol, measurement of estrogen receptor expression in metastatic breast cancer, 108(ab)
^{66}Ga as potential imaging agent, 817(ab)
gamma camera coincidence imaging comparison, lung lesions, 959(le)
graphical analysis method, 854(ab)
head and neck cancer, recurrence, 1251(ab)
herpes simplex virus thymidine kinase, 1157(ab)
high-dose conformal radiation for glioblastoma multiforme, 269(ab)
hormone replacement therapy, assessment of, 11(ab)
hybrid CT machines, 961(le)
hybrid PET, optimizing geometry for, 803(ab)
^{123}I BMIPP, aortic valve disease, 761(ab)
image reconstruction, 524(ab), 863(ab)
IndyPET scanner, 875(ab)
infection imaging of total-knee prosthesis, 1419(ab)
insulin-sensitive tissues, 29(ab)
^{38}K, uptake, heart, kidney, brain, rabbit, 763
levels of tau protein in dementia, 252(ab)
lung cancer, comparison of coincidence detection camera and dedicated PET camera, 1274(ab)
lymphoma
  hybrid PET vs dedicated PET analysis of, 280(ab)
  whole-body imaging with ^{11}C acetate and FDG, 1211(ab)
measurement of ^{11}C CO_2 exhaled during, 605
measurement of cholinergic terminal density, 832(ab)
metabolic response to treatment of head and neck cancer, 1198(ab)
methylphenidate and nicotine elevate dopamine, 411(ab)
molecular imaging, 661

Monte Carlo scatter correction, 880(ab)
Monte Carlo simulation, 399(ab)
movement correction, 395(ab)
^{94m}Tc sestamibi, biodistribution and radiation dose estimates, 334(ab)
myocardial blood flow reduction in hibernating myocardium, 174(ab)
myocardial viability studies, coronary abnormalities on, 345(ab)
N-13-ammonia to measure infarct size, 358(ab)
neonatal asphyxia, 962(ab)
neuroreceptor imaging, 932(ab)
neuroreceptor studies, statistical noise effects, 2083
nonlinear registration of FDG PET thoracic datasets, 234(ab)
obesity, evaluation of brain dopamine receptors, 550(ab)
obsessive compulsive disorder, 912(ab)
opioid binding during methadone treatment, 418(ab)
ovarian cancer, cost analysis, 459(ab)
^{15}O water, parametric images of tumor blood flow, 1784
^{15}O water-perfusable tissue fraction, experimental old myocardial infarction, 1737
with partial volume correction, cerebral blood flow in aging, 1842, 1849
partial volume correction protocols, 852(ab)
Phoswich detector module, 74(ab)
pilocytic astrocytomas, 995(ab)
positive cardiac findings, gender differences, 263
post-traumatic stress disorder, 910(ab)
prognostic value in dilated cardiomyopathy, 744(ab)
prostate cancer, comparison of ^{11}C acetate and FDG studies, 560(ab)
protein synthesis rate pre- and post-therapy, 1199(ab)
proton MR spectroscopy and, brain metabolism in carotid artery disease, 1357, 1363
pulmonary distribution of fluticasone propionate, 1413(ab)
pulmonary fibrosis, 505(ab)
quantitation, 171(ab), 260(ab)
  assessing therapeutic response, 830(ab)
  cardiac, glucose measurements, 346(ab)
  dopamine transporter occupancy for cocaine, 263(ab)
  evaluation of cerebral oxygen metabolism, 957(ab)
  ^{18}F (ab)MPPF binding to serotonin receptors, 547(ab)
  FDG tumor imaging, 236(ab)
  of gene induction, 147(ab)
  myocardial perfusion scan, 187(ab)
  neoplasms, Cu-60-ATSM analysis of, 229(ab)
  recovery correction, 895(ab)
  weighted integral method, 242(ab)
radiolabeled neuronal nitric oxide synthase inhibitors, 1417
radioligands to study 5-HT1A receptors, 152(ab)
radiopharmaceuticals, performance of, 309, 315
rapid sinogram recovery, 822(ab)
^{82}Rb, serial changes in myocardial perfusion, 1426
receptor studies of depression and anger attacks, 899(ab)
reconstruction with nonlinear thresholding estimators, 519(ab)
regional differences in cerebral vascular response, 950(ab)
renal cell cancer, staging of, 461(ab)
repetitive stunning, myocardial, 1227, 1235
reveals emotions, 32N(11)
ROC/LROC, lesions size, contrast, and SNR, 745
role in clinical diagnosis and management, 36N(8)
scintillation crystals for, 1051
segmented attenuation correction, 871(ab)
serotonin re-uptake site tracers, 1064(ab)
serotonin transporter, factor analysis, 546(ab)
serotonin transporter ligands, 149(ab)
spatial resolution, 219(ab)
striatal dopamine release, aerobic exercise effects, 1352
synthesis of ^{11}C flumazenil, 1121(ab)
thoracic disease patterns, 1289(ab)
three-dimensional, lung cancer, 439
Tourette syndrome and, 24N(10)
tracers, ^{18}F FAU, 1162(ab)
tumor aggressiveness, 460(ab)
tumor imaging, 1325(ab)
  EGF receptor inhibitor for, 1035(ab)
tumor tracers
  bladder cancer, detection of, 293(ab)
  deoxyuridine distribution in prostatic tumors, 1160(ab)
  FDG in preoperative staging of breast cancer, 107(ab)
  ^{18}F FLT vs FDG, 291(ab)
  ^{18} F fluoropropy, 1075(ab)
  ^{66}Ga, 164(ab)
  hypoxia, evaluation of, 130(ab)
  pancreatic cancer, 1138(ab)
  pharmacokinetic analysis, 163(ab)
  radiochemical yield and reactivity of F-18-F2, 1087(ab)
  tumor-induced angiogenesis, 162(ab)
vesicular monoamine transporter type 2, 968(ab)
visual stimulation with regional cerebral blood flow, 959(ab)
volume visualization software tools, 402(ab)
whole-body
  biliary carcinoma, 1300(ab)
  clinical outcome, 821(ab)
  ^{11}C MET and FDG comparison, staging of lymphoma, 1980
  colorectal cancer evaluation with FDG and ^{11}C methionine PET, 556(ab)
  image quality, hybrid systems, 859(ab)
  lung cancer, 298(ab)
  three-dimensional radiation therapy, 1242(ab)
Potassium-38, uptake, heart, kidney, brain, rabbit, 763
Precursors
  radiolabeling of thymine, 1123(ab)
  retention time, 1121(ab)
Pretargeting
  ^{64}Cu, dosimetry of, 1054(ab)
  ^{64}Cu DOTA-biotin, 565(ab)
  peptidic chelator, 473(ab)
  radioimmunotherapy, colorectal xenografts, 480
  streptavidin-conjugated anti-CEA in colorectal cancer, 1186(ab)
Probe systems
  colorectal cancer, localization of, 816(ab)
  FDDNP tangles and plaques, 95(ab)
  intraoperative beta probe, 221(ab)
  lesion detection with hybrid PET systems, 82(ab)
  prostate, 68(ab)
  reporter probes to image herpes simplex virus type 1 thymidine kinases reporter gene expression, 317(ab)
  segmented attenuation correction, 531(ab)
Prognosis
  cardiac event-free survival with PET, 356(ab)
  effect of diabetes mellitus on survival in CAD patients, 751(ab)
  FDG PET assessment of chemotherapy for non-Hodgkin's lymphoma, 1216(ab)
  FDG uptake in non-small-cell lung cancer, 1296(ab)
  myocardial perfusion scans, 4(ab)
Prostate adenocarcinoma
  deoxyuridine distribution, 1160(ab)
  FDG PET staging of, 457(ab)
Prostate cancer
  bone metastases from, ^{186}Re HEDP toxicity and efficacy, 1689
  bone pain, ^{89}Sr chloride therapy, E-selectin concentration after, 1021
  comparison of whole-body ^{11}C acetate and FDG PET, 560(ab)
  cross-modality registration, 232(ab)
  effect of ^{89}Sr therapy on fibrinolysis and coagulation, 1166(ab)
  ^{18}F flurocholine, 1025(ab)
  image optimization, 456(ab)
  labeled anti-PSMA in treatment of, 315(ab)
  PET with ^{11}C choline, 294(ab)
  uptake and metabolism of labeled monoclonal antibodies by carcinoma cells, 562(ab)
Prostate cryoablation, antibody-streptavidin, 1148(ab), 1150(ab)
Protein binding, effect on renal extraction, ^{131}I OIH and ^{99m}Tc MAG3 tubular agents, 2077
PubMed Central, editorial, 1123
Pulmonary biodistribution, ^{11}C TAA, 1603
Pulmonary embolism
  acute, antithrombotic agents, incomplete lung perfusion after, 1043, 1049
  imaging with ^{99m}Tc bitistatin, 1056
  ^{99m}TC fibrin imaging, 161
Pulmonary fibrosis, single-lung transplant for, value of perfusion lung scintigraphy, 1771
Pulmonary hypertension
  effect on right ventricular function, 782(ab)
  gated SPECT and radionuclide angiography evaluation of, 16(ab)
Pulmonary lesions, malignancy in, dual-head coincidence imaging with FDG, 1801
Pyelonephritis, acute
  accuracy of dimercaptosuccinic acid scintigraphy, 986
  diuretic MAG3 scintigraphy in, 1955

Q

Quality control
  angulation errors, parallel-hole and fanbeam collimators, 548
  calibration methods for segmented camera, 806(ab)
  high-performance liquid chromatography, 1099(ab)
  radiochemical purity, 1109(ab)
  SPECT, NEMA recommendations, 383
Quantification, simplified
  lymphoscintigraphy, 1223(ab)
  parametric imaging, 953(ab)
Quantitation
  automatic, myocardial perfusion SPECT, 712, 720
  conjugate view method for image registration, 860(ab)
Quantitative image analysis, iterative reconstruction vs filtered backprojection in PET, 406(ab)

R

Raclopride, PET study, upregulation of dopamine D2 receptors in early Parkinson's, 65
Radiation injury, recurrent brain tumor, PET differentiation of, 1861
Radiation Internal Dose Information Center (RIDIC), 13N(6)
Radiation safety
  intracoronary brachytherapy, 1040(ab)
  release criteria and patient instructions following radioimmunotherapy for lymphoma, 1179(ab)
Radiation synovectomy, ^{165}Dy ferric-hydroxide, oxidative DNA damage, in arthritis, 250
Radiation therapy
  assessing alveolar permeability post-therapy, 507(ab)
  differential effects PET tumor tracers in glioma cells, 937(ab)
  dosimetry of radioiodinated polymer gel, 1063(ab)
  dosimetry of radioiodine in treatment of thyroid carcinoma, 1341(ab)
  head and neck cancer, salivary gland dysfunction after, 512(ab)
  high-dose ^{166}Ho DOTMP treatment of multiple myeloma, 576(ab)
  long-term survival of CA20948 tumor, 440(ab)
  multiple myeloma, 463(ab)
  radionuclide-targeted, bone metastases from breast or prostate cancer, 1689
  in situ, somatostatin analogs, progressive nuclear translocation, 1256
  three-dimensional radiation treatment planning, 1242(ab)
  treatment planning, SPECT/Coincidence imaging for, 1197(ab)
  tumor cell uptake of FMAU and deoxyglucose, 1161(ab)
Radioaerosol deposition, nebulizer hood aerosol therapy, 1412(ab)
Radiochemical purity
  ^{99m}Tc TRODAT-1, 1102(ab)
  tetrabutylammonium ion, Krytofix, 583(ab)
Radiographic absorptiometry, bone densitometry and, 2015
Radiographic courses, union of cervical interbody fusion, 1642
Radioimmunoassay, radioimmunodetection with ^{99m}Tc BDI-1, 1306(ab)
Radioimmunoconjugates, brain, conjugate imaging of, 861(ab)
Radioimmunodetection
  ^{111}In and ^{90}Y DTPA-anti-CEA MAbs, human colorectal cancer in mice, 337
  radioiodine tumor quantification, 808(ab)
Radioimmunoscintigraphy
  bone uptake of ^{186}Re HEDP and ^{153}Sm EDTMP, 377(ab)

colorectal cancer detection with FDG and ^{11}C methionine PET, 556(ab)
renal cell carcinoma, 462(ab)
Radioimmunotherapy, 1055(ab)
Ac-225-labeled antibody, 116(ab)
acute side effects, 310(ab)
apoptosis-related gene expression, 567(ab)
biodistribution and dosimetry of zevalin, 115(ab)
bispecific fusion antibodies, 1185(ab)
bone marrow dosimetry, 328(ab)
colorectal cancer, 1186(ab)
colorectal cancer treatment with ^{131}I-labeled hMN-14, 313(ab)
combination, radiolabeled antibodies and fractionated external beam, 1905
conditioning and, before stem cell transplantation, 531
cytotoxicity of Bi-213, 1177(ab)
dose escalation of ^{186}Re-labeled Mab in non-Hodgkin's lymphoma, 1182(ab)
dosimetric validation of whole-body ^{90}Y, 312(ab)
dosimetry of intratumoral injection yttrium, 1056(ab)
effect of anti-lymphoma antibody in non-Hodgkin's lymphoma, 1215(ab)
G250, upregulation of, 563(ab)
high-dose, medullary thyroid cancer, 93
high-dose ^{131}I-labeled monoclonal antibodies, 1022(ab)
human SCFV antibodies, creation of, 561(ab)
^{131}I-anti-B_1 antibody, tumor dosimetry, 1579
^{131}I-labeled chimeric monoclonal antibody MOv18, ovarian cancer, 1168
^{131}I-labeled monoclonal antibody for non-Hodgkin's lymphoma, 1178(ab)
^{111}In and ^{90}Y DTPA-anti-CEA MAbs, human colorectal cancer in mice, 337
intralesional therapy of glioblastoma, 1191(ab)
labeling mutation-specific Mab, 1174(ab)
lymphoma, 1175(ab)
MC57 spheroids to asses therapeutic response, 1176(ab)
medullary thyroid cancer, 213(ab), 1327(ab)
effect of Taxol on, 215(ab)
metabolic response of non-Hodgkin's lymphoma, FDG PET, 999
myeloablative high-dose therapy, 117(ab)
non-Hodgkin's lymphoma, 113(ab)
tumor response predictors, 114(ab)
optimizing timing of hyperthermia, 1189(ab)
patient release, patient instructions for, 1179(ab)
pharmacologic intervention, human colon cancer xenografts, 1244
pretargeted
antibody-streptavidin conjugate and ^{90}Y-DOTA-biotin, 131
colorectal xenografts, 480
radiation safety during sentinel node imaging, 1042(ab)
radioiodinated monoclonal antibodies, 1180(ab)
receptor targeting, 564(ab)
^{188}Re for myeloablation prior to stem cell transplantation, 119(ab)
residualizing therapy nuclides, preclinical efficacies of, 566(ab)
single-dose *versus* fractionated, uniform tumor dosimetry, 538
squamous cell carcinoma, head and neck, 1999, 2011
stem-cell therapy for non-Hodgkin's lymphoma, 118(ab)
thyroid carcinoma, effect of hormone withdrawal on radioiodine therapy, 1344(ab)
utility of ^{90}Y- and ^{111}In-labeled antibodies in ovarian and colorectal cancer, 1151(ab)
V-48 for PET, 1057(ab)
whole-body mild hyperthermia, 1190(ab)
^{90}Y-2IT-BAD-Lym-1, in non-Hodgkin's lymphoma, 952
Radioiodinated benzamides, transalveolar permeability, 1409(ab)
Radioiodine therapy
ablation, ^{131}I whole-body scanning, absence of thyroid stunning after, 1198
differentiated thyroid cancer, 1340(ab)
effect of hormone withdrawal and recombinant human thyrotropin in thyroid carcinoma, 1344(ab)
negative thyroid cancer scans, 214(ab)
neoplastic meningitis, treatment of, 1204(ab)
predictor of late hypothyroidism, 1351(ab)
target system construction, 1110(ab)
thyroid cancer scans during Thyrogen stimulation, 1201(ab)
thyroid remnants, after tracer dosimetry, 1082
time-dependence and exhalation of after therapy, 1108(ab)
treatment, hyperthyroidism, thyroid cancer after, 1006
uptake, diuretic effect on, 1349(ab)
volume reduction of hypothyroidism, 1337(ab)
whole-body scintigraphy vs FDG whole-body imaging in thyroid cancer recurrence, 33(ab)
Radioisotopes
availability of North America-produced, 10N(9)
kinetics of hypoxic tracer, myocardium, 1102
Radiolabeled antibodies
dosimetric validation of high-dose Y-90 radioimmunotherapy, 312(ab)
lung disease imaging, 1407(ab)
patient-specific characteristics of I-131-labeled antibodies, 311(ab)
Radiolabeled peptides
anti-pulmonary surfactant associated protein monoclonal antibody, 1147(ab)
optimizing labeling of lanreotide and octreotide, 1116(ab)
somatostatin receptor-binding, 1142(ab)
somatostatin receptor targeting, 156(ab)
in vivo tumor targeting properties of, 161(ab)
Radiological Society of North American (RSNA), nuclear medicine presentations scheduled for 2000, 23N(11)
Radiolucent stripe, union of cervical interbody fusion, 1642
Radiometals
nonporous ceramic coatings, 1076(ab)
optimizing timing of hyperthermia combined with, 1189(ab)
^{186}Re- vs ^{131}I-labeled anti-colorectal antibody to assess tumor size, 1183(ab)
stability of high radioactivity solutions of ^{186}Re, 1111(ab)
Radionuclide cystography, quantitation of day- and night-wetting children, 1433(ab)
Radionuclide imaging
hilar uptake of ^{67}Ga citrate, residual disease after CHOP chemotherapy and, 269
^{99m}Tc DMSA uptake, kidneys, after radical nephrectomy, 1025
Radionuclides
auger-electron-emitting, DNA cleavage, 1093
beta- and photon-emitting, reevaluation of absorbed fractions, 149
^{124}I production, 1110(ab)
^{186}Re, formulation and stability of, 1111(ab)
therapy of bone cancer pain, marrow-sparing effects of ^{117}Sn DTPA, 2043
Radionuclide therapy
At-211-labeled Mab images of gliomas, 332(ab)
automated registration method for I-131-MIBG therapy using external markers, 825(ab)
autosynthetic device, 1122(ab)
bone pain, metastatic osseous lesions, 682, 688
breast cancer, ^{186}Re HEDP and external radiation therapy, comparison of, 1168(ab)
^{64}Cu ATSM, therapeutic effect of, 455(ab)
dose planning based on SPECT quantitation, 329(ab)
instructions for radiation safety, 1050(ab)
internal dosimetry, 297
peptide receptor, 1704
radiation nephrotoxicity, 441(ab)
^{186}Re HEDP, treatment of painful bone metastases, 647, 655
skin patch for melanoma, 1164(ab)
somatostatin receptor therapy of neuroendocrine tumors, 1170(ab)
thyroid cancer, 333(ab)
toxicity of ^{64}Cu agents, 565(ab)
tumor-targeted, patient dosimetry and, 104
Radionuclide ventriculography
assessment of left ventricular function, 770(ab)
chronic postembolic pulmonary hypertension, 768(ab)
Radiopharmaceutical
^{17}F fluoromethane, production of, 1074(ab)
^{124}I, 1015(ab)
^{123}I ERC9, 288(ab)
increased FDG yields with recycled ^{18}O target water, 584(ab)
kit preparation of ^{111}In DTPA-Folate, 1113(ab)
mapping opioid receptors with radioiodinated ligand, 482(ab)
metabolism studies, 1073(ab)
polyvinyl alcohol embolization particle labeling, 1094(ab)
Radiopharmaceutical chemistry
antibody labeling, 1118(ab)
^{11}C methyl iodide, 1078(ab)
^{64}Cu cyclen-TPN, 322(ab)
kit compatibility, 1107(ab)
synthesis of ^{11}C fatty acids, 484(ab)
Radiopharmaceutical development
F-HT1A receptor, 483(ab)
^{122}I perfusion agents, 1093(ab)
kit preparation of ^{188}Re HEDP, 1124(ab)
SPECT tracers for ischemic myocardium, 23(ab)
Radiopharmaceuticals
biologic mechanisms, $^{89}SrCl_2$ incorporation, 183
breast milk excretion of, 863
^{18}F-4-cis and trans FCWAY, 153(ab)
generator-produced, in clinical PET, 309, 315
myocardial uptake, force-generating preparation from atria, 1587
reduction of background activity, radiolabeling of antifibrin Fab', 1264
selection of, palliation of bone pain, 682, 688
Radiosensitivity
human leukemic cell lines, 1047(ab)
^{186}Re, radiosensitization with methylxanthine derivatives, 1188(ab)
Radiosynovectomy
pretherapeutic three-phase bone scan, 1429(ab)
rheumatoid arthritis, 375(ab)
Randomized controlled trials (RCT), imaging technology evaluation, editorial, 1123
Rao, Dandamundi, 28N(7)
Receiver operating characteristic (ROC)
attenuation correction, myocardial SPECT, 502
detection with SPECT, 858(ab)
lesion size, contrast and SNR, PET, 745
Receptor-binding radiopharmaceutical
effect of gold surfaces on tracer kinetics, 487(ab)
^{18}F labeling agents, 1098(ab)
mapping with radioiodinated ligand, 482(ab)
research and development projects, 940(ab)
scintigraphic detection of insulinomas by I-123-glucagon-like peptide-1, 31(ab)
Receptor imaging
dynamic displacement of serotonin receptors, 935(ab)
^{18}F-labeled antisense oligodeoxynucleotide probes, 1081(ab)
pharmacokinetics of ^{18}F SAA-labeled peptides, 162(ab)
reproducibility of SPECT estimates, 954(ab)
stereotactic standardization of brain receptor data in SPECT, 240(ab)
Receptor recycling
^{11}C, captive solvent synthesis of, 585(ab)
^{18}F-labeled antisense oligodeoxynucleotide probes, 1081(ab)
^{18}F labeling agents, 1098(ab)
Reconstruction
Poisson noise reduction, 893(ab)
projector and backprojector, 877(ab)
SPECT data, strategies for, 881(ab)
Recovery effect, PET, discrimination of reduced tracer uptake and atrophy, 844(ab)
Red cell labeling, drug-tracer interaction, effect of chayote, cauliflower and caffeine on, 1101(ab)
Red cell mass, prediction of, obesity effects, 390(le)
Reflex sympathetic dystrophy, pinhole bone SPECT, 1426(ab)
Regional cerebral blood flow (rCBF). *see also* Blood flow, cerebral
liniac radiosurgery, effect on, 973(ab)
prognostic index in Alzheimer's disease, 978(ab)
SPECT and MRI striatal patterns in Parkinson's disease, 994(ab)
Regions of interest (ROI)
brain SPECT, ^{99m}TC HMPAO brain templates, elderly, 45
semiautomated, evaluation of renal function with ^{99m}Tc MAG3, 1947

Registration
multimodality, planar emission data with CT, 700
spatially noncoherent interferometry, 375
Reimbursements, 13N(4)
Relative renal function, supranormal function, 1434(ab)
in congenital hydronephrosis, 202(ab)
Renal artery stenosis
diagnosis, aspirin renography and captopril renography, 1337
MAG3 clearance in, captopril-induced changes, renal angioplasty effects, 1203
^{99m}Tc DTPA, parenchymal mean transit time analysis, 1627
predicting response to revascularization, 1369(ab)
Renal cancer, FDG uptake by, coincidence detection gamma camera, 78
Renal cell carcinoma
FDG whole-body imaging, 460(ab)
interferon, upregulation of, 563(ab)
PET staging of, 461(ab)
Renal colic, MAG3-F_0 scintigraphy, after helical CT positive for urolith, 1813
Renal imaging
cortical defects in acute pyelonephritis, 1359(ab)
dynamic SPECT, 894(ab)
monitoring response to antirejection treatment of renal allografts, 1360(ab)
new criteria for Lasix renogram, 210(ab)
new N3S ligands, 1082(ab)
role of unenhanced helical computerized tomography in ureterolithiasis, 197(ab)
three-dimensional ^{99m}Tc DMSA images, 1371(ab)
Renography
aspirin, diagnosis of renal artery stenosis, 1337
attenuation correction in, children and adults, 823
captopril
diagnosis of renal artery stenosis, 1337
^{99m}Tc DTPA, parenchymal mean transit time analysis, 1627
deconvolution analysis, renal outflow efficiency or, letter, 1595
diuretic
^{99m}Tc MAG3 to predict surgery in neonates, 1432(ab)
quantitative gravity-assisted drainage, infants and children, 1030
effect of injection time, 200(ab)
furosemide, evaluation of acute pyelonephritis, 1955
management of urinary tract obstruction, 203(ab)
Renovascular hypertension, percutaneous transluminal renal angioplasty, 1368(ab)
Reperfusion injury
fatty acid extraction after low-flow ischemia, 792(ab)
selective detection of infarct, 785(ab)
Reproducibility
dose-fractionated radioimmunotherapy, 324(ab)
extrastriatal dopamine D2 receptor imaging, SPECT, 1343
gated myocardial perfusion SPECT images, 737(ab)
gated myocardial SPECT images, 493(ab)
^{99m}Tc MAG3 clearance, 366(ab)
Republic of China Society of Nuclear Medicine (ROC SNM), 9N(9)
Resolution improvement
coincidence detection camera, 222(ab)
hybrid PET, 876(ab)
SPECT imaging systems, evaluation of using activity estimation, 819(ab)
Restenosis
intracoronary irradiation to reduce, 504(ab)
prevention of, 27(ab)
prevention of following percutaneous transluminal angioplasty, 503(ab)
Revascularization, laser effect on cardiac sympathetic innervation, 13(ab)
Reynolds, James C., 24N(9)
Rhenium-186, chimeric monoclonal antibody U36 labeled with, squamous cell carcinoma, head and neck, 1999, 2011
dosimetry, 1059(ab)
effective concentration of, alumina-based ^{188}W---^{188}Re generator, 1271
intracoronary radiation therapy, 1122(ab)
irradiation of tungsten target, 588(ab)
kit preparations of labeled HEDP, 1124(ab)
N2S2 bifunctional chelating agents, 1095(ab)
optimizing labeling lanreotide and octreotide, 1116(ab)
pain palliation agent, 1165(ab)
pain palliation in bone cancer, 1167(ab)
peptide radiolabeled with, noninvasive monitoring of gene transfer, 887
quantitation of in radionuclide therapy planning, 1202(ab)
radiation safety of labeled tin colloid, 373(ab)
radioimmunotherapy, stem cell transplantation, 531
treatment of restenosis, 28(ab)
Rhenium-186 HDPT, toxicity and efficacy, bone metastases from breast or prostate cancer, 1689
Rhenium-186 HEDP, treatment of painful bone metastases, short- and long-term effects, 647, 655
Rhenium-188
apoptosis and proliferation of smooth muscle cells, 2(ab)
balloon system to reduce stenosis, 504(ab)
biodistribution and excretion kinetics of three labeled agents, 801(ab)
bispecific antibodies for CEA-positive tumors, 473(ab)
Rheumatoid arthritis
radiation synovectomy, 373(ab)
radiosynovectomy, 375(ab)
Right ventricular function
effectiveness of gated perfusion SPECT, 17(ab)
gated SPECT study of effect of primary pulmonary hypertension on, 782(ab)

S

Salivary glands
quantitative studies of function in Sjøgren's syndrome, 1375(ab)
scintigraphic assessment of function of, 512(ab)
scintigraphy, contrast sialography *versus,* in Sjøgren's syndrome, 257
Samarium-153 EDTMP
dosimetry of by whole-body scintigraphy, 1163(ab)
pain palliation for skeletal metastases, 575(ab)
Sarcoidosis, FDG PET detection of, 1411(ab)
Sarcoma
FDG PET evaluation or therapeutic response, 125(ab)
metabolic activity and multidrug resistance, 1256(ab)
tumors and tumorlike lesions, grading with FDG PET, 1695, 1702
Sasaki, Yasuhito, 27N(7)
Scanners
clinical performance of, 818(ab)
effects of field of view and patient shielding, 81(ab)
synthesis of F-18-fluoride, 1114(ab)
Scatter correction
brain SPECT, inferring head anatomy, 1569
dual-isotope images, 528(ab)
hepatic SPECT, human observer correlation, 514
Monte Carlo simulation, ^{131}I imaging, 123
multiple-energy window acquisition, 873(ab)
myocardial SPECT images, 522(ab)
relative impact, cardiac SPECT, 1400
sestamibi cardiac images, 718(ab)
Scatter fraction, PET, with dual-head coincidence camera, 1067
Schizophrenia
clozapine interaction with dopamine D2 receptors, 264(ab)
functional transcranial Doppler sonography and PET assessment of, 914(ab)
reduced muscarinic receptor availability, 99(ab)
serotonin function pre- and postsynaptic, 925(ab)
Scintigraphic courses, union of cervical interbody fusion, 1642
Scintigraphy
bone, evaluation of experimental chronic osteomyelitis, 896
dimercaptosuccinic acid, accuracy in acute pyelonephritis, 986
hepatobiliary, gallbladder visualization, biliary atresia in infants, 1209
^{123}I IL2-labeled, in Crohn's disease, 242
^{123}I IMT, carcinoid tumors, 1793
^{123}I MIBG, cardiac neuronal function after carvedilol, 845
^{123}I MIBG study, childhood dilated cardiomyopathy, 400
^{99m}Tc aprotinin detection of amyloid deposits, 464(ab)
^{99m}Tc furifosmin, nonpalpable breast lesions, 426
perfusion lung, lung transplant patients, 1771
planar, ^{99m}TC DMSA, interobserver reproducibility, 23
receptor, ^{111}In pentetreotide, detection of insulinomas, 459
salivary gland, *versus* sialography, in Sjøgren's syndrome, 257
somatostatin receptors, gastric carcinoids, 1646
whole-body, ^{99m}Tc sestamibi and ^{131}I, thyroid cancer, 631
Scintillation camera, performance, detectability index as a measure of, 804(ab)
Scintillation crystals, PET, 1051
Scintimammography
characteristics of three different scintillator arrays, 810(ab)
lesions detection, 804(ab)
^{99m}Tc MIBI breast tumors, 1324
mammography and, suspected breast cancer, 390(le)
^{99m}Tc sestamibi, breast imaging, diagnostic accuracy of, 1973
recurrent breast cancer, 1257(ab)
scintigraphy, nonpalpable breast lesions, 426
Scintirenography, diuretic MAG3, children with HIV nephropathy, 1037
Sclerotherapy, endoscopic variceal, bleeding after, SPECT evaluation, 600
Segrè, Emilio, 20N(2), 30N(11)
Seidlin, Sam, 29N(11)
Seizures
after temporal lobectomy, FDG PET as predictor of outcome, 1964
ictal SPECT primary, 258(ab)
Selective serotonin reuptake inhibitors, quantification of serotonin transporters, ^{11}C McN 5652 PET, 1465
Semiconductor detectors, CdTe, 805(ab)
Sentinel node imaging
breast cancer, 1229(ab)
clinical utility in, 1227(ab)
detection, 308(ab)
predictive value for small tumors, 306(ab)
comparison of lymphoscintigraphy with pinhole SPECT in breast cancer, 1259(ab)
comparison with lymphoscintigraphy in breast cancer, 282(ab)
correlation with FDG PET in breast cancer, 573(ab)
detection with encapsulating blue dye, 1019(ab)
detection with human colloides, 1133(ab)
detection with ^{99m}Tc nanocolloid, 284(ab)
estimation of lymph node retention, 857(ab)
identification, intratumor injection for, mammary lymphoscintigraphy, 1500
injection technique for lymphoscintigraphy, 1231(ab)
localization, preoperative breast lymphoscintigraphy, 1682
lymphatic mapping in breast cancer, 1226(ab)
lymphoscintigraphy in esophageal cancer, 1222(ab)
melanoma, detection of lymph node basins, 302(ab)
prognostic value in melanoma, 305(ab)
radiation safety, 1042(ab)
radiocolloid imaging, 286(ab)
scattered photons to outline body contour, 1223(ab)
stage T1 and T2 breast cancer, 1230(ab)
subareolar injection in breast cancer, 233(ab)
subdermal injection methods, 281(ab)
Serotonin
FDG PET imaging of responsiveness, 903(ab)
5-HT_{2A} receptors, PET quantification, human brain, 234
measurement of induced synaptic changes, 533(ab)
paroxetine, modification of in depression, 536(ab)
pre- and postsynaptic function in schizophrenia, 925(ab)
in vivo binding of tritiated methylspiperone, 261(ab)
Serotonin-1A receptor agonist, radiopharmaceutical development of, 483(ab)
Serotonin receptors
aging effects on, 951(ab)
autoradiography, 1069(ab)
binding potential of 5HT ligands, 1068(ab)
binding potential of frontal 5-HT2a, 908(ab)
comparisons of radioligands for SPECT, 150(ab)
delineation in brain, ^{18}F MPPF, 1830
effect of 5-HT releasers, 261(ab)
graphical analysis without arterial sampling, 547(ab)

preparation of IDAM for SPECT imaging of serotonin transporters, 1120(ab)
reduced frontal 5HT2A binding potential, 534(ab)
reference tissue model, 953(ab)
reproducibility of SPECT estimates of, 954(ab)
Serotonin transporters
binding characteristics, 930(ab)
brain, ^{11}C McN 5652 PET, 1465
characterization of ADAM, 1065(ab)
gender differences, 900(ab)
5-HT density in Parkinson's disease, 985(ab)
5-HT transporter density differences in ecstasy users, 419(ab)
^{123}I ENT imaging of, 151(ab)
imaging with ^{123}I-β-CIT SPECT, aging effects, 36
improved ligand for SPECT images, 1066(ab)
phenylthiobenzylamine, 932(ab)
plasma cortisol concentrations linked to transporter reduction in alcoholism, 537(ab)
Sestamibi
differentiated thyroid carcinoma, clinical effect in detection of, 1343(ab)
false-positive findings, myocardial perfusion scintigraphy, 1935
non-Hodgkin's lymphoma, 1218(ab)
parathyroid imaging protocol, 1332(ab)
role of preoperative imaging in primary hyperparathyroidism, 216(ab)
SPECT imaging of lung cancer compared to computed tomography, 1276(ab)
three-dimensional quantitative perfusion SPECT analysis, 763(ab)
Sialography, contrast, salivary gland scintigraphy *versus,* in Sjøgren's syndrome, 257
Signal-to-noise ratio (SNR)
PET activation images, cold-bolus, switched protocol, 926
ROC/LROC study of lesions, PET, 745
Simultaneous dual-isotope imaging
model for Pb X-ray contamination, 892(ab)
myocardial SPECT, 807(ab)
Single photon emission computed tomography (SPECT)
activation study, refractory epilepsy, 1145
Alzheimer's disease, diagnosis of early onset, 963(ab)
Alzheimer's disease and, 50N(8)
anatomical and functional imaging in radiotherapy, 1197(ab)
Anscombe and K-L transforms, 893(ab)
apolipoprotein E genotype in Alzheimer's disease, 964(ab)
artifactual inferior wall defects on sestamibi images, 884(ab)
assessing therapeutic response with ^{99m}Tc MIBI, 1250(ab)
assessment of functional recovery after acute myocardial infarction, 355(ab)
attenuation correction
cardiac images, 84(ab)
cardiac slices, 872(ab)
myocardial perfusion imaging, 340(ab), 530(ab), 733(ab)
quality control of, 869(ab)
attenuation correction and enhanced acquisition, improved uniformity, 1139
attenuation map reconstruction, 529(ab)
automated evaluation of ^{123}I IBZM studies of parkinsonism, 969(ab)
automated quantification of ^{123}I IBZM uptake, Parkinsonism, 220
backprojection artifact due to gallbladder uptake of ^{99m}Tc sestamibi, 725(ab)
biloma, evaluation of, 1392(ab)
binding of ^{99m}Tc to dopamine transporters, Parkinson's disease, 584
brain, 12N(1)
attenuation distributions inferred from head atlas, 1569
cerebral perfusion in autism, 911(ab)
cerebral perfusion reserve, double-injection methodology, 836(ab)
dementia, differential diagnosis of, 424(ab)
ictal-interictal imaging, 259(ab)
^{123}I ENT, biosynthesis, 151(ab)
Machado-Joseph's disease, 996(ab)
noninvasive measurement of input function, 841(ab)
nonuniform transmission in, 2051
partial volume effect, 405(ab)
perfusion in depression disorders, 905(ab)
in progressive aphasia, 228
risperidone D2 receptor occupancy, 920(ab)
stroke assessment, 997(ab)
subacute infarction, 795
subclinical hepatic encephalopathy, 405
voxel-based template analysis, 842(ab)
brain perfusion, early Alzheimer's disease, 1155
cardiac
attenuation correction for, 919
motion-correction techniques in, 1298(le)
relative impact of corrections in, 1400
ROC study of attenuation correction, 502
cerebral cortical perfusion, Alzheimer's disease, 57
chest, ^{99m}Tc MIBI, 1969
chronic fatigue syndrome, 898(ab), 970(ab)
clinical evaluation of MIBG in tachyarrhythmias, 707(ab)
combined CT/SPECT for improved quantitative imaging, 67(ab)
compared with MRI FAIR, 26N(2)
comparison of ^{99m}Tc MIBI and ^{201}T in recurrent brain tumors, 273(ab)
cone-beam collimation, 820(ab)
cortical dysplasia, 258(ab)
cost effective in chest pain diagnosis, 26N(2)
cost-effectiveness of myocardial imaging, 781(ab)
data-based correction for patient motion, 239(ab)
data reconstruction, 881(ab)
diffusion MRI and, acute stroke, 788
3-dimensional colon-modulated display, coronary artery disease, 1941
dynamic, artificial kidneys, 224(ab)
dynamic displacement of serotonin receptors, 935(ab)
dynamic renal imaging, 894(ab)
early and delayed parathyroid scans, 1346(ab)
exercise, lung ^{201}Tl uptake with, coronary artery disease, 567
fatty acid metabolism, dynamic imaging of, 501(ab)
FDG collimated, myocardial perfusion and viability, 1318
FDG to detect viable myocardium, 354(ab)
^{18}F FBT, cholinergic terminal density, monkey brain, 2069
F-HT transporter parameters, 947(ab)
filtering, 519(ab)
gated
cardiac, experimental validation with MRI, 874, 883
chronic postembolic pulmonary hypertension, 16(ab), 522(ab)
comparison of regional perfusion, 495(ab)
cost–benefit analysis, 343(ab)
diastolic function measurements, 715(ab)
echocardiographic validation of, 1308
ejection fraction measures with Myotrack, 491(ab)
increased myocardial blood flow with dobutamine, 173(ab)
isolated cortical atrophy, 747(ab)
left ventricular ejection fraction, 19(ab), 714(ab), 1120(le)
left ventricular function, 769(ab), 770(ab)
left ventricular hypertrophy, 713(ab)
left ventricular post-stress stunning, 21(ab)
low-dose dobutamine, 351(ab)
myocardial defects, 496(ab)
myocardial ischemia, ^{99m}Tc sestamibi and degree of left ventricular dysfunction, 339(ab)
myocardial wall thickening, 755(ab)
reproducibility of perfusion images, 493(ab)
revascularization, 732(ab)
septal wall motion, 494(ab)
Tc-labeled tracers, optimization of, 717(ab)
^{201}Tl detection of stunned myocardium, 735(ab)
triple-vessel CAD, 731(ab)
ventricular performance, evaluation of, 15(ab)
wall motion and wall thickening, evaluation of, 20(ab)
gated myocardial
likelihood of CAD, 852, 860
stunning by dipyridamole stress, 27
gated myocardial contractile reserve in subendocardial infarction, 497(ab)
gated studies of volume measurement, 390(ab)
geometric and intensity normalization, effect of, 179(ab)
helical scan, 83(ab)
hepatic, human observer correlation, 514
hippocampal inactivation, 960(ab)
hypercapnia, cerebrovascular response to, 975(ab)
^{111}In pentetreotide, detection of insulinomas, 459
^{123}I-β CIT, aging effects on serotonin transporter, 36
^{123}I BMIPP, predictor of left ventricular remodeling following myocardial infarction, 728(ab)
^{123}I BMIPP and ^{201}Tl, preinfarction angina and, 830
ictal brain, image registration and subtraction, seizures, 1619
^{123}I I-A-85380, measurement of nicotinic receptors, 1552
with ^{123}I IAFCT, quantification of dopamine transporters, 1086
^{123}I IMP SPECT, non-Hodgkin's lymphoma, 1777
^{123}I IPPA, myocardial viability, 1299
image reproducibility, 737(ab)
improved lesion detection in systemic lupus erythematosus, 1009(ab)
^{131}I, scatter and penetration, 123
^{131}I-anti-B_1 antibody therapy, lymphoma, 1579
^{131}I quantification, ultra-high-energy collimator, 1760
knee, anterior cruciate ligament injury, 1427(ab)
list mode rebinning of gated myocardial perfusion images, 778(ab)
lung, ventilation/perfusion studies, 46(ab)
lung imaging, 883(ab)
Monte Carlo downscatter, 521(ab)
MRI fusion, automatic and interactive methods, 1823
^{99m}Tc, normal brain patterns in adults, 1456
^{99m}Tc DSMA, renal length measurements with, 1632
^{99m}Tc ECD
lesions near central sulcus, 411
quantitation of brain perfusion, 838(ab)
^{99m}TC ECD brain perfusion, carotid shunting, 1836
^{99m}Tc ECD imaging of autistic disorders, 913(ab)
^{99m}TC GSA, prognostic estimation after hepatectomy, 421
^{99m}Tc HMPAO
Alzheimer's disease, 1451
crossed cerebellar diaschisis, 416
^{99m}TC HMPAO brain templates, elderly, 45
^{99m}Tc HMPAO to predict hemorrhagic cerebral infarction, 1012(ab)
^{99m}Tc metronidazole for hypoxic tissue, 1245(ab)
^{99m}Tc O-1505T, quantification of, 839(ab)
^{99m}Tc TRODAT-1, in Machado-Joseph disease, 994
myocardial
3D scan with electrophysiology, 184(ab)
intrinsic dual-energy processing, 1287
ordered-subset algorithms in, 737
quantitation of, 712, 720
transposition of great arteries, 383(ab)
myocardial gated, 492(ab)
left ventricular ejection fraction, evaluation of, 734(ab)
left ventricular ejection fraction, 1445
measurement of infarct size with sestamibi, 360(ab)
postischemic stunning, 780(ab)
regional function and perfusion, 69(ab)
reverse distribution of artifacts, 767(ab)
ventricular function and volume measurements in dystrophic myotony, 192(ab)
wall motion, quantitative evaluation of with ^{99m}Tc tetrofosmin, 747(ab)
myocardial imaging, ^{123}I MIBG, 194(ab)
myocardial perfusion, minimizing liver, bowel, and gastric activity, 1315
myocardial perfusion imaging
cost-effectiveness after acute MI, 364(ab)
single stress image, 724(ab)
stress tests, 746(ab)
nonuniform attenuation and scatter correction, 1425(ab)
Parkinson's disease, ^{123}I CIT assessment of, 543(ab)
pinhole collimator, 75(ab)
portosystemic collaterals, bleeding after sclerotherapy, 600
positive cardiac findings, gender differences, 263
pulmonary perfusion studies, 1405(ab)
quality control, NEMA recommendations for, 383
quantification of scatter, 873(ab)
quantitation, point source calibration, 398(ab)
quantitative
attenuation map, effect on brain images, 241(ab)

brain, small structures, 819(ab)
diagnostic test comparison, 736(ab)
left ventricular determination with ^{99m}Tc tetrofosmin, 758(ab)
motion correction for myocardial studies, 177(ab)
myocardial, infarct size and severity, 1383
renal function after nephrectomy, 1025
quantitative images of left ventricular hypertrophy, 779(ab)
radionuclide angiography, 799(ab)
regional cerebral blood flow, 952(ab)
regional cerebral blood flow, Huntington's disease, 773
renal cortical defects, detection of, 1359(ab)
rest-redistribution after myocardial infarction, 756(ab)
rest-redistribution studies, 342(ab)
serotonin transporter radioligands for, 150(ab)
sestamibi, false-positive findings, 1935
simultaneous dual-isotope imaging, 892(ab)
slant-hole collimation, 813(ab)
spatial and temporal registration, 1075
spatially noncoherent interferometry, 375
technegas, regional severity of emphysema, 590
^{201}Tl, brain tumor, 5
varying focal-length collimator, 877(ab)
vertebral metastases, diagnosis of, 1270(ab)
voxel-based template analysis, 842(ab)

Single-sample method
algorithms for estimating MAG3 clearance, 365(ab)
glomerular filtration rate measurements, 1366(ab)

Sjøgren's syndrome
functional evaluation of salivary glands, 1375(ab)
quantitative salivary gland scintigraphy, contrast sialography *versus*, 257

Skin cancer, radionuclide skin patch, 1164(ab)

Skull, cancer, 476(ab)

Smith, James Joseph, in memoriam, 32N(11)

Smooth muscle cells, proliferating, radiolabeled uptake to, coronary stent restenosis, 1535, 1541

Society of Nuclear Medicine (SNM)
ACNP, partnership agreement with, 32N(4)
comment o NRC petition, 22N(10)
Aebersold award, 2000, 23N(6)
2000 annual business meeting, 27N(7)
2000 annual meeting preview, 15N(3), 30N(5)
2000 annual meting, 9N(9), 13N(7), 44N(8)
Henry N. Wagner, Jr., lecture, 36N(8)
highlights 2000 lecture, 9N(8)
Brain Imaging Council, 13N(1)
comments on HCFA's physician payment for 2000, 21N(2)
comments on NRC inspection document, 40N(5)
comments on NRC policy guide, 19N(2)
DeHevesy award, 30N(7)
DuPont Pharmaceutical Award, 30N
Education and Research Foundation (ERF), 17N(9)
Alavi-Madell awards, 14N(9)
awards announced, 14N(4)
Bradley-Alavi awards, 14N(9)
Cassen award, 13N(5)
Tetalman award, 18N(9)
elections
results, 2000-2001, 23N(60
state of candidates for 2000, 14N(4)
international initiatives, 9N(9)
lines from the president, 11N(1), 16N(7)
Loevinger-Berman award, 28N(7)
2000 mid-winter meeting preview, 21N(2)
Practice Accreditation Program (PAP), 32N(5)
Practice Acquisition Assessment Program (PAAP), 19N(3)
President's Distinguished Service awards, 27N(7)
Proficiency Testing Program (PTP), 32N(5)
Public affairs, upstate, 14N(11), 19N(3), 21N(1), 21N(2), 22N(9), 22N(10), 24N(6), 32N(5), 37N(7), 49N(8)
Quantitative Cardiac Phantom Study Program, 34N(7)
Reimbursement Roadshow, 19N(3), 21N(1)

Society of Nuclear Medicine-Technologist Section (SNM-TS)
lines from the president, 20N(7)
public forum on women's health, 21N(9)

Sodium iodide symporter, breast cancer cell line expressing, radioiodide concentrator gene therapy, 1898

Soft-tissue tumor
assessment of estimation performance, 837(ab)
diagnosis with FDG PET, 1319(ab)

Somatostatin, dosimetry comparisons of peptides, 1043(ab)

Somatostatin analogs, progressive nuclear translocation, 1256

Somatostatin receptors
angiogenesis, 133(ab)
experimental radiopeptide therapy with Y-90-DOTA-octreotide, 578(ab)
long-term survival of tumors treated with, 440(ab)
^{99m}Tc or ^{188}Re radiolabeled peptide for, monitoring of gene transfer, 887
neuroendocrine tumors, 1311(ab)
localization with ^{111}In, 1514, 1519
octreotide binding and, thyroid tumors, 636
predictor of impending cardiac allograft, 499(ab)
receptor subtypes, 435(ab)
scintigraphy, gastric carcinoids, 1646
tumor detection, 590(ab)
tumors positive for, octreotide imaging in, 1114
Y-90-octreotide, dose-effect relationship for kidney damage, 1046(ab)

Somatostatin receptor scintigraphy, detection of insulinoma, 459

Sonography
bone densitometry and, 2015
intravascular studies, abnormal exercise perfusion findings and, 1935

South African Society of Nuclear Medicine (SASNM), 23N(10)

Spatial resolution
finite, cardiac SPECT, 1400
PET, with dual-head coincidence camera, 1067

Spectral analysis
benzodiazepine binding with PET, 897(ab)
kinetic parameters, 227(ab)
regional function of irradiated liver, detection of, 1389(ab)

Sphincter of Oddi spasm, endoscopic manometry, assessment with, 1385(ab)

Squamous cell carcinoma, esophageal, individual nodal involvement, FDG PET, 808

Stabin, Michael, 13N(6)

Staging, *see* specific type

Standardized uptake value (SUV)
effect of body size and glucose corrections on, 1284(ab)
effect of weight changes on, 1236(ab)
FDG, three-dimensional clinical PET in lung cancer, 439
FDG in pediatric patients, 381(ab)
recovery correction, clinical impact of, 1233(ab)
tumor metabolism, quantification of, 237(ab)

Statistical parametric mapping, comparison with HMPAO SPECT, imaging of Alzheimer's disease, 1451

Stents
coronary, restenosis, radiolabeled antibody uptake in, 1535, 1541
lung clearance of, 1402(ab)
^{186}Re labeling of, 27(ab)
rescue stenting, 753(ab)
restenosis therapy with ^{188}Re-labeled stents, 28(ab)

Steroids, inhaled ^{11}C TAA, pulmonary distribution and kinetics, 1603

Striatum, regional blood flow, SPECT, in Huntington's disease, 773

Stroke
acute, diffusion-weighted MRI and SPECT in, 788
subacute, hypoxification and hyperfixation of ^{99m}Tc HMPAO, 795

Strontium-89, incorporation in type I collagen, during bone mineralization, 183

Strontium-89 chloride, therapy
for prostate cancer bone pain, E-selectin concentration after, 1021
therapeutic effects on fibrinolysis and coagulation, 1166(ab)

Stunning
dipyridamole stress, gated myocardial SPECT, 27
dual-isotope SPECT to detect stunned myocardium, 794(ab)
Grave's disease, 1345(ab)
occurrence on gated SPECT myocardial perfusion images, 21(ab)
radiation absorbed dose, 1061(ab)
thyroid remnants, after ^{131}I scanning, therapy and, 2038

Substance abuse
^{11}C diprenorphine PET imaging of opioid binding during methadone treatment, 418(ab)
downregulation of dopamine D2 receptors, 413(ab)
5-HT transporter density differences in ecstasy users, 419(ab)
metabolic changes in methamphetamine abusers, 420(ab)

SW620 cells, treatment with Tomudex and Oxaliplatin, glucose transport, 1753

Switched protocol, cold-bolus, PET activation images, signal-to-noise ratio in, 926

Sympathetic nervous activity, neurological recovery, 965(ab)

Sympathetic nervous system
^{11}C hydroxyephedrine imaging after heart transplant, 773(ab)
^{123}I MIBG myocardial scintigraphic imaging, 707(ab)
laser revascularization, 13(ab)
pulmonary hypertension effects, ^{123}I MIBG left ventricular imaging, 1127

Sympathetic stimulation, coronary microvascular reactivity to, idiopathic dilated cardiomyopathy, PET, 837

Symposium on Isotope and Radiation Applications (SIRA), 9N(9)

Systemic sclerosis, renal impairment in, 199(ab)

T

Technegas, SPECT, regional severity of emphysema, 590

Technetium-99m
arcitumomab imaging, colorectal cancer, 1016
chelators, 1097(ab)
effect of antisense imaging on cell membrane transport, 1028(ab)
generator, evaluation of elution volumes and Tc-99m yields, 1103(ab)
high-specific activity using gold surfaces, 487(ab)
imaging chronic osteomyelitis, 896
infection imaging, 40(ab)
labeled antibody fragments, FDG PET in colorectal cancer, 1657
labeled peptides for somatostatin receptor imaging, 318(ab)
labeled somatostatin receptor, 590(ab)
peptide radiolabeled with, noninvasive monitoring of gene transfer, 887
peptide receptor imaging, 1086(ab)
protocols for quality control, 1099(ab)
pyrophosphate, rest-redistribution after myocardial infarction, 756(ab)
radiolabeled proteins to detect microvascular injury, 188(ab)
radiolabeling of DAT ligand O-1505T, 1067(ab)
sentinel node detection in breast cancer, 286(ab)
sentinel node imaging, new tracer for, 285(ab)
synthesis of N3S chelators, 586(ab)
in vitro blood labeling, effect of chayote and caffeine on, 1101(ab)
Yale CQ method, 1436

Technetium-99m anti-CD15, infection imaging, diagnosis of equivocal appendicitis, 449, 456

Technetium-99m anti-granulocyte antibody, bone marrow distribution of anti-NCA-95, 1212(ab)

Technetium-99m apcitide
acute thromboscintigraphy with, imaging acute deep vein thrombosis, 1214, 1224
scintigraphy, acute deep vein thrombosis, letter, 1768

Technetium-99m benzamides, panic disorder, 706(ab)

Technetium-99m biotin-PEG liposomes, avidin-induced clearance, infection imaging, 912

Technetium-99m bitistatin, imaging, pulmonary embolism and deep venous thrombosis, 1056, 1065

Technetium-99m carbonyl
biodistribution and preparation, 489(ab)
cancer-seeking peptides, 1079(ab)
chelate optimization, 156(ab)
dopamine transporters, 148(ab)

Technetium-99m cardiolite, morphological transformation of C3H 10T1/2 cells by, 1545

Technetium-99m complexes
alpha and gamma isomers of ^{99m}Tc oxa-folate, 470(ab)
isomeric mixture, 1082(ab)
synthesis of substituted pyrrolylthiones, 587(ab)
Technetium-99m dextran, radiolabeling of antifibrin Fab' with, reduction of background activity, 1264
Technetium-99m DISIDA
comparison with MR cholangiography, 1374(ab)
utility in predicting postoperative complications, 52(ab)
Technetium-99m DMP 444, quantitative study of ventilatory impairment, 508(ab)
Technetium-99m DMSA
planar scintigraphy, interobserver reproducibility in reporting, 23
renal uptake in diabetes mellitus, 1352(ab)
SPECT, 476(ab)
three-dimensional images in chronic renal disease, 1371(ab)
uptake in unilateral hydronephrosis, 1434(ab)
urinary tract infections, 1372(ab)
Technetium-99m DSMA, SPECT, renal length measurements with, 1632
Technetium-99m DTPA
attenuation correction during aerosol imaging, 1410(ab)
captopril renography, parenchymal mean transit time analysis, 1627
early retardation of in transalveolar clearance, 1409(ab)
modified diuretic renography, 203(ab)
renography, attenuation correction in, children and adults, 823
Technetium-99m DTPA-galactosyl, diagnosis of inflammatory diseases, 42(ab)
Technetium-99m ECD
acetazolamide challenge, 91(ab)
acetazolamide stress brain-perfusion SPECT, carotid shunting, 1836
activity stability in syringes, 1106(ab)
cerebral vasospasm in aneurysmal subarachnoid hemorrhage, 86(ab)
chronic fatigue syndrome, 898(ab)
deterioration of vascular territories in Moyamoya disease, 1431(ab)
improved lesion detection in systemic lupus erythematosus, 1009(ab)
metabolism in infarcted brain tissue, 551(ab)
quantitative brain perfusion imaging, 838(ab)
SPECT
brain, normal patterns in adults, 1456
lesions near central sulcus, 411
SPECT imaging of multiple system atrophy, 425(ab)
Technetium-99m ethyl cysteinate dimer, ictal brain SPECT, neocortical seizures, 1619
Technetium-99m exametazime-labeled leukocytes, stabilized, radiation dosimetry and biodistribution of, 934
Technetium-99m fibrin, imaging vascular thrombosis with, 161, 1065
Technetium-99m furifosmin, scintigraphy, nonpalpable breast lesions, 426
Technetium-99m galactosyl-neoglycoalbumin, segmental decreased uptake in nontumorous liver tissue, 1387(ab)
Technetium-99m GSA
primary biliary cirrhosis, staging of, 1391(ab)
SPECT, prognostic estimation after hepatectomy, 421
Technetium-99m HL91, kinetics, myocardium, 1102
Technetium-99m HMDP, pinhole bone scan, 1426(ab)
Technetium-99m HMPAO
brain SPECT, in progressive aphasia, 228
brain SPECT region-of-interest templates, elderly, 45
hypoxification and hyperfixation of, subacute cerebral infarction, 795
SPECT
Alzheimer's disease, 1451
crossed cerebellar diaschisis, 416
Technetium-99m-HMPAO
acute ischemic stroke, 1005(ab)
multidrug associated protein, 592(ab)
Technetium-99m HMPAO-labeled lymphocytes
joint prosthesis infection, 1398(ab)
pyogenic pelvic inflammatory disease, 1397(ab)
Technetium-99m HSA, in protein-losing enteropathy, children, 215
Technetium-99m human neutrophil peptide-1, imaging of bacterial infections, 2099(le)
Technetium-99m human serum albumin
peripheral arterial occlusive disease, 182(ab)
protein loss gastroenteropathy, 1105(ab)
Technetium-99m HYNIC-Tyr^3-octreotide, imaging, somatostatin-receptor-positive tumors, 1114
Technetium-99m IDA, hepatobiliary drainage, effect of remifentanil on, 55(ab)
Technetium-99m-labeled microsphere, SPECT measurement of dopamine transporters, 989(ab)
Technetium-99m liposomes, scintigraphy, detection of infection and inflammation, 622
Technetium-99m MAA
cerebral embolization, detection of with, 87(ab)
intrapulmonary shunting in liver cirrhosis, detection of, 1393(ab)
pulmonary perfusion studies, 1405(ab)
pulmonary redistribution in horses, 1414(ab)
Technetium-99m MAG3
background correction method in renal imaging, 202(ab)
captopril-induced changes in clearance, renal arterial stenosis and renal angioplasty, 1203
diuretic renography and surgery for ureteropelvic junction obstruction in neonates, 1432(ab)
reproducibility studies, 366(ab)
scintigraphy, emergency intervention for renal colic, 1813
scintirenography, HIV nephropathy, pediatric, 1037
semiautomated regions of interest, evaluation of renal function, 1947
tubular agent, protein binding on renal extraction of, 2077
Technetium-99m MDP
anterior cruciate ligament tear of the knee, 1427(ab)
bone scintigraphy
photopenic lesion patterns in pediatric irritable hip, 384(ab)
spine metastasis, detection of, 1423(ab)
global and regional skeletal uptake, aging and, 1478
Technetium-99m mebrofenin, auxiliary liver, hepatobiliary imaging of, 53(ab)
Technetium-99m-meso-hexa-methyl propyleneamine, cerebral blood flow, 1010(ab)
Technetium-99m-methylene diphosphonate, Graves' ophthalmopathy, immunosuppression in, 217(ab)
Technetium-99m MIBI
chest SPECT, detection of esophagitis, 1969
clinical utility of mammography, 1258(ab)
clinical utility of scintimammography, 568(ab)
comparison with MRI and bone marrow biopsy in breast cancer, 1263(ab)
comparison with tetrofosmin scintimammography, 569(ab)
comparison with ^{201}Tl scintigraphy, suppressed thyroid tissue, 1163
defect severity in myocardium, 496(ab)
deoxyglucose and, intratumoral distribution, mouse breast cancer models, 1561
detection of recurrent breast cancer, 572(ab)
effectiveness in assessing chemotherapeutic response in breast cancer, 448(ab)
efflux rate in breast cancer, 1261(ab)
gated SPECT, dipyridamole stress-induced stunning shown, 27
gated SPECT imaging of myocardial wall thickening, 755(ab)
mismatching, myocardial scintigraphy, 213 (le)
multidrug resistance in mice, 1137(ab)
myocardial contractile reserve with gated SPECT, 497(ab)
parathyroid disease, 1353(ab)
perfusion index and tumor uptake of, 447(ab)
prognostic value in recurrent breast cancer, 1257(ab)
proliferative activity and malignant transformation potential, 268(ab)
rest/stress myocardial perfusion SPECT, likelihood of CAD, 852, 860
scintimammography, mammography and, suspected breast cancer, 390(le)
stereotactic techniques for guided biopsy of breast lesions, 235(ab)
uptake, malignant and nonmalignant breast cell lines, 1495
washout, correlation with prognostic factors in breast cancer, 1264(ab)
Technetium-99m nitroheterocycle, myocardial uptake, swine model of occlusion and reperfusion, 1237
Technetium-99m nitroimidazole, imaging, hypoxia in tumors, 169
Technetium-99m NOET, myocardial perfusion imaging, biodistribution, dosimetry, and safety, 141
Technetium-99m peptide conjugates
HYNIC-conjugation, optimization of, 1088(ab)
labeling methods, 1127(ab)
pharmacokinetics, optimization of, 1013(ab)
rapid tumor detection properties, 132(ab)
Technetium-99m peptides
neutrophil elastase inhibitor, inflammation and infection imaging with, monkeys, 363
pharmacokinetics, renal handling and, 177
Technetium-99m pertechnetate
evaluation of chronic liver diseases, 1378(ab)
per-rectal portal scintigraphy of primary biliary cirrhosis, 1394(ab)
uptake in thyroid cancer, 1140(ab)
Technetium-99m phytate, hyposplenism, detection with liver/spleen imaging, 385(ab)
Technetium-99m RBC, blood pool changes, liver and other organs, 474
Technetium-99m sestamibi
administration error, reduction of, 1104(ab)
bone myeloma, 1208(ab)
comparison with ^{99m}Tc MDP in detection of breast cancer, 571(ab)
decreasing artifactual inferior wall defects, 884(ab)
detection of paraffinomas, 1262(ab)
dual-isotope imaging with, photon energy recovery for crosstalk correction, 728
myocardial fatty acid uptake and perfusion, evaluation of, 710(ab)
myocardial gated SPECT, left ventricular ejection fraction and volume, 1445
myocardial SPECT, ROC study of attenuation correction, 502
postexercise lung uptake, new automatic technique, 1190
scintimammography, breast imaging, diagnostic accuracy of, 1973
SPECT, infarct size and severity, 1383
whole-body scintigraphy, management of thyroid cancer, 631
Technetium-99m sulfur colloid
gastric emptying studies, early gastric emptying in children, 596
gastroesophageal scintigraphy, evaluation of posterior laryngitis, 1597
polyvinyl alcohol embolization particle labeling, 1094(ab)
Technetium-99m tetrofosmin
comparison with sestamibi in diagnostic accuracy for breast cancer, 1265(ab)
FDG collimated SPECT and, myocardial perfusion and viability, 1318
perfusion imaging, 774(ab)
quantitative analysis of perfusion studies, 338(ab)
revascularization in ischemic heart disease, 742(ab)
scintigraphy, pulmonary tuberculosis, 1120(le)
sentinel node biopsy, 1259(ab)
SPECT, minimizing liver, bowel, and gastric activity in, 1315
SPECT assessment of myocardial viability, 352(ab)
stunned myocardium, predicting functional outcome with BMIPP early images, 721(ab)
uptake, malignant and nonmalignant breast cell lines, 1495
Technetium-99m TRODAT-1
binding to dopamine transporters, Parkinson's disease, 584
dopamine transporter measurements, 988(ab)
Parkinson's disease and vascular parkinsonism, diagnosis of, 426(ab)
pathophysiology in Parkinson's disease, 541(ab)
radiochemical purity, 1102(ab)
SPECT, dopamine transporter binding in Machado-Joseph disease, 994
Technetium-99m VIP, rapid localization of tumors, 107
Technologists support, 28N(6)

Telemedicine
Java-based remote viewing, nuclear medicine images, 111
Java language in image processing, 865(ab)
Linux-based teleradiology system, 866(ab)
Ter-Pogossian, Michel, 30N(11)
Tetrapeptides, ^{99m}Tc-labeled, pharmacokinetics and renal handling, 177
Tetrofosmin scintigraphy
comparison with sestamibi scintimammography, 569(ab)
myocardial hypertrophy, 712(ab)
stress-induced postischemic stunning, 780(ab)
Thakur, Mathew, 30N(7), 30N(7)
Thalamus
ipsilateral and contralateral hypometabolism, after temporal lobectomy for seizures, 1964
vagus nerve stimulation, refractory epilepsy, SPECT activation study, 1145
Thallium-201
detection of thymic abnormality in myasthenia gravis, 374(ab)
dual-isotope imaging with, photon energy recovery for crosstalk correction, 728
follow-up regimen, thyroid cancer after thyroid hormone withdrawal, 643
giant-cell bone tumor, 1321(ab)
iodinated free fatty acid and, uptake, chronically hypoperfused myocardium, 293
myocardial perfusion imaging of left ventricular remodeling postinfarction, 777(ab)
myocardial SPECT, acute myocardial infarction, 830
myocardial uptake, force-generating preparation from atria, 1587
parameters of left ventricular dysfunction, 716(ab)
reverse redistribution, acute myocardial infarction, 393
scintigraphy, ^{99m}Tc MIBI comparison, suppressed thyroid tissue, 1163
SPECT
clinical applications to brain tumors, 5
lung uptake with exercise, coronary artery disease, 567
Yale CQ method, 1436
Therapy
ablative therapy for leptomeningeal metastasis, 1051(ab)
ciprofloxacin, pretreatment effect of, 1401(ab)
effect of low-iodine diet following treatment for thyroid cancer, 1354(ab)
I-125 for brachytherapy of malignant brain tumors, 1044(ab)
incurable thyroid cancer, 212(ab)
multi-dose regimen for pheochromocytoma, 581(ab)
radioiodine therapy of neoplastic meningitis, 1204(ab)
radiolabeled antisense oligonucleotides in follicular lymphoma, 1145(ab)
Sm-153-EDTMP, efficacy and toxicity of, 575(ab)
Three-dimensional imaging, methodology for high-resolution cerebral glucose imaging, 403(ab)
Three-dimensional volume imaging, hybrid PET camera, 525(ab)
Thrombolysis in myocardial infarction (TIMI), trial grade 3, microvascular reperfusion, 393
Thromboscintigraphy, with ^{99m}Tc apcitide, imaging of deep vein thrombosis, 1214, 1224
Thrombosis imaging, DMP-444 following total-knee arthroplasty, 45(ab)
Thrombus, ^{111}In oxine-labeled platelet imaging, 1418(ab)
Thymus, FDG PET imaging, 382(ab)
Thyroglobulin, withdrawal, after thyroidectomy, follow-up regimen, 643
Thyroid
ablation, ^{131}I therapy in outpatients, regulations, 1868, 1876
collimators for solid-state gamma cameras in thyroid studies, 1355(ab)
radiobiological effectiveness, 1048(ab)
radioiodine therapy of nontoxic goiter, 1337(ab), 1351(ab)
scintigraphic assessment of thyroid nodules, 1357(ab)
stunning
absence of, after ^{131}I whole-body scanning, 1198
after dosimetry, 1082
suppressed tissue, comparison of ^{99m}TC MIBI and ^{201}TL scintigraphy, 1163
Thyroid cancer
after radioiodine treatment, hyperthyroidism, 1006
cervical lymph node metastases, 214(ab)
comparison of ^{131}I whole-body scintigraphy and FDG PET, 1358(ab)
cost-effectiveness of adjuvant radioiodine therapy, 1328(ab)
diagnosis of remission and residual thyroid tissue, 32(ab)
differentiated, effect of low-iodine diet on thyroid ablation, 1354(ab)
low-activity radioiodine, 1203(ab)
management, ^{99m}Tc sestamibi and ^{131}I whole body scintigraphy, 631
medullary, high-dose radioimmunotherapy, 93
^{99m}Tc sestamibi, role in selecting high-risk patients, 1343(ab)
PET imaging of, 1331(ab)
radioiodine therapy, 1340(ab)
radioiodine uptake, after tracer dosimetry, 1082
recombinant (Thyrogen), 1348(ab)
recurrent or metastatic, FDG PET, 1010
sodium iodide symporter expression, 1338(ab)
sodium iodide symporter gene, expression of, 1140(ab)
somatostatin receptors, octreotide binding and, 636
thyroidectomy, thyroid hormone withdrawal after, follow-up regimen, 643
treatment with ^{131}I, adaptive response of patients, 17
treatment with isotretinoin, 212(ab)
TSH effects, FDG uptake in PET, 1989, 1996
undifferentiated, ^{131}I effects, 2038
Thyroid carcinoma, medullary
limitations of FDG PET in localization of, 1339(ab)
peptide receptor imaging for detection of, 30(ab)
radioimmunotherapy and chemotherapy for, 213(ab)
tissue-specific AAV vectors in gene therapy, 1136(ab)
Thyroid disease, low iodine diet vs diuretic, effect on radioiodine uptake, 1349(ab)
Thyroidectomy, follow-up after, thyroid hormone withdrawal and, 643
Thyroid-stimulating hormone (TSH)
effects on FDG uptake, PET, in thyroid cancer, 1989, 1996
Iodine-avid lesions, detection of, 1201(ab)
radioiodine clearance, 1348(ab)
whole-body imaging in thyroid cancer, 1336(ab)
Thyroid tumors
FDG PET diagnosis of, 1335(ab)
whole-body imaging of, 1356(ab)
Thyrotoxicosis, treatment with ^{131}I, adaptive response of patients, 17
Tickovsky, Ronald, 16N(1)
Tin-117m, Sn-117m-chelates, 1119(ab)
Tin-117m(4+)DTPA, stability in vivo and in vitro, 1119(ab)
Tissue metabolites, PET data correction for, dual-scan approach, 706
Tissue plasminogen activator (T-PA), 12N(1)
Tomographic multigated analysis
evaluation of noniodine-avid tumor, 1347(ab)
Hurthle cell carcinoma, 1333(ab)
thyroid cancer, 1330(ab)
Toohey, Richard E., 13N(6)
Tourette's syndrome, increased monoamine transporter binding, 968(ab)
Trabecular bone, radionuclides localized within the skeleton, S values for, 189
Tracer kinetic modeling, PET/SPECT quantification of neuroreceptors, 833(ab)
Transmission CT
nonuniform attenuation correction, 843(ab)
stereotactic standardization of brain receptor data, 240(ab)
Transmission scanning system, for gamma camera coincidence scanner, 692
Transplantation. *see also* specific organ
allograft rejection, scintigraphic assessment of, 500(ab)
coronary flow reserve after heart transplant, 172(ab)
hepatobiliary imaging to diagnose biliary complications after living donor liver, 52(ab)
liver function, scintigraphic assessment of, 53(ab)
lung, for emphysema and pulmonary fibrosis, perfusion scintigraphy in, 1771
monitoring response to antirejection treatment of renal allografts, 1360(ab)
myeloablation, 119(ab)
renal, prediction of survival, radioisotope studies, 1332
scintigraphic detection of vascular complications of liver transplants, 1386(ab)
stem cells, conditioning before, radioimmunotherapy and, 531
^{133}Xe ventilation studies post-transplant, 1417(ab)
Tuberculosis, pulmonary, ^{99m}Tc tetrofosmin scintigraphy for, 1120(le)
Tubular necrosis, acute, prediction of survival after renal transplant, radioisotope studies, 1332
Tumor detection
cervical cancer, FDG PET assessment of, 1309(ab)
FDG uptake and GLUT expression, 1131(ab)
hybrid PET data acquisition, 874(ab)
soft-tissue sarcoma, 379(ab)
uptake of FLT in tumor cells, 142(ab)
Tumor grading, kinetic modeling of FHBG, 228(ab)
Tumor hypoxia
correlation with ^{64}Cu ATSM, 454(ab)
^{99m}Tc HL91, monitoring of oxygenation status with, 453(ab)
Tumor imaging
dual-time point imaging, 451(ab)
effectiveness of labeled metalloporphyrin derivative, 1031(ab)
gene therapy imaging agents, 1034(ab)
hypoxia in, ^{99m}Tc-labeled nitroimidazole imaging of, 169
^{131}I and ^{99m}Tc endostatin, 127(ab)
incidentaloma, Cushing's syndrome, 1334(ab)
iodinated nucleoside as tumor imaging agent, 1036(ab)
PET tumor agents, 167(ab)
receptor-specific, ^{99m}TC VIP analog for, 107
somatostatin receptor, ^{90}Y DOTA-octreotide, experimental radiopeptide therapy, 578(ab)
standardized uptake values, recovery correction of, 1233(ab)
Tc complexes of alpha and gamma isomers of folate, 470(ab)
tumor hypoxia, detection of, 131(ab)
whole-body three-dimensional PET, 402(ab)
Tumor markers
FDG and, pulmonary lesions, 1801
proliferation, 582(ab)
Tumor pretargeting
polylysine as biotin carrier, 1033(ab)
site-specific delivery of small molecules, 1023(ab)
Tumor quantitation
anti-vascular therapy with PET, 827(ab)
FDG uptake after chemoradiotherapy, 1253(ab)
Tumor response
angiogenesis inhibitor, 453(ab)
FDG uptake after chemoradiotherapy, 1253(ab)
glucose transport, 1156(ab)
single-dose versus fractionated radioimmunotherapy, 538
Tumor targeting
biotin derivative, 474(ab)
DNA-complexed polyamidoamine dendrimers or avidin, 1144(ab)
DNA fragments as indicator for receptor-mediated radiation effects, 1037(ab)
^{111}In DTPA-N-TIMP-2 to image matrix metalloproteinase expression in tumors, 159(ab)
matrix metalloproteinase inhibitor, labeled, 1134(ab)
melanotropins, 1021(ab)
properties of radiolabeled peptides, 161(ab)
Two-compartment model, kinetic analysis, 230(ab)

U

University of Missouri-Columbia research reactor (MURR), 31N(9)
Urea breath test, heliocbacter pylori, 1380(ab)
Urinary tract infection, ^{99m}Tc DMSA, 1372(ab)
Urolith, helical CT positive for, MAG3-F_0 scintigraphy for emergency intervention after, 1813

V

Vagus nerve, stimulation, in refractory epilepsy, SPECT activation study, 1145

Vascular endothelial growth factor receptors
effect of modified LDL, 786(ab)
receptor targeting, 564(ab)
Vasoactive intestinal peptide, ^{99m}TC analog, tumor imaging in humans, 107
Vasomotion, mental stress effects, with coronary artery disease, 11
Vasoreactivity, cerebellar, stroke patients, acetazolamide and ^{99m}Tc HMPAO SPECT, 416
Venography, thromboscintigraphy with ^{99m}Tc apcitide, deep vein thrombosis, 1214, 1225
Venous thrombosis, peptide scintigraphy, 44(ab)
Ventilation/perfusion imaging, ^{99m}Tc antibody studies, 1407(ab)
Ventilation/perfusion lung scan, SPECT studies, 883(ab)
Ventilation perfusion scintigraphy, increased alveolar-arterial gradient, 48(ab)
Ventilation study, technegas SPECT, regional severity of emphysema, 590
Ventricular volume
gated SPECT assessment of, 734(ab)
measurement, echocardiographic validation of gated SPECT, 1308
Vesico-ureteral reflux, screening for renal parenchymal consequences, 208(ab)
Volume visualization, multidimensional analysis, 864(ab)

W

Wagner, Henry N. Jr., 30N(11)
Watson, Evelyn E., 13N(6)
White blood cells
comparison of leukocyte imaging and ultrasound in pediatric inflammatory bowel disease, 205(ab)
comparison of leukocyte scan with FDG PET for chronic orthopedic infections, 59(ab)
radiocolloid study for inflammatory bowel disease, 204(ab)
Whole-body image registration, thyroid tumors, 1356(ab)
Whole-body scintigraphy, ^{153}Sm EDTMP, dosimetry of in, 1163(ab)
Wilson, Robert R, memorialized at Fermilab, 42N(7)
Wilson's disease, increased cerebral iron uptake, ^{52}Fe-citrate PET study, 781
World Federation of Nuclear Medicine and Biology (WFNMB), 2000 meeting, 9N(9), 20N(3)

X

Xenograft, labeled antibody to assess tumor size, 1183(ab)
X-ray absorptiometry, dual-energy, bone densitometry and, 2015
X-ray attenuation, coincidence imaging, image fusion with, 1364, 1380

Y

Yale circumferential quantification method, validation of, 1436
Year 2000 rollover, 25N(2)
Yttrium-86, electrolytical purification, 1118(ab)
Yttrium-90
assay in nuclear pharmacy, 1117(ab)
$CaNa_2EDTA$ for improvement of, human colorectal cancer in mice, 337
^{64}Cu- and ^{90}Y-labeled peptide comparisons, 1043(ab)
microspheres
intrahepatic treatment of hepatocellular carcinoma, 1673
liver tumors, injection method effects, 1892
photosensitizer activation by Cerenkov radiation, 314(ab)
radiolabeled antibody therapy for ovarian and colorectal cancer, 1151(ab)
renal toxicity during peptide-receptor radiotherapy, 1173(ab)
Yttrium-90 DOA, peptide receptor imaging and therapy, 1704
Yttrium-90 DOTA-biotin, antibody-streptavidin conjugate and, pretargeted radioimmunotherapy, 131
Yttrium-90 2IT-BAD-Lym-1, radiation dosimetry for, in non-Hodgkin's lymphoma, 952
Yttrium-90 octreotide
biodistribution, effect of peptide amount on, 1143(ab)
dosimetric predictor of tumor response, 437(ab)
dosimetry in neuroendocrine tumors, 436(ab)
radiotherapy with, 438(ab)
somatostatin receptor, Y-90-octreotide, clinical value of, 577(ab)

Z

62-Zinc/62-copper generator, PET, performance, 309
Zollinger–Ellison syndrome
cerebral glucose metabolism changes, 992(ab)
gastric carcinoids, somatostatin receptor scintigraphy localization, 1646